NZ712576B2 - Dna-pk inhibitors - Google Patents
Dna-pk inhibitors Download PDFInfo
- Publication number
- NZ712576B2 NZ712576B2 NZ712576A NZ71257614A NZ712576B2 NZ 712576 B2 NZ712576 B2 NZ 712576B2 NZ 712576 A NZ712576 A NZ 712576A NZ 71257614 A NZ71257614 A NZ 71257614A NZ 712576 B2 NZ712576 B2 NZ 712576B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- compound
- acceptable salt
- pharmaceutically acceptable
- cycloalkyl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 29
- 239000003112 inhibitor Substances 0.000 title abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 408
- -1 -C1-4alkyl Chemical group 0.000 claims description 168
- 125000000217 alkyl group Chemical group 0.000 claims description 122
- 239000011780 sodium chloride Substances 0.000 claims description 92
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 86
- 150000003839 salts Chemical class 0.000 claims description 85
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 68
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 67
- 125000001153 fluoro group Chemical group F* 0.000 claims description 58
- 150000003852 triazoles Chemical class 0.000 claims description 46
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 41
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 38
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 37
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 36
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 35
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 30
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 229940113083 morpholine Drugs 0.000 claims description 23
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 23
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 23
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 22
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 21
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 20
- 229910052794 bromium Inorganic materials 0.000 claims description 19
- 229910052801 chlorine Inorganic materials 0.000 claims description 19
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 17
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 16
- 150000003536 tetrazoles Chemical class 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000002950 monocyclic group Chemical group 0.000 claims description 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000002393 azetidinyl group Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 125000004193 piperazinyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 8
- 125000004429 atoms Chemical group 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 7
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 claims description 6
- IDAICLIJTRXNER-UHFFFAOYSA-N 5,6,7,8-tetrahydropteridine Chemical compound C1=NC=C2NCCNC2=N1 IDAICLIJTRXNER-UHFFFAOYSA-N 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 101700041618 nhr-4 Proteins 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 6
- FHLXQXCQSUICIN-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine Chemical compound C1=CC=C2NCNCC2=N1 FHLXQXCQSUICIN-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 5
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 5
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010025650 Malignant melanoma Diseases 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 201000011231 colorectal cancer Diseases 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 2
- CPBZARXQRZTYGI-UHFFFAOYSA-N 3-cyclopentylpropylcyclohexane Chemical compound C1CCCCC1CCCC1CCCC1 CPBZARXQRZTYGI-UHFFFAOYSA-N 0.000 claims description 2
- 125000006414 CCl Chemical group ClC* 0.000 claims description 2
- 230000001235 sensitizing Effects 0.000 claims description 2
- 231100000202 sensitizing Toxicity 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 7
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 210000000481 Breast Anatomy 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 95
- 201000010099 disease Diseases 0.000 abstract description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 394
- 101700067048 CDC13 Proteins 0.000 description 256
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 197
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 147
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- 230000002829 reduced Effects 0.000 description 36
- 239000007787 solid Substances 0.000 description 34
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 32
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 17
- 239000008079 hexane Substances 0.000 description 17
- 210000004027 cells Anatomy 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N NMP Substances CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 210000001519 tissues Anatomy 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 7
- 239000005909 Kieselgur Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 210000004881 tumor cells Anatomy 0.000 description 7
- WGIRHQHUQAYUNZ-UHFFFAOYSA-N C1=CN=C2C(O)=CC(Br)=CC2=N1 Chemical compound C1=CN=C2C(O)=CC(Br)=CC2=N1 WGIRHQHUQAYUNZ-UHFFFAOYSA-N 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 101700061400 PRKDC Proteins 0.000 description 6
- 102100003225 PRKDC Human genes 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000000240 adjuvant Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 150000002829 nitrogen Chemical group 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 201000009030 carcinoma Diseases 0.000 description 5
- GITFHTZGVMIBGS-UHFFFAOYSA-M chloropalladium(1+);ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C GITFHTZGVMIBGS-UHFFFAOYSA-M 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- DXQWHZNIOIXYMW-UHFFFAOYSA-N (7-bromoquinoxalin-5-yl)oxy-tert-butyl-dimethylsilane Chemical compound C1=CN=C2C(O[Si](C)(C)C(C)(C)C)=CC(Br)=CC2=N1 DXQWHZNIOIXYMW-UHFFFAOYSA-N 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 102100000648 ATM Human genes 0.000 description 4
- 108060006202 ATM Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000005842 heteroatoms Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000000968 intestinal Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- RXBSDOXVGFXJQX-UHFFFAOYSA-N 2,3-diamino-5-bromophenol Chemical compound NC1=CC(Br)=CC(O)=C1N RXBSDOXVGFXJQX-UHFFFAOYSA-N 0.000 description 3
- PMNIWLIWFPHKDA-UHFFFAOYSA-N C1CN(CCO1)C1=CC=C2N=CC=NC2=C1 Chemical compound C1CN(CCO1)C1=CC=C2N=CC=NC2=C1 PMNIWLIWFPHKDA-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- FNFMQIWXTYFRKA-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1[CH]CC(N)CC1 FNFMQIWXTYFRKA-UHFFFAOYSA-N 0.000 description 3
- TZZXCFSNKBFOOG-UHFFFAOYSA-M cyclohexylmethanesulfonate Chemical compound [O-]S(=O)(=O)CC1CCCCC1 TZZXCFSNKBFOOG-UHFFFAOYSA-M 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 150000002780 morpholines Chemical class 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- YLHCMDNAKVPTIO-UHFFFAOYSA-N 2-(4-hydroxycyclohexyl)isoindole-1,3-dione Chemical compound C1CC(O)CCC1N1C(=O)C2=CC=CC=C2C1=O YLHCMDNAKVPTIO-UHFFFAOYSA-N 0.000 description 2
- AYPPYTAGQANWFK-UHFFFAOYSA-N 2-[4-[7-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)quinoxalin-5-yl]oxycyclohexyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(OC=2C3=NC=CN=C3C=C(C=2)N2CC3CC(O3)C2)CC1 AYPPYTAGQANWFK-UHFFFAOYSA-N 0.000 description 2
- XMJNQKQINSXSHA-UHFFFAOYSA-N 2-amino-5-bromo-3-nitrophenol Chemical compound NC1=C(O)C=C(Br)C=C1[N+]([O-])=O XMJNQKQINSXSHA-UHFFFAOYSA-N 0.000 description 2
- OBUCBGNHAVKMKN-UHFFFAOYSA-N 4-N-pyrimidin-2-ylcyclohexane-1,4-diamine;hydrochloride Chemical compound Cl.C1CC(N)CCC1NC1=NC=CC=N1 OBUCBGNHAVKMKN-UHFFFAOYSA-N 0.000 description 2
- AXVZKXQBGLRAQH-UHFFFAOYSA-N 4-pyrimidin-2-yloxycyclohexan-1-ol Chemical compound C1CC(O)CCC1OC1=NC=CC=N1 AXVZKXQBGLRAQH-UHFFFAOYSA-N 0.000 description 2
- SDRGWVVFJBAFNR-UHFFFAOYSA-N 5-bromo-7-fluoroquinoxaline Chemical compound N1=CC=NC2=CC(F)=CC(Br)=C21 SDRGWVVFJBAFNR-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- MCQSIFHQQMVWCK-UHFFFAOYSA-M ClC1=C(C(S(=O)(=O)[O-])(I)Br)C=CC=C1 Chemical compound ClC1=C(C(S(=O)(=O)[O-])(I)Br)C=CC=C1 MCQSIFHQQMVWCK-UHFFFAOYSA-M 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- VVWRJUBEIPHGQF-KTKRTIGZSA-N Diisopropyl azodicarboxylate Chemical compound CC(C)OC(=O)\N=N/C(=O)OC(C)C VVWRJUBEIPHGQF-KTKRTIGZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000004392 Genitalia Anatomy 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 206010061289 Metastatic neoplasm Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 101710027499 Os03g0268000 Proteins 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940066842 Petrolatum Drugs 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 108091000081 Phosphotransferases Proteins 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N Phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 210000000664 Rectum Anatomy 0.000 description 2
- 101700072540 SMG1 Proteins 0.000 description 2
- 102100004167 SMG1 Human genes 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N SPhos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 235000020127 ayran Nutrition 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001351 cycling Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 230000001394 metastastic Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000009740 moulding (composite fabrication) Methods 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 description 2
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- FEYLUKDSKVSMSZ-UHFFFAOYSA-N tert-butyl N-(4-aminocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(N)CC1 FEYLUKDSKVSMSZ-UHFFFAOYSA-N 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- FDKFPAWOURLDER-UHFFFAOYSA-N (4-pyrimidin-2-yloxycyclohexyl) methanesulfonate Chemical compound C1CC(OS(=O)(=O)C)CCC1OC1=NC=CC=N1 FDKFPAWOURLDER-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- ITZHHMQIKLMWIN-UHFFFAOYSA-N 1,3$l^{2}-thiazolidine Chemical group C1CSC[N]1 ITZHHMQIKLMWIN-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- JWEBNERCVJZDNC-UHFFFAOYSA-N 1-N-(6-morpholin-4-yl-2,1,3-benzoxadiazol-4-yl)-4-N-pyrimidin-2-ylcyclohexane-1,4-diamine Chemical compound C1COCCN1C1=CC2=NON=C2C(NC2CCC(CC2)NC=2N=CC=CN=2)=C1 JWEBNERCVJZDNC-UHFFFAOYSA-N 0.000 description 1
- YMLFZVXUGYQVFW-UHFFFAOYSA-N 1-ethyl-3-[4-[[7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)quinoxalin-5-yl]amino]cyclohexyl]urea Chemical compound C1CC(NC(=O)NCC)CCC1NC1=CC(N2CC3CCC(O3)C2)=CC2=NC=CN=C12 YMLFZVXUGYQVFW-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical class OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
- KUCWUAFNGCMZDB-UHFFFAOYSA-N 2-amino-3-nitrophenol Chemical compound NC1=C(O)C=CC=C1[N+]([O-])=O KUCWUAFNGCMZDB-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- YMDSUQSBJRDYLI-UHFFFAOYSA-N 2-chloropyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(Cl)=N1 YMDSUQSBJRDYLI-UHFFFAOYSA-N 0.000 description 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- OIGXNHYFKZCTCH-UHFFFAOYSA-N 2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC=CC=N1 OIGXNHYFKZCTCH-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LMWBCTADNYACQV-UHFFFAOYSA-N 2H-pyrrole Chemical group C1C=C=C=N1 LMWBCTADNYACQV-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- VCINLTLIJKUOQC-UHFFFAOYSA-N 3-bromo-5-fluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(Br)=C1N VCINLTLIJKUOQC-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QRZTYUJBKOPHSD-UHFFFAOYSA-N 4-(8-bromoquinoxalin-6-yl)morpholine Chemical compound C=1C2=NC=CN=C2C(Br)=CC=1N1CCOCC1 QRZTYUJBKOPHSD-UHFFFAOYSA-N 0.000 description 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
- ZYWHXNPWXUXKSX-UHFFFAOYSA-N 4-chloro-2-(4-methylpiperazin-1-yl)pyrimidine Chemical compound C1CN(C)CCN1C1=NC=CC(Cl)=N1 ZYWHXNPWXUXKSX-UHFFFAOYSA-N 0.000 description 1
- QHYZSUBOWOYSRT-UHFFFAOYSA-N 4-chloro-N-methylpyrimidine-2-carboxamide Chemical compound CNC(=O)C1=NC=CC(Cl)=N1 QHYZSUBOWOYSRT-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- JBVWSJGFMFZTJL-UHFFFAOYSA-N 4-morpholin-4-yl-2,1,3-benzoxadiazole Chemical compound C1COCCN1C1=CC=CC2=NON=C12 JBVWSJGFMFZTJL-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CTWZYPZCDJKBRS-UHFFFAOYSA-N 5-bromo-2-fluoropyrimidine Chemical compound FC1=NC=C(Br)C=N1 CTWZYPZCDJKBRS-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- RWSPRTBXAXZIOS-UHFFFAOYSA-N 6-chloropyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=NC=N1 RWSPRTBXAXZIOS-UHFFFAOYSA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- ILYBMUDLGFMEMU-UHFFFAOYSA-N 7-$l^{1}-oxidanyl-2,3,4,5,6,7-hexaoxoheptan-1-olate Chemical compound [O]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C[O-] ILYBMUDLGFMEMU-UHFFFAOYSA-N 0.000 description 1
- PXVQWJPOMIRXQL-UHFFFAOYSA-N 7-bromo-1H-quinoxalin-2-one Chemical compound C1=CC(Br)=CC2=NC(O)=CN=C21 PXVQWJPOMIRXQL-UHFFFAOYSA-N 0.000 description 1
- BRHLUMXQJTXKMY-UHFFFAOYSA-N 8-oxa-1-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCN1O2 BRHLUMXQJTXKMY-UHFFFAOYSA-N 0.000 description 1
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100006824 ATR Human genes 0.000 description 1
- 108060000721 ATR Proteins 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 210000004404 Adrenal Cortex Anatomy 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000182185 Alfalfa virus S Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 210000003567 Ascitic Fluid Anatomy 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- FEYLUKDSKVSMSZ-DTORHVGOSA-N CC(C)(C)OC(=O)N[C@@H]1CC[C@H](N)CC1 Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@H](N)CC1 FEYLUKDSKVSMSZ-DTORHVGOSA-N 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 241000565118 Cordylophora caspia Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N Cyclohexylamine Chemical class NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N Disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 229940095399 Enema Drugs 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000035521 G2 Phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- 101710007250 H3C1 Proteins 0.000 description 1
- 102100001900 H3C1 Human genes 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N IPA isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 101700078085 MAP6 Proteins 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 102100013322 MTOR Human genes 0.000 description 1
- 206010026673 Malignant pleural effusion Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940042472 Mineral Oil Drugs 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N N'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- LQZPJQKYAOYUJS-UHFFFAOYSA-N N,N-diethyl-2-phenothiazin-10-ylethanamine;hydron;chloride Chemical compound Cl.C1=CC=C2N(CCN(CC)CC)C3=CC=CC=C3SC2=C1 LQZPJQKYAOYUJS-UHFFFAOYSA-N 0.000 description 1
- BWJYPABMMFBINC-UHFFFAOYSA-N N-[2-(4-azido-3-iodophenyl)ethyl]-4-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]pentanamide Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNC(C)CCC(=O)NCCC1=CC=C(N=[N+]=[N-])C(I)=C1 BWJYPABMMFBINC-UHFFFAOYSA-N 0.000 description 1
- ZYESGWGOSDQFDM-MAEOIBBWSA-N N1=CC(Br)=CN=C1N[C@@H]1CC[C@H](OC=2C3=NC=CN=C3C=C(C=2)N2CCOCC2)CC1 Chemical compound N1=CC(Br)=CN=C1N[C@@H]1CC[C@H](OC=2C3=NC=CN=C3C=C(C=2)N2CCOCC2)CC1 ZYESGWGOSDQFDM-MAEOIBBWSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- AXVZKXQBGLRAQH-DTORHVGOSA-N O[C@H]1CC[C@H](CC1)Oc1ncccn1 Chemical compound O[C@H]1CC[C@H](CC1)Oc1ncccn1 AXVZKXQBGLRAQH-DTORHVGOSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000008798 Osteoma Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 210000002394 Ovarian Follicle Anatomy 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010061529 Polyp Diseases 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N Propadiene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 229940100618 Rectal Suppository Drugs 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000036191 S Phase Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 210000000582 Semen Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 208000000649 Small Cell Carcinoma Diseases 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N Tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 208000007097 Urinary Bladder Neoplasm Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- 210000003905 Vulva Anatomy 0.000 description 1
- 101700032709 XRCC6 Proteins 0.000 description 1
- 102100009954 XRCC6 Human genes 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MLKBJNPMHYNXCV-UHFFFAOYSA-N [O-]B([O-])C1=CCOCC1 Chemical class [O-]B([O-])C1=CCOCC1 MLKBJNPMHYNXCV-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003140 astrocytic Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- MGWNCZWPMHBQNV-UHFFFAOYSA-N methanol;1-methylpyrrolidin-2-one Chemical compound OC.CN1CCCC1=O MGWNCZWPMHBQNV-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 101710031899 moon Proteins 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000637 radiosensitizating Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- YKLJDMCXKMIXBD-UHFFFAOYSA-M sodium;3-(2-dicyclohexylphosphanylphenyl)-2,4-dimethoxybenzenesulfonate Chemical compound [Na+].COC1=CC=C(S([O-])(=O)=O)C(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 YKLJDMCXKMIXBD-UHFFFAOYSA-M 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QKSQWQOAUQFORH-QXMHVHEDSA-N tert-butyl (NZ)-N-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)\N=N/C(=O)OC(C)(C)C QKSQWQOAUQFORH-QXMHVHEDSA-N 0.000 description 1
- UXDSVOYTFOJDOJ-UHFFFAOYSA-N tert-butyl N-[4-[(7-morpholin-4-ylquinoxalin-5-yl)amino]cyclohexyl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCC1NC1=CC(N2CCOCC2)=CC2=NC=CN=C12 UXDSVOYTFOJDOJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 230000002992 thymic Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The present invention relates to compounds (I) useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Description
DNA-PK INHIBITORS
This application claims the benefit to US. Provisional Application No. 61/777,816,
filed on March 12, 2013, the entire t of which is incorporated herein by reference.
TECHNICAL FIELD OF THE INVENTION
The present ion relates to nds useful as inhibitors of DNA—
dependent protein kinase (DNA-PK). The invention also provides pharmaceutically
acceptable compositions comprising the compounds of the invention and methods of using
the compositions in the treatment of cancer,
OUND OF THE INVENTION
ng radiation (IR) induces a variety of DNA damage of which double
strand breaks (DSBs) are the most cytotoxic. These DSBs can lead to cell death via
apoptosis and/or mitotic catastrophe if not rapidly and completely repaired. In addition to
IR, certain chemotherapeutic agents including topoisomerase II inhibitors, bleomycin, and
doxorubicin also cause DSBs. These DNA lesions trigger a x set of s
through the DNA damage response network that function to repair the d DNA and
maintain cell viability and genomic stability. In mammalian cells, the predominant repair
y for DSBs is the mologous End Joining Pathway (NHEJ). This pathway
functions regardless of the phase of the cell cycle and does not require a template to re-
ligate the broken DNA ends. NHEJ requires coordination of many proteins and signaling
pathways. The core NHEJ machinery consists of the Ku70/80 dimer and the
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which together comprise
the active DNA-PK enzyme complex. DNA-PKcs is a member of the phosphatidylinositol
3-kinase-related kinase (PIKK) family of serine/threonine protein kinases that also
includes ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 -related
(ATR), mTOR, and four PI3K isoforms. However, while DNA-PKcs is in the same
protein kinase family as ATM and ATR, these latter kinases function to repair DNA
damage through the Homologous Recombination (HR) pathway and are restricted to the S
and G2 phases of the cell cycle. While ATM is also recruited to sites of DSBs, ATR is
recruited to sites of single stranded DNA breaks.
NHEJ is thought to proceed through three key steps: recognition of the DSBs,
DNA processing to remove non-ligatable ends or other forms of damage at the termini,
and finally ligation of the DNA ends. Recognition of the DSB is carried out by binding of
the Ku heterodimer to the ragged DNA ends followed by recruitment of two molecules of
cs to adjacent sides of the DSB; this serves to protect the broken termini until
additional processing enzymes are recruited. Recent data supports the hypothesis that
DNA-PKcs phosphorylates the processing enzyme, Artemis, as well as itself to prepare the
DNA ends for additional processing. In some cases DNA polymerase may be required to
synthesize new ends prior to the ligation step. The hosphorylation of DNA-PKcs is
believed to induce a conformational change that opens the central DNA binding cavity,
es DNA-PKcs from DNA, and facilitates the ultimate religation of the DNA ends.
It has been known for some time that DNA-PK'/' mice are hypersensitive to the
effects of IR and that some non-selective small molecule inhibitors of cs can
radiosensitize a variety of tumor cell types across a broad set of genetic backgrounds.
While it is expected that tion of DNA-PK will radiosensitize normal cells to some
extent, this has been observed to a lesser degree than with tumor cells likely due to the fact
that tumor cells possess higher basal levels of endogenous replication stress and DNA
damage (oncogene—induced replication stress) and DNA repair mechanisms are less
efficient in tumor cells. Most importantly, an improved therapeutic window with greater
sparing of normal tissue will be imparted from the ation of a DNA-PK inhibitor
with recent advances in precision delivery of focused IR, including image-guide RT
(IGRT) and intensity-modulated RT (IMRT).
tion of DNA-PK activity induces effects in both cycling and non-cycling
cells. This is highly significant since the majority of cells in a solid tumor are not ly
replicating at any given moment, which limits the efficacy of many agents targeting the
cell cycle. Equally intriguing are recent reports that suggest a strong tion between
inhibition of the NHEJ y and the y to kill traditionally radioresistant cancer
stem cells (CSCs). It has been shown in some tumor cells that DSBs in t CSCs
predominantly activate DNA repair through the NHEJ pathway; it is believed that CSCs
are usually in the quiescent phase of the cell cycle. This may explain why half of cancer
patients may experience local or distant tumor e despite treatment as current
strategies are not able to effectively target CSCs. A DNA-PK inhibitor may have the
ability to sensitize these potential metastatic progenitor cells to the effects of IR and select
DSB-inducing chemotherapeutic agents.
Given the involvement of DNA-PK in DNA repair processes, an application of
ic DNA-PK tory drugs would be to act as agents that will enhance the efficacy
of both cancer chemotherapy and radiotherapy. Accordingly, it would be desirable to
develop compounds useful as inhibitors of .
SUMMARY OF THE ION
It has been found that compounds of this ion, and pharmaceutically
acceptable compositions thereof, are effective as inhibitors of DNA-PK. Accordingly, the
invention features compounds having the general formula:
(I),
or a pharmaceutically acceptable salt thereof, where each of R1, R2, X, Ring A, Ring B and
Ring C is as d elsewhere herein.
[0007A] In a particular aspect, the present invention provides a compound having
the formula:
(I),
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is
[FOLLOWED BY PAGE 3a]
, , , , or ;
Ring B is
, , , , , , , , , , or ,
n Ring B is optionally tuted with up to 4 fluorine atoms, up to two OH, or
up to two C1-4alkyl which is optionally tuted with up to 3 fluorine atoms, up to
two OH, or up to two OC1-2alkyl groups;
Ring C is a cyclohexane or a cyclobutane ring;
X is –NH-, -O-, or -OC1-4 alkyl-;
each of R1 and R2 is, independently, hydrogen, -C(O)NHR4, -C(O)OR4, -NHC(O)R4,
-NHC(O)OR4, -NHC(O)NHR4, -NHS(O)2R4, -C0-4 alkyl-NHR4, or -OR4, wherein R1
and R2 cannot simultaneously be hydrogen, and wherein R1 and R2 and the intervening
carbon atom can form a dioxane or dioxolane ring;
R3 is hydrogen, -C1-4alkyl, fluoro, chloro, -OC1-2alkyl, -C(O)H, H, -C(O)OC1-
3 alkyl is
2alkyl, -CN, -C(O)NHC1-2alkyl, or -C(O)NH2, wherein each of said R
optionally substituted with up to 3 fluorine atoms, up to two OH, or up to two -OC1-
2alkyl ;
R4 is hydrogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-5cycloalkyl, phenyl, a 5
membered clic or ic heteroaryl ring selected from pyrrole, imidazole,
pyrazole, triazole, thiazole, isothiazole, oxazole, pyridine, dine, pyrimidinone,
pyrazine, pyridazine, and quinoline, or a 4membered monocyclic or bicyclic
heterocyclyl ring selected from oxetane, tetrahydrofuran, tetrahydropyran,
dihydroisoxazole, pyrimidine-2,4(1H,3H)-dione, dihydrofuropyrimidine,
dihydropyranopyrimidine, dihydropyrrolopyrimidine, tetrahydropteridine, and
tetrahydropyridopyrimidine, wherein each of said R4 groups is optionally substituted
[FOLLOWED BY PAGE 3b]
with up to four Br, Cl, F, or C1-4alkyl, up to three CN, NO2, C2-4alkenyl, C2-4alkynyl,
C3-6cycloalkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4
C3-5 cycloalkyl, C(O)OC1-4 alkyl, C(O)OC0-4 C3-5 cycloalkyl, C0-4 alkyl-
C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, C(O)NH(C0-4 alkyl-C3-5 cycloalkyl),
CH 5, C 5, C 5) 5, C
2OR 0-4 alkyl-C(O)R 0-4 alkyl-C(O)N(R 2, C0-4 alkyl-C(O)OR 0-4 alkyl-
NHC(O)R 5, C 5)
0-4 alkyl-N(R 2, a heterocyclic ring system selected from oxetane,
azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine,
pyrrolidine, and piperazine, a heteroaryl ring system selected from furan, oxazole,
oxadiazole, pyrrole, pyrazole, triazole, zole, and tetrazole, or up to two OR5,
wherein each of said optional R4 substituents is optionally substituted with up to four
fluorine atoms, up to two C1-4alkyl groups, up to two OH groups, up to two OC1-4alkyl
groups, up to two SC1-4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a
C(O)OC 0-4 alkyl-C3-5 cycloalkyl; and
each R5 is, independently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from
ole, le, thiazole, pyridine, and pyrimidine, or a 4membered heterocyclyl
selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is
optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH,
CN, up to two OH, up to two OC1-2alkyl, a xetane, pyrrolidine, or triazole, or two R5
groups er with the intervening nitrogen atom form a morpholine ring, azetidine ring,
pyrrolidine ring, piperidine ring, or piperazine 0007B]In a further particular aspect,
the present ion provides a compound, or a ceutically acceptable salt thereof,
selected from the list of compounds in Table 1 herein.
[0007C] In a still further particular aspect, the present invention provides a a
compound, or a pharmaceutically acceptable salt thereof, selected from the list of
compounds in Table 2 herein.
[FOLLOWED BY PAGE 3c]
[0007D] In another ular aspect, the present invention provides a compound of
the formula:
O N
O N
N N
O N
O N
H CH3 , N CH3 O , ,
, ,
, ,
[FOLLOWED BY PAGE 3d]
or , or a pharmaceutically acceptable salt thereof.
[0007E] In a still further particular aspect, the present invention provides a
compound of the a:
, or a ceutically acceptable salt thereof.
The invention also provides pharmaceutical compositions that include a
compound of formula I and a pharmaceutically acceptable r, adjuvant, or vehicle.
These compounds and pharmaceutical compositions are useful for treating or lessening the
severity of .
The compounds and compositions provided by this invention are also useful
for the study of DNA-PK in biological and pathological phenomena; the study of
intracellular signal transduction pathways mediated by such s; and the comparative
evaluation of new kinase inhibitors.
[FOLLOWED BY PAGE 4]
DETAILED DESCRIPTION OF THE INVENTION
Definitions and General Terminology
As used , the following definitions shall apply unless otherwise
indicated. For purposes of this invention, the chemical elements are identified in
accordance with the Periodic Table of the Elements, CAS version, and the Handbook of
Chemistry and Physics, 75th Ed. 1994. Additionally, general ples of organic
chemistry are bed in “Organic Chemistry,” Thomas Sorrell, University Science
Books, Sausalito: 1999, and “March’s ed Organic Chemistry,” 5th Ed., Smith,
MB. and March, J., eds. John Wiley & Sons, New York: 2001, the entire contents of
which are hereby incorporated by reference.
As bed herein, compounds of the invention may optionally be substituted
with one or more substituents, such as are illustrated generally above, or as exemplified by
particular classes, subclasses, and species of the invention. It will be appreciated that the
phrase “optionally tuted” is used interchangeably with the phrase “substituted or
unsubstituted.” In l, the term “substituted,” whether ed by the term
“optionally” or not, refers to the replacement of one or more hydrogen radicals in a given
structure with the radical of a specified substituent. Unless otherwise indicated, an
optionally tuted group may have a tuent at each substitutable position of the
group. When more than one position in a given structure can be substituted with more
than one substituent selected from a specified group, the substituent may be either the
same or different at each on.
As described herein, when the term “optionally substituted” precedes a list,
said term refers to all of the subsequent substitutable groups in that list. For example, if X
is halogen; optionally substituted C1_3 alkyl or phenyl; X may be either optionally
substituted alkyl or ally substituted phenyl. Likewise, if the term “optionally
substituted” follows a list, said term also refers to all of the substitutable groups in the
prior list unless ise indicated. For example: ifX is halogen, C1_3 alkyl, or phenyl,
wherein X is optionally substituted by JX, then both C1_3 alkyl and phenyl may be
optionally substituted by IX. As is apparent to one having ordinary skill in the art, groups
such as H, halogen, N02, CN, NHz, OH, or OCF3 would not be included because they are
not substitutable groups. As is also apparent to a skilled person, a heteroaryl or
heterocyclic ring ning an NH group can be optionally substituted by replacing the
hydrogen atom with the substituent. If a substituent radical or structure is not identified or
d as “optionally substituted,” the substituent radical or structure is unsubstituted.
Combinations of substituents envisioned by this invention are preferably those
that result in the formation of stable or chemically feasible nds. The term “stable,”
as used herein, refers to compounds that are not substantially altered when ted to
conditions to allow for their production, detection, and, preferably, their recovery,
purification, and use for one or more of the purposes disclosed herein. In some
embodiments, a stable compound or chemically feasible compound is one that is not
substantially altered when kept at a temperature of 40°C or less, in the e of moisture
or other chemically reactive ions, for at least a week.
The term “alkyl” or “alkyl group,” as used herein, means a straight-chain (i.e.,
unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is
tely saturated. Unless otherwise specified, alkyl groups contain 1—8 carbon atoms.
In some embodiments, alkyl groups contain 1-6 carbon atoms, and in yet other
embodiments, alkyl groups contain 1-4 carbon atoms (represented as “C1_4 alkyl”). In
other embodiments, alkyl groups are characterized as “C0_4 alkyl” representing either a
nt bond or a C1_4 alkyl chain. es of alkyl groups include methyl, ethyl,
propyl, butyl, isopropyl, isobutyl, sec—butyl, and tert—butyl. The term “alkylene,” as used
, represents a saturated nt straight or branched chain hydrocarbon group and is
exemplified by methylene, ethylene, isopropylene and the like. The term “alkylidene,” as
used , represents a divalent straight chain alkyl linking group. The term “alkenyl,”
as used , represents monovalent straight or branched chain arbon group
containing one or more carbon—carbon double bonds. The term “alkynyl,” as used ,
represents a monovalent straight or branched chain hydrocarbon group containing one or
more carbon—carbon triple bonds.
The term “cycloalkyl” (or “carbocycle”) refers to a monocyclic C3—C8
hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated and has a single
point of attachment to the rest of the molecule, and wherein any individual ring in said
bicyclic ring system has 3—7 members. Suitable cycloalkyl groups include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
The term “heterocycle,” “heterocyclyl,” “heterocycloalkyl,” or “heterocyclic”
as used herein refers to a monocyclic, bicyclic, or tricyclic ring system in which at least
one ring in the system contains one or more heteroatoms, which is the same or different,
and that is completely saturated or that contains one or more units of unsaturation, but
which is not aromatic, and that has a single point of attachment to the rest of the molecule.
In some embodiments, the “heterocycle,” “heterocyclyl,” “heterocycloalkyl,” or
“heterocyclic” group has three to fourteen ring members in which one or more ring
members is a heteroatom independently selected from , sulfur, nitrogen, or
phosphorus, and each ring in the system contains 3 to 8 ring s.
Examples of heterocyclic rings include, but are not limited to, the following
monocycles: 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl,
3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, morpholino, 3-
thiomorpholino, 4-thiomorpholino, l-pyrrolidinyl, 2-pyrrolidinyl, olidinyl,
l-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, ahydropiperazinyl, ridinyl, 2-
piperidinyl, 3-piperidinyl, l-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, lpiperidinyl
, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl,
4-thiazolidinyl, l-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl;
and the ing bicycles: 3-lH-benzimidazolone, 3-(l-alkyl)-benzimidazol-2—one,
indolinyl, ydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and
1,3 -dihydro-imidazolone.
The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, or
phosphorus, ing any oxidized form of nitrogen, sulfur, or phosphorus; the
quatemized form of any basic nitrogen; or a tutable nitrogen of a heterocyclic ring,
for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-
substituted pyrrolidinyl).
The term “unsaturated,” as used , means that a moiety has one or more
units of unsaturation.
The term “alkoxy,” or “thioalkyl,” as used herein, refers to an alkyl group, as
preViously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or
sulfur alkyl”) atom.
The terms “haloalkyl,” “haloalkenyl,” and “haloalkoxy” mean alkyl, alkenyl, or
alkoxy, as the case may be, substituted with one or more halogen atoms. The term
“halogen” means F, Cl, Br, or I.
The term “aryl” used alone or as part of a larger moiety as in “aralkyl,”
“aralkoxy,” or “aryloxyalkyl,” refers to a monocyclic, bicyclic, or tricyclic yclic
ring system having a total of six to fourteen ring members, n said ring system has a
single point of attachment to the rest of the molecule, at least one ring in the system is
aromatic and wherein each ring in the system contains 4 to 7 ring members. The term
“aryl” may be used interchangeably with the term “aryl ring.” Examples of aryl rings
include phenyl, naphthyl, and anthracene.
The term “heteroaryl,” used alone or as part of a larger moiety as in
“heteroaralkyl,” or “heteroarylalkoxy,” refers to a monocyclic, bicyclic, and tricyclic ring
system haVing a total of five to fourteen ring members, n said ring system has a
single point of attachment to the rest of the molecule, at least one ring in the system is
aromatic, at least one ring in the system contains one or more heteroatoms independently
selected from nitrogen, oxygen, sulfur or orus, and wherein each ring in the system
contains 4 to 7 ring members. The term “heteroaryl” may be used interchangeably with
the term “heteroaryl ring” or the term “heteroaromatic.”
Further examples of heteroaryl rings include the ing monocycles:
2-furanyl, 3-furanyl, N—imidazolyl, azolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl,
4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-
pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl,
pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e. g., 5-
tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g.,
2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl,
1,2,3-triazolyl, thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, pyrazinyl, 1,3,5-
nyl, and the following es: benzimidazolyl, benzofuryl, benzothiophenyl,
l (e.g., 2-indolyl), purinyl, inyl (e. g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl),
and isoquinolinyl (e.g., l-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl)..
As bed herein, a bond drawn from a substituent to the center of one ring
within a multiple-ring system (as shown below) represents substitution of the substituent
at any substitutable position in any of the rings within the multiple ring system. For
example, Structure a represents possible substitution in any of the positions shown in
Structure b.
WO 59690
X X
| .
/ ) I
N X N X
H |
X X
Structure a Structure b
This also applies to multiple ring systems fused to optional ring systems (which
would be represented by dotted lines). For example, in Structure c, X is an optional
tuent both for ring A and ring B.
ure c
If, however, two rings in a multiple ring system each have different
substituents drawn from the center of each ring, then, unless otherwise specified, each
substituent only represents substitution on the ring to which it is attached. For example, in
Structure d, Y is an ally tuent for ring A only, and X is an al substituent
for ring B only.
\Zr'_‘\‘
| A B _,_x
/, ,
Structure d
The term “protecting group,” as used herein, represent those groups intended to
protect a functional group, such as, for example, an alcohol, amine, carboxyl, carbonyl,
etc., against undesirable reactions during synthetic procedures. Commonly used
protecting groups are disclosed in Greene and Wuts, Protective Groups In Organic
Synthesis, 3rd Edition (John Wiley & Sons, New York, 1999), which is incorporated herein
by reference. Examples of nitrogen protecting groups include acyl, aroyl, or carbamyl
groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-
bromoacetyl, roacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, oc-
chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, obenzoyl and chiral
auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine,
leucine, phenylalanine and the like; sulfonyl groups such as benzenesulfonyl, p—
toluenesulfonyl and the like; carbamate groups such as benzyloxycarbonyl, pchlorobenzyloxycarbonyl
, oxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-
nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl,
3,5—dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-
methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-
trimethoxybenzyloxycarbonyl, l-(p-biphenylyl)— l -methylethoxycarbonyl, dimethyl-
3,5—dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl,
ropylmethoxycarbonyl, isopropyloxycarbonyl, carbonyl, methoxycarbonyl,
allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy
carbonyl, fluorenylmethoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl,
cyclohexyloxycarbonyl, phenylthiocarbonyl and the like, arylalkyl groups such as benzyl,
triphenylmethyl, benzyloxymethyl and the like and silyl groups such as trimethylsilyl and
the like. Preferred N—protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl,
alanyl, phenylsulfonyl, benzyl, loxycarbonyl (Boc) and oxycarbonyl (Cbz).
Examples of hydroxyl protecting groups include ethers, such as tetrahydropyranyl, tert
butyl, benzyl, allyl, and the like; silyl ethers such as trimethyl silyl, triethyl silyl,
triisopropylsilyl, tert-butyl diphenyl silyl, and the like; esters such as acetyl,
trifluoroacetyl, and the like; and carbonates. Hydroxyl protecting groups also include
those appropriate for the protection of phenols.
Unless otherwise depicted or , structures recited herein are meant to
include all isomeric (e. g., enantiomeric, diastereomeric, and geometric (or
conformational)) forms of the ure; for e, the R and S configurations for each
asymmetric , (Z) and (E) double bond isomers, and (Z) and (E) conformational
isomers. Therefore, single stereochemical isomers as well as enantiomeric,
diastereomeric, and geometric (or conformational) mixtures of the present compounds are
within the scope of the invention. Compounds that have been drawn with stereochemical
centers def1ned, usually through the use of a hatched (will) or bolded (—-) bond, are
stereochemically pure, but with the absolute stereochemistry still undefined. Such
compounds can have either the R or S uration. In those cases where the absolute
configuration has been determined, the chiral (s) are labeled (R) or (53 in the
drawing.
Unless otherwise stated, all tautomeric forms of the compounds of the
invention are within the scope of the invention. Additionally, unless otherwise stated,
ures depicted herein are also meant to include compounds that differ only in the
presence of one or more isotopically enriched atoms. For example, nds having the
present structures except for the replacement of hydrogen by deuterium or tritium, or the
replacement of a carbon by a 13C— or 14C—enriched carbon are within the scope of this
invention. Such compounds are useful, for example, as analytical tools, probes in
ical assays, or as DNA-PK inhibitors with an improved therapeutic profile.
Description ofCompounds 0fthe Invention
In one aspect, the invention features compounds having the formula:
X N
R1@ 0
9 (I), n
Ring A is a ring system selected from
R3 R3 R3 R3
”Ql QSNQ‘lQN SQNA/ / ‘/
Ring B is a ring system selected from
[Jooooooooh)
wherein Ring B is optionally substituted with up to 4 fluorine atoms, up to two OH or
up to two C1_4alkyl which is optionally substituted with up to 3 fluorine atoms, up to
two OH, or up to two OC1_2alkyl groups;
Ring C is a cyclohexane or a cyclobutane ring;
X is —NH-, -O-, or -OC1_4 alkyl-;
each of R1 and R2 is, independently, hydrogen, —C(O)NHR4, —C(O)OR4, —NHC(O)R4,
—NHC(O)OR4, )NHR4, —NHS(O)2R4, —co_4 alkyl—NHR4, or —OR4, n R1
and R2 cannot simultaneously be en, and wherein R1 and R2 and the intervening
carbon atom can form a dioxane or dioxolane ring;
R3 is hydrogen, -C1_4alkyl, fluoro, chloro, —OC1_2alkyl, —C(O)H, —C(O)OH, —C(O)OC1_
zalkyl, —CN, —C(O)NHC1_2alkyl, or -C(O)NH2, wherein each of said R3 alkyl is
optionally substituted with up to 3 fluorine atoms, up to two OH, or up to two 0C1-
zalkyl groups;
R4 is hydrogen, C1_4alkyl, C2_4alkenyl, C2_4alkynyl, C3_5cycloalkyl, phenyl, a 5
membered monocyclic or ic heteroaryl ring selected from pyrrole, imidazole,
pyrazole, triazole, thiazole, isothiazole, oxazole, pyridine, pyrimidine, pyrimidinone,
pyrazine, pyridazine, or quinoline, or a 4—lO—membered monocyclic or bicyclic
heterocyclyl ring selected from oxetane, tetrahydrofuran, tetrahydropyran,
dihydroisoxazole, pyrimidine-2,4(lH,3H)—dione, dihydrofuropyrimidine,
opyranopyrimidine, opyrrolopyrimidine, tetrahydropteridine, or
tetrahydropyridopyrimidine, wherein each of said R4 groups is optionally substituted
with up to four Br, Cl, F, or C1_4alkyl, up to three CN, NOZ, C2_4alkenyl, C2_4alkynyl,
C3_6cycloalkyl, C0_4 alkyl-C3_5 cycloalkyl, C0_4 alkyl-O-C1_4 alkyl, C0_4 O-C0_4
C3_5 lkyl, C(O)OC1_4 alkyl, C(O)OC0_4 alkyl-C3_5 cycloalkyl, C0_4 alkyl-
C(O)NH2, C(O)NHC1_4 alkyl, C(O)N(C1_4 alkyl)2, C(O)NH(C0_4 alkyl—C3_5 cycloalkyl),
CHZORS, 00.4 alkyl—C(O)R5, 00.4 alkyl—C(O)N(R5)2, 00.4 alkyl—C(O)OR5, 00.4 alkyl-
NHC(O)R5, C0_4 alkyl-N(R5)2, a heterocyclic ring system selected from oxetane,
ine, ydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine,
idine or zine, a heteroaryl ring system selected from furan, oxazole,
oxadiazole, pyrrole, pyrazole, le, oxadiazole or tetrazole, or up to two 0R5,
wherein each of said optional R4 substituents is optionally substituted with up to four
fluorine atoms, up to two C1_4alkyl groups, up to two OH groups, up to two OC1_4alkyl
groups, up to two SC1_4alkyl groups, a C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or a
C(O)OC0_4 alkyl—C3_5 cycloalkyl, and
each R5 is, independently, hydrogen, C1_4alkyl, a 5—6—membered heteroaryl selected from
imidazole, le, thiazole, pyridine, or pyrimidine, a 4membered heterocyclyl
selected from oxetane, tetrahydrofuran, or tetrahydropyran, and each R5 group is
optionally substituted with chloro, up to three fluorine atoms, up to two kyl, CHzOH,
CN, up to two OH, up to two OC1_2alkyl, a xetane, pyrrolidine, or triazole, or two R5
groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring,
pyrrolidine ring, piperidine ring, or piperazine ring.
In one embodiment, Ring C is utane.
In another aspect, the invention features nds having the formula:
X N
9 (11), wherein R1 and R2 are as defined for
compounds of formula I.
In another aspect, the invention features compounds having the formula:
,x N
R23...
0 , wherein R2 is as defined for compounds
of formula 1.
In another aspect, the invention es compounds having the formula:
NA/j
X II / N
a (II-A-l), wherein R2 is as defined for
compounds of formula I.
In another aspect, the invention features compounds having the formula:
WO 59690
,X N
a (II-B), wherein R1 is as defined for compounds
of formula 1.
In another aspect, the invention features compounds having the formula:
IX N
a (II-B-l), wherein R1 is as defined for
nds of formula I.
In one embodiment, R1 is -C0_4 alkyl-NHR4.
In another ment, X is —O- or —OC1_4 alkyl—.
In one embodiment, Ring C is cyclohexane.
In another aspect, the invention es compounds having the formula:
a (111), wherein R1 is as defined for compounds of
formula I.
In one embodiment, X is —NH—.
In another aspect, the invention features compounds having the formula:
H A
N N
R2“NO,
6 ), wherein R2 is as defined for compounds of
formula I.
In another aspect, the invention features compounds having the formula:
H \
I /N
U oN /N O;
e (III-A-1)0r (III-A-Z),
wherein R2 is as defined for compounds of formula I.
In one embodiment, R2 is —co_4 alkyl—NHR4 or —OR4.
In another embodiment, R2 is -NHR4 or -OR4.
In another aspect, the invention features nds having the formula:
H A
U” DN
6 ), wherein R1 is as defined for compounds of
formula 1.
In another aspect, the invention features compounds having the formula:
N \/\7 N/O
H H ‘
I / N
R10N UN UN /
(III-B-l) or (III-B-
2), wherein R1 is as defined for compounds of formula I.
2014/024767
In one embodiment, R1 is -C0_4 alkyl—NHR4 or -OR4.
In r embodiment, R1 is -NHR4 or -OR4.
In another embodiment, X is —O-.
In another aspect, the invention features compounds having the formula:
0’0 N
(III-C), wherein R2 is as defined for compounds of formula I.
In another , the invention features compounds having the formula:
MIA/j N’0
0’0 ON 00 oN /
R2‘\ sz“
e (III-C-l) or e (III-C-Z), wherein
R2 is as defined for compounds of formula I.
In another aspect, the invention features compounds having the formula:
U" o“
\:e (III-D), wherein R1 is as defined for nds of formula I.
In another aspect, the invention features compounds having the formula:
N ‘/x N/O
I I
9 (III-D-l) or e (III-D-Z), wherein
R1 is as defined for compounds of formula I.
In one embodiment, R1 is -C0_4 alkyl—NHR4 or -OR4.
In another embodiment, R1 is -NHR4 or -OR4.
In another aspect, the invention features compounds having the a:
R4,Ycor:
(III-D-3), wherein Y is —O— or —NH—.
In one embodiment of nds having formula I, II, II-A, II-A-l, II-B, II-
B-1,III, III-A, l, III-A-Z, III-B, III-B-l, III-B-Z, III-C, III-C-l, III-C-Z, III-D,
l, III-D-Z, or III-D-3,
lsUEJEflOQ
In another embodiment,
In another embodiment, R3 is hydrogen.
In another embodiment, R4 is hydrogen, C1_4alkyl, C2_4alkenyl, C2_4alkynyl, C3.
5cycloalkyl, phenyl, wherein each of said R4 groups is optionally substituted with up to
four Br, Cl, F, or C1_4alkyl, up to three CN, N02, C2_4alkenyl, kynyl, C3_6cycloalkyl,
C0_4 C3_5 cycloalkyl, C0_4 alkyl-O-C1_4 alkyl, C0_4 O-C0_4 alkyl-C3_5 cycloalkyl,
C(O)OC1.4 alkyl, C(O)OC0.4 alkyl—C3.5 cycloalkyl, C0_4 alkyl—C(O)NH2, C(O)NHC1_4 alkyl,
C(O)N(C1_4 alkyl)2, C(O)NH(C0_4 alkyl—C3_5 cycloalkyl), CHZORS, 00.4 alkyl—C(O)R5, 00-4
alkyl—C(O)N(R5)2, 00.4 alkyl—C(O)OR5, 00.4 alkyl—NHC(O)R5, 00.4 alkyl—N(R5)2, a
heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, opyran,
tetrahydropyran, morpholine, piperidine, pyrrolidine or piperazine, a heteroaryl ring
system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole or
tetrazole, or up to two 0R5, wherein each of said al R4 substituents is optionally
substituted with up to four fluorine atoms, up to two C1_4alkyl groups, up to two OH
groups, up to two OC1_4alkyl groups, up to two SC1_4alkyl groups, a C(O)C1_4 alkyl, a
C(O)OC1_4 alkyl, or a C(O)OC0_4 alkyl-C3_5 cycloalkyl, and
each R5 is, ndently, hydrogen, C1_4alkyl, a 5—6—membered heteroaryl selected from
imidazole, triazole, thiazole, ne, or pyrimidine, a 4membered heterocyclyl
selected from oxetane, tetrahydrofuran, or tetrahydropyran, and each R5 group is
optionally substituted with chloro, up to three fluorine atoms, up to two C1_2alkyl, CHZOH,
CN, up to two OH, up to two OC1_2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5
groups together with the intervening nitrogen atom form a morpholine ring, ine ring,
pyrrolidine ring, piperidine ring, or piperazine ring.
In another embodiment, R4 is a 5—lO—membered monocyclic or bicyclic
heteroaryl ring selected from pyrrole, ole, pyrazole, triazole, thiazole, azole,
oxazole, pyridine, pyrimidine, pyrimidinone, pyrazine, pyridazine, or quinoline, wherein
each of said R4 groups is ally substituted with up to four Br, Cl, F, or C1_4alkyl, up
to three CN, N02, C2_4alkenyl, C2_4alkynyl, C3_6cycloalkyl, C0_4 alkyl-C3_5 cycloalkyl, C0_4
alkyl—O—C1_4 alkyl, C0_4 alkyl—O—C0_4 alkyl—C3_5 cycloalkyl, C(O)OC1_4 alkyl, 0_4
alkyl-C3_5 cycloalkyl, C0_4 alkyl-C(O)NH2, C(O)NHC1_4 alkyl, C(O)N(C1_4 alkyl)2,
C(O)NH(C0_4 alkyl—C3_5 cycloalkyl), CHZORS, 00.4 C(O)R5, 00.4 alkyl—C(O)N(R5)2,
Co_4 alkyl-C(O)OR5, Co_4 alkyl-NHC(O)R5, Co_4 alkyl-N(R5)2, a heterocyclic ring system
selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran,
morpholine, piperidine, pyrrolidine or piperazine, a heteroaryl ring system selected from
furan, e, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole or ole, or up to two
0R5, wherein each of said optional R4 substituents is optionally substituted with up to four
fluorine atoms, up to two C1_4alkyl groups, up to two OH groups, up to two OC1_4alkyl
groups, up to two SC1_4alkyl groups, a C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or a C(O)OC0_4
alkyl-C3_5 cycloalkyl, and
each R5 is, independently, hydrogen, C1_4alkyl, a mbered aryl selected from
imidazole, triazole, thiazole, pyridine, or pyrimidine, a 4membered heterocyclyl
selected from oxetane, tetrahydrofuran, or tetrahydropyran, and each R5 group is
optionally substituted with , up to three fluorine atoms, up to two kyl, CHZOH,
CN, up to two OH, up to two OC1_2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5
groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring,
pyrrolidine ring, piperidine ring, or piperazine ring.
WO 59690
In yet another embodiment, R4 is pyridine or pyrimidine, which is optionally
substituted with up to four Br, Cl, F, or C1_4alkyl, up to three CN, N02, C2_4alkenyl, C2.
4alkynyl, C3_6cycloalkyl, C0_4 alkyl-C3_5 cycloalkyl, C0_4 alkyl-O-C1_4 alkyl, C0_4 alkyl-O-C0_
4 alkyl-C3_5 cycloalkyl, C(O)OC1_4 alkyl, C(O)OC0_4 alkyl-C3_5 lkyl, C0_4 alkyl-
2, C(O)NHC1_4 alkyl, C(O)N(C1_4 2, C(O)NH(C0_4 alkyl—C3_5 cycloalkyl),
CHZORS, 00.4 alkyl—C(O)R5, 00.4 alkyl—C(O)N(R5)2, 00.4 alkyl—C(O)OR5, 00.4 alkyl-
NHC(O)R5, C0_4 alkyl-N(R5)2, a heterocyclic ring system selected from oxetane, azetidine,
tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine or
piperazine, a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole,
pyrazole, triazole, oxadiazole or ole, or up to two 0R5, wherein each of said optional
R4 substituents is optionally tuted with up to four fluorine atoms, up to two C1_4alkyl
groups, up to two OH groups, up to two OC1_4alkyl groups, up to two SC1_4alkyl groups, a
C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or a C(O)OC0_4 C3_5 cycloalkyl, and
each R5 is, ndently, en, C1_4alkyl, a 5—6—membered heteroaryl selected from
imidazole, triazole, thiazole, pyridine, or pyrimidine, a 4membered heterocyclyl
selected from oxetane, tetrahydrofuran, or tetrahydropyran, and each R5 group is
optionally substituted with chloro, up to three fluorine atoms, up to two C1_2alkyl, CHZOH,
CN, up to two OH, up to two OC1_2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5
groups er with the intervening nitrogen atom form a morpholine ring, azetidine ring,
pyrrolidine ring, piperidine ring, or piperazine ring.
In another embodiment, R4 is a embered monocyclic or bicyclic
heterocyclyl ring selected from oxetane, tetrahydrofuran, tetrahydropyran,
dihydroisoxazole, pyrimidine-2,4(lH,3H)-dione, dihydrofuropyrimidine,
dihydropyranopyrimidine, dihydropyrrolopyrimidine, tetrahydropteridine, or
tetrahydropyridopyrimidine, wherein each of said R4 groups is optionally substituted with
up to four Br, Cl, F, or C1_4alkyl, up to three CN, N02, C2_4alkenyl, kynyl, C3.
6cycloalkyl, C0_4 alkyl-C3_5 cycloalkyl, C0_4 O-C1_4 alkyl, C0_4 alkyl-O-Co_4 C3_5
cycloalkyl, C(O)OC1_4 alkyl, C(O)OC0_4 alkyl-C3_5 cycloalkyl, C0_4 alkyl-C(O)NH2,
C(O)NHC1_4 alkyl, C(O)N(C1_4 alkyl)2, C(O)NH(C0_4 alkyl—C3_5 lkyl), CHZORS, C0_4
alkyl—C(O)R5, 00.4 alkyl—C(O)N(R5)2, 00.4 alkyl—C(O)OR5, 00.4 alkyl—NHC(O)R5, 00.4
alkyl-N(R5)2, a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran,
dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine or piperazine, a
aryl ring system selected from furan, oxazole, oxadiazole, pyrrole, le,
triazole, oxadiazole or tetrazole, or up to two 0R5, wherein each of said optional R4
substituents is optionally substituted with up to four fluorine atoms, up to two C1_4alkyl
groups, up to two OH groups, up to two OC1_4alkyl groups, up to two SC1_4alkyl groups, a
_4 alkyl, a C(O)OC1_4 alkyl, or a C(O)OC0_4 alkyl-C3_5 cycloalkyl, and
each R5 is, independently, hydrogen, C1_4alkyl, a 5—6—membered heteroaryl selected from
imidazole, triazole, thiazole, pyridine, or pyrimidine, a 4membered heterocyclyl
selected from oxetane, tetrahydrofuran, or tetrahydropyran, and each R5 group is
optionally substituted with chloro, up to three fluorine atoms, up to two C1_2alkyl, CHZOH,
CN, up to two OH, up to two OC1_2alkyl, a spirooxetane, pyrrolidine, or le, or two R5
groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring,
pyrrolidine ring, piperidine ring, or piperazine ring.
In another aspect, the invention features nds haVing the formula:
N/§/\‘|I
Uo / N
H'?‘
R“ [”1
0 (IV), wherein
R3 is hydrogen, C1_4alkyl, fluoro, chloro, -OC1_2alkyl, or -C(O)NH2, _
C(O)H, or -CN, wherein each of said R3 alkyl is ally substituted with OH or up to 3
e atoms;
R4 is
NAX‘I
R4aJ|\ x2’J\ R4b
X1 is N, CH, CF, CCl, or CC1_2 alkyl optionally substituted with up to 3
fluorine atoms;
X2 is N or CR“; wherein X1 and X2 cannot simultaneously be N,
each of R4a and R4c is, independently, hydrogen, F, Cl, Br, CN, N02,
, R“,
C1_4 alkyl, C0_4 alkyl-C3-5 cycloalkyl, C0_4 alkyl-O-C1_4 alkyl, Co_4 alkyl-O-C0_4 C3_5
cycloalkyl, C2_4 alkenyl, C2_4 alkynyl, 1_4 alkyl, C(O)OC0_4 alkyl-C35 cycloalkyl,
C(O)NH2, C(O)NHC1_4 alkyl, C(O)N(C1_4 alkyl)2, (C0_4 alkyl—C35 cycloalkyl), a
heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran,
tetrahydropyran, morpholine, piperidine, or piperazine, or a heteroaryl ring system
selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, or tetrazole, or R“,
R4a, and the intervening atoms form a dihydrofuran, a dihydropyran, or a
tetrahydropiperidine heterocyclic ring system;
wherein each of said R4a, R“, or R40 cyclic or heteroaryl ring systems
is optionally substituted with up to four fluorine atoms, up to two C1_4 alkyl, up to two OH
groups, a C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or a C(O)OC0_4 alkyl—C3-5 cycloalkyl; and
wherein each of said R4a or R4c alkyl or cycloalkyl is optionally
, R“,
substituted with up to 2 non-geminal OH groups or up to 3 fluorine atoms.
In one embodiment, R3 is hydrogen.
In another embodiment, each of X1 and X2 is, ndently, CH or N.
In another embodiment, each of R4a and R4b is, independently, a cyclic
ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran,
tetrahydropyran, line, dine, or piperazine, n each of said R4a or R4b
heterocyclic or heteroaryl ring systems is ally substituted with up to four fluorine
atoms, up to two C1_4 alkyl, up to two OH groups, a C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or
a C(O)OC0_4 alkyl—C3_5 cycloalkyl; and wherein each of said R4a or R4b alkyl or cycloalkyl
is optionally substituted with up to 2 non-geminal OH groups or up to 3 fluorine atoms.
In another embodiment, each of R4a and R4b is, independently, a heteroaryl ring
system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, le, or tetrazole,
wherein each of said R4a or R4b heterocyclic or aryl ring s is optionally
substituted with up to four fluorine atoms, up to two C1_4 alkyl, up to two OH groups, a
C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or a C(O)OC0_4 alkyl-C3_5 cycloalkyl; and n each
of said R4a or R4b alkyl or cycloalkyl is optionally substituted with up to 2 minal
OH groups or up to 3 fluorine atoms.
In another embodiment, each of R4a and R4b is, independently, hydrogen, F, Cl,
Br, CN, NOZ, C1_4 alkyl, C0_4 alkyl-C3_5 cycloalkyl, C0_4 alkyl-O-C1_4 alkyl, C0_4 alkyl-O-C0_4
alkyl-C35 cycloalkyl, C2_4 alkenyl, C2_4 l, C(O)OC1_4 alkyl, C(O)OC0_4 alkyl—C35
cycloalkyl, C(O)NH2, C(O)NHC1_4 alkyl, C(O)N(C1_4 alkyl)2, or C(O)NH(C0_4 alkyl—C3_5
cycloalkyl), wherein each of said R4a or R4b heterocyclic or heteroaryl ring systems is
optionally substituted with up to four fluorine atoms, up to two C1_4 alkyl, up to two OH
groups, a C(O)C1_4 alkyl, a C(O)OC1_4 alkyl, or a 0_4 alkyl—C3_5 cycloalkyl; and
wherein each of said R4a or R4b alkyl or cycloalkyl is optionally substituted with up to 2
non—geminal OH groups or up to 3 fluorine atoms.
In another embodiment, the invention features a compound selected from the
group of compounds listed in Table l.
In another embodiment, the invention features a compound selected from the
group of compounds listed in Table 2.
Compositions, Formulations, and Administration ofCompounds ofthe Invention
In another embodiment, the invention es a pharmaceutical ition
comprising a compound of any of the formulae described herein and a pharmaceutically
acceptable excipient. In a further ment, the invention provides a pharmaceutical
composition sing a compound of Table 1. In a further ment, the
composition onally comprises an additional therapeutic agent.
According to another embodiment, the invention provides a composition
comprising a compound of this invention or a pharmaceutically acceptable derivative
thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In one
embodiment, the amount of nd in a composition of this invention is such that is
effective to measurably inhibit a DNA-PK in a biological sample or in a patient. In
another embodiment, the amount of compound in the compositions of this ion is
such that is effective to measurably inhibit DNA-PK. In one embodiment, the
ition of this invention is formulated for administration to a patient in need of such
composition. In a further embodiment, the composition of this invention is formulated for
oral administration to a patient.
The term “patient,” as used herein, means an animal, preferably a mammal, and
most preferably a human.
It will also be appreciated that certain of the compounds of present invention
can exist in free form for treatment, or where appropriate, as a pharmaceutically
acceptable derivative thereof. According to the present invention, a ceutically
acceptable derivative includes, but is not limited to, pharmaceutically able gs,
salts, esters, salts of such esters, or any other adduct or derivative which upon
2014/024767
administration to a patient in need is capable of providing, directly or indirectly, a
compound as otherwise described herein, or a metabolite or residue thereof. As used
herein, the term “inhibitory active metabolite or residue thereof ’ means that a metabolite
or residue thereof is also an inhibitor of DNA-PK.
As used herein, the term aceutically acceptable salt” refers to those salts
which are, within the scope of sound medical judgment, suitable for use in contact with the
tissues of humans and lower s without undue ty, irritation, allergic response
and the like.
Pharmaceutically acceptable salts are well known in the art. For example, S.
M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical
es, 66: 1—19, 1977, which is incorporated herein by reference. Pharmaceutically
acceptable salts of the compounds of this invention include those derived from suitable
inorganic and organic acids and bases. Examples of pharmaceutically able,
nontoxic acid addition salts are salts of an amino group formed with inorganic acids such
as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid,
succinic acid or malonic acid or by using other methods used in the art such as ion
exchange. Other pharmaceutically acceptable salts include adipate, te, ascorbate,
aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate,
camphorsulfonate, citrate, entanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, formate, te, glucoheptonate, ophosphate, gluconate,
hemisulfate, heptanoate, ate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,
lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-
naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
persulfate, 3-phenylpropionate, ate, picrate, pivalate, propionate, stearate,
succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and
the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal,
ammonium and 4 alkyl)4 salts. This invention also envisions the quatemization of
any basic nitrogen—containing groups of the compounds disclosed herein. Water or oil—
soluble or dispersable products may be obtained by such quaternization. entative
alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium,
magnesium, and the like. Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using
counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, C1_g
sulfonate and aryl sulfonate.
As described above, the pharmaceutically acceptable compositions of the
present invention onally comprise a pharmaceutically acceptable carrier, adjuvant, or
vehicle, which, as used herein, includes any and all solvents, ts, or other liquid
vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or
emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the
particular dosage form desired. In Remington: The Science and Practice ofPharmacy,
21st edition, 2005, ed. D.B. Troy, cott Williams & Wilkins, Philadelphia, and
Encyclopedia ofPharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988—
1999, Marcel Dekker, New York, the contents of each of which is incorporated by
reference herein, are sed various carriers used in ating pharmaceutically
acceptable itions and known techniques for the preparation thereof Except insofar
as any tional carrier medium is incompatible with the nds of the invention,
such as by producing any undesirable biological effect or otherwise interacting in a
deleterious manner with any other component(s) of the pharmaceutically acceptable
composition, its use is contemplated to be within the scope of this invention.
Some examples of materials which can serve as pharmaceutically acceptable
carriers e, but are not limited to, ion gers, alumina, aluminum stearate,
lecithin, serum proteins, such as human serum albumin, buffer substances such as
phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of
saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate,
disodium hydrogen ate, potassium hydrogen phosphate, sodium de, zinc salts,
colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes,
hylene—polyoxypropylene—block polymers, wool fat, sugars such as lactose, glucose
and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives
such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered
tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils
such as peanut oil, seed oil; er oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol or polyethylene ; esters such as ethyl oleate and
ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum
ide; alginic acid; pyrogen-free water; isotonic saline; 's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants
such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing
agents, g agents, sweetening, flavoring and perfuming agents, preservatives and
antioxidants can also be present in the composition, according to the judgment of the
formulator.
The compositions of the present invention may be stered orally,
parenterally, by inhalation spray, topically, rectally, nasally, ly, vaginally or via an
implanted reservoir. The term “parenteral” as used herein includes subcutaneous,
intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal,
intraocular, intrahepatic, intralesional, epidural, intraspinal, and intracranial injection or
infusion techniques. Preferably, the compositions are administered ,
intraperitoneally or intravenously. Sterile injectable forms of the compositions of this
invention may be s or nous suspension. These suspensions may be
formulated according to techniques known in the art using suitable dispersing or wetting
agents and suspending agents. The sterile injectable preparation may also be a sterile
inj ectable on or suspension in a non-toxic parenterally acceptable diluent or solvent,
for example as a solution in 1,3—butanediol. Among the acceptable es and solvents
that may be employed are water, 's solution and isotonic sodium chloride solution.
In on, e, fixed oils are conventionally employed as a solvent or suspending
medium.
For this purpose, any bland fixed oil may be employed ing synthetic
mono— or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are
useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils,
such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil
solutions or suspensions may also contain a long-chain alcohol t or dispersant, such
as carboxymethyl cellulose or similar dispersing agents that are commonly used in the
formulation of pharmaceutically acceptable dosage forms including ons and
suspensions. Other commonly used surfactants, such as Tweens, Spans and other
emulsifying agents or bioavailability enhancers which are commonly used in the
manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also
be used for the purposes of formulation.
WO 59690
The pharmaceutically acceptable compositions of this invention may be orally
administered in any orally acceptable dosage form ing, but not limited to, capsules,
tablets, s sions or solutions. In the case of tablets for oral use, carriers
commonly used include lactose and corn starch. Lubricating agents, such as magnesium
stearate, are also typically added. For oral administration in a capsule form, useful
diluents include lactose and dried cornstarch. When aqueous suspensions are required for
oral use, the active ingredient is combined with emulsifying and suspending agents. If
desired, n ning, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutically acceptable compositions of this invention
may be administered in the form of suppositories for rectal administration. These can be
prepared by mixing the agent with a suitable ritating excipient that is solid at room
temperature but liquid at rectal ature and therefore will melt in the rectum to release
the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
The pharmaceutically acceptable compositions of this invention may also be
administered lly, especially when the target of treatment includes areas or organs
readily accessible by topical application, including diseases of the eye, the skin, or the
lower intestinal tract. Suitable topical formulations are readily prepared for each of these
areas or organs.
l application for the lower intestinal tract can be effected in a rectal
suppository formulation (see above) or in a suitable enema formulation. Topically—
transdermal patches may also be used.
For topical applications, the pharmaceutically acceptable itions may be
formulated in a suitable ointment containing the active component suspended or ved
in one or more carriers. Carriers for topical administration of the compounds of this
invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum,
ene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and
water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a
suitable lotion or cream ning the active components suspended or dissolved in one
or more pharmaceutically acceptable rs. Suitable carriers include, but are not limited
to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,
2—octyldodecanol, benzyl alcohol and water.
For lmic use, the pharmaceutically able compositions may be
formulated, e. g., as micronized sions in isotonic, pH adjusted sterile saline or other
aqueous solution, or, preferably, as solutions in isotonic, pH ed sterile saline or other
aqueous solution, either with or without a preservative such as benzylalkonium chloride.
Alternatively, for ophthalmic uses, the pharmaceutically able itions may be
formulated in an ointment such as petrolatum. The pharmaceutically acceptable
compositions of this invention may also be administered by nasal aerosol or inhalation.
Such compositions are prepared ing to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl
alcohol or other suitable vatives, absorption promoters to enhance bioavailability,
fluorocarbons, and/or other conventional solubilizing or dispersing agents.
Most preferably, the pharmaceutically acceptable compositions of this
invention are formulated for oral administration.
Liquid dosage forms for oral administration include, but are not limited to,
pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups
and s. In addition to the active compounds, the liquid dosage forms may contain
inert diluents commonly used in the art such as, for example, water or other solvents,
solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
ate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3—butylene
glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive,
castor, and sesame oils), glycerol, ydrofurfuryl alcohol, polyethylene glycols and
fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral
compositions can also e adjuvants such as wetting agents, fying and
suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile inj ectable aqueous or oleaginous
sions may be formulated according to the known art using suitable dispersing or
wetting agents and suspending agents. The sterile injectable ation may also be a
sterile inj ectable solution, suspension or emulsion in a nontoxic parenterally acceptable
diluent or solvent, for example, as a solution in l,3-butanediol. Among the acceptable
vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and
isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally
employed as a solvent or suspending medium. For this purpose any bland fixed oil can be
employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic
acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through
a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water or other e inj ectable
medium prior to use.
In order to prolong the effect of a compound of the present invention, it is often
desirable to slow the absorption of the compound from subcutaneous or intramuscular
injection. This may be accomplished by the use of a liquid suspension of crystalline or
amorphous al with poor water solubility. The rate of tion of the compound
then depends upon its rate of dissolution that, in turn, may depend upon crystal size and
crystalline form. atively, dissolving or suspending the nd in an oil vehicle
accomplishes delayed absorption of a parenterally administered nd form.
Inj ectable depot forms are made by forming microencapsule matrices of the nd in
biodegradable polymers such as polylactide—polyglycolide. Depending upon the ratio of
compound to polymer and the nature of the particular polymer ed, the rate of
compound release can be controlled. Examples of other biodegradable polymers include
poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or mulsions that are compatible with
body tissues.
itions for rectal or vaginal administration are preferably suppositories
which can be prepared by mixing the compounds of this invention with le non-
irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository
wax which are solid at ambient ature but liquid at body temperature and therefore
melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration e capsules, tablets, pills,
powders, and granules. In such solid dosage forms, the active compound is mixed with at
least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or
dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose,
glucose, mannitol, and silicic acid, b) binders such as, for example,
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c)
humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate,
potato or tapioca , alginic acid, certain silicates, and sodium ate, e) solution
retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol
monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as
talc, calcium stearate, magnesium stearate, solid hylene s, sodium lauryl
sulfate, and es thereof. In the case of capsules, s and pills, the dosage form
may also comprise ing agents.
Solid compositions of a similar type may also be employed as fillers in soft and
hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high
molecular weight hylene glycols and the like. The solid dosage forms of tablets,
dragees, capsules, pills, and granules can be prepared with coatings and shells such as
enteric coatings and other coatings well known in the pharmaceutical formulating art.
They may optionally contain opacifying agents and can also be of a composition that they
release the active ingredient(s) only, or preferentially, in a certain part of the intestinal
tract, optionally, in a delayed manner. Examples of embedding compositions that can be
used include polymeric substances and waxes. Solid compositions of a r type may
also be employed as fillers in soft and hard-filled n capsules using such excipients as
lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
The active compounds can also be in encapsulated form with one or
more excipients as noted above. The solid dosage forms of tablets, dragees, capsules,
pills, and granules can be prepared with coatings and shells such as enteric coatings,
release controlling coatings and other coatings well known in the pharmaceutical
formulating art. In such solid dosage forms the active compound may be admixed with at
least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also
comprise, as is normal practice, additional substances other than inert diluents, e. g.,
tableting lubricants and other tableting aids such a magnesium stearate and
microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may
also comprise buffering agents. They may optionally contain opacifying agents and can
also be of a composition that they release the active ingredient(s) only, or entially, in
a certain part of the intestinal tract, optionally, in a d . Examples of
embedding compositions that can be used include polymeric substances and waxes.
2014/024767
Dosage forms for topical or transdermal stration of a compound of this
invention include ointments, pastes, creams, lotions, gels, powders, solutions, ,
inhalants or patches. The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or s as may be
required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being
within the scope of this invention. onally, the present invention contemplates the
use of transdermal patches, which have the added advantage of providing controlled
delivery of a compound to the body. Such dosage forms can be made by dissolving or
dispensing the compound in the proper medium. Absorption enhancers can also be used to
increase the flux of the compound across the skin. The rate can be lled by either
providing a rate controlling membrane or by dispersing the compound in a polymer matrix
or gel.
The compounds of the invention are preferably formulated in dosage unit form
for ease of administration and uniformity of dosage. The expression "dosage unit form" as
used herein refers to a physically discrete unit of agent appropriate for the t to be
treated. It will be understood, r, that the total daily usage of the compounds and
compositions of the present invention will be decided by the attending physician within
the scope of sound medical judgment. The specific effective dose level for any particular
patient or sm will depend upon a variety of factors including the disorder being
treated and the severity of the er; the activity of the specific nd employed;
the specific ition employed; the age, body weight, general health, sex and diet of
the patient; the time of administration, route of administration, and rate of excretion of the
specific compound employed; the duration of the treatment; drugs used in combination or
coincidental with the specific nd employed, and like factors well known in the
medical arts.
The amount of the compounds of the present invention that may be combined
with the carrier materials to produce a composition in a single dosage form will vary
depending upon the host treated, the particular mode of administration. Preferably, the
compositions should be formulated so that a dosage of between 0.01 — 100 mg/kg body
weight/day of the inhibitor can be administered to a patient receiving these itions.
Depending upon the particular proliferative condition or cancer to be treated,
additional therapeutic agents, which are normally administered to treat or prevent that
ion, may also be present in the itions of this invention. As used herein,
additional therapeutic agents which are ly administered to treat or prevent a
particular proliferative condition or cancer are known as “appropriate for the disease, or
condition, being treated.” Examples of additional therapeutic agents are provided infra.
The amount of additional therapeutic agent present in the compositions of this
invention will be no more than the amount that would normally be administered in a
composition comprising that therapeutic agent as the only active agent. Preferably the
amount of additional therapeutic agent in the presently disclosed compositions will range
from about 50% to 100% of the amount normally present in a ition comprising that
agent as the only eutically active agent.
Uses ofthe Compounds and Compositions ofthe Invention
In one embodiment, the invention es a method of sensitizing a cell to a
theraputic agent or a disease state that induces a DNA lesion comprising the step of
contacting the cell with one or more DNA-PK inhibitors of formulae 1, II, or III, or
subformula thereof (e. g., formulae I-A, I-A-l, I-A-2, I-B, I-B-l, I-B-Z, I-C, I-C-l, I-C-2,
I-C-3, I-C-4, I-D, I-D-1, I-D-2, I-D-3, I-D-4, or I-D-5).
The invention further provides s of potentiating a therapeutic regimen
for treatment of cancer comprising the step of administering to an individual in need
thereof an effective amount of a DNA-PK inhibitor of formula I, II, or III, or a
subformula thereof. In one aspect, the therapeutic n for treatment of cancer
es radiation therapy.
Compounds of the invention are useful in ces where radiation therapy is
indicated to enhance the therapeutic benefit of such ent. In addition, radiation
therapy frequently is indicated as an adjuvent to surgery in the treatment of cancer. The
goal of radiation y in the adjuvant setting is to reduce the risk of recurrence and
enhance disease—free survival when the primary tumor has been controlled. Adjuvant
radiation therapy is indicated in several diseases including colon, rectal, lung,
gastroesophageal, and breast cancers as described below.
The invention also can be practiced by including another anti-cancer
chemotherapeutic agent with a compound of the invention in a therapeutic regimen for the
treatment of , with or without radiation therapy. The combination of a DNA-PK
inhibitor compound of the invention with such other agents can potentiate the
chemotherapeutic protocol. For example, the inhibitor nd of the invention can be
stered with etoposide or bleomycin, agents known to cause DNA strand breakage.
The invention further relates to radiosensitizing tumor cells utilizing a
compound of formula I, II, or III, or a subformula thereof. The preferred compounds are
those as described for the pharmaceutical compositions of the invention. A compound that
can sensitize” a cell, as used herein, is defined as a molecule, preferably a low
molecular weight molecule, administered to s in therapeutically effective amount to
increase the sensitivity of cells to electromagnetic radiation and/or to promote the
treatment of diseases that are treatable with electromagnetic radiation (e.g., X-rays).
Diseases that are treatable with omagnetic ion include neoplastic diseases,
benign and malignant tumors, and cancerous cells.
The present invention also provides s of treating cancer in an animal
that includes administering to the animal an effective amount of a DNA-PK inhibitor such
as, for example, a compound of the invention. The invention further is directed to
methods of inhibiting cancer cell , including processes of cellular proliferation,
veness, and asis in ical systems. Methods include use of a compound of
the invention as an inhibitor of cancer cell growth. Preferably, the methods are employed
to inhibit or reduce cancer cell growth, invasiveness, metastasis, or tumor incidence in
living animals, such as mammals. The compounds of the invention can be used, either
alone or in combination with the use of IR or one or more chemotherapeutic agents, in
treating cancer or inhibiting cancer cell growth. Methods of the invention also are readily
adaptable for use in assay systems, e. g., assaying cancer cell growth and properties
thereof, as well as identifying compounds that affect cancer cell growth.
Tumors or sms include growths of tissue cells in which the
multiplication of the cells is uncontrolled and progressive. Some such growths are benign,
but others are termed “malignant” and can lead to death of the organism. Malignant
neoplasms or “cancers” are distinguished from benign growths in that, in addition to
exhibiting sive cellular proliferation, they can invade surrounding tissues and
metastasize. Moreover, malignant neoplasms are characterized in that they show a greater
loss of differentiation (greater “dedifferentiation”) and their organization relative to one
r and their surrounding tissues. This property is also called “anaplasia.”
Neoplasms treatable by the present invention also e solid tumors, i.e.,
carcinomas and sarcomas. omas include those malignant neoplasms d from
epithelial cells which infiltrate (invade) the surrounding tissues and give rise to metastases.
Adenocarcinomas are carcinomas derived from glandular tissue, or from tissues which
form recognizable glandular structures. r broad category of cancers includes
sarcomas, which are tumors whose cells are embedded in a fibrillar or homogeneous
substance like embryonic connective tissue. The invention also enables treatment of
cancers of the myeloid or lymphoid systems, including leukemias, lymphomas, and other
cancers that lly do not present as a tumor mass, but are distributed in the vascular or
lymphoreticular systems.
DNA-PK activity can be associated with s forms of cancer in, for
example, adult and pediatric oncology, growth of solid tumors/malignancies, myxoid and
round cell carcinoma, locally ed tumors, metastatic cancer, human soft tissue
sarcomas, including Ewing's sarcoma, cancer metastases, including lymphatic metastases,
squamous cell carcinoma, particularly of the head and neck, esophageal us cell
carcinoma, oral carcinoma, blood cell malignancies, ing multiple myeloma,
leukemias, including acute lymphocytic leukemia, acute nonlymphocytic leukemia,
c lymphocytic leukemia, chronic myelocytic ia, and hairy cell leukemia,
effusion lymphomas (body cavity based lymphomas), thymic lymphoma lung cancer,
including small cell lung carcinoma, cutaneous T cell lymphoma, Hodgkin's ma,
non-Hodgkin's lymphoma, cancer of the adrenal cortex, ACTH-producing tumors,
nonsmall cell cancers, breast cancer, including small cell carcinoma and ductal carcinoma,
intestinal cancers, ing stomach cancer, colon cancer, colorectal cancer, polyps
associated with colorectal neoplasia, pancreatic , liver cancer, urological cancers,
including bladder cancer, including primary superficial bladder tumors, invasive
transitional cell carcinoma of the bladder, and muscle—invasive bladder cancer, prostate
cancer, malignancies of the female genital tract, including ovarian carcinoma, primary
peritoneal epithelial sms, cervical carcinoma, uterine endometrial cancers, vaginal
cancer, cancer of the vulva, uterine cancer and solid tumors in the ovarian follicle,
malignancies of the male genital tract, ing testicular cancer and penile cancer,
kidney cancer, including renal cell carcinoma, brain cancer, including intrinsic brain
, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in
the central nervous system, bone s, including osteomas and osteosarcomas, skin
cancers, including malignant melanoma, tumor progression of human skin keratinocytes,
squamous cell cancer, thyroid cancer, retinoblastoma, neuroblastoma, peritoneal effusion,
malignant pleural effusion, mesothelioma, Wilms's , gall bladder cancer,
blastic neoplasms, hemangiopericytoma, and Kaposi's sarcoma. Methods to
potentiate treatment of these and other forms of cancer are embraced by the invention.
The invention provides a method of inhibiting DNA-PK activity in a biological
sample that includes contacting the biological sample with a nd or composition of
the ion. The term “biological sample,” as used herein, means a sample e a
living organism and includes, t limitation, cell cultures or extracts thereof; biopsied
material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces,
semen, tears, or other body fluids or extracts thereof. Inhibition of kinase activity,
particularly DNA—PK activity, in a biological sample is useful for a variety of purposes
known to one of skill in the art. Examples of such purposes include, but are not limited to,
biological specimen storage and biological assays. In one embodiment, the method of
inhibiting DNA-PK activity in a biological sample is limited to non-therapeutic methods.
Preparation ofCompounds ofthe Invention
As used , all abbreviations, s and tions are consistent with
those used in the contemporary scientific literature. See, e. g., Janet S. Dodd, ed., The ACS
Style Guide: A Manualfor Authors and Editors, 2nd Ed., Washington, DC: American
Chemical Society, 1997. The following definitions describe terms and abbreviations used
BPin pinacol boronate ester
Brine a saturated NaCl on in water
DCM dichloromethane
DIAD diisopropylazodicarboxylate
DIEA diisopropylethylamine
DMA dimethylacetamide
DMF dimethylformamide
DMSO dimethylsulfoxide
DTT dithiothreitol
ESMS electrospray mass spectrometry
EtZO ethyl ether
EtOAc ethyl acetate
EtOH ethyl alcohol
HEPES 4-(2-hydroxyethyl)— l azineethanesulfonic acid
HPLC high performance liquid chromatography
IPA isopropanol
LAH lithium aluminum hydride
LC—MS liquid chromatography-mass spectrometry
LDA lithium diisoproylethylamide
Me methyl
MeOH methanol
MsCl methanesulfonyl chloride
MTBE methyl t—butyl ether
NMP N—methylpyrrolidine
Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)
Pd(dppf)Clz 1,1' bis(diphenylphosphino)-ferrocene dichloro-palladium
PG protecting group
Ph phenyl
(rac)—BINAP racemic is(diphenylphosphino)-l,l'-binaphthyl
RockPhos di— tert—butyl(2',4',6'-triisopropyl-3 ,6-dimethoxy-[ l l '-biphenyl]—2—
yl)phosphine
RT or rt room temperature
SFC supercritical fluid tography
SPhos 2—dicyclohexylphosphino-2',6'-dimethoxybiphenyl
TBAI tetrabutylammonium iodide
tBu tertiary butyl
THF tetrahydrofuran
TEA triethylamine
TMEDA ethylethylenediamine
VPhos [3 —(2—dicyclohexylphosphanylphenyl)—2,4-dimethoxy-
phenyl]sulfonyloxysodium
General Synthetic Procedures
In general, the nds of this invention may be prepared by methods
described herein or by other methods known to those skilled in the art.
e 1. General preparation of the compounds of formula G
H NH2
E 1 A H A
Br N Br N N N
o [C]
—> —> R1U
F NMP, 180°C
N Pol2(o|ba)3, rac—BINAP, N
(step H) ngcos, toluene, 100°C
[A] [0Bl] (step 1-ii) [D]
PGHHEN’O/ AN deprotect HQ
(step 1--iii) (UN
H2N U—>(step 1--iv)R1a_|_ WHOHQ
[E] [G] P
Scheme 1
Compounds of formula I, n X1 is NH (i.e., compounds of formula I-A),
can be prepared as outlined below in Scheme 1. Accordingly, as shown in step l—i of
Scheme 1, heteroaryl compounds of formula A can be reacted with morpholine or a
morpholine analog by heating the mixture in a polar, non-protic solvent to produce
compounds of formula B. Utilizing a palladium-catalyzed, phosphine ligand-assisted
Buchwald/Hartwig-type coupling, as shown in step l—ii of Scheme 1, a compound of
formula B can be reacted with aminocyclohexanes of formula C to e compounds of
formula D, wherein R1 and R2 are as described elsewhere herein. In one e, when
monoprotected meso cyclohexane—l,4—diamines of a E are prepared, removal of the
protecting group forms compounds of formula F, as shown in step l-iii of Scheme 1. The
resulting free amine can then be reacted with various moieties having groups reactive
towards amines (e.g., Rla—L, where L is a leaving group such as chloro, bromo, iodo,
toluenesulfonate, methanesulfonate, or trifluoromethanesulfonate; or where L is a reactive
2014/024767
carbonyl—containing moiety such as an active ester or an isocyanato group) to produce a
compound of formula G, as shown in step l—iv of Scheme 1.
Example 2. General preparation of the compounds of formula M, N, R, and S
A A
Ho (3N
HO N protect PG’O N [“3
O deprotect
—> —> —>
NW: 180°C
(step 24) (step 2—iii)
[H] Br [J] Br (step 2—ii) [K] E j
[I],
N I UU
or 00
base
(step 2—-iv) 00 0
Scheme 2a
Compounds of formula I, wherein X1 is O can be prepared as outlined below in
Schemes 2a and 2b. Accordingly, as shown in step 2—i of Scheme 2a, the hydroxyl group
of heteroaryl compounds of formula H can be protected to produce compounds of formula
J, which can then be reacted with morpholine or a morpholine analog by heating the
mixture in a polar, non-protic solvent to produce nds of formula K after removal
of the protecting group, as shown in steps 2-ii and 2-iii of Scheme 2a. Subsequently, as
shown in step 2—iv of Scheme 2a, a compound of formula K can be d with a
compound of formula L under conditions sufficient to affect the SN2 displacement of its
leaving group (e.g., where L is a leaving group such as chloro, bromo, iodo,
toluenesulfonate, esulfonate, or trifluoromethanesulfonate) to produce a compound
of formula M or formula M, depending on r R1 or R2 is en. In those
instances when R1 or R2 are protected nitrogen or oxygen moieties, nds of the
invention can be produced by removal of the protecting group and subsequent synthetic
manipulation of the resulting free amine/alcohol.
WO 59690
Alternatively, as shown in Scheme 2b, the hydroxyl group of a compound of
a 0 can be reacted with a compound of formula L to produce a fused
bicycloheteroaryl e of formula P, which can subsequently be reacted with
morpholine or a morpholine analog to produce a compound of formula M or formula N.
\\\L H
m RI—O A
U
HO N R2 o
[L] N 0
—> [M] or [N]
—, NMP, 180°C
base R5 (step 2—vi)
[Bor] Br
(step 2—v) [P]
Scheme 2b
Alternatively, as shown in Scheme 2c, compounds of the invention in which
Ring B is a dihydropyran ring can be prepared by reacting compounds of formula Q with
dialkyl (3,6—dihydro—2H—pyran—4—yl)boronates to produce compounds of formula R.
Compounds of formula R can then be uently reduced to form compounds of
formula S.
mm A
0 Q 61
RE (Step 2--viii)R
[Q] Br Pd(dppf) Na2C03 DMF
[R] {31
(step 2—-\/ii) 0 0
Scheme 2c
Example 3. Preparation of ethyl (4-((7-morpholinoquinoxalin
yl)amino)cyclohexyl)carbamate (Compound 6) and N1-(7-morpholinoquinoxalinyl)—
N4-(pyrimidinyl)cyclohexane-1,4-diamine (Compound 18)
H NH
NH \
2 ONH ”(N /N
Boc\ (0’
Br NH2 Br /N N
___£L_, ___Ji______*
MeOH NMP 180°C Pd2(dba)3, rac—BINAP,
(step 3-i) F (step 3 ll) CsZCO3, toluene, 100°C
“001] 0 (flep34m
I10031
H Nfl\
N /N
N \ N \
| NO 0 DIEA, 3DCM 03:0
/N /N ME IO
TFAJDCM H’[::]’ (step3-v)
[:::I’
(tS ep3V')
(step 3- iv) * N N \
Br 1 a,
1004 [:1 [1005 0
TEA, NMP, N N
130°C v [13] E 1
Scheme 3
As shown in step 3—i of Scheme 3, to a solution of 3—bromo—5—fluoro—benzene—
1,2-diamine (compound 1001, 1.11 g, 5.41 mmol) in methanol (11 mL) was added
oxaldehyde (1.57 mL of 40 % w/V, 10.8 mmol). The reaction mixture was stirred at room
temperature under nitrogen. After 2 hours a yellow solid precipitated. The reaction
mixture was diluted with water (20 mL), d an additional 5 minutes, filtered, and the
ted solid dried under high vacuum to produce 5—bromo—7—fluoroquinoxaline
(compound 1002, 868 mg, 70.6% yield): 1H—NMR (3 00 MHz, DMSO—d6) 8 9.06 (s, 2H),
8.36 (dd, J = 8.5, 2.7 Hz, 1H), 8.00 (dd, J = 9.2, 2.7 Hz, 1H); ESMS (M+H+) = 227.14.
As shown in step 3—ii of Scheme 3, to a solution of 5—bromo—7—
fluoroquinoxaline (4.5 g, 19.8 mmol) in NMP (67.5 mL) was added morpholine (3.1 mL,
.6 mmol). The reaction mixture was heated to 140°C and stirred for 15 hours. After
cooling, the mixture was poured into water (200 mL), ted with ethyl acetate (2 x
2014/024767
100mL), dried over magnesium sulfate, filtered, evaporated under reduced re, and
purified by medium pressure silica gel chromatography (10 to 80% EtOAc/hexanes
gradient) to provide 4—(8-bromoquinoxalin—6—yl)morpholine (compound 1003, 3.86g, 66%
yield) as a yellow solid: 1H—NMR (400 MHz, g) 5 8.82 (d, J = 1.6 Hz, 1H), 8.73
(d, J = 1.6 Hz, 1H), 8.12 (d, J = 2.5 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 3.87-3.69 (m, 4H),
3.44—3.34 (m, 4H); ESMS (M+H+) = 227.14.
As shown in step 3-iii of Scheme 3, a mixture of 4-(8-bromoquinoxalin
yl)morpholine (1.57 g, 5.34 mmol), tert—butyl-N—(4-aminocyclohexyl)carbamate (1.37 g,
6.40 mmol), (rac)—BINAP (664 mg, 1.07 mmol), cesium carbonate (5.22 g, 16.0 mmol),
and Pd2(dba)3 (489 mg, 0.534 mmol) in toluene (50 mL) was heated at 100°C for 12
hours. After cooling, the mixture was diluted with ethyl acetate (150 mL) and water (25
mL), then filtered through diatomaceous earth which was subsequently washed with ethyl
acetate. The combined organics were washed with brine, dried over sodium sulfate,
concentrated under reduced pressure, and purified by medium pressure silica gel
chromatography (0 to 60% EtOAc/hexanes nt) to provide tert—butyl(—4—((7—
morpholinoquinoxalin—5—yl)amino)cyclohexyl)carbamate (compound 1004, 1.83 g, 83.2%
yield): 1H-NMR (300 MHz, CDC13) 8 8.65 (d, J = 2.0 Hz, 1H), 8.35 (d, J = 2.0 Hz, 1H),
6.60 (d, J = 2.4 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 6.11 (d, J = 7.8 Hz, 1H), 4.60 (s, 1H),
.86 (m, 4H), 3.67 (s, 2H), 3.41-3.25 (m, 4H), 1.85 (d, J = 3.0 Hz, 5H), 1.74—1.57 (m,
3H), 1.45 (s, 9H).
As shown in step 3—iv of Scheme 3, to a solution of tert—butyl (—4—((7—
morpholinoquinoxalinyl)amino)cyclohexyl)carbamate (900 mg, 2.00 mmol) in
dichloromethane (16 mL) was added trifluoroacetic acid (3 mL, 38.9 mmol). The
ing black reaction mixture was stirred under an atmosphere of nitrogen at room
ature for 2 hours. Saturated aqueous sodium bicarbonate (150 mL) was added
slowly until the color turned from black to orange. The mixture was extracted with
dichloromethane (2 x 100 mL) and the combined organics washed with brine (50 mL),
dried over sodium sulfate, and concentrated under reduced pressure to provide—Nl—(7—
morpholinoquinoxalin—5-yl)cyclohexane—1,4-diamine, oroacetate (compound 1005):
1H NMR (300 MHz, CDCl3) 8 8.64 (d, J = 1.9 Hz, 1H), 8.36 (d, J =1.9 Hz, 1H), 6.59 (d, J
= 2.3 Hz, 1H), 6.34 (d, J = 2.3 Hz, 1H), 6.20 (d, J = 7.9 Hz, 1H), 3.95-3.84 (m, 4H), 3.69
(s, 1H), 3.41-3.25 (m, 4H), 2.93 (d, J = 8.9 Hz, 1H), 2.09—1.87 (m, 2H), 1.90—1.68 (m, 6H),
1.58 (dd, J = 11.2, 8.7 Hz, 2H); ESMS (M+H+) = 328.34. This compound was used as is
without r purification.
As shown in step 3—v of Scheme 3, to solution of N1—(7—morpholinoquinoxalin-
-yl)cyclohexane-1,4-diamine (25 mg, 0.07 mmol) and diisopropylethylamine (18.0 mg,
24.3 11L, 0.14 mmol) in dichloromethane (750 11L) was added ethyl chloroformate (11.4
mg, 10.0 11L, 0.105 mmol). The reaction mixture was stirred for 12 hours, diluted with
dichloromethane (10mL), washed with saturated s sodium bicarbonate (5mL), dried
over sodium sulfate, and concentrated under reduced pressure. The resulting residue was
purified by HPLC preparative chromatography using a 10-90% acetonitrile/water (0.1%
TFA) gradient as eluant to provide ethyl (4-((7-morpholinoquinoxalin
yl)amino)cyclohexyl)carbamate (compound 6, 14 mg, 50% yield): 1H—NMR (3 00 MHz,
CDCl3) 8 8.65 (d, J = 2.0 Hz, 1H), 8.36 (d, J = 2.0 Hz, 1H), 6.61 (d, J = 2.4 Hz, 1H), 6.35
(d, J = 2.4 Hz, 1H), 6.10 (d, J = 7.6 Hz, 1H), 4.72 (s, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.96—
3.82 (m, 4H), 3.68 (s, 2H), 3.42—3.23 (m, 4H), 1.93—1.78 (m, 6H), 1.69 (dd, J = 15.0, 6.3
Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H); ESMS (M+H+) = 400.17.
] As shown in step 3—vi of Scheme 3, A e of N1—(7—morpholinoquinoxalin-
-yl)cyclohexane—1,4-diamine (185 mg, 0.56 mmol), 2—bromopyrimidine (93 mg, 0.58
mmol), and triethylamine (143 mg, 197 11L, 1.41 mmol) in 1-methylpyrrolidinone (3
mL) was heated to 130°C and stirred for 15 hours. After cooling to room ature, the
mixture was diluted with ethyl acetate (70 mL) and methyl tert-butyl ether (20 mL),
washed with water (3 x 20 mL), washed with brine (15 mL), dried over sodium sulfate,
concentrated under reduced pressure, and purified by medium pressure silica gel
tography (10 to 100% EtOAc/hexanes gradient) to provide Nl—(7—
morpholinoquinoxalinyl)-N4-(pyrimidinyl)cyclohexane-1,4-diamine und 18,
102 mg, 45% yield): 1H—NMR (300 MHz, CDCl3) 8 8.65 (d, J = 2.0 Hz, 1H), 8.37 (d, J =
2.0 Hz, 1H), 8.27 (d, J = 4.8 Hz, 2H), 6.60(d, J = 2.4 Hz, 1H), 6.51 (t, J = 4.8 Hz, 1H),
6.36 (d, J =2.4 Hz, 1H), 6.15 (d, J = 7.8 Hz, 1H), 5.20 (d, J = 7.7 Hz, 1H), 4.04 (d, J = 7.9
Hz, 1H), 3.96—3.82 (m, 4H), 3.70 (s, 1H), 3.39—3.24 (m, 4H), 1.94 (dd, J = 13.7, 4.4 Hz,
6H), 1.78 (dt, J = 28.8, 16.1 Hz, 2H); ESMS (M+H+) = 328.34.
e 4. Preparation of 1-(4-((7-(8-oxa—3-azabicyclo[3.2.1]octanyl)quinoxalin
yl)amino)cyclohexyl)—3—ethylurea (Compound 22)\
MN @N Br NI/m/ / N
B r / N BOC\N
—> H—>BocN
NMP, 180°C N Pd2(dba)3, rac—BINAP
F (step 4-i) (332003 toluene 100°C [1007]
0 0
(step 4- ii)
TFA/DCM
_> HzNN’O’NN #
(step 4—iii) *TFA DIEA DCM HN/gMOI-I:
(step 4-iv)
E29 kc: [22] 0
Scheme 4
As shown in step 4—i of Scheme 4, to a on of o—7—
fluoroquinoxaline (compound 1002, 150 mg, 0.66 mmol) in NMP (2.3 mL) was added 8—
oxaazabicyclo[3.2.1]octane (178 mg, 1.2 mmol) at RT. The reaction e was
sealed in a microwave vial and heated at 180°C for 20 s. Afte cooling to RT and
pouring into water, the aqueous phase was extracted with EtOAc (3x). The combined
extracts were dried over MgSO4, filtered, concentrated under reduced pressure, and
purified by medium pressure silica gel chromatography (0 to 100% EtOAc/hexanes
gradient) to e 3-(8-bromoquinoxalinyl)—8-oxaazabicyclo[3.2.1]octane
(compound 1006, 87 mg, 41% yield) as a dark orange oil: ESMS (M+H+) = 320.07.
As shown in step 4—ii of Scheme 4, a degassed solution of 3—(8—
bromoquinoxalinyl)oxa—3-azabicyclo[3.2.1]octane (261 mg, 0.815 mmol), tert—butyl
N—(4-aminocyclohexyl)carbamate (210 mg, 0.98 mmol), rac-BINAP (102 mg, 0.163
mmol), CszCO3 (797 mg, 2.45mmol), and Pd2(dba)3 (75 mg, 0.0815 mmol) in toluene
(10.5 mL) was heated at 100°C (oil bath temp) in a sealed microwave tube for 15 hours.
After cooling, the mixture was applied directly to a chromatography column and purified
by medium pressure silica gel chromatography (0 to 100% EtOAc/hexanes gradient) to
afford tert—butyl (4—((7-(8-oxaazabicyclo[3 .2. 1]octan-3 -yl)quinoxalin
yl)amino)cyclohexyl)carbamate (compound 1007, 141 mg, 36% yield) as a white solid:
1H—NMR (400 MHz, CDCl3) d 8.49 (s, 1H), 8.23 (d, J = 1.5 Hz, 1H), 6.48 (s, 1H), 6.18 (d,
J = 1.9 Hz, 1H), 6.06 (s, 1H), 4.52 (s, 1H), 4.47 (s, 2H), 3.60 (s, 2H), 3.45 (d, J = 11.6 Hz,
2H), .12 (m, 2H), 1.96—1.84 (m, 4H), 1.79 (s, 5H), 1.54 (s, 3H) and 1.38 (s, 9H)
ppm; ESMS (M+H+) = 453.96.
As shown in step 4-iii of Scheme 4, to a solution of compound 1007 (141 mg,
0.295 mmol) in CHzClz (2.5 mL) was added TFA (656 mg, 443 uL, 5.75 mmol) at RT.
The resulting black solution was stirred for 2 hours and then the reaction was quenched by
the addition of saturated NaHCO3 until the black color gradually turned into an orange
color. The reaction mixture was extracted with CH2Clz (3x) and the combined organic
extracts were dried over NaZSO4 and evaporated to dryness to provide Nl—(7—(8—oxa—3—
azabicyclo [3 .2. 1]octan-3 inoxalinyl)cyclohexane-1,4-diamine, oroacetate
(compound 1008): ESMS (M+H+) = . This material was used in subsequent
reactions without any further purification.
As shown in step 4—iV of Scheme 4, to a solution of compound 1008 (45 mg,
0.071 mmol) and DIEA (36.5 mg, 49.0 uL, 0.28 mmol) in CH2Clz (1.4 mL) was added
ethyl isocyanate (20 mg, 0.28 mmol) at RT. The solution was stirred at this temperature
for 15 hours and then d directly to a chromatography column and purified by
medium re silica gel chromatograph (0 to 100% hexanes gradient) to afford
1-(4-((7-(8-oxa-3 -azabicyclo[3.2.1]octan-3 -yl)quinoxalin-5 -yl)amino)cyclohexyl)-3 -
ethylurea (compound 22, 8 mg, 27% yield) as a white solid: 1H-NMR (400 MHz, CDCl3)
8 8.54 (s, 1H), 8.22 (s, 1H), 6.43 (s, 1H), 6.19 (s, 1H), 6.02 (s, 1H), 4.47 (s, 2H), 4.38 (d, J
= 5.2 Hz, 1H), 4.28 (s, 1H), 3.74 (s, 1H), 3.60 (s, 1H), 3.42 (s, 4H), 3.14—3.09 (m, 4H),
2.05—1.87 (m, 3H), 1.79 (s, 3H), 1.55 (d, J = 7.1 Hz, 2H) and 1.21-1.05 (m, 5H) ppm;
ESMS (M+H+) = 425.35.
Example 5. Preparation of N1-(6-morpholinobenzo[c][1,2,5]oxadiazolyl)-N4-
(pyrimidinyl)cyclohexane-1,4-diamine (CompoundH 23)
NBoc NHZ
)0: TEA DMF 4M HCI/THF
—> —>
J'V| / * HCI
(step 5-11)--
N NAN 140°C
(step5-i) v [1010] v [1011]
F5: H I’N
*HCI
VI [1011] HNU
00 N N
Pd2(dba)3, rac—BINAP, v E j
, toluene, 100°C
“012] (step 5-iii) [23]
Scheme 5
As shown in step 5—i of Scheme 5, a mixture of tert—butyl ((cis)—4—
aminocyclohexyl)carbamate (compound 1009, 490 mg, 2.3 mmol), ropyrimidine
(262 mg, 2.3 mmol) and TEA (463 mg, 63 70L, 4.6 mmol) in DMF (10 mL) was subjected
to microwave irradiation for 20 minutes at 150°C. The reaction mixture was diluted with
EtOAc, washed with H20, dried over NazSO4, concentrated under reduced re, and
purified by medium pressure silica gel chromatography (0 to 50 % EtOAc/hexanes
gradient) to provide tert-butyl (pyrimidinylamino)cyclohexyl)carbamate
(compound 1010) as a white solid: 1H—NMR (300 MHz, CDC13) 8 8.28 (d, J = 4.8 Hz,
2H), 6.53 (t, J= 4.8 Hz, 1H), 5.12 (s, 1H), 4.56 (s, 1H), 3.99 (dq, J= 7.0, 3.5 Hz, 1H),
3.65 (s, 1H), 1.83 (tq, J= 10.2, 3.6 Hz, 5H), 1.66 (s, 8H), 8.13—7.91 (m, 3H), 1.47 (s, 9H).
As shown in step 5—ii of Scheme 5, HCl (3 mL, 4M in THF, 12 mmol) was
added to compound 1010. The mixture was stirred for 30 min and concentrated under
reduced pressure to produce N1—(pyrimidin—2—yl)cyclohexane-1,4-diamine
hydrochloride (compound 1011). This material was used in subsequent reactions as is
without further purification.
As shown in step 5—iii of Scheme 5, a mixture of 4-bromo
morpholinobenzo[c][1,2,5]oxadiazole und 1012, 147 mg, 0.5 mmol), (cis)—N1—
(pyrimidinyl)cyclohexane-l,4-diamine hydrochloride (120 mg, 0.6 mmol), (me)—
BINAP (32 mg, 0.05 mmol) 0.026 mmol), and cesium carbonate (506
, a)3 (24 mg,
mg, 1.55 mmol) in toluene (5 mL) was flushed with nitrogen gas and stirred overnight at
90°C under an atmosphere of nitrogen. The mixture was filtered though a layer of
diatomaceous earth, concentrated under reduced pressure, and purified by medium
pressure silica gel chromatography (0 to 80% EtOAc/hexanes gradient) to provide (cis)—
N1—(6—morpholinobenzo[c] [ l ,2,5]oxadiazolyl)-N4-(pyrimidinyl)cyclohexane- l ,4-
diamine (compound 23) as an orange solid: 1H—NMR (300 MHz, CDCl3) 5 8.20 (d, J = 4.9
Hz, 2H), 6.46 (t, J = 4.8 Hz, 1H), 6.05 (d, J = 1.6 Hz, 1H), 5.82 (s, 1H), 5.24 (s, 1H), 4.82
(d, J = 7.0 Hz, 1H), 3.98 (s, 1H), .72 (m, 4H), 3.60 (s, 1H), 3.23-3.06 (m, 4H), 1.95—
1.62 (m, 8H).
Example 6. Preparation of 5-meth0xy-N-((cis)((7-m0rpholin0quin0xalin
yl)0xy)cyclohexyl)pyrimidinamine (Compound 134)
_\\“OH “(\OMS
“10H MsCI, TEA,
i 1
N / N Et3N, iPrOH HN0 DCM HN(O
+ ' —’
\ A --
H2N A
(step 6—i) N/ N (Step ‘3'") N/ N
Br V I
\ [1014]
Br H B \
NH2 NH2
NH2 tr'
H HO NI/er1
HO NO 2 HO NH O /
HO N02 Br2 2 2
Raney Ni O
—> —> —>
dioxane EtOAc MeOH Br
(ste 6-iii ) Br
p (step6lv)_' (steP 6—v)
[1016] [1017]
TBDMS-CI,
| /N
H c (N 1.
3 ‘Si’0 /N
imidazole, E 1
O N[1014]
DCM H3C7( 1 HN
—> —>
WH3C CH3 Pd2(dba)3, rac—BINAP, C32CO3 NAN N
Br C32CO3, toluene, | E 1 dioxane, \
100°C [:1 105°C o
2. TBAF (step 6-Viii)
MeOH, /\(step 6-vii)
(AIIyIPdC|)2, U / N
e 100°C
(step 6-ix) NAN
V UN00
O\ [1341
Scheme 6
As shown in step 6—i of Scheme 6, to a e of 5-bromofluoro-pyrimidine
(l g, 5.651 mmol) in iPrOH (10 mL) was added TEA (1.143 g, 1.574 mL, 11.30 mmol)
and transamin0cyclohexan-l-ol (650.8 mg, 5.651 mmol). The mixture was
microwaved for 20min at 150°C, concentrated under reduced pressure, diluted with
EtOAc washed with water, and dried over NaZSO4. After removal of the volatiles under
reduced pressure, the residue was d by medium pressure silica gel chromatography
(0—80% EtOAc/hexanes gradient) to provide (trans)—4—((5 —bromopyrimidin—2—
WO 59690
yl)amino)cyclohexanol (compound 1013, 1.2 g): 1H—NMR (300 MHz, CDCl3) 8 8.28 (s,
2H), 5.03 (d, J = 8.1 Hz, 1H), 3.91—3.49 (m, 2H), 2.31—1.90 (m, 4H), 1.56—1.19 (m, 4H)..
As shown in step 6—ii of Scheme 6, to compound 1013 (1.2 g, 4.41 mmol) in
DCM (20 mL) was added TEA (1.134 g, 1.84 mL, 13.2 mmol) and MsCl (505 mg, 341
uL, 4.41 mmol). The reaction mixture was stirred for 1 hour, concentrated under reduced
pressure, and purified by medium pressure silica gel chromatography (0 to 80%
EtOAc/hexanes gradient) to e trans((5-bromopyrimidinyl)amino)cyclohexyl
methanesulfonate (compound 1014): 1H—NMR (300 MHz, CDCl3) 8 8.29 (s, 2H), 5.03 (d,
J = 7.8 Hz, 1H), 4.70 (tt, J = 10.6, 3.9 Hz, 1H), 3.80 (dtt, J = 11.2, 7.6, 3.7 Hz, 1H), 3.04
(s, 3H), 2.30-2.12 (m, 4H), 1.93—1.69 (m, 2H), 1.51—1.33 (m, 2H).
As shown in step 6—iii of Scheme 6, to a solution of 2-aminonitrophenol
(5.00 g, 32.4 mmol) in dioxane (50 mL) was added bromine (6.22 g, 2.01 mL, 38.9 mmol).
The mixture was stirred for 2 hours and a precipitate formed, which was collected and
washed with dioxane and ether. The resulting yellow solid treated with a saturated
NaHCO3 solution, which was extracted with EtOAc (3x). The combined organics were
dried over , filtered, and trated under reduced pressure to yield 2—amino—5—
bromo—3—nitrophenol (compound 1015) as a brown solid. This material was carried on as
is in subsequent reactions without futher purification.
As shown in step 6—iv of Scheme 6, to a solution of 2—aminobromo-3—
nitrophenol (7.5 g, 31.8 mmol) in ethyl acetate (60 mL) was added Raney nickelTM (1.90
g, 214 ”L, 32.4 mmol) and the reaction e was shaken for 2 hours under an
atmosphere of H2 at 30 psi. After filtering and drying over NaZSO4, the mixture was
concentrated under reduced pressure to provide 2,3—diamino—5—bromophenol (compound
1016), which was used as is in subsequent reactions without futher purification.
As shown in step 6—v of Scheme 6, 2,3—diamino—5—bromophenol (6.0 g, 29.5
mmol) was dissolved in methanol and to this solution was added glyoxal (3.77 g, 2.98 mL,
64.9 mmol) and d ght. The reaction mixture was concentrated under reduced
pressure to a minimum volume and the resulting tan solid collected by filtration and dried
under high vacuum to produce 7—bromoquinoxalin—5—ol (compound 1017), which was used
as is in uent ons without futher purification.
As shown in step 6—vi of Scheme 6, a solution of 7—bromoquinoxalin—5—ol (2.0
g, 8.89 mmol) in DCM (20 mL) was added imidazole (1.82 g, 26.7 mmol) and tert—
butyldimethylsilyl chloride (1.34 g, 1.65 mL, 8.89 mmol). The reaction mixture was
stirred overnight at RT, concentrated under reduced pressure, and purified by medium
pressure silica gel tography (0 to 20% EtOAc/hexanes gradient) to e 7—
bromo—5—((tert—butyldimethylsilyl)oxy)quinoxaline (compound 1018) as a colorless oil:
1H—NMR (300 MHz, CDCL3) 8 8.69 (q, J = 1.8 Hz, 2H), 7.80 (d, J = 2.1 Hz, 1H), 7.22 (d,
J = 2.1 Hz, 1H), 0.96 (s, 9H), 0.81 (s, 7H).
As shown in step 6—vii of Scheme 6, a mixture of 7—bromo—5—((tert—
butyldimethylsilyl)oxy)quinoxaline (700 mg, 2.06 mmol), line (270 mg, 270 ”L,
3.09 mmol), a)3 (94.50 mg, 0.1032 mmol), (rac)—BINAP (129 mg, 0.206 mmol),
cesium carbonate (2.02 g, 6.19 mmol) in toluene (7 mL) was flushed with nitrogen for 10
minutes. The mixture was then heated overnight at 100°C. After cooling, the reaction
mixture was diluted with EtOAc, filtered through a layer of diatomaceous earth,
concentrated under reduced pressure, and purified by medium pressure silica gel
chromatography (0 to 30% EtOAc/hexanes gradient) to provide 7-morpholinoquinoxalin-
—01. This compound (450 mg, 1.3 mmol) was dissolved in THF (20 mL) and tetra—n-
mmonium fluoride (539 mg, 2.06 mmol) was added. The reaction mixture was
stirred for 0.5 hour, concentrated under reduced pressure, and purified by medium pressure
silica gel chromatography (0 to 100% EtOAc /hexanes gradient) to e 7—
linoquinoxalinol (compound 1019) as a yellow solid: 1H—NMR (300 MHz,
CDC13) 8 8.75 (d, J = 2.0 Hz, 1H), 8.46 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 41.8 Hz, 1H), 7.01
(d, J = 2.6 Hz, 1H), 6.89 (d, J = 2.5 Hz, 1H), 4.12—3.78 (m, 4H), 3.51—3.24 (m, 4H).
As shown in step 6-viii of Scheme 6, a solution of 7-morpholinoquinoxalin
01 (100 mg, 0.432 mmol), (trans)((5-bromopyrimidinyl)amino)cyclohexyl
methanesulfonate (compound 1014, 303 mg, 0.865 mmol), and CsCO3 (282 mg, 0.865
mmol) in dioxane (1.0 mL was d for 16 hours at 105°C. After cooling, the reaction
mixture was diluted with EtOAc, filtered through diatomaceous earth, concentrated under
reduced pressure, and purified by medium pressure silica gel tography (0 to 5%
MeOH/DCM gradient) to produce 5—bromo—N—((cis)—4—((7—morpholinoquinoxalin—5—
yl)oxy)cyclohexyl)pyrimidinamine (compound 1020, 110 mg) as a yellow foam: 1H-
NMR (400 MHz, CDC13) 8 8.70 (d, J = 2.0 Hz, 1H), 8.64 (d, J = 1.9 Hz, 1H), 8.29 (s, 2H),
6.98 (d, J = 2.5 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H), 5.29 (d, J = 8.3 Hz, 1H), 4.81 (s, 1H),
4.04-3.84 (m, 4H), 3.42—3.31 (m, 4H), 2.22 (s, 2H), 1.92 (d, J = 4.9 Hz, 6H).
As shown in step 6-ix of Scheme 6, to a mixture 5—bromo—N—((cis)—4—((7—
linoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine (75 mg, 0.155 mmol),
cesium carbonate (101 mg, 0.309 mmol) chloride dimer (0.28 mg,
, allylpalladium(H)
0.0015 mmol) RockPhos (2.17 mg, 0.0046 mmol) and MeOH (9.9 mg, 12.5 uL, 0.31
mmol) in toluene (2 mL) was flushed with nitrogen gas and heated to 100°C for 18 hours.
The reaction mixture was iluted with EtOAc, d though a layer of diatomaceous
earth, and concentrated under reduced pressure. Purification by medium pressure silica
gel chromatography (0—8% MeOH/DCM gradient) yielded 5—methoxy—N—((cis)—4—((7—
morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine (compound 134, 43 mg):
1H—NMR (300 MHz, CDCl3) 8 8.70 (d, J = 1.9 Hz, 1H), 8.63 (d, J = 1.9 Hz, 1H), 8.07 (s,
2H), 6.96 (d, J = 2.5 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H), 5.01 (d, J = 8.1 Hz, 1H), 4.80 (q, J
= 5.6, 4.2 Hz, 1H), 4.03—3.87 (m, 5H), 3.80 (s, 3H), 3.42—3.27 (m, 4H), 2.29—2.10 (m, 2H),
1.99—1.82 (m, 6H).
Example 7. ation of 4-(8-(((trans)—4-(pyrimidin
yloxy)cyclohexyl)oxy)quinoxalinyl)morpholine (Compound 34) and ((cis)—4—
(pyrimidinyloxy)cyclohexyl)oxy)-quinoxalinyl)morpholine und 42)
NélN
HOUQX 00H MCI, TEA, 1. 6M HCI (aq) SDCM
NaH, DMF /i/Oi}2_ NaBH4 MeOH k (step7— iii)
(step 7--i) N N N / N
(step 7_ ii)
U [1022] U [1023]
UOMS Q
O —> O\\“O,
NAN C82003,
dioxane,110°C NJ\|N N21,“
K) (step 7—iv) V [N] ENj
O V
[42]
Scheme7
As shown in step 7—i of Scheme 7, to a solution of 1,4—dioxaspiro[4.5]decan—8—
01 (compound 1021, 1.0 g, 6.32 mmol) in DMF (10 mL) was added NaH (370 mg, 9.25
mmol). The reaction mixture was stirred for 20 minutes before the addition of 2-
2014/024767
chloropyrimidine (869 mg, 7.59 mmol). The mixture was d for 30 minute at RT and
then heated to 100°C for 9 hours. After cooling, the mixture was diluted with EtOAc,
washed with H20, dried over NazSO4, concentrated under reduced pressure, and purified
by medium pressure silica gel chromatography (0—40% EtOAc/hexanes) to produce 2—(1,4—
dioxaspiro[4.5]decanyloxy)pyrimidine (compound 1022) as a colorless oil: 1H NMR
(300 MHz, Chloroform-d) 8 8.52 (d, J = 4.8 Hz, 2H), 6.92 (t, J = 4.8 Hz, 1H), 5.15 (ddd, J
= 10.7, 6.5, 4.2 Hz, 1H), 4.05-3.87 (m, 4H), 2.14-1.85 (m, 6H), 1.79-1.65 (m, 2H); ESMS
(M+H+) = 237.12.
As shown in step 7—ii of Scheme 7, to 2—(1,4—dioxaspiro[4.5]decan—8—
pyrimidine (620 mg, 2.624 mmol) was added HCl (4.0 mL of 6 M, 8.86 mmol) and
the reaction mixture was stirred for 2 hours. The pH of the mixture was neutralized with
with sat. NaHCO3(aq) and the mixture was concentrated under reduced pressure as a
ol azeotrope. To the residue was added DCM (30mL) to produce a precipitate,
ed by stirring for an additional 20 minutes. The solids were filtered off and the
mother liquor was concentrated under reduced pressure. The ing residue was
dissolved in methanol and sodium borohydride (151 mg, 3.99 mmol) was added as a solid.
The mixture was stirred for 1 hour and the reaction quenched with HCl (6M, 0.70 mL).
Stirring was continued until gas evolution . The pH of the mixture was adjusted to
about 8 with 1N sodium ide and extracted with EtOAc (20mL). The organics were
dried over sodium sulfate and concentrated under d pressure to produce 4—
(pyrimidinyloxy)cyclohexanol (compound 1023, 248mg, 64% yield) as a mixture of
(cis)— and (trans)— isomers. A 12 mg aliquot of the sample was purified Via HPLC
ative reversed—phase chromatography (IO—90% CH3CN/water nt containing
0.1% TFA) to separate the isomers: (trans)pyrimidinyloxycyclohexanol - 1H NMR
(300 MHz, Chloroform-d) 8 8.54 (d, J = 4.8 Hz, 2H), 6.95 (t, J = 4.8 Hz, 1H), 5.05 (tt, J =
9.4, 4.0 Hz, 1H), 3.91-3.75 (m, 1H), 2.26-1.99 (m, 4H), 1.76-1.41 (m, 4H); ESMS (M+H+)
= 195.07, (cis)—4—pyrimidinyloxycyclohexanol -1H NMR (300 MHz, Chloroform-d) 5
8.62 (d, J = 4.9 Hz, 2H), 7.04 (t, J = 4.9 Hz, 1H), 5.21 (tt, J = 5.3, 2.6 Hz, 1H), 4.56 (s,
1H), 3.85 (p, J = 5.9 Hz, 1H), 2.17—2.02 (m, 2H), 1.88-1.67 (m, 6H); ESMS (M+H+) =
195.07. The remaining material was used in subsequent reactions as the cis/trans mixture.
As shown in step 7—iii of Scheme 7, to a solution of a cis/trans mixture of 4—
pyrimidinyloxycyclohexanol (244 mg, 1.256 mmol) and triethylamine (350 ”L, 2.51
mmol) in dichloromethane (5 mL) was added methane sulfonyl de (145 11L, 1.87
mmol). The reaction mixture was stirred for 2 hours, concentrated under reduced
pressure, and purified by medium pressure silica gel tography (0— 20%
EtOAc/dichloromethane gradient) to provide 4-pyrimidinyloxycyclohexyl)
esulfonate (compound 1024, 239 mg, 70% yield) as a mixture of ans isomers:
1H NMR (300 MHz, Chloroform—d) 8 8.51 (d, J = 4.8 Hz, 2H), 6.93 (t, J = 4.8 Hz, 1H),
.13 (dq, J = 9.9, 3.0 Hz, 1H), 4.87 (p, J = 3.8 Hz, 1H), 3.04 (d, J = 2.4 Hz, 3H), .99
(m, 4H), 1.99—1.74 (m, 4H); ESMS (M+H+) = 273.52.
As shown in step 7—iv of Scheme 7, a mixture of (4-pyrimidin—2—
yloxycyclohexyl) methanesulfonate (105 mg, 0.386 mmol), 7-morpholinoquinoxalinol
(178.3 mg, 0.7712 mmol), and CszCO3 (125.6 mg, 0.3856 mmol) in dioxane (1.5 mL) was
sealed in a 5 mL microwave tube and heated to 110°C for 14 hours using an oil bath. The
reaction mixture was cooled to room temperature, diluted with EtOAc, and filtered
h diatomaceous earth which was subsequently washed with ethyl acetate. The
filtrate was concentrated under reduced pressure and the residue purified via preparative
reversed—phase HPLC (10—90% water gradient containing 0.1% TFA). Fractions
containing a mixture of cis and trans isomers were further purified via SFC using a chiral
OJ column and eluting with 40% MeOH in C02 to provide 21mg of 4—(8—(((trans)—4—
(pyrimidinyloxy)cyclohexyl)oxy)quinoxalinyl)morpholine (compound 34): 1H NMR
(300 MHz, Chloroform—d) 8 8.69 (dd, J = 3.4, 1.9 Hz, 1H), 8.62 (dd, J = 3.6, 1.9 Hz, 1H),
8.51 (dd, J = 4.8, 2.2 Hz, 2H), 7.01—6.83 (m, 3H), 5.18 (tt, J = 7.0, 3.4 Hz, 1H), 4.79 (tt, J =
6.9, 3.1 Hz, 1H), .85 (m, 4H), 3.34 (dq, J = 4.8, 2.6 Hz, 4H), 2.44-2.16 (m, 4H),
1.92 (tdd, J = 16.4, 7.7, 2.8 Hz, 4H); ESMS (M+H+) = 408.56, and 22 mg of 4—(8—(((cis)—4—
(pyrimidinyloxy)cyclohexyl)oxy)-quinoxalinyl)morpholine (compound 42): 1H
NMR (300 MHz, Chloroform—d) 8 8.70 (d, J = 1.9 Hz, 1H), 8.63 (d, J = 1.9 Hz, 1H), 8.52
(d, J = 4.8 Hz, 2H), 7.01—6.87 (m, 3H), 5.17 (ddt, J = 8.7, 6.7, 3.4 Hz, 1H), 4.76-4.58 (m,
1H), 4.00—3.87 (m, 4H), 3.40-3.27 (m, 4H), 2.43—2.22 (m, 4H), 2.05-1.87 (m, 2H), 1.86—
1.71 (m, 2H); ESMS (M+H+) = 408.56.
Example 8. N—[(cis)—4-[7-(3,6-dihydro-2H—pyranyl)quinoxalin
yl]oxycyclohexyl]pyrimidinamine (Compound 36)
H30 CH3
\\OMS
O‘B’
NN N/fil/fi N/fi\l/fi [1026]
| /\©N /N
HO /N NJ\IN (0,0 \ [1014]
HN HN
NJ\|N —>
Br 08003,CH30N Pd(dppf)C|2
O V NAIN(60/
90 C [1025] rowave V
(step 8-i) 150 C [36]
(step 8-ii)
Scheme 8
As shown in step 8—i of Scheme 8, to a mixture of 7—bromoquinoxalin—5—ol
(compound 1018, 200 mg, 0.89 mmol) and cesium carbonate (579 mg, 1.78 mmol) in
NMP (4.0 mL) was added (trans)(pyrimidinylamino)cyclohexyl methanesulfonate
(compound 1014, 241.1 mg, 0.8887 mmol). The mixture was stirred for 18 hours at 90°C,
at which time an onal 0.5 eq of compound 1014 (241 mg, 0.89 mmol) was added.
After stirring at 90°C for an additional 6 hours, the reaction mixture was diluted with
EtOAc, washed with H20, dried over NazSO4, concentrated, and purified by medium
pressure silica gel chromatography (0—5% MeOH/DCM) to provide s)—4—((7—
bromoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine und 1025): 1H-NMR
(300 MHz, CDCl3) 8 9.01-8.77 (m, 2H), 8.29 (d, J = 4.8 Hz, 2H), 7.89 (d, J = 1.9 Hz, 1H),
7.25 (d, J = 2.0 Hz, 1H), 6.53 (t, J = 4.8 Hz, 1H), 5.43-5.22 (m, 1H), 4.79 (td, J = 5.2, 2.5
Hz, 1H), 4.18—3.95 (m, 1H), 3.51 (s, 1H), 2.22 (td, J = 10.2, 9.6, 5.4 Hz, 2H), .86
(m, 6H).
As shown in step 8—ii of Scheme 8, a mixture of N—((cis)—4—((7—
bromoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine (compound 1025, 52 mg,
0.1299 mmol) 0.01299 mmol), 2-(3,6-dihydro-2H—pyranyl)-
, Pd(dppf)Clz (10.61 mg,
4,4,5,5—tetramethyl—l,3,2—dioxaborolane (compound 1026, 27.3 mg, 0.13 mmol) , NazCO3
(l95 uL of 2M (aq) solution, 0.39 mmol) in DMF (1 mL) was flushed with nitrogen gas
for 10 minutes. The mixture was subjected to microwave radiation for 20 min at 150 0C.
After cooling, the mixture was diluted with EtOAc washed with H20, dried over NazSO4,
concentrated under reduced re and purified by medium pressure silica gel
chromatography (0—5% MeOH/DCM) to provide N—[(cis)—4—[7—(3,6—dihydro—2H—pyran—4—
yl)quinoxalinyl]oxycyclohexyl]pyrimidinamine (compound 36) as an off-white
solid: 1H—NMR (300 MHz, CDCl3) 5 8.94—8.76 (m, 2H), 8.29 (d, J = 4.8 Hz, 2H), 7.67 (d,
J = 1.7 Hz, 1H), 6.53 (t, J = 4.8 Hz, 1H), 6.37 (tt, J = 31,15 Hz, 1H), 5.30 (d, J = 7.9 Hz,
1H), 4.87 (dt, J = 7.5, 3.6 Hz, 1H), 4.43 (q, J = 2.8 Hz, 2H), 4.02 (t, J = 5.5 Hz, 3H), 2.68
(dqd, J = 6.0, 3.4, 3.0, 1.8 Hz, 2H), 2.35—2.11 (m, 2H), 2.07—1.84 (m, 6H); ESMS (M+H+)
= 404.2.
Example 9. N—((cis)—4-((7-morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine
(Compound 28)
HO\¢¢N H
N/\ N N \
“19—“[1017] ago /N [0j ()1
Cgizo PPh3, DIAD, AP {£1230
THF, 0°c to RT Br a)3
110°C
(step 9—-i) [1°23]
(step 9-ii) [1029] [0N]
0 NI
H2NNH2 / N
/ N H3
M90” RT DIEA, 100°C
(step 9—iii)H (step 9—iv) N / IN [28]
V [N]
Scheme 9
As shown in step 9—i of Scheme 9, 7—bromoquinoxalin—5—ol (compound 1017,
.4 g, 24.0 mmol), 2—((trans)—4—hydroxycyclohexyl)isoindoline—1,3—dione (5.607 g, 22.86
mmol), and triphenylphosphine (8.994 g, 7.945 mL, 34.29 mmol) were dissolved in
anhydrous THF and the flask was cooled in an ice bath. DIAD (6.93 g, 6.64 mL, 34.3
mmol) was added dropwise and the reaction was stirred at 0°C for 5 minutes, then warmed
to room temperature and stirred for 18 hours. The reaction mixture was concentrated
under reduced pressure, the e was treated with EtZO and stirred for 0.5 hour at RT,
the precipitates filtered off, the e concentrated under reduced pressure, and the
residue purified by medium pressure silica gel chromatography (0—50% EtOAc/hexanes
gradient) to produce 2—[(cis)—4—(7—bromoquinoxalinyl)oxycyclohexyl]isoindoline—1,3-
dione (compound 1028, 6.2 g, 60% yield): 1H—NMR (300 MHz, CDCl3) 8 8.95 (d, J = 1.8
Hz, 1H), 8.86 (d, J = 1.8 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), .80 (m, 2H), 7.77—7.68
(m, 2H), 7.31 (d, J = 2.0 Hz, 1H), 4.96 (t, J = 2.9 Hz, 1H), 4.29 (tt, J = 12.5, 3.8 Hz, 1H),
2.88 (qd, J = 12.9, 3.6 Hz, 2H), 2.54—2.32 (m, 2H), 1.94—1.61 (m, 4H).
] As shown in step 9—ii of Scheme 9, In a round bottom flask fitted with a
condenser, a mixture of 2-[4-(7-bromoquinoxalinyl)oxycyclohexyl]isoindoline-1,3-
dione (6.2 g, 12.34 mmol)
, morpholine (1.61 g, 1.62 mL, 18.5 mmol)
and CszCO3 (12.06
g, 37.0 mmol) in anhydrous toluene (73 mL) was treated with rac—BINAP (768.4 mg,
1.234 mmol) and Pd2(dba)3 (565 mg, 0.617 mmol). The reaction mixture was heated at
110°C for 18 hours. After cooling to room temperature, the mixture was filtered through
diatomaceous earth and concentrated under reduced re. The residue was triturated
with EtZO and the solids collected by filtration and washed with EtZO to produce s)—
4—((7—morpholinoquinoxalin—5—yl)oxy)cyclohexyl)isoindoline—1,3—dione (compound 1029,
4.2 g) as yellow solid. The filterate was concentrated under reduced pressure and purified
by medium pressure silica gel chromatography (0—100% hexanes gradient) to
e an additional 300 mg of compound 1029: 1H—NMR (3 00 MHz, CDCl3) 8 8.76—
8.63 (m, 2H), 7.85 (dd, J = 5.4, 3.1 Hz, 2H), 7.79—7.60 (m, 2H), 7.09 (d, J = 2.6 Hz, 1H),
6.99 (d, J = 2.5 Hz, 1H), 5.06 (t, J = 2.8 Hz, 1H), 4.27 (tt, J = 12.3, 3.8 Hz, 1H), 4.02—3.85
(m, 4H), 3.49—3.27 (m, 4H), 3.03—2.75 (m, 2H), 2.37 (d, J = 14.0 Hz, 2H), 1.83-1.56 (m,
4H).
As shown in step 9—iii of Scheme 9, to a suspension of s)—4—(7—
morpholinoquinoxalinyl)oxycyclohexyl]isoindoline-1,3-dione (2.3 g, 5.02 mmol) in
MeOH (25 mL) was added hydrazine (321 mg, 315 ”L, 10.0 mmol) and the reaction
mixture d for 18 hours at RT, over which time the initial suspension became
homogenenous followed by the appearance of a precipitate. EtZO (30 mL) was added and
the reaction mixture stirred an additional 30 minutes. The precipitates were filtered off,
the filtrate concentrated under d pressure, the residue treated with DCM (30 mL),
and any remaining solids removed by filtration. The filtrate was concentrated under
reduced pressure to provide (cis)—4—((7—morpholinoquinoxalinyl)oxy)cyclohexanamine
(compound 1030), which was used as is in subsequent reactions: 1H—NMR (3 00 MHz,
CDCl3) 8 8.69 (d, J = 1.9 Hz, 1H), 8.62 (d, J = 1.9 Hz, 1H), 6.95 (d, J = 2.5 Hz, 1H), 6.90
WO 59690
(d, J = 2.5 Hz, 1H), 5.00—4.67 (m, 3H), 4.03—3.81 (m, 4H), 3.49 (s, 1H), 3.43—3.25 (m, 4H),
2.88 (q, J = 6.2 Hz, 2H), 2.36—1.96 (m, 6H).
As shown in step 9—iv of Scheme 9, to a solution so (cis) 4—(7—
morpholinoquinoxalinyl)oxycyclohexanamine (415 mg, 1.264 mmol) and 2-
methylsulfonylpyrimidine (400 mg, 2.53 mmol) was added DIEA (490 mg, 661 ”L, 3.79
mmol) and the reaction mixture was sealed in a vessel and heated to 100°C for 16 hours.
After this time, the les were removed under a stream of nitrogen gas and the crude
e dissolved in minimal amount of DCM. Purification by medium pressure silica gel
chromatography (0—10% MeOH/DCM, 1% Et3N] produced N—((cis)—4—((7—
morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine containing triethylamine
hydrochloride as an impurity. Dissolved product in DCM and stirred with a silica-
supported amine (Silabond amine® 40—63 ,um). The scavenger mixture was filtered,
concentrated under reduced re, and dried under high vacuum to provide N—((cis)—4—
((7-morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine (Compound 28, 435
mg): 1H—NMR (400 MHz, CDCl3) 8 8.68 (d, J = 1.9 Hz, 1H), 8.61 (d, J = 1.9 Hz, 1H),
8.27 (s, 1H), 8.26 (s, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 6.50 (t, J = 4.8
Hz, 1H), 4.78 (s, 1H), 4.08 — 3.97 (m, 1H), 3.94 — 3.86 (m, 4H), 3.37 — 3.28 (m, 4H), 2.20
(d, J = 9.1 Hz, 2H), 1.95 — 1.85 (m, 6H).
Example 10. Preparation of N-[4-[7-(6-oxaazabicyclo[3.1.1]heptanyl)quinoxalin
yl]oxycyclohexyl]pyrimidinamine (Compound 291)
O N
+ —’
N o
0 / 00
Br N
"”'0H ,filfl:
Scheme 10a
To a mixture of 7-bromoquinoxalinol (47.53 g, 211.2 mmol), 2-(4-
hydroxycyclohexyl)isoindoline-1,3-dione (52.41 g, 213.7 mmol), and PPh3 (87.31 g,
332.9 mmol) in THF (740 mL) at 21 0C was added tert-butyl (NZ)—N—tert—
butoxycarbonyliminocarbamate ) (79.51 g, 328.0 mmol) in portions over 40 min
so as to maintain the temperature below 30 OC and the resultant reaction mixture was
stirred at room temperature for a further 20 h.
The reaction was evaporated in vacuo. The residual reddish—brown viscous oil
was dissolved in CH2Cl2 and filtered through a plug of silica in a glass column using
applied air pressure (plug was made with 1L of dry silica suspended in CH2Cl2). The
plug was eluted with CH2Cl2, the fractions were ed and evaporated in vacuo to
afford a red—brown viscous oil/foam, that was then dissolved in 700 mL of MeOH before
precipitating. The mixture was d at room temperature for 1 h, filtered, washed with
cold MeOH (500 mL) and Et2O (100 mL), then dried in vacuo to yield a tan solid that was
suspended in 300 mL MeOH and brought to reflux for 10 min. The suspension was cooled
to room temperature and ed, washed with a further MeOH and Et2O (4: 1), and dried
in vacuo to provide 2—[4-(7-bromoquinoxalinyl)oxycyclohexyl]isoindoline-1,3-dione
(58.43 g, 126.6 mmol, 59.94%). 1H NMR (400 MHz, CDCl3) 5 8.96 (d, J = 1.8 Hz, 1H),
8.86 (d, J =1.8 Hz, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.89 — 7.82 (m, 2H), 7.78 — 7.67 (m, 2H),
7.30 (d, J =1.9 Hz, 1H), 4.95 (s, 1H), 4.29 (tt, J = 12.5, 3.7 Hz, 1H), 2.87 (qd, J = 13.1, 3.5
Hz, 2H), 2.44 (d, J = 15.2 Hz, 2H), 1.80 (t, J = 14.1 Hz, 2H), 1.67 (d, 2H). EST—MS m/z
calc. 316, found 452.19 (M+1)+; ion time: 0.92 minutes.
WO 59690
0 can.O
N N
J\ \3
Br N N N
Scheme 10b
] A mixture of 2-[4-(7-bromoquinoxalinyl)oxycyclohexyl]isoindoline-1,3-
dione (1 g, 2.211 mmol), 6-oxaazabicyclo[3.1.1]heptane HCl (180 mg, 1.328 mmol),
cesium carbonate (2.161 g, 6.633 mmol), a)3 (202.5 mg, 0.2211 mmol) and rac—
BINAP (275.3 mg, 0.4422 mmol) in dioxane (5 mL) was stirred overnight at 70 0C, then
heated in a microwave reactor for 15 min at 150 °C. The reaction was then diluted with
methylene chloride, filtered though Celite, and concentrated. Silica gel flash column
chromatography (0-5% MeOH/DCM) yielded 2-[4-[7-(6-oxa—3-azabicyclo[3.1.1]heptan—3-
yl)quinoxalin-5—yl]oxycyclohexyl]isoindoline—1,3—dione (750 mg, 72.1%) as a yellow
solid that was carried on to the next reaction.
0 ””00
gm —> N\ $6,N:
Scheme 10c
To a solution of 2—[4—[7—(6-oxa—3—azabicyclo[3.1.1]heptan-3—yl)quinoxalin—5—
yl]oxycyclohexyl]isoindoline-1,3-dione (800 mg, 1.700 mmol) in EtOH (10 mL) was
added hydrazine monohydrate (85.10 mg, 83.35 uL, 1.700 mmol) and the reaction was
stirred at reflux overnight, then concentrated, d with DCM, and filtered. The filtrate
WO 59690
was trated, and purified on a 40 g silica gel cartridge with 0—50% (20%
NH3/MeOH) to yield 4—[7—(6—oxa—3-azabicyclo[3.1.1]heptanyl)quinoxalin
yl]oxycyclohexanamine (450 mg, 77.8%) as a yellow solid. 1H NMR (300 MHz,
form—d) 6 8.65 (d, J = 1.9 Hz, 1H), 8.53 (d, J = 1.9 Hz, 1H), 6.83 (q, J = 2.6 Hz,
2H), 4.83 (t, J = 6.0 Hz, 4H), 3.87 = 8.7, 6.6 Hz, 1H), 3.01
— 3.60 (m, 5H), 3.34 (dt, J —
2.83 (m, 1H), 2.23 (dq, J = 11.3, 5.8, 4.8 Hz, 2H), 2.07 (d, J = 8.7 Hz, 1H), 1.92 — 1.62 (m,
6H).
H2NOH do.
<1: * U —»
N N<1”?N/
Scheme 10d
A mixture of 4-[7-(6-oxa-3 -azabicyclo[3.1.1]heptanyl)quinoxalin
yl]oxycyclohexanamine (190 mg, 0.5581 mmol), 2-fluoropyrimidine (60 mg, 0.6118
mmol) and DIEA (200 ”L, 1.148 mmol) in 2-propanol (2 mL) was heated in a
microwave reactor for 20 min at 150 °C. The reaction mixture was concentrated, and then
purified from 12 g silica gel cartridge with 0-6% MeOH/DCM to yield N—[4—[7—(6—oxa—3—
azabicyclo[3. 1. 1]heptanyl)quinoxalinyl]oxycyclohexyl]pyrimidinamine (120.2
mg, 48.9%) as a yellow solid. Mass + 1: 419.23; Retention Time: 0.72; NMR Annotation:
1H NMR (400 MHz, Chloroform-d) 5 8.42 (d, J = 1.9 Hz, 1H), 8.30 (d, J = 1.9 Hz, 1H),
8.04 (d, J = 4.8 Hz, 2H), 6.65 — 6.56 (m, 2H), 6.28 (t, J = 4.8 Hz, 1H), 4.99 (d, J = 8.1 Hz,
1H), 4.60 (d, J = 6.5 Hz, 3H), 3.79 (dd, J = 8.2, 4.0 Hz, 0H), 3.62 — 3.38 (m, 4H), 3.17 —
3.03 (m, 1H), 2.07 — 1.90 (m, 2H), 1.89 — 1.59 (m, 7H).
Example 11. Preparation of 6-(4-methylpiperazinyl)-N—((1s,4s)((7-
morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine (Compound 537)
H2NU
N CI WN‘ NO
0 NW? NJ
NaOt—Bu O
fiNj t-BuXPhos Palladacycle
/ ENj /
~ QM]
o It J , 100 °C to ~
Scheme 11
A suspension of orpholinoquinoxalin—5—yl)oxycyclohexanamine (500
mg, 1.52 mmol), 4-chloro(4-methylpiperazinyl)pyrimidine (324 mg, 1.52 mmol),
and NaOt—Bu (440 mg, 4.58 mmol) in t—BuOH (10.1 mL) was degassed by bubbling N2
through the mixture for 10 min. t—BuXPhos Palladacycle (53 mg, 0.077 mmol) was added,
and the on mixture was sealed hermetically and heated to 100 0C in an oil bath for 2
h. The t was removed in vacuo, and the crude residue was purified by silica gel
chromatography (40 g Isco gold column, linear gradient 0% —> 10% MeOH/CH2C12
[+0. 1% Et3N]) to yield 6-(4-methylpiperazinyl)-N—((1s,4s)—4-((7-
morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine as a yellow solid (654.7
mg, 83.5% yield). 1H NMR (400 MHz, Chloroform—d) 8 8.69 (d, J = 1.8 Hz, 1H), 8.61 (d,
J =1.8 Hz, 1H), 8.19 (s, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 5.42 (s,
1H), 4.78 (s, 1H), 4.70 (d, J = 8.0 Hz, 1H), 3.97 — 3.87 (m, 4H), 3.83 (s, 1H), 3.64 — 3.50
(m, 4H), 3.40 — 3.27 (m, 4H), 2.53 = 9.2 Hz, 2H),
— 2.42 (m, 4H), 2.34 (s, 3H), 2.19 (d, J
1.97 — 1.77 (m, 6H). ESI—MS m/z calc. 504.2961, found 505.44 (M+1)+; Retention time:
0.5 minutes.
e 12. Preparation of 2-(4-methylpiperazinyl)-N—((1s,4s)((7-
morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine (Compound 535)
H2N0 H
Cl N N
o *J UN /
Eli 0
(\N N’ EtOH, reflux J
OJ {\N N
\N/W
2_ M2
ylpiperazine 0‘0
i-Pr2NEt
i-PrOH, 170 °C uwave
(\Na JN
Scheme 12
To a solution of 4-(7-morpholinoquinoxalinyl)oxycyclohexanamine (500
mg, 1.522 mmol) and Et3N (212 uL, 1.522 mmol) in EtOH (7.25 mL) was added 2,4—
dichloropyrimidine (216.0 mg, 1.450 mmol). The resultant reaction solution was heated to
reflux for 5 h, then cooled to room temperature. The solvent was removed in vacuo, and
the crude residue was purified by silica gel chromatography (40 g Isco gold column, linear
gradient 0% —> 10% MeOH/CHzClz [+0.1% Et3N]) to e 2—chloro—N—[4—(7—
morpholinoquinoxalinyl)oxycyclohexyl]pyrimidinamine as a yellow solid (485 mg,
75% yield). 1H NMR (300 MHz, Chloroform—d) 8 8.70 (d, J = 2.0 Hz, 1H), 8.60 (d, J =
2.0 Hz, 1H), 8.00 (d, J = 4.8 Hz, 1H), 6.96 (d, J = 2.5 Hz, 1H), 6.89 (d, J = 2.5 Hz, 1H),
6.23 (d, J = 5.9 Hz, 1H), 5.18 (d, J = 5.7 Hz, 1H), 4.80 (s, 1H), 3.99 — 3.84 (m, 4H), 3.42 —
3.21 (m, 4H), 2.32 — 2.08 (m, 2H), 2.05 — 1.73 (m, 6H). ESI—MS m/z calc. 440.17276,
found 441.25 ; Retention time: 0.69 minutes.
A solution of 2—chloro-N—[4-(7-morpholinoquinoxalin
yl)oxycyclohexyl]pyrimidinamine (236 mg, 0.5352 mmol), 1-methylpiperazine (190
uL, 1.711 mmol), and Hunig's base (315 uL, 1.808 mmol) in i—PrOH (3.6 mL) was heated
to 170 °C in a microwave for 1 h. The solvent was removed in vacuo. The crude residue
was purified by silica gel chromatography (40 g Isco gold column, linear gradient 0% —>
% MeOH/CHzClz [+0.1% Et3N]) to provide 2-(4-methylpiperazinyl)-N—((1s,4s)
((7-morpholinoquinoxalinyl)oxy)cyclohexyl)pyrimidinamine as a yellow solid (219
mg, 79% yield). 1H NMR (400 MHz, Chloroforrn—d) 8 8.69 (d, J = 1.9 Hz, 1H), 8.61 (d, J
:19 Hz, 1H), 7.88 (d, J = 5.7 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H),
.67 (d, J = 5.8 Hz, 1H), 4.84 — 4.63 (m, 2H), 3.99 — 3.83 (m, 5H), 3.82 — 3.73 (m, 4H),
3.37 — 3.27 (m, 4H), 2.49 — 2.40 (m, 4H), 2.33 (s, 3H), 2.23 — 2.11 (m, 2H), 1.96 — 1.82 (m,
6H). EST—MS m/z calc. 504.2961, found 505.35 (M+1)+; Retention time: 0.51 minutes.
e 13. Preparation of N—methyl(((1s,4s)((7-morpholinoquinoxalin
yl)oxy)cyclohexyl)amino)pyrimidine—4—carboxamide und 359)
GNU-l 1) Oxallyl de 0'
DMF \
2) methyl amine I TH
NVN NV“
NaHCO3
Scheme 13a
A solution of oxalyl chloride (186.2g, 256.0 mmol) and DMF (1.7 mL, 21.96
mmol) was added to a suspension of 6—chloropyrimidine—4—carboxylic acid (9.1 g, 57.40
mmol) in dichloromethane (3 00 mL) dropwise via dropping funnel over 20min. Allowed
to stir for 2hr and concentrated the acid chloride under reduced pressure. The acid
chloride was dissolved in dichloromethane ) and to it was added a solution of
methylamine (30.71 mL of 40 %w/v, 395.5 mmol) in water and NaHCO3 (188.3 mL of
1.2 M, 226.0 mmol) dropwise. The on mixture was d to stir overnight. The
layers were separated and extracted the aqueous layer with dichloromethane (200mL).
The combined organics were washed with brine, dried over sodium sulfate, and
concentrated under reduced pressure. Chromatographed over 120g silica gel using 0—50%
EtOAc/Heptane as eluent. 4.356g (44.94% yield) of ro—N—methylpyrimidine
carboxamide was obtained as a white solid. 1H NMR (400 MHz, Chloroform—d) 5 8.99
(d, J =1.1Hz, 1H), 8.16 (d, J =1.1Hz, 1H), 7.90 (s, 1H), 3.06 (d, J = 5.2 Hz, 3H).
NH2 o’fi
0 V“ /“
O 0 sodium t—butoxide
N CI i N
E /
\ + \ H t-BuXPhos palladacycle
| 0
t—BuOH N “N
N’ N N
N {W W H I
\ '0‘
K/o / H
Scheme 13b
A solution of orpholinoquinoxalinyl)oxycyclohexanamine (7.593 g,
23.12 mmol), 6-chloro-N-methyl-pyrimidinecarboxamide (4.35 g, 25.35 mmol), and t-
BuXPhos palladacycle (1.519 g, 2.333 mmol) in tBuOH (100 mL) was added sodium t—
butoxide (25.5 mL of 2 M, 51.00 mmol). Allowed to stir at room temperature under N2
overnight. The reaction was diluted with dichloromethane (100mL) and filtered through
Celite with dichloromethane wash. The filtrate was concentrated under d pressure
and chromatographed over 330g silica gel using 0—>14% Methanol/DCM as eluent. The
ing product was dissolve in small amount of ethanol (15mL) and the product
precipitated over 1h. Filtered with cold ethanol wash to give a yellow solid. the solid was
dried under vacuum over for 48h at 50°C to yield N—methyl—6—(((1s,4s)—4—((7—
morpholinoquinoxalinyl)oxy)cyclohexyl)amino)pyrimidinecarboxamide (2.58g) as a
yellow solid. 1H NMR (300 MHz, form—d) 8 8.70 (d, J = 1.9 Hz, 1H), 8.61 (d, J =
1.9 Hz, 1H), 8.53 = 5.6 Hz, 1H), 7.20 (d, J = 1.2 Hz, 1H), 6.96
— 8.44 (m, 1H), 8.00 (d, J
(d, J = 2.5 Hz, 1H), 6.90 (d, J = 2.5 Hz, 1H), 5.50 (s, 1H), 4.83 (dt, J = 4.8, 2.5 Hz, 1H),
3.97 = 5.1 Hz, 3H), 2.31
— 3.87 (m, 4H), 3.39 — 3.29 (m, 4H), 3.01 (d, J — 2.19 (m, 2H),
2.06 — 1.70 (m, 6H). EST—MS m/z calc. 463.2332, found 464.25 (M+1)+; Retention time:
0.59 minutes.
2014/024767
Example 14. Preparation of N—methyl(((1s,4s)((7-morpholinoquinoxalin
yl)oxy)cyclohexyl)amino)pyrimidine—4—carboxamide (Compound 350)
O O
\ EDCI, HOBT MLNH
N N gfithflamme N N
Scheme 14a
A solution of 2-chloropyrimidine—4-carboxylic acid (4.425 g, 27.91 mmol) in
DMF (35.40 mL) was added 1-hydroxybenzotriazole (Water (1)) (2.982 g, 19.47 mmol)
and EDCI (Hydrochloric Acid (1)) (6.372 g, 33.24 mmol) at room temperature. After
stirred for 10 min, to the mixture was added METHYL AMINE in tetrahydrofuran(20.93
mL of 2 M, 41.86 mmol) and stirred for 2h. The reaction was diluted with ethyl acetate,
washed with water, and dried over sodium sulfate then concentrated. The resuting residue
was purified from silica gel column 0-30% ethyl acetate/ hexanes to obtain 2-chloro-N—
methylpyrimidinecarboxamide as a white solid. 1H NMR (300 MHz, form—d) 5
8.85 (d, J = 4.9 Hz, 1H), 8.07 (d, J = 4.9 Hz, 1H), 7.82 (s, 1H), 7.27 (s, 0H), 3.06 (d, J =
.2 Hz, 3H).
09 .\ /
sodium t—butoxide o a”N /
N 0v
‘ J\
E + N \N
| N
z W| hos palladacycle \
N N’W NH
t—BuOH I
K/O ,
N N’fi
Scheme 14b
A solution of 4-(7-morpholinoquinoxalinyl)oxycyclohexanamine (6.013 g,
18.31 mmol), ro-N-methyl-pyrimidinecarboxamide (3.41 g, 19.87 mmol) and t-
BuXPhos palladacycle (1.220 g, 1.873 mmol) in tBuOH (100 mL) was added sodium t—
butoxide (20.52 mL of 2 M, 41.04 mmol). Allowed to stir at rt under N2 overnight.
Diluted rxn with dichloromethane (100mL), filtered through celite and concentrated
e under reduced pressure. The resulting residue was chromatographed over 220g
silica gel using 0—>14% Methanol/dichlomethane. The product was ated with ethanol
(40mL) at 70°C for 2h, filtered and dried under vacuum at 50°C overnight to obtain N—
(((1s,4s)—4-((7-morpholinoquinoxalinyl)oxy)cyclohexyl)amino)pyrimidine
carboxamide (5.03 g, 62%yield) as a fine yellow powder. 1H NMR (300 MHz,
Chloroform-d) 8 8.69 (d, J = 1.9 Hz, 1H), 8.62 (d, J = 1.9 Hz, 1H), 8.48 (d, J = 4.9 Hz,
1H), 7.75 (s, 1H), 7.32 (d, J = 4.9 Hz, 1H), 6.96 (d, J = 2.5 Hz, 1H), 6.91 (d, J = 2.5 Hz,
1H), 5.30 (d, J = 7.9 Hz, 1H), 4.85 = 8.5, 4.7 Hz, 1H), 3.99
- 4.73 (m, 1H), 4.07 (dd, J -
3.82 (m, 4H), 3.41 = 5.1 Hz, 3H), 2.20 (q, J = 6.0 Hz, 2H), 2.06
- 3.20 (m, 4H), 3.01 (d, J -
1.82 (m, 6H). EST-MS m/z calc. 463.2332, found 464.31 (M+1)+; Retention time: 0.71
minutes
Tables 1 and 2 provides analytical characterization data for certain compounds
of formula I (blank cells indicate that the test was not performed).
Table 1.
H NMR (300 MHz, unless
indicated otherwise)
NMR oeaks iven as 8 values
(CDC13) 3 8.64 (d, J = 2.0 Hz,
Nfi 1H), 8.36 (d, J=2.0 Hz, 1H),
N 6.61 (d, J = 2.4 Hz, 1H), 6.34
i 0’ (d, J = 2.4 Hz, 1H), 5.90 (s,
N9" 370.52 1H), 5.40 (d, J = 7.7 Hz, 1H),
N 3.98 — 3.76 (m, 5H), 3.51 — 3.24
E j (m, 5H), 2.33 — 2.08 (m, 4H),
0 1.99 (s, 3H), 1.58 — 1.31 (m,
(CDC13) 3 8.63 (d, J = 1.9 Hz,
1H), 8.34 (d, J =19 Hz, 1H),
7.17 (d, J = 8.6 Hz, 2H), 6.90
o’ 3 Nfi (d, J = 8.5 Hz, 2H), 6.59 (d, J =
N 2.2 Hz, 1H), 6.29 (d, J = 2.2
0’ Hz, 1H), 5.86 (d, J = 7.6 Hz,
476.61 1H), 5.29 (d, J = 8.0 Hz, 1H),
N 3.96 — 3.75 (m, 8H), 3.52 (s,
E 1 2H), 3.39 —3.22 (m, 5H), 2.19
0 (d, J: 11.7 Hz, 2H), 2.12 _
1.89 (m, 2H), 1.43 (td, J = 13.0,
2.4 Hz, 2H), 1.32 _ 1.15 (m,
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 5 values
(CDC13) 5 8.65 (d, J = 2.0 Hz,
1H), 8.35 (d, J = 2.0 Hz, 1H),
6.60 (d, J = 2.4 Hz, 1H), 6.34
(d, J = 2.4 Hz, 1H), 6.11 (d, J =
7.8 Hz, 1H), 4.60 (s, 1H), 3.97
— 3.86 (m, 4H), 3.67 (s, 2H),
3.41 =
— 3.25 (m, 4H),1.85(d, J
3.0 Hz, 5H), 1.74 — 1.57 (m,
3H 1.45
, s, 9H
(CDC13) 5 8.64 (d, J = 1.9 Hz,
1H), 8.34 (d, J :19 Hz, 1H),
6.61 (d, J = 2.2 Hz, 1H), 6.35
(d, J = 2.3 Hz, 1H), 6.12 (br s,
1H), 5.56 (d, J = 7.5 Hz, 1H),
4.11 — 3.81 (m, 5H), 3.70 (m,
1H), 3.42 — 3.24 (m, 4H), 1.99
(s, 3H), 1.86 (m, 6H), 1.75 —
1.51 m, 2H
(CDC13) 5 8.65 (d, J = 2.0 Hz,
1H), 8.36 (d, J = 2.0 Hz, 1H),
6.62 (d, J = 2.4 Hz, 1H), 6.34
(d, J = 2.3 Hz, 1H), 6.09 (d, J =
7.6 Hz, 1H), 4.68 (d, J = 7.2
Hz, 1H), 3.97 — 3.82 (m, 4H),
3.76 — 3.47 (m, 2H), 3.40 — 3.23
(m, 4H), 3.01 (s, 3H), 2.04 —
1.65 m, 8H
(CDC13) 5 8.65 (d, J = 2.0 Hz,
1H), 8.36 (d, J = 2.0 Hz, 1H),
6.61 (d, J = 2.4 Hz, 1H), 6.35
(d, J = 2.4 Hz, 1H), 6.10 (d, J =
7.6 Hz, 1H), 4.72 (s, 1H), 4.12
(q, J = 7.0 Hz, 2H), 3.96 — 3.82
(m, 4H), 3.68 (s, 2H), 3.42 —
3.23 (m, 4H), 1.93 — 1.78 (m,
6H), 1.69 (dd, J =15.0, 6.3 Hz,
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 3 8.65 (d, J = 2.0 Hz,
1H), 8.35 (d, J = 2.0 Hz, 1H),
6.61 (d, J = 2.4 Hz, 1H), 6.35
(d, J = 2.3 Hz, 1H), 6.10 (d, J =
7.7 Hz, 1H), 5.26 (s, 1H), 4.85
(d, J = 7.4 Hz, 1H), 4.03 — 3.79
(m, 8H), 3.68 (s, 2H), 3.41 —
3.24 (m, 4H), 2.16 (dd, J =
13.9, 6.0 Hz, 1H), 2.08 — 1.93
(m, 1H), 1.86 (d, J = 3.5 Hz,
6H), 1.76 — 1.54 (m, 2H)
(CDC13) 3 8.65 (d, J = 2.0 Hz,
1H), 8.36 (d, J = 2.0 Hz, 1H),
6.61 (d, J = 2.4 Hz, 1H), 6.35
(d, J = 2.4 Hz, 1H), 6.10 (d, J =
7.6 Hz, 1H), 4.88 (d, J = 6.3
Hz, 1H), 4.21 (d, J = 4.1 Hz,
2H), 3.95 — 3.88 (m, 4H), 3.87 —
3.59 (m, 4H), 3.40 — 3.26 (m,
4H), 1.95 — 1.52 (m, 9H)
(CDC13) 3 8.65 (d, J = 1.9 Hz,
1H), 8.37 (d, J = 2.0 Hz, 1H),
6.61 (d, J = 2.3 Hz, 1H), 6.34
(d, J = 2.3 Hz, 1H), 6.09 (d, J =
7.4 Hz, 1H), 4.81 (s, 1H), 4.66
(s, 2H), 4.01 — 3.86 (m, 4H),
3.65 (s, 2H), 3.42 — 3.24 (m,
4H), 1.87 (t, J = 2.3 Hz, 5H),
1.64 d, J 26.9 Hz, 6H
(CDC13) 3 8.65 (d, J = 1.9 Hz,
1H), 8.36 (d, J =19 Hz, 1H),
6.61 (d, J = 2.3 Hz, 1H), 6.35
(d, J = 2.3 Hz, 1H), 6.10 (d, J =
7.7 Hz, 1H), 4.72 (s, 1H), 4.02
(t, J = 6.6 Hz, 2H), 3.95 — 3.82
(m, 4H), 3.68 (s, 2H), 3.43 —
3.26 (m, 4H), 1.87 (d, J = 3.7
Hz, 6H), 1.78 — 1.50 (m, 4H),
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 3 8.65 (d, J = 2.0 Hz,
1H), 8.35 (d, J = 2.0 Hz, 1H),
6.60 (d, J = 2.4 Hz, 1H), 6.35
(d, J = 2.4 Hz, 1H), 6.10 (d, J =
7.7 Hz, 1H), 4.91 (dt, J = 12.5,
6.2 Hz, 1H), 4.69 (s, 1H), 4.01
— 3.81 (m, 4H), 3.68 (s, 2H),
3.46 — 3.24 (m, 4H), 1.93 — 1.76
(m, 6H), 1.78 — 1.56 (m, 2H),
1.25 (t, J = 9.6 Hz, 6H)
(CDC13) a 8.65 (d, J = 1.9 Hz,
1H), 8.35 (d, J =19 Hz, 1H),
6.61 (d, J = 2.3 Hz, 1H), 6.35
(d, J = 2.3 Hz, 1H), 6.11 (d, J =
7.6 Hz, 1H), 4.74 (s, 1H), 3.99
— 3.79 (m, 6H), 3.68 (s, 2H),
3.40 =
— 3.24 (m, 4H), 1.87 (d, J
3.5 Hz, 7H), 1.78 _ 1.52 (m,
2H), 0.93 (d, J = 6.7 Hz, 6H)
(CDC13) 5 8.65 (t, J = 1.6 Hz,
1H), 8.36 (t, J = 1.6 Hz, 1H),
6.61 (d, J = 2.3 Hz, 1H), 6.35
(d, J = 2.0 Hz, 1H), 6.11 (d, J =
7.6 Hz, 1H), 4.91 (d, J = 7.2
Hz, 1H), 4.80 — 4.18 (m, 4H),
4.00 — 3.84 (m, 4H), 3.81 — 3.56
(m, 2H), 3.46 — 3.21 (m, 4H),
1.87 (d, J: 3.5 Hz,6H), 1.71
dd, J 16.0, 8.2 Hz, 2H
(CDC13) 5 8.65 (d, J = 2.0 Hz,
1H), 8.36 (d, J = 2.0 Hz, 1H),
6.61 (d, J = 2.4 Hz, 1H), 6.34
(d, J = 2.3 Hz, 1H), 6.10 (d, J =
7.1 Hz, 1H), 4.83 (s, 1H), 4.69
(s, 2H), 3.96 — 3.83 (m, 4H),
3.68 (s, 2H), 3.40 — 3.23 (m,
4H), 2.48 (t, J = 2.4 Hz, 1H),
1.87 (d, J = 4.2 Hz,6H), 1.71
H NMR (300 MHz, unless
Compound Structure indicated ise)
NMR peaks given as 8 values
(CDC13) 8 8.66 (d, J = 2.0 Hz,
1H), 8.37 (d, J = 2.0 Hz, 1H),
7.10 =
— 6.98 (m, 2H), 6.87 (d, J
9.0 Hz, 2H), 6.62 (d, J = 2.4
Hz, 1H), 6.36 (d, J = 2.4 Hz,
1H), 6.13 (d, J = 7.3 Hz, 1H),
.06 (d, J = 7.9 Hz, 1H), 3.97 —
3.84 (m, 4H), 3.84 — 3.61 (m,
5H), 3.42 — 3.25 (m, 4H), 1.91
(d, J = 4.2 Hz, 6H), 1.85 — 1.68
(m, 2H)
(CDC13) 8 8.49 (s, 1H), 8.23 (d,
J = 1.5 Hz, 1H), 6.48 (s, 1H),
6.18 (d, J = 1.9 Hz, 1H), 6.06
(s, 1H), 4.52 (s, 1H), 4.47 (s,
2H), 3.60 (s, 2H), 3.45 (d, J =
11.6 Hz, 2H), 3.14 — 3.12 (m,
2H), 1.96 — 1.84 (m, 4H), 1.79
(s, 5H), 1.54 (s, 3H) and 1.38
(s, 9H) 9pm
(CDC13) 8 6.13 (d, J = 1.6 Hz,
1H), 5.89 (d, J = 1.4 Hz, 1H),
4.87 (d, J = 7.0 Hz, 1H), 4.59
(s, 1H), 3.26 (dd, J = 9.2, 4.3
Hz, 4H), 1.98 — 1.74 (m, 6H),
1.65 (dd, J = 15.9, 7.3 Hz, 3H),
1.47 (s, 9H)
(CDC13) 8 8.65 (d, J = 2.0 Hz,
1H), 8.37 (d, J = 2.0 Hz, 1H),
8.27 (d, J = 4.8 Hz, 2H), 6.60
(d, J = 2.4 Hz, 1H), 6.51 (t, J =
4.8 Hz, 1H), 6.36 (d, J = 2.4
Hz, 1H), 6.15 (d, J = 7.8 Hz,
1H), 5.20 (d, J = 7.7 Hz, 1H),
4.04 (d, J = 7.9 Hz, 1H), 3.96 —
3.82 (m, 4H), 3.70 (s, 1H), 3.39
— 3.24 (m, 4H), 1.94 (dd, J
13.7, 4.4 Hz, 6H), 1.78 (dt, J =
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure indicated ise)
(M+H)
NMR peaks given as 8 values
(CDC13) 5 8.64 (d, J = 1.9 Hz,
1H), 8.35 (d, J =1.9 Hz, 1H),
6.58 (t, J = 5.1 Hz, 2H), 6.34
(d, J = 2.3 Hz, 1H), 6.10 (d, J =
7.3 Hz, 1H), 4.03 (d, J = 8.3
19 Map6 400.46
Hz, 1H), 3.88 (t, J = 4.7 Hz,
E J 6H), 3.68 (s, 1H), 3.42 (s, 3H),
3.37 — 3.23 (m, 4H), 1.98 — 1.78
0 (m, 6H), 1.69 (dd, J = 15.8, 7.5
Hz, 2H)
(400.0 MHz, CDC13) 3 8.52 (d,
J: 1.7 Hz, 1H), 8.23 (d, J = 1.6
3 Hz, 1H), 6.47 (d, J = 1.9 Hz,
1H), 6.19 (s, 1H), 6.03 (s, 1H),
.19 (s, 1H), 4.76 (d, J = 7.6
Hz, 1H), 4.47 (s, 2H), 3.87 — 20 468.23
3.76 (m, 4H), 3.60 (s, 2H), 3.45
(d, J: 11.6 Hz, 2H), 3.13 —
3.10 (m, 2H), 2.61 (s, 1H), 2.13
— 2.04 (m, 1H), 1.95 — 1.85 (m,
5H), 1.79 (s, 5H) and 1.62 —
1.58 (m, 2H)
21 426.31
(400.0 MHz, CDC13) 5 8.54 (s,
1H), 8.22 (s, 1H), 6.43 (s, 1H),
Z_ 6.19 (s, 1H), 6.02 (s, 1H), 4.47
(s, 2H), 4.38 (d, J = 5.2 Hz,
1H), 4.28 (s, 1H), 3.74 (s, 1H),
22 425.35
3.60 (s, 1H), 3.42 (s, 4H), 3.14
OQZ — 3.09 (m, 4H), 2.05 — 1.87 (m,
3H), 1.79 (s, 3H), 1.55 (d, J =
7.1 Hz, 2H) and 1.21 — 1.05 (m,
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 3 8.20 (d, J = 4.9 Hz,
2H), 6.46 (t, J = 4.8 Hz, 1H),
6.05 (d, J = 1.6 Hz, 1H), 5.82
(s, 1H), 5.24 (s, 1H), 4.82 (d, J
= 7.0 Hz, 1H), 3.98 (s, 1H),
3.85 — 3.72 (m, 4H), 3.60 (s,
1H), 3.23 — 3.06 (m, 4H), 1.95 —
1.62
m, 8H .
(400 MHz, CDC13) 8 8.65 (s,
1H), 8.37 (d, J =18 Hz, 1H),
8.08 (d, J = 4.9 Hz, 1H), 7.41
(t, J = 7.7 Hz, 1H), 6.61 (s, 1H),
6.58 — 6.53 (m, 1H), 6.46 — 6.30
(m, 2H), 6.15 (d, J = 7.3 Hz,
1H), 4.56 (s, 1H), 3.98 — 3.78
(m, 5H), 3.76 — 3.61 (m, 1H),
3.42 =
— 3.24 (m, 4H), 1.97 (d, J
29.6 Hz, 6H), 1.86 — 1.66 (m,
(CDC13) a 8.69 (d, J = 2.0 Hz,
1H), 8.42 (d, J = 2.0 Hz, 1H),
8.26 (s, 1H), 7.14 (d, J = 2.1
Hz, 1H), 6.64 (d, J = 2.4 Hz,
1H), 6.38 (d, J = 2.3 Hz, 1H),
6.24 (d, J = 6.8 Hz, 1H), 4.31
(q, J = 7.1 Hz, 2H), 3.97 — 3.81
(m, 5H), 3.41 — 3.24 (m, 4H),
2.22 (d, J = 7.5 Hz, 2H), 1.90
(dd, J = 22.4, 10.3 Hz, 6H),
1.35 (t, J = 7.1 Hz, 3H)
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J =19 Hz, 1H),
6.95 (d, J = 2.5 Hz, 1H), 6.88
(d, J = 2.5 Hz, 1H), 4.82 ? 4.60
(m, 2H), 4.00 ? 3.88 (m, 4H),
3.69 (d, J = 6.8 Hz, 1H), 3.42 ?
3.28 (m, 4H), 2.15 (p, J = 6.7,
.6 Hz, 2H), 1.94 ? 1.75 (m,
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.65 (d, J = 2.0 Hz,
1H), 8.36 (d, J = 2.0 Hz, 1H),
7.98 (dd, J = 2.8, 1.5 Hz, 1H),
7.88 (d, J =15 Hz, 1H), 7.79
(d, J = 2.8 Hz, 1H), 6.62 (d, J =
2.4 Hz, 1H), 6.37 (d, J = 2.4
Hz, 1H), 6.17 (s, 1H), 8.69 —
8.61 (m, 1H), 4.60 (d, J = 7.7
Hz, 1H), 4.08 — 3.83 (m, 5H),
8.71 — 8.57 (m, 1H), 3.73 (t, J =
6.9 Hz, 1H), 3.40 — 3.25 (m,
4H), 1.96 (h, J = 4.9 Hz, 6H),
1.77 (q, J = 7.4, 6.1 Hz, 2H)
(400 MHz, CDC13) 5 8.77 —
8.59 (m, 2H), 8.29 (d, J = 4.9
Hz, 2H), 7.01 — 6.87 (m, 2H),
6.61 — 6.48 (m, 1H), 4.82 (s,
1H), 4.05 (s, 1H), 3.93 (t, J =
4.8 Hz, 4H), 3.35 (t, J = 4.8 Hz,
4H), 2.23 (d, J = 13.1 Hz, 2H),
2.05 — 1.82 (m, 6H)
(DMSO—ds) 5 12.65 (s, 1H),
8.69 (d, J = 2.0 Hz, 2H), 8.43
(d, J = 2.0 Hz, 1H), 8.00 (d, J =
7.9 Hz, 1H), 6.54 (d, J = 2.5
Hz, 1H), 6.48 (d, J = 2.3 Hz,
1H), 6.17 (d, J = 8.2 Hz, 1H),
4.06 (s, 1H), 3.77 (dd, J = 5.9,
3.8 Hz, 4H), 3.29 (s, 5H), 2.04
— 1.46 (m, 8H)
(CDC13) 5 8.66 (d, J = 2.0 Hz,
1H), 8.58 (s, 1H), 8.37 (d, J =
2.0 Hz, 1H), 8.13 (s, 2H), 6.63
(d, J = 2.4 Hz, 1H), 6.37 (d, J =
2.4 Hz, 1H), 6.14 (d, J = 7.6
Hz, 1H), 3.96 — 3.86 (m, 4H),
3.76 (d, J = 7.7 Hz, 2H), 3.54
(d, J = 8.3 Hz, 1H), 3.39 — 3.29
(m, 4H), 2.02 — 1.86 (m, 6H),
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure indicated ise)
(M+H)
NMR peaks given as 8 values
(CDC13) a 12.88 — 12.45 (m,
1H), 8.66 (d, J = 2.0 Hz, 1H),
8.37 (d, J = 2.0 Hz, 1H), 7.81
(s, 1H), 6.62 (d, J = 2.3 Hz,
1H), 6.36 (d, J = 2.4 Hz, 1H),
31 422.49 6.12 (d, J = 7.7 Hz, 1H), 5.27
(s, 1H), 5.05 (d, J = 7.6 Hz,
1H), 4.02 — 3.83 (m, 4H), 3.63
(d, J = 47.6 Hz, 2H), 3.44 —
3.22 (m, 4H), 1.91 (q, J = 4.8,
4.3 Hz, 6H), 1.82—1.69 (m, 2H)
(CDC13) 3 8.78 (d, J = 1.3 Hz,
1H), 8.66 (d, J = 2.0 Hz, 1H),
8.37 (d, J = 2.0 Hz, 1H), 7.91
(d, J = 1.3 Hz, 1H), 6.62 (d, J =
2.4 Hz, 1H), 6.37 (d, J = 2.4
32 464.6 Hz, 1H), 6.16 (d, J = 7.6 Hz,
1H), 5.13 (d, J: 7.6 Hz, 1H),
4.10 (s, 1H), 3.99 — 3.86 (m,
7H), 3.76 (s, 1H), 3.39 — 3.28
(m, 4H), 1.98 (h, J = 4.8 Hz,
6H), 1.80 (t, J = 8.7 Hz, 2H)
(CDC13) 5 8.63 (d, J = 1.9 Hz,
1H), 7.99 (dd, J = 2.8, 1.5 Hz,
1H), 7.94 — 7.85 (m, 1H), 7.79
(d, J = 2.8 Hz, 1H), 7.14 (d, J =
1.0 Hz, 1H), 7.03 — 6.87 (m,
33 407.3
2H), 4.82 (d, J = 5.7 Hz, 1H),
4.70 (d, J = 8.0 Hz, 1H), 4.03 —
3.86 (m, 4H), 3.51 (s, 1H), 3.43
— 3.30 (m, 4H), 2.35 — 1.81 (m,
(CDC13) 5 8.69 (dd, J = 3.4, 1.9
Hz, 1H), 8.62 (dd, J = 3.6, 1.9
Hz, 1H), 8.51 (dd, J = 4.8, 2.2
Hz, 2H), 7.01 — 6.83 (m, 3H),
.18 (tt, J = 7.0, 3.4 Hz, 1H),
34 408.5
4.79 (tt, J = 6.9, 3.1 Hz, 1H),
4.00 — 3.85 (m, 4H), 3.34 (dq, J
= 4.8, 2.6 Hz, 4H), 2.44
— 2.16
(m, 4H), 1.92 (tdd, J = 16.4,
7.7, 2.8 Hz, 4H)
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.68 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
6.99 — 6.85 (m, 2H), 4.70 (dq, J
= 7.3, 3.5 Hz, 1H), 4.05
— 3.84
(m, 8H), 3.40 - 3.25 (m, 4H),
2.19 — 1.93 (m, 6H), 1.77 — 1.64
(m, 2H)
(CDC13) 3 8.94 — 8.76 (m, 2H),
8.29 (d, J = 4.8 Hz, 2H), 7.67
(d, J = 1.7 Hz, 1H), 6.53 (t, J =
4.8 Hz, 1H), 6.37 (tt, J = 3.1,
1.5 Hz, 1H), 5.30 (d, J = 7.9
404.2 Hz, 1H), 4.87 (dt, J = 7.5, 3.6
Hz, 1H), 4.43 (q, J = 2.8 Hz,
2H), 4.02 (t, J = 5.5 Hz, 3H),
2.68 (dqd, J = 6.0, 3.4, 3.0, 1.8
Hz, 2H), 2.35 — 2.11 (m, 2H),
2.07 — 1.84 (m, 6H)
(CDC13) a 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
8.18 (dd, J = 3.7, 0.8 Hz, 2H),
7.01 — 6.85 (m, 2H), 5.37 — 5.20
37 425.25
(m, 1H), 4.79 (d, J = 5.5 Hz,
1H), 4.02 — 3.85 (m, 4H), 3.43 —
3.29 (m, 4H), 2.31 — 2.15 (m,
2H), 2.02 — 1.85 (m, 6H)
(CDC13) a 8.61 (d, J = 2.0 Hz,
1H), 8.55 (d, J =19 Hz, 1H),
8.20 (d, J = 4.8 Hz, 2H), 6.87
(d, J = 2.5 Hz, 1H), 6.81 (d, J =
2.5 Hz, 1H), 6.46 (t, J = 4.8 Hz,
38 1H), 4.95 (s, 1H), 4.45 (n, J =
.7, 3.6 Hz, 1H), 3.95 — 3.77
(m, 5H), 3.32 — 3.19 (m, 4H),
2.34 — 2.10 (m, 4H), 1.82 (dt, J
= 12.9, 10.0 Hz, 2H), 1.45
1.20 (m, 2H)
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.72 (d, J = 1.9 Hz,
1H), 8.62 (d, J :19 Hz, 1H),
8.37 (s, 1H), 6.98 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
1H), 6.36 (d, J = 1.0 Hz, 1H),
4.91 - 4.76 (m, 1H), 4.00 — 3.88
(m, 4H), 3.45 - 3.24 (m, 4H),
2.34 - 2.17 (m, 2H), 2.03 — 1.84
m, 6H
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
7.15 (d, J = 9.3 Hz, 1H), 7.00 —
6.87 (m, 2H), 6.64 (d, J = 9.3
Hz, 1H), 4.89 - 4.76 (m, 2H),
4.11 - 4.03 (m, 1H), 4.00 — 3.83
(m, 4H), 3.40 - 3.24 (m, 4H),
2.23 (dq, J = 12.9, 6.3, 5.6 Hz,
2H 2.02 - 1.79
, m, 6H
) 8 8.63 (d, J = 1.9 Hz,
1H), 8.55 (d, J =1.9 Hz, 1H),
7.58 (d, J = 23.6 Hz, 2H), 6.89
(d, J = 2.4 Hz, 1H), 6.84 (d, J =
2.5 Hz, 1H), 4.73 (s, 2H), 3.93
— 3.72 (m, 5H), 3.34 — 3.18 (m,
4H), 2.29 (s, 3H), 2.15 (m, 2H),
1.84 (m, 6H)
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
8.52 (d, J = 4.8 Hz, 2H), 7.01 -
6.87 (m, 3H), 5.17 (ddt, J = 8.7,
6.7, 3.4 Hz, 1H), 4.76 — 4.58
(m, 1H), 4.00 — 3.87 (m, 4H),
3.40 — 3.27 (m, 4H), 2.43 - 2.22
(m, 4H), 2.05 - 1.87 (m, 2H),
1.86 — 1.71 m, 2H
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) a 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J =19 Hz, 1H),
7.36 (s, 1H), 7.12 (d, J = 3.6
Hz, 1H), 6.95 (d, J = 2.5 Hz,
1H), 6.90 (d, J = 2.5 Hz, 1H),
6.48 (d, J = 3.6 Hz, 1H), 5.18
(d, J = 8.0 Hz, 1H), 4.79 (td, J
= 5.4, 2.7 Hz, 1H), 3.97
— 3.85
(m, 4H), 3.70 (q, J = 6.8 Hz,
1H), 3.39 — 3.25 (m, 4H), 2.29 _
2.12 (m, 2H), 2.07 — 1.77 (m,
(CDC13) a 8.71 (d, J = 2.0 Hz,
1H), 8.64 (d, J = 2.0 Hz, 1H),
8.54 (d, J = 2.9 Hz, 1H), 8.47
(d, J = 3.0 Hz, 1H), 6.99 (d, J =
2.4 Hz, 1H), 6.92 (d, J = 2.5
Hz, 1H), 5.81 (d, J = 8.3 Hz,
1H), 4.84 (dt, J = 5.3, 2.8 Hz,
1H), 4.13 — 4.05 (m, 1H), 4.00 —
3.84 (m, 4H), 3.43 — 3.30 (m,
4H), 2.32 — 2.17 (m, 2H), 2.02 —
(CDC13) a 8.70 (d, J = 2.0 Hz,
1H), 8.64 (d, J =19 Hz, 1H),
8.29 (s, 2H), 6.98 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
1H), 5.29 (d, J = 8.3 Hz, 1H),
4.81 (s, 1H), 4.04 — 3.84 (m,
4H), 3.42 _ 3.31 (m, 4H), 2.22
(s, 2H), 1.92 (d, J = 4.9 Hz, 6H)
(CDC13) 3 8.63 (d, J = 2.0 Hz,
1H), 8.52 (d, J = 4.8 Hz, 2H),
8.37 (d, J = 2.0 Hz, 1H), 6.92
(t, J = 4.8 Hz, 1H), 6.62 (d, J =
2.4 Hz, 1H), 6.38 (d, J = 2.4
Hz, 1H), 6.16 (s, 1H), 5.27 (s,
1H), 4.06 — 3.78 (m, 4H), 3.64
(s, 1H), 3.48 — 3.20 (m, 4H),
2.14 (s, 2H), 2.04 — 1.80 (m,
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 5 values
(CDC13) 3 8.66 (dd, J = 20.5,
1.9 Hz, 2H), 6.93 (dd, J = 17.3,
2.5 Hz, 2H), 4.87 — 4.65 (m,
1H), 4.04 — 3.83 (m, 4H), 3.72
(s, 3H), 3.46 — 3.22 (m, 4H),
2.72 — 2.40 (m, 1H), 2.35 — 1.99
(m, 4H), 1.99 — 1.51 (m, 4H)
(DMSO—d6) 5 12.13 (s, 1H),
8.72 (d, J = 1.7 Hz, 1H), 8.58
(d, J: 1.8 Hz,1H), 7.13 (d, J:
2.1 Hz, 1H), 6.83 (d, J = 2.0
Hz, 1H), 4.94 — 4.84 (m, 1H),
3.91 — 3.68 (m, 4H), 3.51 — 3.19
(m, 4H), 2.47 — 2.33 (m, 1H),
2.04 — 1.82 (m, 4H), 1.82 — 1.60
m, 4H
(400 MHz, CDC13) 5 8.70 (d, J
= 1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 7.99 (s, 1H), 6.96 (d, J
= 2.4 Hz, 1H), 6.89 (d, J = 2.3
Hz, 1H), 6.20 (s, 1H), 5.19 (bs,
1H), 4.81 (bs, 1H), 3.96 — 3.84
(m, 4H), 3.40 — 3.27 (m, 4H),
2.29 — 2.14 (m, 2H),1.99 — 1.81
m, 6H
(400 MHz, CDC13) 5 8.69 (d, J
:19 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 8.30 (d, J = 2.1Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.84
(s, 1H), 5.42 (s, 1H), 4.81 (s,
1H), 3.99
— 3.82 (m, 4H), 3.39 — 3.24 (m,
4H), 2.31 — 2.19 (m, 2H), 2.08 —
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.69 (d, J
=19 Hz, 1H), 8.60 (d, J = 1.9
Hz, 1H), 8.30 (d, J = 2.1 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.84
(s, 1H), 5.42 (s, 1H), 4.81 (s,
1H), 3.99 — 3.82 (m, 4H), 3.39 —
3.24 (m, 4H), 2.31 — 2.19 (m,
2H 2.08 — 1.72
, m, 8H
(400 MHz, CDC13) 5 8.68 (d, J
=14 Hz, 1H), 8.60 (d, J = 1.5
Hz, 1H), 6.93 (s, 1H), 6.90 (s,
1H), 6.28 (s, 1H), 5.06 (d, J =
7.9 Hz, 1H), 4.77 (s, 1H), 4.06
(bs, 1H), 3.97 — 3.84 (m, 4H),
3.38 — 3.25 (m, 4H), 2.27 (s,
6H), 2.18 — 2.09 (m, 2H), 1.94 —
1.83 m, 7H
(CDC13) 3.9 Hz, 1H), 8.28 (d, J
= 4.8 Hz, 2H), 6.85 (t, J = 1.9
Hz, 2H), 6.51 (t, J = 4.8 Hz,
1H), 5.29 (d, J = 6.3 Hz, 1H),
4.80 (dq, J = 5.5, 2.8 Hz, 1H),
4.57 (d, J = 3.9 Hz, 2H), 4.02
(t, J = 6.2 Hz, 1H), 3.54 — 3.43
(m, 2H), 3.19 (dd, J = 11.6, 2.6
Hz, 2H), 2.27 — 2.14 (m, 2H),
2.08 — 1.85 m, 10H
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J =19 Hz, 1H),
7.45 (d, J = 7.8 Hz, 2H), 7.02 —
6.81 (m, 2H), 4.78 (ddd, J =
7.3, 5.6, 3.1 Hz, 1H), 4.66 (d, J
= 7.9 Hz, 1H), 4.01
— 3.78 (m,
7H), 3.41 — 3.25 (m, 4H), 2.30 —
2.08 (m, 2H), 1.94 (h, J = 8.8,
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 0 8.73 (d, J = 2.0 Hz,
1H), 8.63 (d, J = 2.0 Hz, 1H),
7.42 (d, J = 9.3 Hz, 1H), 6.96
(dd, J = 19.6, 2.5 Hz, 2H), 6.65
(d, J = 9.3 Hz, 1H), 5.40 (s,
1H), 4.86 (s, 1H), 3.94 (dd, J =
.9, 3.8 Hz, 4H), 3.37 (dd, J =
6.0, 3.7 Hz, 4H), 2.27 (d, J =
12.7 Hz, 2H), 2.05 — 1.80
(m,6H)
(CDC13) a 8.69 (d, J = 1.9 Hz,
1H), 8.61 (d, J =19 Hz,1H),
8.28 (d, J = 4.8 Hz, 2H), 6.98 —
6.86 (m, 2H), 6.53 (t, J = 4.8
Hz, 1H), 5.39 (s, 1H), 4.89 —
4.75 (m, 1H), 4.18 — 3.93 (m,
2H), 3.93 — 3.72 (m, 2H), 3.70 —
3.52 (m, 2H), 3.00 (td, J = 12.0,
3.5 Hz, 1H), 2.66 (dd, J = 12.1,
.3 Hz, 1H), 2.21 (d, J = 8.9
Hz, 2H), 1.93 (d, J = 6.7 Hz,
6H), 1.30 (d, J = 6.2 Hz, 3H)
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.62 (d, J =19 Hz, 1H),
8.28 (d, J = 4.8 Hz, 2H), 7.02 —
6.86 (m, 2H), 6.53 (t, J = 4.8
Hz, 1H), 5.40 (s, 1H), 4.82 (d, J
= 5.8 Hz, 1H), 4.20
— 3.95 (m,
2H), 3.94 — 3.53 (m, 6H), 3.03
(td, J = 12.0, 3.5 Hz, 1H), 2.86
(dd,J=12.1, 10.4 Hz, 1H),
2.20 (d, J = 9.2 Hz, 2H), 2.11 —
1.80 (m, 7H)
(400 MHz, methanol—d4) 5 8.69
(d, J = 2.0 Hz, 1H), 8.56 (d, J =
2.0 Hz, 1H), 7.12 (d, J = 2.3
Hz, 1H), 6.89 (d, J = 2.4 Hz,
1H), 5.36 (s, 1H), 3.97 (s, 1H),
3.91 — 3.86 (m, 4H), 3.84 (s,
6H), 3.43 — 3.35 (m, 4H), 2.23 —
2.10 (m, 2H), 2.00 — 1.81 (m,
WO 59690
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.70 (d, J
= 1.9 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 8.36 (d, J =18 Hz,
1H), 7.54 (dd, J = 8.8, 2.2 Hz,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.4 Hz, 1H), 6.37
(d, J = 8.7 Hz, 1H), 5.11 (s,
1H), 4.80 (s, 1H), 3.94 (s, 1H),
3.94 — 3.79 (m, 4H), 3.38 — 3.25
(m, 4H), 2.32 — 2.12 (m, 2H),
2.02 — 1.78 (m, 6H)
(CDC13) 5 8.71 (d, J = 1.9 Hz,
1H), 8.62 (d, J :19 Hz, 1H),
7.06 — 6.88 (m, 3H), 6.80 (dd, J
= 9.4, 6.3 Hz, 1H), 4.97
— 4.71
(m, 2H), 4.14 (q, J = 7.1 Hz,
1H), 4.01 - 3.85 (m, 4H), 3.44 -
3.24 (m, 4H), 2.23 (d, J = 10.7
Hz, 2H), 1.96 (dt, J = 11.0, 7.6
Hz, 6H)
(400 MHz, CDC13) 8 8.69 (d, J
=18 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 6.94 (d, J = 2.3 Hz,
1H), 6.87 (s, 1H), 5.78 — 5.64
(m, 1H), 4.73 (s, 1H), 4.01 (s,
1H), 3.97 — 3.78 (m, 4H), 3.43 —
3.18 (m, 4H), 2.26 _ 2.05 (m,
2H), 1.98 — 1.73 (m, 6H), 1.36 —
1.26 (m, 1H), 1.01 _ 0.92 (m,
2H), 0.78 — 0.67 (m, 2H)
(400 MHz, CDC13) a 8.69 (d, J
:19 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 6.95 (d, J = 2.3 Hz,
1H), 6.87 (d, J = 2.2 Hz, 1H),
6.79 (d, J = 8.1 Hz, 1H), 4.73
(s, 1H), 4.34 (dd, J = 8.3, 5.9
Hz, 1H), 4.04 — 3.84 (m, 7H),
3.40 — 3.28 (m, 4H), 2.35 — 2.24
(m, 1H), 2.23 — 2.11 (m, 2H),
2.09 — 1.98 (m, 1H), 1.97 — 1.76
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.53 (s, 1H), 8.29 (d,
J = 4.8 Hz, 2H), 6.92 (d, J = 2.5
Hz, 1H), 6.85 (d, J = 2.5 Hz,
1H), 6.52 (t, J = 4.8 Hz, 1H),
.25 (d, J = 8.3 Hz, 1H), 4.79
(s, 1H), 4.07 (d, J = 20.4 Hz,
1H), 3.98 — 3.85 (m, 4H), 3.43 —
3.21 (m, 4H), 3.05 — 2.83 (m,
2H), 2.30 — 2.14 (m, 1H), 2.03 —
1.71 (m, 7H), 1.45 (dq, J =
14.5, 7.3 Hz, 2H), 0.98 (t, J =
7.3 Hz, 3H)
(CDC13) 5 8.55 (s, 1H), 8.29 (d,
J = 1.5 Hz, 2H), 7.05 — 6.93 (m,
1H), 6.85 (d, J = 2.5 Hz, 1H),
.49 (d, J = 8.0 Hz, 1H), 4.80
(d, J = 5.8 Hz, 1H), 4.03 — 3.81
(m, 5H), 3.45 — 3.27 (m, 4H),
2.98 (dd, J = 8.5, 7.0 Hz, 2H),
2.32 — 2.09 (m, 2H), 2.00 — 1.71
(m, 8H), 1.56 — 1.34 (m, 2H),
0.98 (td, J = 7.3, 3.3 Hz, 3H)
(CDC13) a 8.76 — 8.66 (m, 3H),
8.61 (d, J = 1.9 Hz, 1H), 6.99 —
6.87 (m, 2H), 5.71 (d, J = 8.1
Hz, 1H), 4.81 (s, 1H), 4.11 (s,
1H), 3.92 (t, J = 4.9 Hz, 4H),
3.34 (t, J = 4.9 Hz, 4H), 2.22
(d, J = 10.2 Hz, 2H), 2.02 —
1.85 (m, 6H)
(CDC13) 5 8.77 (d, J = 2.3 Hz,
1H), 8.72 (d, J = 2.3 Hz, 1H),
7.12 (d, J = 2.4 Hz, 1H), 7.02
(d, J = 2.4 Hz, 1H), 4.92 (s,
1H), 4.18 — 4.08 (m, 2H), 3.93
(t, J = 4.9 Hz, 4H), 3.85 — 3.76
(m, 2H), 3.60 (q, J = 7.0 Hz,
2H), 3.47 (t, J = 4.9 Hz, 4H),
2.26 (d, J = 13.3 Hz, 2H), 2.07
(t, J = 10.5 Hz, 2H), 2.01 — 1.72
(m, 2H), 1.26 (t, J = 7.0 Hz,
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) a 8.71 (d, J = 2.0 Hz,
1H), 8.64 (d, J =19 Hz, 1H),
8.02 (s, 1H), 6.94 (dd, J = 12.2,
2.5 Hz, 2H), 5.32 (s, 2H), 4.87
(d, J = 8.1 Hz, 1H), 4.79 (s,
1H), 4.01 _ 3.86 (m, 4H), 3.36
(q, J = 5.4, 4.7 Hz, 4H), 2.83 (s,
6H), 2.19 (s, 2H), 1.92 (d, J =
4.8 Hz, 6H)
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J = 1.9 Hz, 1H),
8.34 (s, 2H), 7.02 — 6.86 (m,
2H), 6.00 (tt, J = 3.0, 1.5 Hz,
1H), 5.41 — 5.21 (m, 1H), 4.81
(dt, J = 7.2, 3.6 Hz, 1H), 4.31
(q, J = 2.8 Hz, 2H), 4.03 (dd, J
= 7.8, 4.4 Hz, 1H), 4.00
— 3.82
(m, 6H), 3.42 — 3.25 (m, 4H),
2.44 (tdd, J = 5.7, 2.9, 1.7 Hz,
2H), 2.22 (dq, J = 11.2, 6.6, 6.0
Hz, 2H), 2.02 — 1.83 (m, 6H)
(CDC13) 5 9.05 (s, 1H), 8.88 —
8.71 (m, 3H), 8.49 (s, 1H), 7.06
(d, J = 2.3 Hz, 1H), 6.96 (d, J =
2.3 Hz, 1H), 4.85 (s, 1H), 4.17
(s, 1H), 3.93 (t, J = 4.8 Hz, 4H),
3.42 (t, J = 4.9 Hz, 4H), 2.25 -
2.10 (m, 2H),1.95(d, J = 11.9
Hz, 4H)
NW/ (methanol—d4) 5 8.69 (s, 1H),
,00 N
8.56 (s, 1H), 7.20 (s, 1H), 7.10
(d, J = 2.2 Hz, 1H), 6.88 (d, J =
N 2.4 Hz, 1H), 4.93 (d, J = 14.3
70 NJ\N N
E 1 409.45 Hz, 2H), 3.95 — 3.76 (m, 7H),
I 3.42 —3.32 (m, 4H), 3.09 (d,J=
O 7.3 Hz, 1H), 2.21 — 2.09 (m,
fiN’CHi" 2H,1.856Hi (dd,J=10.8,5.6H,Z
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.79 — 8.64 (m, 3H),
8.59 (d, J =19 Hz, 1H), 6.99 —
6.88 (m, 2H), 6.19 (q, J = 4.7
Hz, 1H), 5.90 (d, J = 8.2 Hz,
1H), 4.81 (dq, J = 5.3, 2.7 Hz,
1H), 4.08 (qd, J = 8.2, 6.5, 2.3
Hz, 1H), 3.97 — 3.87 (m, 4H),
3.39 =
— 3.29 (m, 4H), 2.93 (d, J
4.8 Hz, 3H), 2.27 — 2.14 (m,
2H), 2.06 — 1.79 (m, 6H)
) 5 3.97 — 3.87 (m, 4H),
3.39 — 3.29 (m, 4H), 3.10 (s,
6H), 2.22 (dt, J = 11.3, 5.1 Hz,
2H), 1.94 (dd, J = 8.3, 3.9 Hz,
6H), 4.12 - 4.01 (m, 1H), 8.70
(d, J :19 Hz, 1H), 8.62 (d, J =
1.9 Hz, 1H), 8.46 (s, 2H), 7.00
= 8.1
— 6.87 (m, 2H), 5.57 (d, J
Hz,1H), 4.81 (dq, J = 5.1, 2.4
Hz, 1H)
(400 MHz, CDC13) 8 8.69 (d, J
= 1.2 Hz, 1H), 8.57 (d, J = 21.7
Hz, 1H), 6.93 (d, J = 1.7 Hz,
1H), 6.86 (s, 1H), 5.75 (d, J =
7.4 Hz, 1H), 4.74 (s, 1H), 4.03
— 3.87 (m, 8H), 3.81 (dd, J
.2, 7.5 Hz, 1H), 3.37 — 3.25
(m, 4H), 2.96 - 2.76 (m, 1H),
2.23 - 2.07 (m, 4H), 1.84 — 1.78
m, 6H
(400 MHz, CDC13) 8 8.69 (d, J
:19 Hz, 1H), 8.60 (d, J =1.9
Hz, 1H), 6.94 (d, J = 2.4 Hz,
1H), 6.86 (d, J = 2.4 Hz, 1H),
.42 (d, J = 7.9 Hz, 1H), 4.72
(s, 1H), 3.98 (s, 1H), 3.95 —
3.86 (m, 4H), 3.40 — 3.26 (m,
4H), 3.05 — 2.87 (m, 1H), 2.32 -
2.21 (m, 2H), 2.21 - 2.07 (m,
4H), 2.03 - 1.90 (m, 1H), 1.90 —
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) a 8.72 — 8.51 (m, 2H),
7.01 (d, J = 2.5 Hz, 1H), 6.93
(d, J = 2.5 Hz, 1H), 4.84 (s,
1H), 4.40 (s, 2H), 3.99 (s, 1H),
3.83 (dd, J = 5.9, 3.8 Hz, 4H),
3.65 (s, 2H), 3.35 (t, J = 4.9 Hz,
4H), 2.87 (s, 2H), 2.27 — 1.91
(m, 4H), 1.90 — 1.59 (m, 2H),
1.41 (s, 9H)
(CDC13) 5 8.70 (t, J = 2.2 Hz,
1H), 8.63 (dd, J = 2.7, 1.9 Hz,
1H), 7.97 (s, 1H), 7.00 — 6.86
(m, 2H), 5.05 (d, J = 8.2 Hz,
1H), 4.77 (s, 1H), 4.02 (s, 1H),
3.93 (t, J = 4.7 Hz, 4H), 3.86 (s,
1H), 3.35 (t, J = 4.8 Hz, 4H),
3.17 (t, J = 6.0 Hz, 1H), 2.89
(d, J = 5.5 Hz, 1H), 2.71 (t, J =
6.0 Hz, 1H), 2.21 (dd, J = 9.2,
4.9 Hz, 2H), 1.91 (d, J = 5.5
Hz, 3H), 1.75 (d, J = 5.6 Hz,
(400 MHz, CDC13) 8 8.68 (d, J
= 1.9 Hz, 1H), 8.63
— 8.54 (m,
1H), 6.93 (d, J = 2.4 Hz, 1H),
6.86 (d, J = 2.3 Hz, 1H), 5.76 —
.55 (m, 1H), 4.93 — 4.67 (m,
4H), 3.99 (d, J = 26.0 Hz, 1H),
3.95 — 3.81 (m, 4H), 3.77 — 3.55
(m, 2H), 3.39 _ 3.28 (m, 4H),
2.21 _ 2.09 (m, 2H), 1.90 — 1.75
(400 MHz, CDC13) 8 8.69 (s,
1H), 8.60 (s, 1H), 6.94 (s, 1H),
6.86 (s, 1H), 5.59 (s, 1H), 4.74
(s, 1H), 4.11 — 3.81 (m, 5H),
3.42 — 3.23 (m, 4H), 2.28 — 2.09
(m, 2H), 1.98 (s, 3H), 1.90 —
1.78 (m, 6H)
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.69 (d, J
= 1.9 Hz, 1H), 8.60 (d, J = 1.9
Hz, 1H), 6.93 (d, J = 2.4 Hz,
1H),
6.86 (d, J = 2.3 Hz, 1H), 5.52
(d, J = 7.3 Hz, 1H), 4.73 (s,
1H), 3.99 (s, 1H), 3.96 — 3.87
(m, 4H), 3.38 —
3.30 (m, 4H), 2.24 — 2.08 (m,
4H),1.88 — 1.79 (m, 6H), 1.16
(t, J = 7.6 Hz, 3H)
(400 MHz, CDC13) 5 8.69 (d, J
=19 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 6.93 (d, J = 2.4 Hz,
1H), 6.86 (d, J = 2.3 Hz, 1H),
.53 (d, J = 7.7 Hz, 1H), 4.73
(s, 1H), 4.00 (s, 1H), 3.95 —
3.84 (m, 4H), 3.39 — 3.25 (m,
4H), 2.22 — 2.06 (m, 4H), 1.88 —
1.76 (m, 6H), 1.70 — 1.61 (m,
2H), 0.94 (t, J = 7.4 Hz, 3H)
(400 MHz, CDC13) 5 8.69 (d, J
:19 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 6.94 (d, J = 2.4 Hz,
1H), 6.87 (d, J = 2.2 Hz, 1H),
6.65 (d, J = 8.5 Hz, 1H), 4.72
(s, 1H), 4.06 (s, 1H), 3.96 —
3.85 (m, 6H), 3.43 (s, 3H), 3.38
— 3.28 (m, 4H), 2.24 — 2.09 (m,
2H), 1.95 — 1.76 (m, 6H)
(400 MHz, CDC13) 5 8.68 (d, J
=18 Hz, 1H), 8.59 (d, J: 1.8
Hz, 1H), 6.93 (d, J = 2.3 Hz,
1H), 6.86 (d, J = 2.0 Hz, 1H),
.53 (d, J = 7.8 Hz, 1H), 4.72
(s, 1H), 4.01 (s, 1H), 3.96 —
3.81 (m, 4H), 3.37 — 3.24 (m,
4H), 2.24 — 2.06 (m, 3H), 2.01
(d, J = 7.0 Hz, 2H), 1.87 — 1.76
(m, 6H), 0.94 (d, J = 6.5 Hz,
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.62 (d, J
= 1.9 Hz, 1H), 8.55 (d, J = 1.9
Hz, 1H), 6.87 (d, J = 2.4 Hz,
1H), 6.80 (d, J = 2.3 Hz, 1H),
.62 (d, J = 7.7 Hz, 1H), 4.64
(s, 1H), 3.99 — 3.76 (m, 5H),
3.37 — 3.14 (m, 4H), 2.21 — 1.95
(m, 2H), 1.87 — 1.63 (m, 6H),
1.13 s, 9H
(400 MHz, CDC13) 3 8.69 (d, J
:19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 8.19 (d, J = 4.8 Hz,
1H), 6.95 (d, J = 2.3 Hz, 1H),
6.90 (d, J = 2.4 Hz, 1H), 6.70
(dd, J = 51,12 Hz, 1H), 6.56
(s, 1H), 4.87 (d, J = 7.6 Hz,
1H), 4.80 (s, 1H), 3.96 — 3.88
(m, 4H), 3.85 (s, 1H), 3.38 —
3.28 (m, 4H), 2.28 — 2.14 (m,
2H), 2.00 — 1.85 (m, 6H)
(CDC13) 5 8.67 (d, J = 2.0 Hz,
1H), 8.62 (d, J = 2.0 Hz, 1H),
7.05 — 6.95 (m, 2H), 6.72 (s,
1H), 4.88 (s, 1H), 3.98 — 3.82
(m, 4H), 3.64 (t, J = 5.1 Hz,
2H), 3.41 — 3.31 (m, 4H), 3.24
(s, 3H), 3.09 (t, J = 5.2 Hz, 2H),
2.68 (s, 3H), 2.30 — 1.99 (m,
4H), 1.86 (d, J = 9.0 Hz, 4H)
(CDC13) 3 9.68 (s, 1H), 8.76 —
8.58 (m, 2H), 7.00 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
1H), 6.41 (dd, J = 17.7, 11.1
Hz, 1H), 5.65 (d, J = 17.7 Hz,
1H), 5.33 (d, J = 11.1 Hz, 1H),
4.85 (q, J = 3.6 Hz, 1H), 4.01
(s, 1H), 3.94 — 3.70 (m, 4H),
3.47 — 3.19 (m, 4H), 2.27 — 1.94
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure ted otherwise)
(M+H)
NMR peaks given as 8 values
(CDC13) a 8.63 (d, J = 1.9 Hz,
1H), 8.57 (d, J =19 Hz, 1H),
8.20 (dd, J = 5.0, 1.9 Hz, 1H),
Z_ 7.57 (dd, J = 7.6, 1.9 Hz, 1H),
6.89 (d, J = 2.5 Hz, 1H), 6.85
(d, J = 2.5 Hz, 1H), 6.51 (dd, J
87 MOON 4312
= 7.6, 4.9 Hz, 1H), 5.12 (d, J =
Z \ OZ\_/ 7.7 Hz, 1H), 4.83 _ 4.71 (m,
0H), 4.24 _ 4.03 (m, 1H), 3.92 — /
3.77 (m, 4H), 3.35 — 3.19 (m,
4H), 2.28 — 2.10 (m, 2H), 1.88
(td, J = 8.3, 6.8, 3.9 Hz, 6H)
(400 MHz, CDC13) a 8.69 (s,
Z_ 1H), 8.63 (s, 1H), 8.57 (s, 1H),
WOO 8.30 — 8.12 (m, 2H), 7.85 (t, J =
7.1 Hz, 1H), 7.50 — 7.37 (m,
88 0% 434.25 1H), 6.94 (s, 1H), 6.89 (s, 1H),
4.89 — 4.63 (m, 1H), 4.35 — 4.13
| E:j (m, 1H), 4.01 — 3.78 (m, 4H),
N\ 3.43 — 3.19 (m, 4H), 2.37 — 2.15
(m, 2H), 2.12 — 1.82 (m, 6H)
(400 MHz, CDC13) 3 8.99 (s,
1H), 8.73 (d, J = 3.4 Hz, 1H),
8.70 (d, J = 1.6 Hz, 1H), 8.60
Z_ (d, J: 1.7 Hz, 1H), 8.11 (d, J:
OHNO’O/ 7.8 Hz, 1H), 7.40 (dd, J = 7.6,
4.8 Hz, 1H), 6.95 (d, J = 2.1
89 43422
Hz, 1H), 6.90 (s, 1H), 6.30 (d, J
/ = 7.6 Hz, 1H), 4.81 (s, 1H),
\N [No] 4.22 (s, 1H), 3.97 — 3.85 (m,
4H), 3.41 — 3.23 (m, 4H), 2.32 —
2.17 (m, 2H), 2.01 — 1.84 (m,
(400 MHz, CDC13) a 8.75 (dd,
J = 4.4, 1.7 Hz, 2H), 8.70 (d, J
Nfi =19 Hz, 1H), 8.60 (d, J: 1.9
’0’o N Hz, 1H), 7.62 (dd, J = 4.4, 1.7
Hz, 2H), 6.95 (d, J = 2.4 Hz,
90 HN 434.22 1H), 6.89 (d, J = 2.5 Hz, 1H),
N 6.33 (d, J = 8.2 Hz, 1H), 4.81
0 /
I E j (s, 1H), 4.27 — 4.16 (m, 1H),
o 3.96—3.87 (m, 4H),3.38—3.31
(m, 4H), 2.30 — 2.16 (m, 2H),
2.00 — 1.86 (m, 6H)
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure indicated ise)
(M+H)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.69 (d, J
=19 Hz, 1H), 8.63 — 8.58 (m,
1H), 7.77 (dd, J = 5.2, 3.2 Hz,
2H), 7.54 — 7.40 (m, 3H), 6.95
(d, J = 2.4 Hz, 1H), 6.89 (d, J =
91 433.21 2.4 Hz, 1H), 6.23 (d, J = 8.0
Hz, 1H), 4.78 (s, 1H), 4.31 —
4.13 (m, 1H), 3.95 — 3.87 (m,
4H), 3.38 — 3.27 (m, 4H), 2.31 —
2.17 (m, 2H), 1.97 — 1.85 (m,
(400 MHz, CDC13) 5 8.69 (d, J
=19 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 7.47 (d, J = 8.9 Hz,
1H), 7.00 (d, J =10 Hz, 1H),
6.95 (d, J = 0.7 Hz, 1H), 6.94
92 437.24 (d, J = 2.5 Hz, 1H), 6.89 (d, J =
2.4 Hz, 1H), 4.81 (s, 1H), 4.07
(d, J = 12.3 Hz, 4H), 3.98 —
3.85 (m, 4H), 3.41 — 3.24 (m,
4H), 2.34 — 2.12 (m, 2H), 2.06 —
1.83 (m, 6H)
(methanol—d4) 5 8.69 (d, J = 2.2
Hz, 1H), 8.59 (d, J = 2.2 Hz,
1H), 8.53 (d, J = 4.9 Hz, 1H),
7.19 (d, J = 5.0 Hz, 1H), 7.15
(d, J = 2.3 Hz, 1H), 6.87 (d, J =
93 451.21
2.4 Hz, 1H), 4.95 (d, J = 7.7
Hz,1H), 4.10 (s, 1H), 3.95 —
3.82 (m, 4H), 3.47 — 3.37 (m,
4H), 2.20 (d, J = 10.1 Hz, 2H),
2.04 — 1.81 (m, 6H)
(CDC13) 3 8.68 (d, J = 2.0 Hz,
1H), 8.60 (d, J =19 Hz, 1H),
8.29 (s, 2H), 6.98 — 6.87 (m,
2H), 5.36 (d, J = 8.1 Hz, 1H),
4.79 (q, J = 5.2, 4.0 Hz, 1H),
94 437.44
4.52 (s, 2H), 4.01 (dd, J = 8.1,
4.3 Hz, 1H), 3.95 — 3.84 (m,
4H), 3.39 — 3.28 (m, 4H), 2.25 —
2.12 (m, 2H), 1.99 — 1.82 (m,
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure ted otherwise)
(M+H)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.70 (d, J
= 1.7 Hz, 1H), 8.65
— 8.58 (m,
1H), 7.80 (s, 1H), 7.22 (d, J =
9.6 Hz, 1H), 7.15 (d, J = 7.6
Hz, 1H), 6.95 (d, J = 2.4 Hz,
95 424.21
1H), 6.89 (d, J = 2.4 Hz, 1H),
4.80 (s, 1H), 4.24 — 4.09 (m,
1H), 3.98 — 3.85 (m, 4H), 3.40 —
3.29 (m, 4H), 2.29 — 2.15 (m,
2H), 2.02 — 1.86 (m, 6H)
(400 MHz, CDC13) a 8.89 (d, J
= 4.9 Hz, 2H), 8.69 (d, J = 1.9
Hz, 1H), 8.62 (d, J =19 Hz,
1H), 8.20 (d, J = 8.3 Hz, 1H),
7.45 (t, J = 4.9 Hz, 1H), 6.94
96 435.19 (d, J = 2.4 Hz, 1H), 6.89 (d, J =
2.4 Hz, 1H), 4.75 (s, 1H), 4.39
— 4.21 (m, 1H), 4.00 — 3.84 (m,
4H), 3.41 — 3.21 (m, 4H), 2.29 —
2.13 (m, 2H), 2.12 — 1.87 (m,
(400 MHz, CDC13) 8 9.25 (d, J
= 1.4 Hz, 1H), 8.97 (d, J = 5.0
Hz, 1H), 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
8.22 =
— 8.04 (m, 2H), 6.95 (d, J
97 435.19 2.4 Hz, 1H), 6.89 (d, J = 2.4
Hz, 1H), 4.81 - 4.72 (m, 1H),
4.26 - 4.15 (m, 1H), 3.96 — 3.86
(m, 4H), 3.38 - 3.29 (m, 4H),
2.28 - 2.17 (m, 2H), 2.06 — 1.86
(m, 6H)
(400 MHz, CDC13) 8 9.33 (s,
1H), 9.12 (s, 2H), 8.70 (d, J =
1.9 Hz, 1H), 8.57 (d, J =19
Hz, 1H), 6.95 (d, J = 2.4 Hz,
1H), 6.89 (d, J = 2.4 Hz, 1H),
98 435.19
6.44 (d, J = 7.8 Hz, 1H), 4.83
(s, 1H), 4.23 (qd, J = 9.2, 4.7
Hz, 1H), 3.96 — 3.87 (m, 4H),
3.38 — 3.30 (m, 4H), 2.32 — 2.18
(m, 2H), 2.01 — 1.88 (m, 6H)
H NMR (300 MHz, unless
Compound Structure indicated ise)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 9.29 (dd,
J = 5.0, 1.7 Hz, 1H), 8.70 (d, J
= 1.9 Hz, 1H), 8.64 (d, J :19
Hz, 1H), 8.33 (dd, J = 8.4, 1.7
Hz, 2H), 7.67 (dd, J = 8.4, 5.0
Hz, 1H), 6.95 (d, J = 2.5 Hz,
1H), 6.91 (d, J = 2.5 Hz, 1H),
4.85 (s, 1H), 4.29 — 4.13 (m,
1H), 3.98 — 3.85 (m, 4H), 3.40 —
3.26 (m, 4H), 2.32 — 2.16 (m,
2H), 2.12 — 1.98 (m, 2H), 1.99 —
1.87 (m, 4H)
(400 MHz, CDC13) 3 11.83 (s,
1H), 8.71 (d, J =19 Hz, 1H),
8.59 (d, J =19 Hz, 1H), 7.55
(d, J = 2.4 Hz, 1H), 7.05 (d, J =
8.5 Hz, 1H), 6.94 (d, J = 2.4
Hz, 1H), 6.87 (dd, J = 4.7, 2.3
Hz, 1H), 6.84 (d, J = 2.4 Hz,
1H), 4.74 (s, 1H), 4.18 (s, 1H),
3.96 — 3.88 (m, 4H), 3.38 — 3.29
(m, 4H), 2.17 — 2.09 (m, 2H),
1.94 — 1.81 m, 6H
(400 MHz, CDC13) 3 8.70 (d, J
=19 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.07 (s, 1H), 7.01 (d, J
= 8.3 Hz, 1H), 6.94 (d, J = 2.4
Hz, 1H), 6.88 (d, J = 2.4 Hz,
1H), 4.76 (s, 1H), 4.23 — 4.09
(m, 1H), 3.98 — 3.84 (m, 4H),
3.40 — 3.26 (m, 4H), 2.48 (s,
3H), 2.28 — 2.12 (m, 2H), 1.99 —
1.82 (m, 6H)
(CDC13) 3 8.71 (d, J = 1.9 Hz,
1H), 8.59 (d, J = 2.0 Hz, 1H),
6.96 (d, J = 2.5 Hz, 1H), 6.89
(d, J = 2.5 Hz, 1H), 4.73 (d, J =
.7 Hz, 1H), 4.18 (d, J = 7.7
102 Hz, 1H), 3.93 (dd, J = 5.9, 3.8
Hz, 4H), 3.69 — 3.55 (m, 1H),
3.46 (d, J = 16.5 Hz, 1H), 3.41
= 16.4
— 3.28 (m, 4H), 3.08 (d, J
Hz, 1H), 2.17 (d, J = 11.6 Hz,
2H), 2.00 — 1.75 (m, 6H)
H NMR (300 MHz, unless
Compound ure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.72 (d, J = 2.0 Hz,
1H), 8.64 (d, J = 2.0 Hz, 1H),
6.99 (d, J = 2.5 Hz, 1H), 6.93
(d, J = 2.5 Hz, 1H), 5.74 (s,
1H), 4.80 (s, 1H), 4.02 — 3.87
(m, 4H), 3.36 (t, J = 4.9 Hz,
4H), 2.19 (s, 2H), 2.08 — 1.79
(m, 6H)
(CDC13) 3 8.73 (s, 1H), 8.68 (d,
J = 2.4 Hz, 1H), 6.99 (d, J = 2.4
Hz, 1H), 6.85 (d, J = 2.4 Hz,
1H), 5.69 (d, J = 2.5 Hz, 1H),
4.76 (s, 1H), 3.84 (dd, J = 5.9,
3.9 Hz, 4H), 3.38 (dd, J = 6.0,
3.9 Hz, 4H), 2.15 (d, J: 11.1
Hz, 2H 1.96 — 1.67
, m, 6H
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.59 (d, J =19 Hz, 1H),
8.30 (d, J =13 Hz, 1H), 7.89
(d, J = 1.4 Hz, 1H), 6.93 (dd, J
= 18.4, 2.5 Hz, 2H), 5.52 (d, J
= 7.8 Hz, 1H), 4.83 (tt, J = 4.8,
2.7 Hz, 1H), 4.19 — 4.01 (m,
1H), 3.96 — 3.87 (m, 4H), 3.39 —
3.26 (m, 4H), 2.31 — 2.14 (m,
2H), 2.09 — 1.78 (m, 6H)
(400 MHz, CDC13) a 8.71 (d, J
=19 Hz, 1H), 8.64 (d, J =19
Hz, 1H), 7.88 (dd, J = 7.4, 2.1
Hz, 1H), 7.02 (dd, J = 11.9, 8.3
Hz, 1H), 6.97 (d, J = 2.4 Hz,
106 1H), 6.92 (d, J = 2.4 Hz, 1H),
6.83 (dd, J = 12.4, 7.6 Hz, 1H),
4.78 (s, 1H), 4.25 (s, 1H), 4.03
— 3.85 (m, 4H), 3.44 _ 3.23 (m,
4H), 2.38 (s, 3H), 2.30 — 2.13
H NMR (300 MHz, unless
Compound Structure indicated ise)
NMR peaks given as 8 values
(400 MHz, CDC13) a 8.73 —
8.66 (m, 1H), 8.65 — 8.59 (m,
1H), 8.05 (dd, J = 6.6, 2.8 Hz,
1H), 7.46 — 7.36 (m, 1H), 7.08
(dd, J = 11.1, 8.8 Hz, 1H), 6.95
107 (d, J = 2.4 Hz, 1H), 6.89 (d, J =
2.4 Hz, 1H), 6.84 — 6.66 (m,
1H), 4.76 (bs, 1H), 4.22 (bs,
1H), 3.96 — 3.87 (m, 4H), 3.37 —
3.28 (m, 4H), 2.28 _ 2.10 (m,
2H), 2.01 _ 1.86 (m, 6H)
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.61 (d, J = 2.0 Hz, 1H),
8.49 (d, J = 1.4 Hz, 1H), 7.77
(d, J = 1.4 Hz, 1H), 6.93 (dd, J
= 16.1, 2.5 Hz, 2H), 5.03 (d, J
108 = 7.9 Hz, 1H), 4.81 (td, J = 5.3,
2.6 Hz, 1H), 4.09 — 3.98 (m,
1H), 3.98 — 3.87 (m, 4H), 3.39 —
3.26 (m, 4H), 3.19 (s, 3H), 3.12
(s, 3H), 2.22 (dt, J = 11.2, 4.9
Hz, 2H), 2.02 — 1.82 (m, 6H)
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
8.10 (d, J = 0.5 Hz, 2H), 6.97
(d, J = 2.5 Hz, 1H), 6.92 (d, J =
2.5 Hz, 1H), 5.13 (d, J = 8.3
Hz, 1H), 4.80 (s, 1H), 4.06 — 109
3.86 (m, 5H), 3.35 (dd, J = 5.9,
3.8 Hz, 4H), 2.27 - 2.14 (m,
2H), 1.92 (d, J = 5.1 Hz, 6H),
1.79 - 1.44 (m, 6H), 1.28 (t, J =
7.1 Hz, 1H), 1.03 — 0.83 (m,
2H 0.68 — 0.51
, m, 2H
(400 MHz, CDC13) 8 8.69 (d, J
= 1.9 Hz, 1H), 8.64
— 8.54 (m,
1H), 6.94 (d, J = 2.4 Hz, 1H),
6.86 (d, J = 2.5 Hz, 1H), 6.06 —
.78 (m, 1H), 4.79 — 4.68 (m,
110 HN0° 395.19
1H), 4.11 - 3.96(m,1H), 3.96 —
3.86 (m, 4H), 3.40 — 3.27 (m,
4H), 2.13 (dd, J = 11.0, 5.2 Hz,
2H), 1.94 (s, 3H), 1.90 — 1.78
(m, 6H)
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 8 8.70 (d, J
=19 Hz, 1H), 8.66 — 8.53 (m,
00 3H), 7.93 (dd, J = 6.4, 5.0 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
112 HN 452.18 6.90 (d, J = 2.4 Hz, 1H), 6.78
(s, 1H), 4.78 (bs, 1H), 4.23 (bs,
1H), 3.97 — 3.85 (m, 4H), 3.38 —
3.27 (m, 4H), 2.30 — 2.15 (m,
2H), 2.02 — 1.86 (m, 6H)
(400 MHz, CDC13) 8 8.70 (s,
1H), 8.60 (s, 1H), 6.94 (s, 1H),
6.87 (s, 1H), 5.99 (d, J = 6.8
Hz, 1H), 4.75 (bs, 1H), 4.03
113 439.24
(bs, 1H), 3.99 — 3.83 (m, 4H),
3.43 — 3.21 (m, 4H), 2.33 (s,
1H), 2.24 _ 2.04 (m, 2H), 1.94 —
1.74 (m, 6H), 1.56 (s, 6H)
(400 MHz, CDC13) 8 8.70 (d, J
=19 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.40 (dt, J = 4.3, 1.3
00 Hz, 1H), 8.01 (d, J = 8.5 Hz,
1H), 7.58 — 7.52 (m, 1H), 7.51 —
114 HN 452.15 7.46 (m, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.4 Hz,
1H), 4.74 (s, 1H), 4.29 — 4.17
(m, 1H), 3.97 — 3.88 (m, 4H),
3.39 — 3.30 (m, 4H), 2.25 — 2.16
(m, 2H), 2.06 — 1.88 (m, 6H)
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.69 (d, J
=18 Hz, 1H), 8.62 (d, J: 1.8
Hz, 1H), 8.09 (dd, J = 7.9, 6.1
Hz, 1H), 7.47 (d, J = 8.1 Hz,
1H), 7.13 (dd, J = 11.8, 7.9 Hz,
115 1H), 6.95 (d, J = 2.3 Hz, 1H),
6.90 (d, J = 2.3 Hz, 1H), 6.82
(s, 1H), 4.77 (s, 1H), 4.24 (s,
1H), 3.96 — 3.88 (m, 4H), 3.38 —
3.30 (m, 4H), 2.27 — 2.14 (m,
2H), 2.01 — 1.87 (m, 6H)
(400 MHz, CDC13) 8 8.70 (d, J
= 1.9 Hz, 1H), 8.63 (d, J =1.9
Hz, 1H), 7.83 (d, J = 2.7 Hz,
1H), 7.19 — 6.93 (m, 4H), 6.89
116 (d, J = 2.4 Hz, 1H), 4.75 (s,
1H), 4.21 (s, 1H), 3.95 — 3.89
(m, 4H), 3.38 — 3.30 (m, 4H),
2.26 - 2.13 (m, 2H), 2.03 — 1.86
(m, 6H)
(400 MHz, CDC13) 8 8.69 (d, J
:19 Hz, 1H), 8.62 (d, J =1.9
Hz, 1H), 7.35 (d, J = 2.2 Hz,
1H), 6.99 (d, J = 8.2 Hz, 1H),
6.93 (d, J = 2.4 Hz, 1H), 6.88
117 (d, J = 2.4 Hz, 1H), 6.78 (d, J =
2.3 Hz, 1H), 4.73 (s, 1H), 4.26
- 4.14 (m, 1H), 3.96 — 3.87 (m,
7H), 3.36 — 3.29 (m, 4H), 2.23 -
2.12 (m, 2H), 2.01 - 1.82 (m,
(400 MHz, CDC13) 5 10.00 (s,
1H), 8.63 (d, J =19 Hz, 1H),
8.54 (d, J = 1.9 Hz, 1H), 6.93
(s, 1H), 6.87 (d, J = 2.4 Hz,
1H), 6.81 (d, J = 2.4 Hz, 1H),
6.50 (s, 1H), 4.69 (s, 1H), 4.15
— 4.05 (m, 1H), 3.92 — 3.77 (m,
4H), 3.35 — 3.19 (m, 4H), 2.27
(d, J = 0.5 Hz, 3H), 2.18 — 2.04
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 8 8.70 (s,
1H), 8.63 (s, 1H), 6.99 — 6.50
(m, 3H), 4.76 (d, J = 20.7 Hz,
119 1H), 4.19 (s, 1H), 4.13 — 3.74
(m, 7H), 3.41 - 3.21 (m, 4H),
2.37 — 2.08 (m, 5H), 2.03 — 1.79
(m, 6H)
(400 MHz, CDC13) 8 8.73 (d, J
= 1.9 Hz, 1H), 8.58 (d, J =1.9
Hz, 1H), 6.97 (d, J = 2.4 Hz,
1H), 6.93 (s, 1H), 6.88 (d, J =
120 2.3 Hz, 1H), 6.53 (s, 1H), 4.79
(s, 1H), 4.24 - 4.15 (m, 1H),
3.96 — 3.86 (m, 4H), 3.40 — 3.27
(m, 4H), 2.22 - 2.15 (m, 2H),
1.94 - 1.82 m, 6H
(400 MHz, CDC13) 8 8.70 (d, J
=1.9 Hz, 1H), 8.62 (d, J =1.9
Hz, 1H), 6.95 (d, J = 2.4 Hz,
1H), 6.89 (d, J = 2.4 Hz, 1H),
6.71 (d, J = 2.1 Hz, 1H), 6.54
(dd, J = 3.9, 1.7 Hz, 1H), 6.09
(dd, J = 3.9, 2.6 Hz, 1H), 5.94
(d, J = 8.1 Hz, 1H), 4.76 (s,
1H), 4.11 (s, 1H), 3.98 — 3.86
(m, 7H), 3.39 — 3.27 (m, 4H),
2.27 - 2.14 (m, 2H), 1.95 — 1.83
m, 6H
(400 MHz, CDC13) 8 8.70 (s,
1H), 8.61 (s, 1H), 8.51 (s, 1H),
7.50 (s, 1H), 6.95 (s, 1H), 6.89
(s, 1H), 6.16 (d, 1H), 4.80 (s,
1H), 4.18 (s, 1H), 4.01 — 3.78
(m, 4H), 3.44 - 3.23 (m, 4H),
2.33 — 2.16 (m, 2H), 1.91 (d, J =
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure ted otherwise)
(M+H)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.69 (d, J
=18 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 7.50 (d, J = 1.2 Hz,
1H), 7.36 (d, J = 1.0 Hz, 1H),
7.16 (d, J = 7.9 Hz, 1H), 6.94
123 437.21 (d, J = 2.3 Hz, 1H), 6.88 (d, J =
2.3 Hz, 1H), 4.78 (s, 1H), 4.20
— 4.09 (m, 1H), 3.95 — 3.87 (m,
4H), 3.73 (s, 3H), 3.38 — 3.28
(m, 4H), 2.25 — 2.14 (m, 2H),
2.00 — 1.82 (m, 6H)
(CDC13) 3 8.68 (d, J = 1.9 Hz,
1H), 8.58 (d, J :19 Hz, 1H),
7.85 =
— 7.72 (m, 2H), 6.95 (d, J
2.5 Hz, 1H), 6.86 (d, J = 2.5
124 473.2 Hz, 1H), 4.89 (d, J = 7.5 Hz,
1H), 4.71 (dq, J = 5.5, 2.7 Hz,
1H), 4.00 — 3.85 (m, 7H), 3.47 —
3.27 (m, 5H), 2.19 — 2.07 (m,
2H), 1.97 — 1.65 (m, 6H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.55 (d, J :19 Hz, 1H),
7.46 (d, J = 2.0 Hz, 1H), 6.97
(d, J = 2.5 Hz, 1H), 6.81 (dd, J
= 22.5, 2.3 Hz, 2H), 5.65
— 5.56
125 473.25 (m, 1H), 4.73 (p, J = 2.5 Hz,
1H), 4.10 (s, 3H), 3.95 — 3.85
(m, 4H), 3.47 (d, J = 15.3 Hz,
1H), 3.36 — 3.27 (m, 4H), 2.23 —
2.08 (m, 2H), 1.98 — 1.62 (m,
(CDC13) 5 8.68 (d, J = 1.9 Hz,
1H), 8.58 (d, J :19 Hz, 1H),
7.41 (d, J = 2.3 Hz, 1H), 6.95
(d, J = 2.5 Hz, 1H), 6.86 (d, J =
2.5 Hz, 1H), 6.69 (d, J = 2.3
126 473.25 Hz, 1H), 4.95 (d, J = 7.3 Hz,
1H), 4.72 (h, J = 2.6 Hz, 1H),
4.02 =
— 3.82 (m, 7H), 3.52 (d, J
9.0 Hz, 1H), 3.37 — 3.27 (m,
4H), 2.12 (dt, J = 16.1, 5.7 Hz,
2H), 1.97 — 1.65 (m, 6H)
WO 59690
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.62 (d, J = 1.9 Hz,
1H), 8.54 (d, J :19 Hz, 1H),
8.01 (s, 2H), 6.88 (s, 1H), 6.83
(d, J = 2.5 Hz, 1H), 4.93 (d, J =
8.1 Hz, 1H), 4.72 (d, J = 5.8
Hz, 1H), 4.53 (d, J = 6.0 Hz,
2H), 4.38 (d, J = 6.0 Hz, 2H),
3.89 - 3.75 (m, 4H), 3.35 - 3.13
(m, 4H), 2.10 (s, 3H), 1.95 -
1.72 (m, 6H), 1.36 (s, 3H)
(CDC13) a 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
8.56 (s, 2H), 7.04 — 6.87 (m,
2H), 6.19 (d, J = 6.8 Hz, 1H),
.15 (d, J = 8.2 Hz, 1H), 5.01
(d, J = 6.8 Hz, 1H), 4.81 (s,
1H), 4.11 — 3.85 (m, 6H), 3.43 —
3.22 (m, 4H), 2.21 (d, J = 9.5
Hz, 2H), 1.94 (t, J = 3.9 Hz,
6H), 1.36 (t, J = 7.1 Hz, 3H)
(CDC13) 8 8.60 (d, J = 1.9 Hz,
1H), 8.53 (d, J =19 Hz, 1H),
7.81 (s, 2H), 6.91 — 6.75 (m,
2H), 5.08 — 4.89 (m, 2H), 4.89 —
129 4.77 (m, 2H), 4.67 (ddd, J =
8.2, 4.7, 1.9 Hz, 3H), 3.94 —
3.72 (m, 5H), 3.34 — 3.17 (m,
4H), 2.21 _ 2.00 (m, 2H), 1.91 —
1.69 (m, 6H)
(400 MHz, methanol—d4) 5 8.69
(d, J = 2.0 Hz, 1H), 8.55 (d, J =
2.0 Hz, 1H), 7.10 (d, J = 2.3
Hz, 1H), 6.89 (d, J = 2.4 Hz,
1H), 4.85 — 4.82 (m, 1H), 4.07
(q, J = 6.9 Hz, 2H), 3.95 — 3.81
(m, 4H), 3.64 — 3.53 (m, 1H),
3.42 — 3.35 (m, 4H), 2.20 — 2.02
(m, 2H), 1.94 — 1.66 (m, 6H),
1.24 (t, J = 7.1 Hz, 3H)
H NMR (300 MHz, unless
Compound ure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.73 —
8.65 (m, 1H), 8.60 (d, J = 1.9
Hz, 1H), 6.94 (d, J = 2.4 Hz,
1H), 6.87 (d, J = 2.3 Hz, 1H),
4.90 — 4.58 (m, 2H), 3.97 — 3.88
(m, 4H), 3.83 (d, J = 6.3 Hz,
2H), 3.72 (s, 1H), 3.39 — 3.27
(m, 4H), 2.20 — 2.06 (m, 2H),
1.95 =
— 1.76 (m, 7H), 0.93 (d, J
6.7 Hz, 6H)
(400 MHz, CDC13) 5 8.70 (d, J
= 1.6 Hz, 1H), 8.62 (d, J = 1.7
Hz, 1H), 7.36 (t, J = 7.6 Hz,
2H), 7.19 (t, J = 7.3 Hz, 1H),
7.13 (d, J = 7.7 Hz, 2H), 6.96
(s, 1H), 6.89 (s, 1H), 5.12 (d, J
= 7.2 Hz, 1H), 4.77 (s, 1H),
3.98 — 3.85 (m, 4H), 3.79 (s,
1H), 3.39 — 3.28 (m, 4H), 2.29 —
2.11 (m, 2H), 1.98 — 1.79 (m,
(CDC13) 5 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.04 (s, 2H), 6.97 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.7 Hz,
1H), 4.79 (s, 2H), 4.07 — 3.83
(m, 6H), 3.42 — 3.25 (m, 4H),
2.29 =
— 2.02 (m, 2H), 1.92 (d, J
4.6 Hz, 6H), 1.36 — 1.12 (m,
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.07 (s, 2H), 6.97 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.6 Hz,
1H), 4.99 (d, J = 8.0 Hz, 1H),
4.81 (d, J = 5.9 Hz, 1H), 3.93
(dd, J = 6.0, 3.7 Hz, 5H), 3.81
(s, 3H), 3.45 — 3.24 (m, 4H),
2.21 (d, J = 8.6 Hz, 2H), 2.05 —
1.78 (m, 6H)
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
) 3 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.19 (s, 2H), 6.96 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
1H), 5.12 (d, J = 8.1 Hz, 1H),
135 4.81 (d, J = 5.6 Hz, 1H), 4.09 —
3.85 (m, 5H), 3.63 — 3.41 (m,
4H), 3.43 — 3.26 (m, 4H), 2.69
(t, J = 6.6 Hz, 2H), 2.33 — 2.13
(m, 2H), 2.03 — 1.83 (m, 6H),
1.21 (t, J = 7.0 Hz, 3H)
(methanol—d4) 5 8.77 — 8.65 (m,
3H), 8.56 (d, J = 2.0 Hz, 1H),
7.11 (d, J = 2.4 Hz, 1H), 6.89
(d, J = 2.4 Hz, 1H), 4.92 (s,
1H), 4.02 (dd, J = 8.4, 4.3 Hz,
1H), 3.93 — 3.83 (m, 4H), 3.69
(t, J = 5.7 Hz, 2H), 3.47 (t, J =
.8 Hz, 2H), 3.42 — 3.33 (m,
5H), 2.26 — 2.15 (m, 2H), 2.08 —
1.78 (m, 6H)
(CDC13) 5 8.73 — 8.58 (m, 4H),
7.01 =
— 6.87 (m, 2H), 6.12 (d, J
7.9 Hz, 1H), 5.57 (d, J = 8.1
Hz, 1H), 4.80 (s, 1H), 4.39 —
137 4.28 (m, 1H), 4.10 (d, J = 6.9
Hz, 1H), 3.97 — 3.87 (m, 4H),
3.54 — 3.29 (m, 9H), 2.21 (d, J =
9.9 Hz, 2H), 2.08 — 1.84 (m,
6H), 1.28 (d, J = 6.8 Hz, 3H)
(CDC13) 5 9.04 (d, J = 3.2 Hz,
1H), 8.97 (d, J = 3.3 Hz, 1H),
8.64 (d, J :19 Hz, 1H), 8.55
(d, J :19 Hz, 1H), 6.90 (d, J =
2.5 Hz, 1H), 6.84 (d, J = 2.5
138 Hz, 1H), 6.03 (d, J = 8.2 Hz,
1H), 4.77 (td, J = 5.1, 2.6 Hz,
1H), 4.15 — 4.07 (m, 1H), 3.92 —
3.79 (m, 4H), 3.35 — 3.15 (m,
4H), 2.25 — 2.11 (m, 2H), 1.95 —
1.69 (m, 6H)
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.74 (d, J
=19 Hz, 2H), 8.70 (d, J =19
Hz, 1H), 8.03 (dd, J = 8.9, 2.0
Hz, 1H), 6.97 (d, J = 2.4 Hz,
1H), 6.92 (d, J = 2.4 Hz, 1H),
139 6.37 (d, J = 8.9 Hz, 1H), 6.05
(s, 1H), 4.81 (s, 1H), 3.99 —
3.88 (m, 4H), 3.84 (s, 1H), 3.39
— 3.27 (m, 4H), 2.31 — 2.17 (m,
2H), 2.08 — 1.98 (m, 2H), 1.98 —
1.82 (m, 4H)
(400 MHz, CDC13) 3 8.70 (d, J
=19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 8.53 (d, J = 2.1 Hz,
1H), 7.88 (dd, J = 8.8, 2.4 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.4 Hz, 1H), 6.39
(d, J = 8.7 Hz, 1H), 5.61 (s,
2H), 4.97 (d, J = 7.9 Hz, 1H),
4.80 (s, 1H), 4.02 — 3.82 (m,
5H), 3.42 — 3.26 (m, 4H), 2.27 —
2.14 (m, 2H), 2.00 — 1.81 (m,
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
8.09 (s, 2H), 7.01 — 6.86 (m,
2H), 4.88 — 4.75 (m, 1H), 4.08 — 141
3.80 (m, 9H), 3.43 — 3.27 (m,
4H), 3.09 — 2.96 (m, 4H), 2.31 —
2.15 (m, 2H), 2.05 — 1.81 (m,
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
8.14 (d, J = 0.8 Hz, 2H), 7.01 _
6.90 (m, 2H), 4.81 (td, J = 5.6,
2.7 Hz, 1H), 4.08 — 3.84 (m,
5H), 3.43 — 3.26 (m, 4H), 2.25 _
2.10 (m, 5H), 2.02 — 1.83 (m,
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
) 5 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.02 (s, 2H), 6.95 (dd, J = 11.8,
2.5 Hz, 2H), 4.81 (s, 2H), 4.08
— 3.85 (m, 5H), 3.41 — 3.30 (m,
4H), 2.20 (d, J = 10.1 Hz, 2H),
1.95 (d, J = 19.7 Hz, 6H), 1H
143 NMR (3 00 MHz, Methanol-d4)
? 8.68 (d, J = 2.0 Hz, 1H), 8.56
(d, J = 2.1 Hz, 1H), 7.93 (s,
2H), 7.11 (d, J = 2.5 Hz, 1H),
6.88 (d, J = 2.4 Hz, 1H), 3.96 —
3.71 (m, 5H), 3.37 (dd, J = 5.8,
3.9 Hz, 4H), 2.27 — 2.04 (m,
2H 1.98 — 1.74
, m, 6H.
(400 MHz, CDC13) 5 8.69 (d, J
:19 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.47 (d, J = 2.1 Hz,
1H), 7.84 (dd, J = 8.7, 2.4 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.4 Hz, 1H), 6.37
144 (d, J = 8.7 Hz, 1H), 5.94 (d, J =
3.9 Hz, 1H), 4.92 (d, J = 7.8
Hz, 1H), 4.79 (s, 1H), 3.98 —
3.84 (m, 5H), 3.39 — 3.26 (m,
4H), 2.98 (d, J = 4.8 Hz, 3H),
2.27 — 2.12 (m, 2H), 1.97 — 1.83
(400 MHz, CDC13) a 8.69 (d, J
=19 Hz,1H),8.61(d,J=1.9
Hz, 1H), 8.20 (s, 1H), 7.61 (d, J
= 8.2 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.91 (d, J = 2.4 Hz,
1H), 6.43 (d, J = 7.9 Hz, 1H),
4.81(s,1H),3.98 — 3.81 (m,
5H), 3.40 — 3.27 (m, 4H), 3.09
(s, 6H), 2.27 _ 2.15 (m, 2H),
1.99 — 1.83 (m, 6H)
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
) 5 8.76 (d, J = 2.0 Hz,
1H), 8.71 (d, J = 1.9 Hz, 1H),
8.63 (d, J = 1.9 Hz, 1H), 7.99
(dd, J = 8.8, 2.2 Hz, 1H), 6.97
(d, J = 2.5 Hz, 1H), 6.92 (d, J =
2.5 Hz, 1H), 6.38 (d, J = 8.9
Hz, 1H), 5.13 (s, 1H), 4.82 (s,
1H), 4.11 — 3.73 (m, 8H), 3.44 —
3.27 (m, 4H), 2.30 — 2.17 (m,
2H), 2.07 — 1.79 (m, 6H)
(400 MHz, CDC13) 5 10.77 —
.42 (m, 1H), 8.70 (d, J :19
Hz, 1H), 8.63 (d, J :19 Hz,
1H), 7.30 (d, J = 8.2 Hz, 1H),
7.15 (d, J = 5.7 Hz, 2H), 6.95
147 (d, J = 2.5 Hz, 1H), 6.90 (d, J =
2.4 Hz, 1H), 4.83 (s, 1H), 4.19
— 4.05 (m, 1H), 3.99 — 3.84 (m,
4H), 3.40 — 3.27 (m, 4H), 2.31 —
2.15 (m, 2H), 2.06 — 1.93 (m,
2H), 1.93 — 1.79 (m, 4H)
(DMSO-d6) 5 8.73 (d, J = 1.5
Hz, 3H), 8.59 (d, J :19 Hz,
1H), 8.12 (d, J = 8.2 Hz, 1H),
7.84 (d, J = 7.4 Hz, 1H), 7.14
(d, J = 2.4 Hz, 1H), 6.84 (d, J =
2.3 Hz, 1H), 4.93 (s, 1H), 4.51
148 (ddd, J = 13.3, 8.2, 5.2 Hz, 1H),
4.01 =
— 3.74 (m, 6H), 3.55 (q, J
8.0 Hz, 1H), 3.38 — 3.27 (m,
4H), 2.33 — 2.15 (m, 1H), 2.06
(d,J= 11.1 Hz,2H), 1.96 —
1.67 (m, 8H), 1.02 (d, J = 6.3
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure indicated otherwise)
(M+H)
NMR peaks given as 8 values
(DMSO—d6) 5 8.76 — 8.67 (m,
3H), 8.59 (d, J =19 Hz, 1H),
8.32 (d, J = 6.5 Hz, 1H), 7.84
(d, J = 7.3 Hz, 1H), 7.14 (d, J =
2.5 Hz, 1H), 6.84 (d, J = 2.3
149 520.33 Hz, 1H), 4.93 (s, 1H), 4.49 —
4.37 (m, 1H), 3.96 — 3.63 (m,
9H), 3.55 (dd, J = 8.9, 4.2 Hz,
1H), 3.38 — 3.27 (m, 4H), 2.23 —
2.00 (m, 4H), 1.95 — 1.71 (m,
(DMSO—d6) 5 8.76 — 8.67 (m,
3H), 8.59 (d, J =19 Hz, 1H),
8.32 (d, J = 6.5 Hz, 1H), 7.84
(d, J = 7.3 Hz, 1H), 7.14 (d, J =
2.5 Hz, 1H), 6.84 (d, J = 2.3
150 520.33 Hz, 1H), 4.93 (s, 1H), 4.49 —
4.37 (m, 1H), 3.96 — 3.63 (m,
9H), 3.55 (dd, J = 8.9, 4.2 Hz,
1H), 3.38 — 3.27 (m, 4H), 2.23 —
2.00 (m, 4H), 1.95 — 1.71 (m,
) 5 8.70 (d, J = 1.9 Hz,
1H), 8.64 (d, J = 2.0 Hz, 1H),
7.93 (s, 2H), 7.02 — 6.90 (m,
2H), 4.82 (t, J = 6.7 Hz, 3H),
151 4.66 (t, J = 6.4 Hz, 2H), 4.14
(q, J = 7.1 Hz, 1H), 4.08 — 3.89
(m, 5H), 3.42 — 3.25 (m, 4H),
2.80 (s, 3H), 2.22 (s, 2H), 2.05
— 1.79 (m, 6H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.64 (d, J =1.9 Hz, 1H),
7.94 (s, 2H), 6.99 — 6.90 (m,
2H), 4.82 (s, 1H), 4.05 — 3.87
152 464.21 (m, 5H), 3.44 (q, J = 6.3 Hz,
1H), 3.39 — 3.26 (m, 4H), 2.23
(d, J = 12.4 Hz, 2H), 2.03 -
1.82 (m, 6H), 1.23 (d, J = 6.3
Hz, 6H)
WO 59690
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.64 — 8.49 (m, 2H),
6.93 (d, J = 3.9 Hz, 1H), 6.83
(d, J = 2.4 Hz, 1H), 5.27 (d, J =
8.1 Hz, 1H), 4.94 (t, J = 1.9 Hz,
153 2H), 4.81 (t, J = 1.9 Hz, 2H),
4.72 (s, 1H), 3.96 (s, 1H), 3.89
— 3.78 (m, 4H), 3.37 — 3.25 (m,
4H),2.11 (s, 2H), 1.82 (d, J =
.1 Hz, 6H
(CDC13) 8 8.68 (dd, J = 8.7, 2.0
Hz, 1H), 8.56 (d, J = 2.0 Hz,
1H), 6.92 (d, J = 2.3 Hz, 1H),
6.84 (d, J = 2.4 Hz, 1H), 4.92
154 (t, J = 2.7 Hz, 2H), 4.82 (t, J =
2.7 Hz, 2H), 4.75 (s, 1H), 3.94
— 3.81 (m, 4H), 3.35 — 3.15 (m,
4H), 2.14 (d, J = 12.0 Hz, 2H),
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.64 (d, J :19 Hz, 1H),
7.02 — 6.89 (m, 2H), 4.83 (s,
1H), 4.08 — 3.87 (m, 5H), 3.44 — 155
3.33 (m, 4H), 3.27 (d, J = 26.0
Hz, 4H), 2.23 (d, J = 9.8 Hz,
2H), 2.05 — 1.80 (m, 6H), 1.14
(s, 6H)
(CDC13) 3 8.70 (d, J = 2.0 Hz,
N6} 1H), 8.63 (d, J =19 Hz, 1H),
’0’0 N 7.72 (s, 2H), 6.96 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
HN 1H), 5.03 (s, 1H), 4.80 (q, J =
156 ;\N N 462.23 4.4 Hz, 1H), 4.03 — 3.89 (m,
Vl E 1 4H), 3.83 (t, J = 7.1 Hz, 4H),
o 3.44 — 3.29 (m, 4H), 2.41 (dq, J
N = 8.6, 7.1 Hz, 2H), 2.20 (q, J =
Q 5.9 Hz, 2H), 1.99 — 1.81 (m,
H NMR (300 MHz, unless
Cqungd nd Structure indicated otherwise)
' NMR peaks given as 8 values
(CDC13) 3 8.71 (d, J = 2.0 Hz,
1H), 8.64 (d, J = 1.9 Hz, 1H),
8.41 (s, 2H), 6.97 (d, J = 2.4
Hz, 1H), 6.93 (d, J = 2.5 Hz,
158 1H), 5.32 (d, J = 8.1 Hz, 1H),
4.82 (s, 1H), 4.07 (s, 1H), 4.00
— 3.88 (m, 4H), 3.43 — 3.29 (m,
4H), 2.22 (s, 2H), 2.06 — 1.81
(400 MHz, CDC13) 5 8.69 (d, J
=19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 8.05 (d, J = 2.2 Hz,
1H), 7.46 (dd, J = 8.5, 2.3 Hz,
1H), 6.94 (d, J = 2.4 Hz, 1H),
160 6.90 (d, J = 2.4 Hz, 1H), 6.39
(d, J = 8.6 Hz, 1H), 4.77 (s,
1H), 4.53 (s, 2H), 3.95 — 3.87
(m, 5H), 3.36 — 3.32 (m, 4H),
2.25 =
— 2.12 (m, 2H), 1.90 (d, J
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
) 3 8.69 (d, J = 1.9 Hz,
1H), 8.61 (d, J =19 Hz, 1H),
8.26 (s, 2H), 6.95 (d, J = 2.5
Hz, 1H), 6.90 (d, J = 2.6 Hz,
1H), 5.23 (d, J = 8.1 Hz, 1H),
4.80 (d, J = 5.8 Hz, 1H), 4.26
(s, 2H), 4.03 (s, 1H), 3.97 —
3.85 (m, 4H), 3.44 — 3.21 (m,
7H), 2.32 — 2.09 (m, 2H), 2.06 —
1.70 (m, 6H)
(DMSO-d6) 8 8.81 - 8.64 (m,
3H), 8.58 (d, J =1.9 Hz, 1H),
7.99 (d, J = 7.6 Hz, 1H), 7.76
(d, J = 7.4 Hz, 1H), 7.14 (d, J =
2.5 Hz, 1H), 6.84 (d, J = 2.3
Hz, 1H), 4.92 (s, 1H), 3.98 -
3.84 (m, 1H), 4.05 (dq, J =
13.5, 6.7 Hz, 1H), 3.79 (d, J =
9.6 Hz, 4H), 3.32 (d, J = 8.2
Hz, 4H), 2.06 (d, J = 11.8 Hz,
2H), 1.96 — 1.66 (m, 6H), 1.14
(d, J = 6.6 Hz, 6H)
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.65 — 8.53 (m, 3H), 6.93
(dd, J = 14.6, 2.5 Hz, 2H), 5.48
(d, J = 8.0 Hz, 1H), 4.81 (d, J =
6.1 Hz, 1H), 4.19 — 4.03 (m,
1H), 3.92 (dd, J = 6.0, 3.7 Hz,
4H), 3.65 — 3.54 (m, 4H), 3.34
(dd, J = 5.9, 3.7 Hz, 4H), 2.27 —
2.15 (m, 2H), 2.08 — 1.81 (m,
10H)
(400 MHz, CDC13) 5 8.60 (d, J
:19 Hz, 1H), 8.52 (d, J :19
Hz, 1H), 8.01 (d, J = 2.1 Hz,
1H), 7.35 (dd, J = 8.8, 2.5 Hz,
1H), 6.86 (d, J = 2.5 Hz, 1H),
6.80 (d, J = 2.5 Hz, 1H), 6.20
(d, J = 8.4 Hz, 1H), 4.68 (s,
1H), 4.47 (d, J = 8.0 Hz, 1H),
3.92 — 3.80 (m, 4H), 3.74 (s,
1H), 3.34 — 3.14 (m, 4H), 2.18 —
2.02 (m, 2H), 1.94 — 1.67 (m,
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.69 (d, J
=19 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.44 — 8.37 (m, 1H),
8.33 (d, J = 8.1 Hz, 1H), 7.58
(dd, J = 7.8, 0.9 Hz, 1H), 7.31
(dd, J = 7.7, 4.6 Hz, 1H), 6.95
(d, J = 2.4 Hz, 1H), 6.90 (d, J =
2.4 Hz, 1H), 4.75 (s, 1H), 4.25
— 4.10 (m, 1H), 3.97 — 3.85 (m,
4H), 3.41 — 3.26 (m, 4H), 2.75
(s, 3H), 2.29 — 2.13 (m, 2H),
2.06 — 1.85 (m, 6H)
(400 MHz, CDC13) 3 8.69 (d, J
=19 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.41 (d, J = 4.5 Hz,
1H), 8.21 (d, J = 8.0 Hz, 1H),
8.08 — 7.98 (m, 1H), 7.25 — 7.22
(m, 1H), 6.95 (d, J = 2.5 Hz,
1H), 6.90 (d, J = 2.4 Hz, 1H),
4.76 (s, 1H), 4.27 — 4.15 (m,
1H), 3.98 — 3.86 (m, 4H), 3.40 —
3.29 (m, 4H), 2.43 (s, 3H), 2.29
— 2.16 (m, 2H), 2.07 — 1.86 (m,
(400 MHz, CDC13) 5 8.70 (d, J
=19 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.37 (dd, J = 1.4, 0.7
Hz, 1H), 8.16 (d, J = 8.4 Hz,
1H), 8.09 (d, J = 8.0 Hz, 1H),
7.66 =
— 7.61 (m, 1H), 6.95 (d, J
2.4 Hz, 1H), 6.90 (d, J = 2.4
Hz, 1H), 4.75 (s, 1H), 4.29 —
4.16 (m, 1H), 3.97 — 3.86 (m,
4H), 3.39 — 3.29 (m, 4H), 2.41
(s, 3H), 2.28 — 2.15 (m, 2H),
2.04 — 1.84 m, 6H
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.69 (d, J
=18 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.39 (d, J =16 Hz,
1H), 8.17 (d, J = 8.6 Hz, 1H),
8.11 (d, J = 8.0 Hz, 1H), 7.66
(dd, J = 7.9, 2.0 Hz, 1H), 6.95
(d, J = 2.3 Hz, 1H), 6.90 (d, J =
2.4 Hz, 1H), 4.76 (s, 1H), 4.31
— 4.14 (m, 1H), 4.00 — 3.85 (m,
4H), 3.42 — 3.25 (m, 4H), 2.73
(q, J = 7.6 Hz, 2H), 2.30 — 2.14
(m, 2H), 1.99 (ddd, J = 34.6,
19.6, 10.3 Hz, 7H), 1.29 (t, J =
7.6 Hz, 3H
(400 MHz, CDC13) 3 8.70 (d, J
:19 Hz, 1H), 8.64 (d, J :19
Hz, 1H), 8.24 (d, J = 7.8 Hz,
1H), 8.01 (d, J = 7.5 Hz, 1H),
7.72 (t, J = 7.7 Hz, 1H), 7.27
(d, J = 6.6 Hz, 1H), 6.95 (d, J =
2.4 Hz, 1H), 6.90 (d, J = 2.4
Hz, 1H), 4.82 — 4.68 (m, 1H),
4.27 — 4.13 (m, 1H), 3.98 — 3.86
(m, 4H), 3.41 — 3.28 (m, 4H),
2.60 (s, 3H), 2.30 — 2.18 (m,
2H ,2.09 — 1.88 m, 6H
(400 MHz, CDC13) 3 8.69 (d, J
=18 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 7.90 (d, J = 7.2 Hz,
1H), 7.83 — 7.78 (m, 1H), 7.76 —
7.69 (m, 1H), 6.96 (d, J = 2.3
Hz, 1H), 6.94 — 6.86 (m, 2H),
4.77 (s, 1H), 4.17 (s, 1H), 4.00
(s, 3H), 3.95 — 3.86 (m, 4H),
3.40 — 3.29 (m, 4H), 2.30 — 2.17
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.76 (dd,
J = 4.9, 0.8 Hz, 1H), 8.70 (d, J
=19 Hz, 1H), 8.62 (d, J =19
Hz, 1H), 8.48 — 8.38 (m, 1H),
8.09 (d, J = 8.0 Hz, 1H), 7.67
171 HN’O’O (dd, J = 4.9, 1.6 Hz, 1H), 6.96
”fig 1: (d, J = 2.4 Hz, 1H), 6.90 (d, J =
2.4 Hz, 1H), 4.76 (s, 1H), 4.31
— 4.14 (m, 1H), 4.01 — 3.83 (m,
4H), 3.43 — 3.26 (m, 4H), 2.31 —
2.15 (m, 2H), 2.08 — 1.87 (m,
(400 MHz, CDC13) 5 8.70 (d, J
=19 Hz, 1H), 8.64 (d, J =19
Hz, 1H), 8.11 (dd, J: 7.4, 1.4
Hz, 1H), 7.96 (dd, J = 15.6, 7.7
Hz, 1H), 7.82 (d, J = 7.7 Hz,
1H), 7.09 (dd, J = 8.1,18 Hz,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.91 (d, J = 2.4 Hz, 1H), 4.80
(s, 1H), 4.26 — 4.09 (m, 1H),
3.99 — 3.86 (m, 4H), 3.41 — 3.25
(m, 4H), 2.31 — 2.17 (m, 2H),
2.05 — 1.86 m, 6H
(400 MHz, CDC13) a 8.69 (d, J
=19 Hz, 1H), 8.62 (d, J =19
Hz, 1H), 8.30 (d, J = 2.1 Hz,
1H), 7.80 (d, J = 7.9 Hz, 1H),
7.32 (ddd, J = 10.3, 8.1, 2.3 Hz,
174 1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 4.74
(s, 1H), 4.27 — 4.15 (m, 1H),
4.00 — 3.86 (m, 4H), 3.41 — 3.27
(m, 4H), 2.27 — 2.13 (m, 2H),
2.08 — 1.86 m, 6H
H NMR (300 MHz, unless
ngd nd Structure indicated otherwise)
' NMR peaks given as 8 values
(400 MHz, CDC13) 8 12.21 (s,
1H), 8.70 (d, J = 1.9 Hz, 1H),
8.63 (d, J =1.9 Hz, 1H), 8.17
(d, J = 7.4 Hz, 1H), 8.07 (dd, J
= 4.2, 1.5 Hz, 1H), 7.33 (ddd, J
= 10.0, 8.5, 2.9 Hz, 2H), 6.97
(d, J = 2.4 Hz, 1H), 6.90 (d, J =
2.5 Hz, 1H), 4.83 — 4.74 (m,
1H), 4.24 — 4.11 (m, 1H), 3.99 —
3.86 (m, 4H), 3.41 — 3.26 (m,
4H), 2.30 — 2.18 (m, 2H), 2.08 —
1.87 (m, 6H)
(400 MHz, CDC13) 5 11.13 (s,
1H), 8.71 (d, J :19 Hz, 1H),
8.59 (d, J :19 Hz, 1H), 7.64 —
7.39 (m, 2H), 7.07 (d, J = 6.8
177 Hz, 1H), 7.02 — 6.79 (m, 3H),
4.76 (s, 1H), 4.32 — 4.15 (m,
1H), 3.96 — 3.85 (m, 4H), 3.42 —
3.24 (m, 4H), 2.39 — 2.14 (m,
2H ,2.10 — 1.82 m, 6H
(400 MHz, CDC13) 5 8.70 (d, J
=19 Hz, 1H), 8.64 (d, J :19
”q Hz, 1H), 8.14 (dd, J = 7.6, 0.7
Hz, 1H), 7.91 (d, J = 8.1 Hz,
0 N
1H), 7.81 (t, J: 7.8 Hz, 1H),
7.46 (dd, J = 7.9, 0.7 Hz, 1H),
178 468.17 6.96 (d, J = 2.4 Hz, 1H), 6.91
\ (d, J = 2.4 Hz, 1H), 4.80 (s,
/ E 1 1H), 4.24 —4.08 (m, 1H), 3.99 —
O 3.83 (m, 4H), 3.41 — 3.26 (m,
4H), 2.33 _ 2.18 (m, 2H), 2.11 _
1.98 (m, 2H), 1.98 — 1.87 (m,
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.70 (d, J
=19 Hz, 1H), 8.63 (d, J: 1.9
m Hz, 1H), 8.13 (d, J = 7.7 Hz,
00 N 1H), 8.02 (d, J = 7.8 Hz, 1H),
7.86 (t, J = 7.7 Hz, 1H), 7.48
HN (d, J = 7.8 Hz, 1H), 6.96 (d, J =
[N] 2.4 Hz, 1H), 6.91 (d, J = 2.4
Hz, 1H), 4.85 (s, 2H), 4.79 (s,
1H), 4.28 — 4.15 (m, 1H), 4.00 —
3.87 (m, 4H), 3.41 — 3.27 (m,
4H), 2.88 (s, 1H), 2.33 — 2.16
(m, 2H), 2.07 — 1.88 (m, 6H)
(400 MHz, CDC13) 5 8.68 (d, J
:19 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.16 (d, J = 7.8 Hz,
,0 1H), 7.56 (dd, J = 8.4, 7.3 Hz,
1H), 7.43 (d, J = 6.7 Hz, 1H),
180 GAG 6.96 (d, J = 2.4 Hz, 1H), 6.91
(:1 (d, J = 2.4 Hz, 1H), 6.50 (d, J =
7.8 Hz, 1H), 4.74 (s, 1H), 4.21
— 4.07 (m, 1H), 3.97 — 3.86 (m,
L7 4H), 3.54 — 3.48 (m, 4H), 3.40 —
3.29 (m, 4H), 2.26 — 2.14 (m,
2H 2.07 — 1.88
, m, 10H
(400 MHz, CDC13) 5 8.91 (s,
2H), 8.71 (d, J :19 Hz, 1H),
8.64 (d, J :19 Hz, 1H), 8.30
(dd, J = 7.7, 0.7 Hz, 1H), 8.11
(t, J = 7.9 Hz, 1H), 7.74 (d, J =
8.2 Hz, 1H), 7.57 (dd, J = 8.0,
181 0.7 Hz, 1H), 6.97 (d, J = 2.4
Hz, 1H), 6.92 (d, J = 2.4 Hz,
1H), 4.82 (s, 1H), 4.27 — 4.11
(m, 1H), 3.99 — 3.85 (m, 4H),
3.42 — 3.27 (m, 4H), 2.34 — 2.20
(m, 2H), 2.12 — 2.00 (m, 2H),
2.00 — 1.84 m, 4H
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 8 8.71 (d, J
= 1.9 Hz, 1H), 8.63 (d, J =1.9
Hz, 1H), 8.15 (s, 1H), 7.43 (d, J
= 8.1 Hz, 1H), 6.97 (d, J = 2.3
182 Hz, 1H), 6.90 (d, J = 2.4 Hz,
1H), 4.82 (s, 1H), 4.24 — 4.13
(m, 1H), 3.98 — 3.86 (m, 4H),
3.40 — 3.27 (m, 4H), 2.30 — 2.16
m, 2H 2.05 — 1.78
, m, 6H
(400 MHz, CDC13) a 8.69 (d, J
:19 Hz, 1H), 8.63 (d, J :19
Nfi Hz, 1H), 7.86 (d, J = 3.1 Hz,
0 N
0 1H), 7.57 (d, J = 3.1 Hz, 1H),
7.38 (d, J = 8.0 Hz, 1H), 6.95
183 HN 440.12 (d, J = 2.4 Hz, 1H), 6.90 (d, J =
AVS N 2.4 Hz, 1H), 4.79 (s, 1H), 4.25
\ — 4.09 (m, 1H), 3.97 — 3.88 (m,
N / E j
0 4H), 3.39 — 3.29 (m, 4H), 2.28 —
2.17 (m, 2H), 2.07 — 1.96 (m,
2H), 1.96 — 1.85 (m, 4H)
(400 MHz, CDC13) 5 8.69 (d, J
=19 Hz, 1H), 8.62 (d, J :19
Nfi Hz, 1H), 7.50 (d, J =
1.1 Hz, 1H), 7.28 (d, J = 8.3
(0’ \©/O
HZ, 1H), 6.95 (d, J = 2.4 HZ,
1H), 6.89 (d, J = 2.4 Hz, 1H),
184 “N 45409
DAW/ 4.78 (s, 1H), 4.23 — 4.07 (m,
S N
CH3[ ] 1H),3.99 _ 3.87 (m,4H),3.40 _
3.27 (m, 4H), 2.53 (d, J =10
0 Hz, 3H), 2.28 — 2.14 (m, 2H),
2.04 — 1.95 (m, 2H), 1.95 — 1.84
(m, 4H)
(400 MHz, CDC13) a 8.70 (t, J
= 5.6 Hz, 1H), 8.61 (dd, J =
Nfi 12.5,1.9 Hz, 1H), 7.35 (d, J =
0 N 8.0 Hz, 1H), 7.11 (d, J = 0.9
0 Hz, 1H), 7.01 — 6.92 (m, 1H),
HN 6.89 (d, J = 2.4 Hz, 1H), 4.85 —
185 454-13
470 (m, 1H), 4.26 — 4.11 (m,
S N
\ / E 1 1H), 3.90 (dd, J = 15.3, 10.4
0 Hz, 4H), 3.42 — 3.25 (m, 4H),
CH3 2.49 (d, J = 0.9 Hz, 3H), 2.30 —
2.16 (m, 2H), 2.12 — 1.84 (m,
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
8.01 (d, J = 5.8 Hz, 1H), 7.00 -
6.86 (m, 2H), 6.03 (d, J = 5.8
Hz, 1H), 4.80 (d, J = 5.8 Hz,
1H), 4.07 (s, 1H), 3.97 - 3.83
(m, 7H), 3.41 — 3.28 (m, 4H),
2.20 (dd, J = 12.3, 5.6 Hz, 2H),
1.95 (dh, J = 11.8, 5.6, 4.7 Hz,
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
7.70 (s, 1H), 6.96 (q, J = 2.6
Hz, 2H), 5.75 (d, J = 6.5 Hz,
187 1H), 4.82 (s, 1H), 4.65 (s, 1H),
3.93 (dd, J = 5.9, 3.8 Hz, 4H),
3.63 (s, 4H), 3.36 (dd, J = 6.1,
3.7 Hz, 4H), 2.14 (s, 2H), 1.95
(d, J = 31.2 Hz, 6H)
(400 MHz, CDC13) 8 9.02 (d, J
= 2.6 Hz, 1H), 8.70 (d, J =1.9
Hz, 1H), 8.61 (d, J =1.9 Hz,
1H), 8.17 (dd, J = 9.3, 2.6 Hz,
1H), 6.97 (d, J = 2.4 Hz, 1H),
188 6.91 (d, J = 2.4 Hz, 1H), 6.36
(d, J = 9.3 Hz, 1H), 5.37 (s,
1H), 4.82 (s, 1H), 4.04 (s, 1H),
3.96 - 3.87 (m, 4H), 3.40 - 3.27
(m, 4H), 2.31 — 2.18 (m, 2H),
2.03 - 1.84 (m, 6H)
(400 MHz, CDC13) 8 8.69 (d, J
= 1.6 Hz, 1H), 8.61 (d, J= 1.7
Hz, 1H), 8.32 (s, 1H), 7.56 (d, J
= 6.7 Hz, 1H), 6.96 (d, J = 2.2
Hz, 1H), 6.90 (d, J = 2.3 Hz,
189 474.147
1H), 6.40 (d, J = 8.7 Hz, 1H),
4.96 (s, 1H), 4.80 (s, 1H), 4.01
- 3.84 (m, 5H), 3.42 — 3.24 (m,
4H), 2.21 (d, J = 8.4 Hz, 2H),
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.52 (s, 1H), 8.29 (d,
J = 4.8 Hz, 2H), 6.90 (d, J = 2.5
Hz, 1H), 6.85 (d, J = 2.5 Hz,
1H), 6.52 (t, J = 4.8 Hz, 1H),
.36 (s, 1H), 4.79 (dq, J = 5.6,
2.9 Hz, 1H), 4.04 (dp, J = 8.0,
3.8 Hz, 1H), 3.97 — 3.85 (m,
4H), 3.38 — 3.26 (m, 4H), 2.70
(s, 3H), 2.29 — 2.11 (m, 2H),
2.00 — 1.78 (m, 6H)
(CDC13) 5 8.52 (s, 1H), 8.29 (d,
J = 4.8 Hz, 2H), 6.90 (d, J = 2.5
Hz, 1H), 6.85 (d, J = 2.5 Hz,
1H), 6.53 (t, J = 4.8 Hz, 1H),
.42 (d, J = 7.9 Hz, 1H), 4.80
(dq, J = 5.9, 2.9 Hz, 1H), 4.11 —
3.98 (m, 1H), 3.91 (dd, J = 5.9,
3.8 Hz, 4H), 3.42 — 3.21 (m,
4H), 2.71 (s, 3H), 2.31 — 2.07
(m, 2H), 2.04 — 1.77 (m, 6H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
7.97 (s, 1H), 6.97 (d, J = 2.5
Hz, 1H), 6.93 (d, J = 2.5 Hz,
1H), 5.36 (s, 1H), 4.80 (d, J =
192 6.2 Hz, 1H), 4.65 (d, J = 0.9
Hz, 2H), 4.02 (t, J = 5.8 Hz,
3H), 3.98 — 3.82 (m, 4H), 3.42 —
3.30 (m, 4H), 2.80 (t, J = 5.8
Hz, 2H), 2.29 — 2.11 (m, 2H),
2.03 — 1.77 (m, 7H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
7.95 (s, 2H), 7.05 — 6.88 (m,
2H), 4.92 (s, 1H), 4.79 (s, 1H),
3.93 (t, J = 4.8 Hz, 5H), 3.60 —
3.44 (m, 4H), 3.37 (d, J = 10.5
Hz, 9H), 2.20 (d, J = 6.9 Hz,
2H), 1.91 (d, J = 4.6 Hz, 6H)
H NMR (300 MHz, unless
Compound ure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J =19 Hz, 1H),
8.28 (d, J = 0.9 Hz, 1H), 6.97
(d, J = 2.5 Hz, 1H), 6.91 (d, J =
2.5 Hz, 1H), 5.74 — 5.58 (m,
194 1H), 5.16 (d, J = 8.0 Hz, 1H),
4.82 (dq, J = 5.4, 2.7 Hz, 1H),
4.06 =
— 3.85 (m, 7H), 3.70 (d, J
14.0 Hz, 1H), 3.42 — 3.28 (m,
4H), 2.30 — 2.16 (m, 2H), 1.99 —
1.75 (m, 6H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J = 2.0 Hz, 1H),
7.43 (dd, J = 8.6, 7.2 Hz, 1H),
7.02 — 6.86 (m, 3H), 6.55 (dd, J
195 = 8.6, 0.8 Hz, 1H), 4.80 (d, J =
6.6 Hz, 2H), 4.10 — 3.81 (m,
5H), 3.47 — 3.25 (m, 4H), 2.30 —
2.11 (m,2H), 1.99 — 1.81 (m,
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
7.61 (d, J = 9.4 Hz, 1H), 7.41
(d, J = 7.2 Hz, 1H), 7.05 — 6.87
196 (m, 2H), 6.65 (s, 1H), 4.86 (s,
1H), 4.04 — 3.87 (m, 7H), 3.74
(s, 1H), 3.43 — 3.27 (m, 4H),
2.21 (d, J = 10.8 Hz, 2H), 1.98
d, J: 23.5 Hz, 6H
(400 MHz, CDC13) 8 8.68 (d, J
=19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 8.13 — 8.04 (m, 1H),
7.67 (d, J = 2.4 Hz, 1H), 6.99 —
6.93 (m, 2H), 6.90 (d, J = 2.4
Hz, 1H), 6.33 (d, J = 8.7 Hz,
1H), 4.77 (s, 1H), 3.99 — 3.65
(m, 7H), 3.39 — 3.27 (m, 4H),
2.25 — 2.10 (m, 2H), 1.96 — 1.82
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.69 (d, J
= 1.6 Hz, 1H), 8.61 (d, J: 1.7
Hz, 1H), 8.57 (d, J = 2.1 Hz,
1H), 7.89 (dd, J = 8.9, 2.3 Hz,
1H), 6.95 (s, 1H), 6.90 (s, 1H),
6.62 (d, J = 9.0 Hz, 1H), 5.99
198 (d, J = 7.7 Hz, 1H), 4.78 (s,
1H), 4.18 (s, 1H), 4.03 — 3.81
(m, 4H), 3.76 — 3.60 (m, 4H),
3.42 — 3.25 (m, 4H), 2.62 — 2.44
(m, 4H), 2.36 (s, 3H), 2.29 —
2.14 (m, 2H), 1.99 — 1.84 (m,
(400 MHz, CDC13) 5 8.73 —
8.65 (m, 3H), 8.60 (d, J =19
Hz, 1H), 6.95 (d, J = 2.4 Hz,
1H), 6.89 (d, J = 2.4 Hz, 1H),
.93 (d, J = 8.0 Hz, 1H), 4.79
(s, 1H), 4.23 — 4.09 (m, 1H),
3.97 — 3.88 (m, 8H), 3.40 — 3.25
(m, 4H), 2.53 — 2.42 (m, 4H),
2.34 (s, 3H), 2.26 — 2.18 (m,
2H 1.97 — 1.83
, m, 6H
(400 MHz, CDC13) 5 8.69 (d, J
=19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 7.51 — 7.42 (m, 2H),
6.98 =
— 6.85 (m, 3H), 6.07 (d, J
8.0 Hz, 1H), 4.77 (s, 1H), 4.25
— 4.11 (m, 1H), 3.99 — 3.85 (m,
4H), 3.40 — 3.27 (m, 4H), 3.26 —
3.14 (m, 4H), 2.67 — 2.52 (m,
4H), 2.36 (s, 3H), 2.28 — 2.13
(m, 2H), 1.98 — 1.84 (m, 6H)
(400 MHz, CDC13) 5 9.47 (s,
1H), 8.68 (d, J :17 Hz, 1H),
8.56 (d, J =17 Hz, 1H), 8.21 —
8.11 (m, 1H), 6.97 — 6.85 (m,
201 4H), 4.82 (s, 1H), 4.23 — 4.07
(m, 1H), 3.96 — 3.87 (m, 4H),
3.38 — 3.29 (m, 4H), 3.03 (s,
4H), 2.65 (s, 4H), 2.37 — 2.25
(m, 5H), 2.02 — 1.84 (m, 6H)
H NMR (300 MHz, unless
Compound ure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.69 (d, J
=18 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.27 (dd, J = 4.7, 1.9
Hz, 1H), 8.19 (s, 1H), 8.11 (d, J
= 6.8 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.92 (d, J = 2.3 Hz,
1H), 6.51 (dd, J = 7.4, 4.9 Hz,
1H), 4.76 (s, 1H), 4.30 (s, 1H),
4.02 — 3.90 (m, 4H), 3.88 (s,
3H), 3.41 — 3.26 (m, 4H), 2.29 —
2.11 (m, 2H), 2.11 — 1.85 (m,
(CDC13) a 8.70 (d, J = 1.9 Hz,
1H), 8.60 (d, J :19 Hz, 1H),
8.15 (s, 1H), 6.93 (dd, J = 17.9,
2.5 Hz, 2H), 6.43 (d, J = 6.1
Hz, 1H), 5.20 (s, 1H), 4.82 (s,
1H), 4.00 — 3.82 (m, 4H), 3.44 —
3.25 (m, 4H), 2.23 (d, J = 11.2
Hz, 2H), 1.91 (s, 6H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
8.09 (d, J = 6.0 Hz, 1H), 6.93
(dd, J = 16.1, 2.5 Hz, 2H), 6.15
(d, J = 6.0 Hz, 1H), 5.10 (d, J =
204 8.0 Hz, 1H), 4.81 (td, J = 5.5,
2.7 Hz, 1H), 3.97 — 3.87 (m,
4H), 3.49 (s, 1H), 3.39 — 3.27
(m, 4H), 2.49 (s, 3H), 2.27 —
2.14 (m, 2H), 2.03 — 1.80 (m,
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.61 (dd, J = 53,19 Hz,
1H), 8.19 — 8.06 (m, 1H), 6.99 —
6.84 (m, 2H), 5.34 _ 5.21 (m,
1H), 4.76 (d, J = 9.7 Hz, 3H),
3.92 (t, J = 4.9 Hz, 4H), 3.81 (s,
1H), 3.33 (dd, J = 5.7, 4.1 Hz,
4H), 2.87 (d, J = 5.2 Hz, 3H),
2.19 (d, J = 8.5 Hz, 2H), 1.88
2014/024767
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 3 8.68 (d, J
=19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 7.82 (d, J = 2.8 Hz,
1H), 7.09 (dd, J = 8.9, 3.0 Hz,
1H), 6.94 (d, J = 2.5 Hz, 1H),
6.90 (d, J = 2.5 Hz, 1H), 6.37
(d, J = 8.8 Hz, 1H), 4.77 (s,
1H), 4.29 (bs, 1H), 3.98 — 3.87
(m, 4H), 3.85 — 3.79 (m, 1H),
3.77 (s, 3H), 3.41 — 3.24 (m,
4H), 2.27 — 2.12 (m, 2H), 1.97 —
1.79 (m, 6H)
(CDC13) 5 8.71 (d, J = 2.0 Hz,
1H), 8.64 (d, J :19 Hz, 1H),
8.44 (s, 1H), 6.98 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
1H), 6.82 (d, J = 4.7 Hz, 1H),
.56 (d, J = 30.8 Hz, 1H), 4.83
(d, J = 5.2 Hz, 1H), 4.04 (s,
2H), 3.97 — 3.84 (m, 4H), 3.44 —
3.29 (m, 4H), 2.23 (d, J = 8.2
Hz, 2H), 2.02 — 1.77 (m, 6H)
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.64 (d, J :19 Hz, 1H),
8.16 (s, 2H), 7.00 — 6.84 (m,
2H), 5.32 (s, 1H), 4.81 (s, 1H),
208 4.03 (s, 1H), 3.96 — 3.85 (m,
4H), 3.43 — 3.32 (m, 4H), 2.49
(q, J = 7.6 Hz, 2H), 2.21 (d, J =
8.8 Hz, 2H), 2.06 — 1.75 (m,
6H), 1.21 (t, J = 7.6 Hz, 3H)
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.18 (s, 2H), 7.01 — 6.88 (m,
2H), 5.30 (d, J = 9.0 Hz, 1H),
4.81 (d, J = 5.9 Hz, 1H), 4.02
(s, 1H), 3.96 — 3.85 (m, 4H),
3.42 =
— 3.29 (m, 4H), 2.78 (p, J
6.9 Hz, 1H), 2.31 — 2.14 (m,
2H), 2.01 — 1.83 (m, 6H), 1.25
H NMR (300 MHz, unless
ngd Compound ure indicated otherwise)
' NMR peaks given as 8 values
(400 MHz, methanol—d4) 5 8.69
(d, J = 2.0 Hz, 1H), 8.57 (d, J =
2.0 Hz, 1H), 7.92 (d, J = 6.2
Hz, 1H), 7.17 - 7.10 (m, 2H),
7.02 (d, J = 7.1 Hz, 1H), 6.90
(d, J = 2.5 Hz, 1H), 4.93 (s,
1H), 3.93 — 3.87 (m, 4H), 3.84 —
3.79 (m, 1H), 3.44 — 3.37 (m,
4H), 2.24 - 2.15 (m, 2H), 1.97 —
1.82 (m, 6H)
213 OYO’ 434.15
N / E J
N6} (400 MHz, CDC13) 5 8.98 —
,0;0 N 8.83 (m, 1H), 8.79 — 8.67 (m,
1H), 8.64 — 8.50 (m, 1H), 8.35
HN (d, J = 9.2 Hz, 1H), 7.04 — 6.86
214 N 474.12
N / (m, 2H), 6.75 (d, J = 9.0 Hz,
\ E 1 2H), 4.78 (s, 1H), 4.00 — 3.79
0 (m, 5H), 3.42 _ 3.21 (m, 4H),
2.17—2.11(m, 2H), 2.02—1.81
N/ NH
‘NZNI (m, 6H)
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
8.25 (d, J = 0.9 Hz, 1H), 6.93
(dd, J = 17.1, 2.5 Hz, 2H), 5.64
(d, J = 0.9 Hz, 1H), 5.00 (d, J =
8.1 Hz, 1H), 4.80 (dq, J = 5.5,
2.7 Hz, 1H), 4.33 (q, J = 7.1
Hz, 2H), 3.97 — 3.87 (m, 4H),
3.71 (s, 1H), 3.38 — 3.29 (m,
4H), 2.27 - 2.14 (m, 2H), 2.03 —
1.80 (m, 6H), 1.37 (t, J = 7.1
Hz, 3H)
) 3 8.69 (d, J = 1.9 Hz,
1H), 8.62 (d, J :19 Hz, 1H),
6.95 (d, J = 2.5 Hz, 1H), 6.90
(d, J = 2.5 Hz, 1H), 0.23 — 0.16
(m, 0H), 4.93 (s, 1H), 4.76 (s,
1H), 4.19 — 4.01 (m, 1H), 3.97 —
3.87 (m, 4H), 3.38 — 3.29 (m,
4H), 2.49 (s, 3H), 2.26 (s, 3H),
2.21 =
— 2.10 (m, 2H), 2.05 (d, J
1.8 Hz, 3H), 2.00 — 1.85 (m,
(400 MHz, CDC13) 8 8.69 (d, J
=19 Hz, 1H), 8.61 (d, J: 1.9
Hz, 1H), 8.15 (d, J = 5.3 Hz,
1H), 7.06 (dd, J = 5.4, 1.3 Hz,
1H), 7.00 (s, 1H), 6.95 (d, J =
2.4 Hz, 1H), 6.91 (d, J = 2.4
Hz, 1H), 5.15 (s, 1H), 4.81 (d, J
= 2.5 Hz, 1H), 3.95
— 3.83 (m,
8H), 3.38 — 3.30 (m, 4H), 2.27 _
2.16 (m, 2H), 1.97 — 1.85 (m,
(CDC13) 5 8.70 (d, J = 2.0 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.17 (d, J = 0.9 Hz, 1H), 7.02 —
6.85 (m, 2H), 5.40 (s, 1H), 5.05
218 (td, J = 1.8, 0.8 Hz, 2H), 4.91 —
4.73 (m, 3H), 4.05 (s, 0H), 3.99
— 3.85 (m, 4H), 3.43 — 3.27 (m,
4H), 2.30 — 2.12 (m, 2H), 2.02 —
1.82 (m, 6H)
WO 59690
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
6.96 (d, J = 2.5 Hz, 1H), 6.89
(d, J = 2.5 Hz, 1H), 6.03 (s,
1H), 5.00 (s, 1H), 4.79 (s, 1H),
3.92 (d, J = 9.3 Hz, 7H), 3.41 —
3.25 (m, 4H), 2.28 — 2.13 (m,
(400 MHz, CDC13) 3 8.69 (s,
1H), 8.62 (s, 1H), 8.54 (s, 1H),
8.21 (d, J = 4.9 Hz, 1H), 7.22 —
7.08 (m, 2H), 6.96 (s, 1H), 6.93
(s, 1H), 4.84 (s, 1H), 3.98 —
3.86 (m, 5H), 3.38 — 3.26 (m,
4H), 2.31 — 2.19 (m, 2H), 2.03 —
1.86 (m, 6H)
(400 MHz, CDC13) a 8.75 (d, J
:19 Hz, 1H), 8.69 (d, J :19
Hz, 1H), 8.61 (d, J :19 Hz,
1H), 8.39 (s, 1H), 8.05 (dd, J =
8.8, 2.3 Hz, 1H), 6.95 (d, J =
2.4 Hz, 1H), 6.91 (d, J = 2.4
Hz, 1H), 6.49 (d, J = 8.8 Hz,
1H), 5.23 (s, 1H), 4.88 — 4.71
(m, 1H), 4.05 — 3.95 (m, 1H),
3.95 — 3.85 (m, 4H), 3.39 — 3.26
(m, 4H), 2.28 — 2.16 (m, 2H),
2.00 — 1.83 m, 6H
(CDC13) 3 8.63 (d, J = 1.9 Hz,
1H), 8.53 (dd, J = 1.9, 0.6 Hz,
1H), 7.71 (d, J = 9.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 6.83
(d, J = 2.5 Hz, 1H), 6.68 (d, J =
222 9.4 Hz, 1H), 5.33 (s, 1H), 4.76
(dq, J = 5.0, 2.5 Hz, 1H), 4.14
(s, 1H), 3.93 — 3.77 (m, 4H),
3.28 (d, J = 5.1 Hz, 7H), 2.18
(dt, J = 13.4, 4.6 Hz, 2H), 2.02
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
6.94 (dd, J = 15.2, 2.5 Hz, 2H),
6.07 (s, 1H), 4.82 (dt, J = 5.8,
223 3.0 Hz, 1H), 4.02 — 3.83 (m,
4H), 3.77 — 3.57 (m, 1H), 3.43 —
3.28 (m, 4H), 2.52 (s, 3H), 2.37
(s, 3H), 2.30 - 2.16 (m, 2H),
2.05 — 1.78 m, 6H
) 8 8.72 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
8.27 (s, 1H), 6.98 (d, J = 2.4
Hz, 1H), 6.92 (d, J = 2.6 Hz,
224 1H), 6.44 (d, J = 6.0 Hz, 1H),
4.84 (s, 1H), 3.93 (dd, J = 6.0,
3.7 Hz, 4H), 3.43 — 3.25 (m,
4H), 2.23 (s, 2H), 2.08 — 1.83
m, 6H
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J :19 Hz, 1H),
8.49 (d, J = 1.1 Hz, 1H), 6.93
(dd, J = 16.7, 2.5 Hz, 2H), 6.45
(d, J = 1.2 Hz, 1H), 5.01 (s,
1H), 4.81 (s, 1H), 4.39 (d, J =
0.9 Hz, 2H), 3.97 — 3.87 (m,
4H), 3.49 (s, 3H), 3.39 — 3.29
(m, 4H), 2.22 (d, J = 9.4 Hz,
2H 1.99 — 1.87
, m, 6H
(CDC13) 8 8.70 (d, J = 2.0 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
6.95 (d, J = 2.5 Hz, 1H), 6.91
(d, J = 2.5 Hz, 1H), 4.75 (d, J =
.6 Hz, 1H), 4.66 (s, 1H), 4.32
(s, 1H), 4.00 — 3.83 (m, 4H),
3.43 =
— 3.22 (m, 4H), 2.46 (d, J
.1 Hz, 5H), 2.36 (s, 3H), 2.19
(q, J = 6.3, 3.9 Hz, 2H), 1.12 (t,
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.72 (d, J = 1.9 Hz,
1H), 8.64 (d, J =19 Hz, 1H),
8.33 (d, J =18 Hz, 1H), 7.04 —
6.87 (m, 2H), 5.15 (s, 1H), 4.82
(dq, J = 5.2, 2.6 Hz, 1H), 4.24
227 (dt, J = 8.3, 4.7 Hz, 1H), 4.03 —
3.86 (m, 4H), 3.44 — 3.28 (m,
4H), 2.74 (qd, J = 7.6, 2.3 Hz,
2H), 2.24 (dq, J = 9.6, 4.6 Hz,
2H), 2.09 — 1.85 (m, 6H), 1.29
(t, J = 7.6 Hz, 3H)
(CDC13) 5 8.60 (dd, J = 8.1, 1.9
Hz, 1H), 8.54 (d, J =19 Hz,
1H), 8.00 (s, 1H), 6.92 — 6.75
(m, 2H), 5.06 (d, J = 8.0 Hz,
228 1H), 4.70 (s, 1H), 3.94 (s, 1H),
3.89 — 3.76 (m, 4H), 3.75 — 3.62
(m, 4H), 3.34 — 3.17 (m, 4H),
2.50 (s, 3H), 2.11 (s, 2H), 1.82
(d, J = 5.0 Hz, 5H)
(400 MHz, CDC13) 3 8.70 (d, J
=19 Hz, 1H), 8.62 (d, J =19
Hz, 1H), 8.44 (d, J = 2.0 Hz,
1H), 7.91 (d, J = 8.8 Hz, 1H),
6.97 (d, J = 2.4 Hz, 1H), 6.92
229 (d, J = 2.4 Hz, 1H), 6.60 (d, J =
8.6 Hz, 1H), 5.52 (s, 1H), 4.83
(s, 1H), 4.18 (s, 3H), 4.00 —
3.87 (m, 5H), 3.39 — 3.24 (m,
4H), 2.31 — 2.18 (m, 2H), 2.04 —
1.87 (m, 6H)
(400 MHz, CDC13) 8 8.81 (d, J
= 1.8 Hz, 1H), 8.69 (d, J =1.9
Hz,1H), 8.61 (d, J =1.9 Hz,
1H), 8.13 (dd, J = 8.8, 2.2 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
230 6.92 (d, J = 2.4 Hz, 1H), 6.52
(d, J = 8.8 Hz, 1H), 4.82 (s,
1H), 4.36 (s, 3H), 3.96 — 3.85
(m, 5H), 3.41 - 3.28 (m, 4H),
2.28 - 2.17 (m, 2H), 2.06 — 1.83
(m, 6H)
H NMR (300 MHz, unless
Cmpd. ESMS
Compound Structure indicated otherwise)
(M+H)
NMR peaks given as 8 values
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J = 2.0 Hz, 1H),
7.70 (d, J = 3.4 Hz, 1H), 6.93
(dd, J = 14.6, 2.5 Hz, 2H), 4.96
(dd, J = 17.8, 7.1 Hz, 2H), 4.76
(d, J = 6.2 Hz, 1H), 4.62 (ddt, J
231 510.2
= 12.6, 7.1, 3.5 Hz, 1H), 4.05
3.82 (m, 8H), 3.75 (dd, J = 9.4,
3.2 Hz, 1H), 3.40 — 3.27 (m,
4H), 2.35 (ddt, J = 13.0, 8.2,
7.1 Hz, 1H), 2.25 — 2.08 (m,
2H), 2.00 — 1.77 (m, 6H)
(CDC13) a 8.61 (d, J = 1.9 Hz,
1H), 8.54 (d, J =19 Hz, 1H),
7.98 (s, 2H), 6.94 — 6.75 (m,
2H), 5.01 (s, 1H), 4.71 (d, J =
.9 Hz, 1H), 3.96 — 3.78 (m,
232 477.18
5H), 3.68 (d, J = 7.0 Hz, 2H),
3.37 — 3.17 (m, 4H), 2.21 — 1.96
(m, 2H), 1.92 — 1.75 (m, 6H),
1.25 — 1.06 (m, 1H), 0.66 — 0.44
(m, 2H), 0.34 — 0.18 (m, 2H)
) 3 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
8.06 (s, 2H), 7.01 — 6.86 (m,
2H), 5.00 (d, J = 8.1 Hz, 1H),
233 451.2 4.80 (d, J = 5.6 Hz, 1H), 4.10 —
3.82 (m, 7H), 3.42 — 3.26 (m,
5H), 2.20 (d, J = 8.2 Hz, 2H),
2.01 — 1.80 (m, 6H), 1.39 (t, J:
7.0 Hz, 3H)
(CDC13) 5 8.72 (d, J = 1.9 Hz,
1H), 8.60 (t, J = 1.9 Hz, 2H),
6.97 (d, J = 2.5 Hz, 1H), 6.91
(d, J = 2.5 Hz, 1H), 6.70 (d, J =
234 432.17
1.2 Hz, 1H), 4.85 (d, J = 4.9
Hz, 1H), 3.98 — 3.84 (m, 4H),
3.42 — 3.26 (m, 4H), 2.33 — 2.17
(m, 2H), 2.01 — 1.77 (m, 5H)
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.68 (d, J = 2.0 Hz,
1H), 8.59 (d, J =19 Hz, 1H),
8.36 (s, 2H), 6.97 — 6.86 (m,
2H), 5.53 (d, J = 8.1 Hz, 1H),
4.96 — 4.72 (m, 3H), 4.09 — 3.86
(m, 5H), 3.33 (dd, J = 5.8, 4.0
Hz, 4H), 2.28 — 2.10 (m, 2H),
1.98 — 1.78 (m, 6H)
(CDC13) 5 8.68 (d, J = 2.0 Hz,
1H), 8.59 (d, J =19 Hz, 1H),
8.36 (s, 2H), 6.97 — 6.86 (m,
2H), 5.53 (d, J = 8.1 Hz, 1H),
4.96 — 4.72 (m, 3H), 4.09 — 3.86
(m, 5H), 3.33 (dd, J = 5.8, 4.0
Hz, 4H), 2.28 — 2.10 (m, 2H),
1.98 — 1.78 (m, 6H)
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz,1H),
8.31 (s, 2H), 6.99 — 6.87 (m,
2H), 5.34 (d, J = 8.1 Hz, 1H),
237 4.87 — 4.73 (m, 2H), 4.06 — 3.87
(m, 6H), 3.38 — 3.29 (m, 4H),
2.20 (q, J = 5.8 Hz, 2H), 2.04 -
1.84 (m, 6H), 1.51 (d, J = 6.5
Hz, 3H)
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.64 (d, J =19 Hz, 1H),
8.15 (s, 2H), 6.99 — 6.86 (m,
2H), 5.11 (td, J = 7.9, 7.4, 3.8
Hz, 1H), 4.82 — 4.55 (m, 3H),
4.10 (dd, J = 4.1, 2.7 Hz, 2H),
3.93 (dd, J = 6.0, 3.7 Hz, 5H),
3.60 — 3.43 (m, 1H), 3.36 (dd, J
= 6.0, 3.7 Hz, 4H), 2.85
— 2.61
(m, 1H), 2.30 — 2.10 (m, 2H),
1.92 (s, 6H), 1.24 (q, J = 6.9
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) a 8.61 (d, J = 1.9 Hz,
1H), 8.54 (d, J :19 Hz, 1H),
7.95 (d, J = 13.9 Hz, 2H), 6.92
— 6.72 (m, 2H), 4.85 — 4.64 (m,
3H), 4.41 (t, J = 6.2 Hz, 2H),
3.83 (q, J = 6.7, 5.7 Hz, 6H),
3.33 — 3.18 (m, 5H), 2.20 — 1.97
(m, 1H), 1.82 (s, 7H)
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.63 (d, J =1.9 Hz, 1H),
8.08 (s, 2H), 7.01 — 6.87 (m,
2H), 5.11 (d, J: 8.1 Hz, 1H),
4.95 =
— 4.74 (m, 3H), 4.56 (t, J
6.0 Hz, 2H), 4.17 (d, J = 6.7
Hz, 2H), 4.05 - 3.81 (m, 4H),
3.51 — 3.29 (m, 5H), 2.21 (q, J =
6.4, 5.7 Hz, 2H), 2.03 — 1.80
m, 8H
(400 MHz, CDC13) 8 8.69 (d, J
:19 Hz, 1H), 8.61 (d, J=1.9
Hz, 1H), 7.52 (d, J = 8.7 Hz,
1H), 6.96 (d, J = 2.5 Hz, 1H),
6.90 (d, J = 2.5 Hz, 1H), 6.23
(d, J = 8.7 Hz, 1H), 5.09 (s,
1H), 4.80 (s, 1H), 4.00 — 3.78
(m, 5H), 3.40 - 3.24 (m, 4H),
2.56 (s, 3H), 2.29 - 2.14 (m,
2H 2.01 —1.80
, m, 6H
(400 MHz, CDC13) 8 8.70 (d, J
= 1.8 Hz, 1H), 8.62 (d, J =1.9
Hz, 1H), 8.30 (d, J =1.8 Hz,
1H), 7.37 (s, 1H), 6.96 (d, J =
2.3 Hz, 1H), 6.91 (d, J = 2.3
Hz, 1H), 4.79 (s, 1H), 4.74 (s,
1H), 4.28 (s, 1H), 4.01 — 3.83
(m, 4H), 3.40 - 3.25 (m, 4H),
2.30 — 2.17 (m, 2H), 2.11 (s,
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
) 8 8.69 (d, J = 2.0 Hz,
1H), 8.62 (d, J :19 Hz, 1H),
.36 (s, 1H), 4.03 (s, 1H), 1.57
(s, 6H), 2.02 — 1.80 (m, 6H),
243 8.42 (s, 2H), 6.99 — 6.87 (m,
2H), 4.80 (s, 1H), 3.92 (dd, J =
6.0, 3.7 Hz, 4H), 3.39 — 3.29
(m, 4H), 2.20 (d, J = 9.0 Hz,
(CDC13) 5 8.98 — 8.86 (m, 2H),
8.66 (dd, J = 23.8, 1.9 Hz, 2H),
8.44 (s, 1H), 7.00 — 6.88 (m,
2H), 5.89 (d, J = 8.1 Hz, 1H),
244 4.83 (dq, J = 5.4, 2.6 Hz, 1H),
4.22 — 4.04 (m, 1H), 3.97 — 3.87
(m, 4H), 3.43 — 3.29 (m, 4H),
2.24 (td, J = 8.3, 7.4, 4.0 Hz,
2H), 2.15 — 1.81 (m, 6H)
(CDC13) 8 8.61 (d, J = 1.9 Hz,
1H), 8.53 (d, J =1.9 Hz, 1H),
6.84 (dd, J = 18.2, 2.5 Hz, 2H),
.26 (s, 1H), 4.78 (d, J = 8.0
245 Hz, 1H), 4.68 (d, J = 5.6 Hz,
1H), 3.82 (t, J = 4.0 Hz, 10H),
3.30 =
— 3.15 (m, 4H), 2.10 (q, J
6.2, 5.7 Hz, 2H), 1.94 — 1.69
m, 6H
(CDC13) 8 8.61 (d, J = 1.9 Hz,
1H), 8.54 (d, J :19 Hz, 1H),
8.06 (d, J = 5.0 Hz, 1H), 6.94 -
6.78 (m, 2H), 6.32 (d, J = 5.0
246 Hz, 1H), 5.09 (s, 1H), 4.70 (d, J
= 6.0 Hz, 1H), 3.95 (s, 1H),
3.91 — 3.77 (m, 5H), 3.37 — 3.13
(m, 4H), 2.20 - 2.00 (m, 2H),
1.94 - 1.71 m, 6H
H NMR (300 MHz, unless
Compound Structure indicated ise)
NMR peaks given as 8 values
(CDC13) 5 8.71 (d, J = 1.9 Hz,
1H), 8.64 (t, J = 2.4 Hz, 1H),
8.05 (s, 2H), 7.04 — 6.87 (m,
2H), 5.20 (s, 1H), 4.80 (s, 1H),
247 4.30 (p, J = 6.1 Hz, 1H), 4.05 —
3.81 (m, 4H), 3.44 — 3.27 (m,
4H), 2.22 (t, J = 7.3 Hz, 2H),
1.93 (d, J = 4.6 Hz, 6H), 1.33
(d, J = 6.1 Hz, 6H)
(400 MHz, CDC13) 5 8.69 (d, J
:19 Hz, 1H), 8.66 (d, J :19
Hz, 1H), 8.62 (d, J =19 Hz,
1H), 8.05 (d, J = 8.5 Hz, 1H),
6.96 (d, J = 2.4 Hz, 1H), 6.92
(d, J = 2.5 Hz, 1H), 6.51 (d, J =
8.7 Hz, 1H), 4.82 (s, 1H), 3.99
— 3.85 (m, 5H), 3.38 — 3.27 (m,
4H), 2.59 (s, 3H), 2.29 — 2.18
(m, 2H), 2.01 — 1.84 (m, 6H)
(400 MHz, CDC13) 8 8.69 (d, J
:19 Hz, 1H), 8.61 (d, J=1.9
Hz, 1H), 8.45 (d, J = 1.9 Hz,
1H), 7.86 (d, J = 7.7 Hz, 1H),
7.60 (d, J = 2.3 Hz, 1H), 6.96
(d, J = 2.4 Hz, 1H), 6.92 (d, J =
249 472.54
2.4 Hz, 1H), 6.50 (d, J = 2.3
Hz, 1H), 6.48 (d, J = 8.9 Hz,
1H), 4.81 (s, 1H), 3.95 — 3.85
(m, 5H), 3.39 — 3.30 (m, 4H),
2.26 - 2.17 (m, 2H), 1.99 — 1.84
(m, 6H)
WO 59690
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 8 8.69 (d, J
= 1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.09 (d, J = 1.7 Hz,
1H), 7.56 — 7.45 (m, 2H), 6.96
(d, J = 2.4 Hz, 1H), 6.93 (d, J =
250 2.4 Hz, 1H), 6.55 (d, J = 8.5
Hz, 1H), 6.25 (d, J = 1.9 Hz,
1H), 4.84 (s, 1H), 3.96 — 3.83
(m, 8H), 3.39 — 3.30 (m, 4H),
2.28 — 2.19 (m, 2H), 2.03 — 1.83
(m, 6H)
(CDC13) 3 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
8.18 (s, 2H), 7.04 — 6.87 (m,
2H), 5.21 (d, J = 8.2 Hz, 1H),
4.80 (s, 1H), 4.2—4.0 (m, 3H),
3.98 — 3.85 (m, 4H), 3.61 — 3.44
(m, 2H), 3.41 — 3.21 (m, 4H),
2.75 — 2.47 (m, 1H), 2.21 (d, J =
9.6 Hz, 2H), 1.92 (t, J = 6.4 Hz,
6H), 1.83 — 1.66 (m, 4H)
(CDC13) 8 3.97 — 3.87 (m, 4H),
3.39 — 3.29 (m, 4H), 2.50 (s,
3H), 2.28 _ 2.16 (m, 2H), 2.02 _
1.89 (m, 6H), 4.26 _ 4.17 (m,
1H), 8.70 (d, J =19 Hz, 1H),
8.63 (d, J =19 Hz, 1H), 7.88
(d, J = 3.3 Hz, 1H), 6.93 (dd, J
= 18.7, 2.5 Hz, 2H), 5.10 (d, J
= 7.9 Hz, 1H), 4.79 (d, J = 3.7
Hz, 1H
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J = 2.0 Hz, 1H),
Nfi 8.38 (d, J = 1.1 Hz, 1H), 6.93
O N (dd, J = 17.3, 2.5 Hz, 2H), 6.18
(d, J = 1.2 Hz, 1H), 5.03 (s,
253 HN0’ 453.19 1H), 4.81 (d, J = 6.1 Hz, 1H),
N 3.97 — 3.87 (m, 4H), 3.83
/ (s,
Nk | E 1 1H), 3.39 — 3.29 (m, 4H), 2.51
\ /CH3 (s, 3H), 2.21 (d, J = 8.8 Hz,
2H), 2.05 (s, 0H), 1.91 (d, J =
.6 Hz, 6H)
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.71 (d, J
= 1.9 Hz, 1H), 8.63 (d, J: 1.9
Hz, 1H), 8.15 — 8.04 (m, 1H),
7.46 =
— 7.39 (m, 1H), 6.97 (d, J
2.5 Hz, 1H), 6.93 (d, J = 2.5
254 Hz, 1H), 6.60 — 6.52 (m, 1H),
6.41 (d, J = 8.4 Hz, 1H), 4.80
(s, 1H), 4.68 (s, 1H), 3.98 —
3.85 (m, 5H), 3.41 — 3.30 (m,
4H), 2.27 — 2.15 (m, 2H), 1.97 —
1.86 (m, 6H)
nol-d4) 5 8.71 (dd, J =
7.5, 2.1 Hz, 1H), 8.57 (dd, J =
8.8, 2.1Hz, 1H), 7.12 (d, J =
2.5 Hz, 1H), 6.88 (d, J = 2.4
Hz,1H), 3.88 (t, J = 4.8 Hz,
4H), 3.45 — 3.35 (m, 4H), 3.19
(s, 3H), 2.25 — 2.01 (m, 2H),
2.00 — 1.80 (m, 6H)
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.64 (d, J :19 Hz, 1H),
7.80 (d, J = 1.5 Hz, 1H), 7.47
(d, J =1.5 Hz, 1H), 7.02 — 6.86
256 (m, 2H), 4.80 (s, 1H), 4.27 (d, J
= 8.3 Hz, 1H), 4.00
— 3.72 (m,
7H), 3.35 (dd, J = 6.0, 3.8 Hz,
4H), 2.23 (s, 2H), 2.02 — 1.80
(m, 6H)
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.63 (dd, J =1.9, 0.7 Hz,
1H), 7.99 — 7.88 (m, 1H), 7.02 —
6.87 (m, 2H), 6.34 (d, J = 8.4
257 Hz, 1H), 4.78 (s, 1H), 4.40 (d, J
= 8.2 Hz, 1H), 4.03
— 3.75 (m,
5H), 3.35 (dd, J = 6.0, 3.7 Hz,
4H), 2.18 (s, 5H), 2.03 — 1.81
(m, 6H)
H NMR (300 MHz, unless
Compound Structure indicated ise)
NMR peaks given as 8 values
(CDC13) 5 8.78 — 8.59 (m, 3H),
8.38 (s, 1H), 7.85 (s, 1H), 6.95
(d, J = 2.4 Hz, 1H), 6.91 (d, J =
2.3 Hz, 1H), 4.79 (s, 1H), 4.67
(d, J = 7.6 Hz, 1H), 4.32 (s,
1H), 3.99 — 3.82 (m, 4H), 3.40 —
3.27 (m, 4H), 2.33 — 2.06 (m,
5H), 2.03 — 1.87 (m, 6H)
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, 1H), 8.41 (s, 1H),
8.04 =
— 7.93 (m, 1H), 6.96 (d, J
2.5 Hz, 1H), 6.91 (d, J = 2.1
Hz, 1H), 6.35 (d, J = 9.1 Hz,
1H), 5.07 (s, 1H), 4.82 (s, 1H),
4.02 — 3.79 (m, 5H), 3.41 — 3.27
(m, 4H), 2.83 - 2.72 (m, 3H),
2.30 — 2.17 (m, 2H), 2.02 — 1.80
(m, 6H)
(CDC13) 8 8.70 (d, J = 1.9 Hz,
1H), 8.62 (d, J =1.9 Hz, 1H),
6.93 (dd, J = 14.5, 2.5 Hz, 2H),
6.79 (d, J = 9.4 Hz, 1H), 6.64
(d, J = 9.4 Hz, 1H), 4.80 (d, J =
260 5.5 Hz, 1H), 4.27 (d, J = 7.5
Hz, 1H), 4.14 (s, 1H), 4.02 (s,
3H), 3.98 — 3.88 (m, 4H), 3.42 -
3.29 (m, 4H), 2.31 - 2.12 (m,
2H), 1.95 (ddd, J = 17.2, 9.2,
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.64 (d, J =1.9 Hz, 1H),
8.20 (s, 2H), 7.04 — 6.84 (m,
2H), 5.16 (d, J = 8.0 Hz,1H),
4.80 (s, 1H), 4.19 — 3.85 (m,
7H), 3.66 (dd, J = 8.5, 7.1 Hz,
1H), 3.35 (dd, J = 5.9, 3.8 Hz,
4H), 3.24 (t, J = 7.5 Hz, 1H),
2.48 - 2.11 (m, 4H), 2.05 — 1.82
(m, 6H)
H NMR (300 MHz, unless
Compound Structure ted otherwise)
NMR peaks given as 8 values
(CDC13) 0 8.69 (d, J = 1.9 Hz,
1H), 8.62 (d, J :19 Hz, 1H),
7.61 (d, J = 1.0 Hz, 1H), 6.98 —
6.86 (m, 2H), 4.96 (s, 1H), 4.82
- 4.71 (m, 1H), 4.63 — 4.56 (m,
1H), 4.08 — 3.87 (m, 5H), 3.38 —
3.29 (m, 4H), 2.80 (tdd, J = 6.8,
.0, 3.1 Hz, 1H), 2.23 - 2.11
(m, 2H), 2.08 - 1.82 (m, 9H),
0.90 — 0.72 (m, 2H), 0.59 — 0.47
(m, 2H)
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
8.11 (d, J = 0.9 Hz, 1H), 6.93
(dd, J = 15.5, 2.5 Hz, 2H), 5.30
(d, J =10 Hz, 1H), 5.16 (s,
1H), 4.95 (s, 1H), —0.17 — —0.23
(m, 0H), 4.80 (s, 1H), 3.92 (dd,
J = 5.9, 3.7 Hz, 4H), 3.74 (s,
1H), 3.57 (dd, J = 5.6, 4.6 Hz,
2H), 3.50 — 3.29 (m, 9H), 2.20
(d, J = 9.1 Hz, 2H), 1.93 (d, J =
13.1 Hz, 6H
(CDC13) 3 8.69 (d, J = 1.9 Hz,
1H), 8.62 (d, J = 2.0 Hz, 1H),
7.76 (d, J = 5.8 Hz, 1H), 7.02 —
6.86 (m, 2H), 5.66 (d, J = 5.9
Hz, 1H), 4.80 (d, J = 5.5 Hz,
1H), 4.63 (s, 1H), 3.97 — 3.84
(m, 5H), 1.30 — 1.20 (m, 1H),
3.64 (s, 2H), 3.38 — 3.28 (m,
4H), 1.37 (s, 6H), 5.16 — 4.86
(m, 1H), 2.24 — 2.13 (m, 2H),
1.96 —1.82 m, 6H
(CDC13) 3 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
8.47 (d, J = 1.1 Hz, 1H), 6.93
(dd, J = 16.7, 2.5 Hz, 2H), 6.17
(t, J = 0.9 Hz, 1H), 4.95 (s, 1H),
4.81 (td, J= 5.3, 2.5 Hz, 1H),
4.07 — 3.83 (m, 5H), 3.39 — 3.29
(m, 4H), 2.34 (s, 3H), 2.21 (dt,
J: 11.1, 5.1 Hz, 2H), 2.04 —
1.76 (m, 6H)
H NMR (300 MHz, unless
Compound ure indicated otherwise)
NMR peaks given as 8 values
m (CDC13) 5 11.49 (s, 1H), 8.69
(d, J = 1.9 Hz, 1H), 8.59 (d, J =
13:0, 60 N
1.9 Hz, 1H), 7.73 (d, J = 3.0
Hz, 1H), 7.03 — 6.89 (m, 2H),
266 6.56 (d, J = 7.2 Hz, 1H), 4.82
N (s, 1H), 3.91 (dd, J = 6.0, 3.8
51 [:1 Hz, 5H), 3.39 — 3.29 (m, 4H),
2.27 - 2.14 (m, 2H), 2.07 — 1.81
m, 6H
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.60 (d, J :19 Hz, 1H),
8.03 (d, J = 6.1 Hz, 1H), 6.93
(dd, J = 18.6, 2.5 Hz, 2H), 6.13
(d, J = 6.1Hz, 1H), 5.09 (s,
267 1H), 4.79 (s, 1H), 4.03 — 3.78
(m, 5H), 3.34 (dd, J = 6.0, 3.8
Hz, 4H), 2.20 (d, J = 8.1 Hz,
2H), 1.96 (s, 7H), 1.10 (d, J =
2.8 Hz, 2H), 1.00 (d, J = 8.0
Hz, 2H)
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.60 (d, J =19 Hz, 1H),
7.95 (d, J = 5.8 Hz, 1H), 6.92
(dd, J = 17.9, 2.5 Hz, 2H), 5.99
268 (d, J = 5.9 Hz, 1H), 5.01 (s,
1H), 4.79 (dt, J = 6.9, 3.4 Hz,
1H), 3.91 (d, J = 8.7 Hz, 8H),
3.43 — 3.25 (m, 4H), 2.32 — 2.09
m, 2H 2.05 — 1.74
, m, 6H
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.62 (d, J =19 Hz, 1H),
7.70 (d, J = 6.8 Hz, 1H), 6.92
(dd, J = 14.4, 2.5 Hz, 2H), 4.86
(d, J = 8.1 Hz, 1H), 4.75 (dt, J
= 8.6, 4.0 Hz, 1H), 3.97
— 3.87
(m, 5H), 3.38 — 3.28 (m, 4H),
3.14 (d, J = 2.2 Hz, 6H), 2.24 —
2.07 (m, 2H), 2.02 — 1.79 (m,
H NMR (300 MHz, unless
Cmpd. ESMS
Compound ure indicated otherwise)
(M+H)
NMR peaks given as 8 values
(CDC13) 8 8.71 (d, J = 1.9 Hz,
1H), 8.64 (d, J = 2.0 Hz, 1H),
8.15 (s, 2H), 7.01 — 6.87 (m,
2H), 5.13 (d, J: 8.1 Hz, 1H),
4.80 (s, 1H), 4.24 (s, 1H), 4.01
270 (s, 2H), 3.93 (dd, J = 6.0, 3.7
Hz, 4H), 3.35 (dd, J = 5.9, 3.9
Hz, 4H), 2.80 (t, J = 12.7 Hz,
2H), 2.51 (t, J = 12.1 Hz, 1H),
2.21 (d, J = 8.3 Hz, 2H), 2.05 —
1.72 (m, 8H), 1.49 (s, 9H)
(CDC13) a 8.62 (d, J = 1.9 Hz,
1H), 8.55 (d, J :19 Hz, 1H),
8.09 (s, 2H), 6.93 — 6.78 (m,
2H), 5.03 (d, J = 8.1 Hz, 1H),
4.72 (d, J = 5.8 Hz, 1H), 4.02 —
3.75 (m, 5H), 3.34 — 3.21 (m,
271 z —z \_/ 490.2
/ 4H), 3.20 — 3.06 (m, 2H), 2.66
(td, J = 12.1, 2.5 Hz, 2H), 2.38
(ddt, J = 12.2, 7.6, 3.8 Hz, 1H),
2.12 (d, J = 8.9 Hz, 2H), 1.96 —
IZ 1.65 (m, 10H), 1.53 (qd, J =
12.3, 3.9 Hz, 2H)
(CDC13) 8 8.69 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz,1H),
8.04 (d, J = 2.8 Hz, 1H), 7.94
(dd, J = 47,13 Hz,1H), 7.11
(dd, J = 8.3, 4.7 Hz, 1H), 7.00 —
272 406.53
6.84 (m, 3H), 4.78 (s, 1H), 3.98
= 8.1
— 3.88 (m, 4H), 3.85 (d, J
Hz, 1H), 3.38 - 3.28 (m, 4H),
2.27 - 2.15 (m, 2H), 1.97 — 1.84
(m, 6H)
H NMR (300 MHz, unless
nd Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 5 8.70 (d, J = 1.9 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
8.18 (d, J = 6.3 Hz, 2H), 6.96
(d, J = 2.4 Hz, 1H), 6.90 (d, J =
2.4 Hz, 1H), 6.51 — 6.42 (m,
2H), 4.79 (s, 1H), 4.47 (d, J =
7.7 Hz, 1H), 3.98 — 3.86 (m,
4H), 3.56 (s, 1H), 3.39 — 3.26
(m, 4H), 2.27 — 2.15 (m, 2H),
2.01 — 1.79 (m, 6H)
(CDC13) 5 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J :19 Hz, 1H),
8.18 (s, 2H), 7.03 — 6.86 (m,
2H), 5.11 (d, J: 8.1 Hz, 1H),
4.81 (d, J = 5.9 Hz, 1H), 4.12 —
3.84 (m, 5H), 3.42 — 3.29 (m,
4H), 3.05 — 2.89 (m, 2H), 2.33
(s, 4H), 2.21 (d, J = 8.8 Hz,
2H), 2.11 — 1.61 (m, 10H)
(CDC13) 5 8.62 (d, J = 1.9 Hz,
1H), 8.54 (d, J :19 Hz, 1H),
6.93 — 6.77 (m, 2H), 5.20 (s,
1H), 4.78 — 4.60 (m, 2H), 3.92 —
3.79 (m, 5H), 3.64 (s, 0H), 3.51
(t, J: 5.1 Hz, 4H), 3.36 — 3.16
(m, 4H), 2.40 (t, J = 5.1 Hz,
4H), 2.27 (d, J = 4.8 Hz, 6H),
2.16 —2.02 (m, 2H), 1.81 (q, J:
8.1, 5.7 Hz, 6H
(CDC13) 5 8.69 (d, J = 1.8 Hz,
1H), 8.61 (d, J :19 Hz, 1H),
6.94 (d, J = 2.3 Hz, 1H), 6.90
(d, J = 2.3 Hz, 1H), 5.87 (s,
1H), 5.13 (s, 1H), 4.76 (s, 1H),
4.04 (s, 1H), 3.98 — 3.89 (m,
4H), 3.87 (s, 3H), 3.41 — 3.23
(m, 4H), 2.25 (s, 3H), 2.23 —
2.09 (m, 2H), 1.99 — 1.80 (m,
WO 59690
H NMR (300 MHz, unless
Compound Structure indicated otherwise)
NMR peaks given as 8 values
(CDC13) 3 8.71 (d, J = 1.9 Hz,
1H), 8.62 (d, J =19 Hz, 1H),
8.17 (d, J = 0.9 Hz, 1H), 6.94
(dd, J = 15.8, 2.5 Hz, 2H), 5.31
(s, 1H), 4.83 (dp, J = 4.6, 2.5
Hz, 1H), 4.22 (qt, J = 8.5, 4.9
Hz, 1H), 4.03 — 3.87 (m, 4H),
3.39 — 3.29 (m, 4H), 2.25 (td, J
= 7.9, 6.6, 3.9 Hz, 2H), 2.09
1.80 (m, 6H)
(400 MHz, CDC13) 3 8.83 (d, J
= 2.2 Hz, 1H), 8.69 (d, J :19
Hz, 1H), 8.61 (d, J =19 Hz,
1H), 8.02 (dd, J = 8.8, 2.3 Hz,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.91 (d, J = 2.5 Hz, 1H), 6.45
(d, J = 8.9 Hz, 1H), 5.12 (s,
1H), 4.81 (d, J = 2.6 Hz, 1H),
3.98 (s, 1H), 3.95 — 3.87 (m,
4H), 3.40 — 3.26 (m, 5H), 2.42
(s, 3H), 2.29 — 2.16 (m, 2H),
1.99 — 1.87 (m, 6H)
(CDC13) 5 8.69 (d, J = 1.9 Hz,
1H), 8.60 (d, J = 2.0 Hz, 1H),
7.21 — 7.11 (m, 1H), 7.00 — 6.85
(m, 2H), 5.51 (s, 1H), 4.95 —
279 4.70 (m, 2H), 4.53 — 4.34 (m,
1H), 4.01 — 3.74 (m, 5H), 3.45 —
3.25 (m, 4H), 2.25 — 2.09 (m,
2H), 2.03 — 1.73 (m, 6H), 1.39 —
1.25 (m, 3H)
(methanol—d4) 5 8.68 (d, J = 2.0
Hz, 1H), 8.54 (d, J = 2.0 Hz,
1H), 7.30 (d, J = 7.2 Hz, 1H),
7.10 (d, J = 2.4 Hz, 1H), 6.87
(d, J = 2.4 Hz, 1H), 5.79 (d, J =
7.2 Hz, 1H), 4.13 (qd, J = 8.5,
6.7, 2.4 Hz, 1H), 3.87 (dd, J =
.9, 3.8 Hz, 4H), 3.42 — 3.32
(m, 5H), 2.21 — 2.07 (m, 2H),
2.01 — 1.78 m, 6H
H NMR (300 MHz, unless
Compound Structure indicated ise)
NMR peaks given as 8 values
(400 MHz, CDC13) 8 8.68 (d, J
= 1.9 Hz, 1H), 8.61 (d, J= 1.9
Hz, 1H), 8.18 (d, J = 2.2 Hz,
1H), 7.58 (dd, J = 8.7, 2.5 Hz,
1H), 6.95 (d, J = 2.5 Hz, 1H),
6.91 (d, J = 2.4 Hz, 1H), 6.39
(d, J = 8.8 Hz, 1H), 4.78 (s,
1H), 4.69 (s, 1H), 3.96 — 3.83
(m, 5H), 3.49 (s, 1H), 3.38 —
3.28 (m, 4H), 2.26 — 2.13 (m,
2H), 1.95 — 1.84 (m, 6H), 1.56
(s, 6H)
(CDC13) 5 8.71 (d, J = 1.9 Hz,
1H), 8.63 (d, J =19 Hz, 1H),
7.93 — 7.74 (m, 2H), 7.04 — 6.82
(m, 2H), 4.80 (s, 1H), 4.50 (d, J
282 = 8.1 Hz, 1H), 3.93 (dd, J =
6.4, 3.4 Hz, 5H), 3.41 — 3.25
(m, 4H), 2.51 — 2.33 (m, 3H),
2.23 (s, 2H), 2.04 — 1.82 (m,
(CDC13) 3 8.62 (d, J = 1.9 Hz,
1H), 8.55 (d, J =19 Hz, 1H),
7.88 (dd, J = 5.3, 0.7 Hz, 1H),
6.95 — 6.79 (m, 2H), 6.32 (ddd,
J = 5.2, 1.5, 0.7 Hz, 1H), 6.12
(dt, J = 1.6, 0.8 Hz, 1H), 4.71
(d, J = 5.9 Hz, 1H), 4.40 (d, J =
8.2 Hz, 1H), 3.98 — 3.67 (m,
4H), 3.35 — 3.17 (m, 4H), 2.15
(s, 4H), 1.83 (d, J = 5.2 Hz, 5H)
(CDC13) a 8.62 (d, J = 1.9 Hz,
1H), 8.54 (d, J =19 Hz, 1H),
6.86 (dd, J = 16.6, 2.5 Hz, 2H),
.97 (d, J =12 Hz, 1H), 5.02
284 (s, 1H), 4.71 (dt, J = 5.7, 3.0
Hz, 1H), 3.91 — 3.75 (m, 4H),
3.63 — 3.42 (m, 1H), 3.33 — 3.17
(m, 4H), 2.21 — 2.03 (m, 5H),
1.94 — 1.71 m, 6H
H NMR (300 MHz, unless
ESMS
Compound Structure indicated ise)
(M+H)
NMR peaks given as 8 values
(400 MHz, CDC13) 5 8.69 (d, J
= 1.9 Hz, 1H), 8.61 (d, J: 1.9
Hz 1H) 8.08 (d J = 5.7 Hz
N /fiIN 7 7 7 7
0 1H), 6.96 (d, J = 2.4 Hz, 1H),
0’ 6.90 (d, J = 2.4 Hz, 1H), 6.30
(s, 1H), 6.28 (dd, J = 5.7, 2.2
285 ”N 42057
Hz, 1H), 4.78 (s, 1H), 4.19 (d, J
/ = 7.7 Hz, 1H), 3.97
— 3.82 (m,
| 1 4H), 3.53 (s, 1H), 3.40 — 3.24
N CH3 0
(m, 4H), 2.41 (s, 3H), 2.27 —
2.11 (m,2H), 1.92 _ 1.84 (m,
(400 MHz, CDC13) 8 8.69 (d, J
m =19 Hz
N / 7 1H)
8.60 (d J =19
7 7
Hz, 1H), 6.95 (d, J = 2.4 Hz,
1H), 6.89 (d, J = 2.4 Hz, 1H),
286 “N0’0
6.15 (s, 2H), 4.77 (s, 1H), 4.12
43456
(d, J = 7.8 Hz, 1H), 3.99 — 3.81
l E 1 (m, 4H), 3.53 (s, 1H), 3.40 —
3.23 (m, 4H), 2.36 (d, J = 14.5
CH3 0
Hz, 6H), 2.25 — 2.14 (m, 2H),
1.89 (t, J: 7.8 Hz, 6H)
WO 59690
Compound H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 8.33 (s, 1H), 6.94
(dd, J = 14.3, 2.5 Hz, 2H),
.80 (d, J = 4.9 Hz, 1H), 5.42
287 (d, J = 8.1 Hz, 1H), 4.88 - 4.74
(m, 1H), 4.08 (s, 2H), 3.99 -
3.86 (m, 4H), 3.50 (s, 3H),
3.42 - 3.28 (m, 4H), 3.01 (dd,
J = 18.4, 5.0 Hz, 3H), 2.54 (s,
3H), 2.28 - 2.08 (m, 2H), 2.03
- 1.79 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.68 (t, J = 5.2 Hz, 1H), 8.65
(d, J = 1.7 Hz, 1H), 8.02 (d, J
= 5.9 Hz, 1H), 7.26 (d, J = 1.5
Hz, 1H), 7.08 (d, J =1.6 Hz,
1H), 7.00 (d, J =1.6 Hz, 1H),
6.07 (d, J = 6.0 Hz, 1H), 4.91
(s, 1H), 4.75 (s, 1H), 4.54 (t, J
= 9.6 Hz, 2H), 3.03 (td, J =
9.8, 1.6 Hz, 2H), 2.42 (s, 3H),
2.21 — 2.06 (m, 2H), 1.91 —
1.74 (m, 7H).
1H NMR (400 MHz, CDCI3) 5
8.79 — 8.71 (m, 2H), 8.03 (d, J
= 5.8 Hz, 1H), 7.39 (s, 1H),
6.38 (s, 1H), 6.08 (d, J = 5.9
289 Hz, 1H), 5.06 (s, 2H), 4.83 (d,
J = 29.0 Hz, 4H), 2.42 (s, 3H),
2.16 (d, J = 7.2 Hz, 2H), 1.88
(dd, J = 21.2, 8.7 Hz, 6H),
1.58 (s, 2H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 6
8.62 (d, J = 1.9 Hz, 1H), 8.53
(d, J = 1.9 Hz, 1H), 8.03 (d, J
= 5.9 Hz, 1H), 6.88 (td, J =
19.2, 3.6 Hz, 2H), 6.07 (d, J =
6.0 Hz, 1H), 4.87 (s, 1H), 4.74
(s, 1H), 4.06 — 3.93 (m, 1H),
3.80 — 3.69 (m, 2H), 3.58 —
3.38 (m, 2H), 2.94 (td, J =
11.9, 3.5 Hz, 1H), 2.65 — 2.52
(m, 1H), 2.42 (s, 3H), 2.13 (d,
J = 10.1 Hz, 2H), 1.81 (d, J =
9.7 Hz, 6H), 1.32 — 1.08 (m,
3H .
1H NMR (400 MHz,
Chloroform-d) 6 8.42 (d, J =
1.9 Hz, 1H), 8.30 (d, J = 1.9
Hz, 1H), 8.04 (d, J = 4.8 Hz,
2H), 6.65 - 6.56 (m, 2H), 6.28
(t, J = 4.8 Hz, 1H), 4.99 (d, J =
8.1 Hz, 1H), 4.60 (d, J = 6.5
Hz, 3H), 3.79 (dd, J = 8.2, 4.0
Hz, 0H), 3.62 - 3.38 (m, 4H),
3.17 - 3.03 (m, 1H), 2.07 -
1.90 (m, 2H), 1.89 - 1.59 (m,
7H).
1H NMR (400 MHz, CDCI3) 6
8.83 (dd, J = 2.3, 0.8 Hz, 1H),
8.77 — 8.68 (m, 2H), 8.54 (dd,
J = 4.8, 1.6 Hz, 1H), 7.95 (d, J
= 6.0 Hz, 1H), 7.86 (ddd, J =
7.9, 2.4, 1.6 Hz, 1H), 7.76 (d,
292 J = 1.7 Hz, 1H), 7.31 (ddd, J =
7.9, 4.8, 0.8 Hz, 1H), 7.21 (d,
J =1.6 Hz, 1H), 7.11 (d, J =
0.9 Hz, 1H), 6.00 (d, J = 6.0
Hz, 1H), 4.80 (d, J = 27.2 Hz,
2H), 2.34 (s, 3H), 2.18 — 2.04
(m, 2H), 1.84 — 1.71 (m, 6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (400 MHz, CDCI3) 5
11.20 (s, 1H), 8.74 (t, J = 6.1
Hz, 1H), 8.71 (d, J :18 Hz,
1H), 8.03 (d, J = 5.9 Hz, 1H),
7.96 (s, 2H), 7.75 (t, J = 8.0
293 Hz, 1H), 7.26 (d, J = 1.5 Hz,
1H), 6.08 (d, J = 6.0 Hz, 1H),
.09 (s, 1H), 4.82 (s, 1H),
3.77 (s, 1H), 2.43 (s, 3H),
2.24 — 2.08 (m, 2H), 1.93 —
1.76 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.10 (d, J =
6.0 Hz, 1H), 7.36 - 7.28 (m,
1H), 6.65 (d, J = 2.0 Hz, 1H),
6.13 (d, J = 6.0 Hz, 1H), 4.81
(d, J = 8.0 Hz, 1H), 4.00 - 3.80
(m, 6H), 3.80 - 3.56 (m, 1H),
3.29 (dd, J = 5.8, 3.8 Hz, 4H),
3.02 - 2.84 (m, 2H), 2.48 (s,
3H), 2.36 (td, J = 11.4, 10.9,
2.5 Hz, 2H), 2.14 - 1.98 (m,
2H), 1.70 - 1.46 (m, 2H).
1H NMR (300 MHz,
Chloroform-d) 6 8.98 - 8.78
(m, 2H), 8.33 (d, J = 1.9 Hz,
1H), 7.67 (d, J = 1.8 Hz, 1H),
7.30 (d, J :18 Hz, 1H), 6.49 -
6.31 (m, 1H), 5.07 (d, J = 7.6
Hz, 1H), 4.87 (d, J = 5.5 Hz,
1H), 4.43 (q, J = 2.8 Hz, 2H),
4.24 (s, 1H), 4.02 (t, J = 5.4
Hz, 2H), 2.71 (dtd, J = 13.1,
7.7, 2.7 Hz, 4H), 2.26 (dt, J =
.4, 5.3 Hz, 2H), 1.97 (d, J =
.3 Hz, 6H), 1.28 (t, J = 7.6
Hz, 3H .
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.79 - 8.67
(m, 1H), 8.64 (d, J :19 Hz,
1H), 6.93 (dd, J = 13.0, 2.6
Hz, 2H), 4.77 (s, 1H), 3.94 (q,
296 550.6
J = 6.6, 5.0 Hz, 5H), 3.35 (t, J
= 4.8 Hz, 4H), 2.16 (d, J =
33.6 Hz, 2H), 1.86 (mJ = 4.9
, 1.51 (q, J = 20,16
Hz, 9H).
1H NMR (400 MHz, CDCI3) 6
8.60 (d, J = 1.9 Hz, 1H), 8.49
(d, J :19 Hz, 1H), 8.02 (d, J
= 6.0 Hz, 1H), 6.78 (dd, J =
.1, 2.5 Hz, 2H), 6.08 (d, J =
6.0 Hz, 1H), 4.96 (s, 1H), 4.74
(d, J = 2.4 Hz, 1H), 4.49 (d, J
= 2.3 Hz, 2H), 3.41 (t, J = 5.4
Hz, 2H), 3.12 (dd, J = 11.6,
2.5 Hz, 2H), 2.43 (s, 3H), 2.14
(dd, J = 9.6, 4.9 Hz, 2H), 1.98
— 1.68 (m, 10H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.65 (d, J :19
Hz, 1H), 7.53 (dt, J = 81,10
Hz, 1H), 7.35 (ddd, J = 8.1,
6.8, 1.1 Hz, 1H), 7.20 (dt, J =
8.5, 0.9 Hz, 1H), 7.07 - 6.89
(m, 3H), 4.79 (td, J = 6.1, 3.1
Hz, 1H), 4.02 - 3.91 (m, 4H),
3.87 (s, 3H), 3.43 - 3.25 (m,
4H), 2.34 - 2.15 (m, 2H), 2.10
- 1.88 (m, 6H).
WO 59690
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.02 - 6.89 (m, 2H),
6.57 (d, J = 1.0 Hz, 1H), 4.87 -
299 4.76 (m, 1H), 4.76 - 4.62 (m,
1H), 4.09 - 3.88 (m, 5H), 3.45
- 3.25 (m, 4H), 2.65 (d, J = 0.8
Hz, 3H),2.56(s, 3H), 2.31 -
2.12 (m, 2H), 2.09 - 1.81 (m,
6H).
1H NMR (400 MHz, CDCI3) 5
8.71 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.13 (d, J
= 5.9 Hz, 1H), 6.94 (d, J = 2.4
Hz, 1H), 6.85 (d, J = 2.4 Hz,
1H), 6.13 (d, J = 6.0 Hz, 1H),
300 5.17 (s, 1H), 4.50 (s, 1H),
4.29 (d, J = 6.7 Hz, 2H), 4.03 —
3.82 (m, 4H), 3.45 — 3.32 (m,
4H), 3.04 — 2.93 (m, 1H), 2.58
— 2.50 (m, 2H), 2.49 (s, 3H),
2.24 (ddd, J = 20.4, 10.3, 6.0
Hz, 2H).
1H NMR (400 MHz, CDCI3) 5
8.76 (s, 2H), 8.09 (d, J = 5.7
Hz, 1H), 6.94 (d, J = 2.3 Hz,
1H), 6.80 (d, J = 2.2 Hz, 1H),
6.73 (s, 1H), 6.19 (d, J = 5.1
Hz, 1H), 4.35 (s, 1H), 4.17 (d,
J = 3.9 Hz, 2H), 4.03 — 3.77
(m, 4H), 3.45 — 3.21 (m, 4H),
2.85 (dd, J = 19.9, 9.1 Hz,
2H), 2.80 — 2.70 (m, 1H), 2.51
(s, 3H), 2.06 (dt, J = 12.7, 6.4
Hz, 2H).
WO 59690
Compound ESMS H NMR
8.70 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.13 (d, J
= 5.8 Hz, 1H), 6.92 (d, J = 2.4
Hz, 1H), 6.55 (d, J = 2.4 Hz,
1H), 6.18 (d, J = 6.0 Hz, 1H),
302 I1H NMR (400 MHz, CDCI3) 5 5.07 — 4.97 (m, 1H), 4.91 (s,
1H), 3.99 — 3.82 (m, 4H), 3.50
(d, J = 5.5 Hz, 1H), 3.38 — 3.23
(m, 4H), 2.72 (dd, J = 8.1, 4.8
Hz, 1H), 2.65 (dt, J = 15.2, 7.7
Hz, 2H), 2.51 (s, 3H), 2.45
(ddd, J = 11.1, 6.8, 3.4 Hz,
2H).
I1H NMR (400 MHz, CDCI3) 5 8.71 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.10 (d, J
= 5.8 Hz, 1H), 6.92 (d, J = 2.4
Hz, 1H), 6.67 (d, J = 2.4 Hz,
1H), 6.15 (d, J = 6.0 Hz, 1H),
4.95 (s, 1H), 4.79 (p, J = 7.1
Hz, 1H), 3.98 — 3.83 (m, 4H),
3.45 (bt, 2H), 3.36 — 3.27 (m,
4H), 2.79 (dtd, J = 9.8, 7.2,
2.8 Hz, 2H), 2.48 (s, 3H), 2.38
(dt, J = 16.0, 8.0 Hz, 1H), 2.19
(ddd, J = 17.0, 9.7, 2.8 Hz,
2H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
m (d, J = 1.9 Hz, 1H), 8.27 (d, J
= 4.8 Hz, 2H), 6.93 (d, J = 2.4
i fw‘xe Hz, 1H), 6.85 (d, J = 2.4 Hz,
. “if f, . N
N w \ 1H), 6.54 (t, J = 4.8 Hz, 1H),
304 H i 393.21 5.36 (d, J = 7.2 Hz, 1H), 4.70 —
\ x”j 4.58 (m, 1H), 4.31 (d, J = 7.7
N R Hz, 2H), 4.01 — 3.86 (m, 4H),
w 3.44 — 3.30 (m, 4H), 3.04 —
2.93 (m, 1H), 2.50 (ddd, J =
13.5, 7.8, 3.1 Hz, 2H), 2.31 —
2.19 (m, 2H).
2014/024767
Compound ESMS H NMR
Compound Structure
1H NMR (400 MHz, CDCI3) 5
8.81 (d, J = 1.9 Hz, 1H), 8.74
(d, J = 1.9 Hz, 1H), 8.29 (d, J
= 4.8 Hz, 2H), 6.93 (d, J = 2.4
Hz, 1H), 6.80 (d, J = 2.4 Hz,
1H), 6.64 (d, J = 8.5 Hz, 1H),
305 6.50 (t, J = 4.8 Hz, 1H), 4.60
(dq, J = 15.6, 7.6 Hz, 1H),
4.19 (d, J = 4.6 Hz, 2H), 4.01 —
3.84 (m, 4H), 3.43 — 3.27 (m,
4H), 2.88 — 2.78 (m, 2H), 2.78
— 2.68 (m, 1H), 2.08 — 1.97 (m,
2H).
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.29 (d, J
= 4.8 Hz, 2H), 6.91 (d, J = 2.4
Hz, 1H), 6.63 — 6.51 (m, 2H),
306 5.21 (s, 1H), 5.03 (p, J = 6.6
Hz, 1H), 4.02 — 3.79 (m, 4H),
3.63 (dd, J = 7.3, 5.9 Hz, 2H),
3.42 — 3.19 (m, 4H), 2.79 —
2.68 (m, 1H), 2.68 — 2.54 (m,
2H), 2.52 — 2.40 (m, 2H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.8 Hz, 1H), 8.61
(d, J = 1.8 Hz, 1H), 8.26 (d, J
= 4.8 Hz, 2H), 6.91 (d, J = 2.0
Hz, 1H), 6.68 (d, J = 2.1 Hz,
1H), 6.53 (t, J = 4.8 Hz, 1H),
307 5.19 (s, 1H), 4.76 (p, J = 7.2
Hz, 1H), 3.99 — 3.79 (m, 4H),
3.56 (t, J = 6.4 Hz, 2H), 3.41 —
3.23 (m, 4H), 2.77 (dt, J = 9.7,
7.3 Hz, 2H), 2.39 (dt, J = 16.5,
8.3 Hz, 1H), 2.19 (dd, J =
19.6, 9.7 Hz, 2H).
WO 59690
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.64 (d, J :19
Hz, 1H), 7.79 (s, 1H), 7.23 (s,
1H), 6.95 (dd, J = 14.0, 2.5
Hz, 2H), 5.23 (d, J = 8.1 Hz,
1H), 4.80 (s, 1H), 4.09 (s, 1H),
3.94 (dd, J = 6.1, 3.6 Hz, 4H),
3.43 - 3.23 (m, 4H), 3.02 (d, J
= 5.1 Hz, 3H), 2.43 (s, 3H),
2.31 - 2.12 (m, 2H), 1.95 (p, J
= 10.0 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 6.85 (s, 2H), 6.30 (s,
1H), 5.06 (d, J = 16.2 Hz,1H),
4.85 (d, J = 6.5 Hz, 3H), 4.44 -
4.30 (m, 2H), 4.14 (q, J = 7.1
Hz, 1H), 3.89 - 3.60 (m, 5H),
3.50 (s, 3H), 3.35 (q, J = 7.2
Hz, 1H), 2.49 (s, 3H), 2.24 (d,
J = 8.7 Hz, 2H), 2.08 (d, J =
7.7 Hz, 2H), 1.92 (q, J = 9.6,
6.9 Hz, 6H), 1.28 (t, J = 7.1
Hz, 2H .
1H NMR (300 MHz, CDCI3) 6
8.72 (d, J = 1.8 Hz, 1H), 8.66
(d, J =19 Hz, 1H), 7.35 (d, J
= 4.3 Hz, 1H), 7.17 (d, J = 4.8
Hz, 1H), 6.97 (dd, J = 12.0,
2.2 Hz, 2H), 4.92 (s, 1H), 4.35
(s, 1H), 4.01 — 3.84 (m, 4H),
3.48 — 3.26 (m, 4H), 2.72 (s,
3H), 2.36 — 2.21 (m, 2H), 2.13
— 1.85 (m, 6H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3) 5
8.71 (d, J = 1.9 Hz, 1H), 8.65
(d, J = 1.9 Hz, 1H), 7.57 (d, J
= 3.2 Hz, 1H), 7.35 — 7.28 (m,
2H), 6.97 (d, J = 2.4 Hz, 1H),
312 6.91 (d, J = 2.4 Hz, 1H), 5.23
(s, 1H), 4.76 (s, 1H), 4.20 (s,
1H), 4.01 (s, 3H), 3.98 — 3.84
(m, 4H), 3.44 — 3.29 (m, 4H),
2.27 — 2.14 (m, 2H), 2.05 —
1.85 (m, 6H).
1H NMR (300 MHz, CDCI3) 5
8.68 (dd, J = 21.2, 1.9 Hz,
2H), 7.86 (s, 1H), 7.18 (d, J =
4.9 Hz, 1H), 7.00 (d, J = 4.9
Hz, 1H), 6.96 (dd, J = 12.1,
2.4 Hz, 2H), 5.18 (d, J = 7.4
Hz, 1H), 4.80 (s, 1H), 4.30
(dd, J = 11.9, 6.0 Hz, 1H),
4.05 — 3.77 (m, 4H), 3.45 —
3.14 (m, 4H), 2.75 (s, 3H),
2.37 — 2.14 (m, 2H), 2.14 —
1.87 (m, 6H).
Compound ESMS H NMR
“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3) 6
8.71 (d, J = 1.9 Hz, 1H), 8.63
(d, J = 1.9 Hz, 1H), 7.66 (s,
1H), 6.94 (dd, J = 14.9, 2.4
Hz, 2H), 4.84 — 4.74 (m, 1H),
4.47 (s, 1H), 4.02 — 3.87 (m,
4H), 3.87 — 3.75 (m, 1H), 3.47
— 3.21 (m, 4H), 2.38 (d, J = 4.0
Hz, 6H), 2.26 — 2.13 (m, 2H),
2.01 — 1.78 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
1.9 Hz, 1H), 8.59 - 8.46 (m,
2H), 7.98 (s, 1H), 7.18 (s, 1H),
6.85 (s, 2H), 4.85 (d, J = 6.6
Hz, 2H), 3.90 - 3.62 (m, 5H),
3.35 (d, J = 8.2 Hz, 1H), 3.03
(d, J = 5.1 Hz, 3H), 2.27 (s,
2H), 2.13 - 1.80 (m, 7H),
.58(s, 2H)
1H NMR (300 MHz,
Chloroform-d) 6 8.14 (d, J =
6.2 Hz, 1H), 6.50 (d, J = 1.7
Hz, 1H), 6.43 (d, J = 1.6 Hz,
316 1H), 6.21 (d, J = 6.2 Hz, 1H),
4.98 (s, 1H), 4.01 - 3.81 (m,
5H), 3.37 - 3.18 (m, 5H), 2.54
(s, 3H), 2.20 (d, J = 9.1 Hz,
3H), 2.05 - 1.71 (m, 6H).
WO 59690
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
1.9 Hz, 1H), 8.62 - 8.41 (m,
2H), 7.79 (s, 1H), 7.33 (d, J =
4.9 Hz, 1H), 6.85 (q, J = 2.6
317 Hz, 3H), 4.85 (d, J = 6.3 Hz,
4H), 4.08 (s, 0H), 3.88 - 3.58
(m, 5H), 3.35 (q, J = 6.8 Hz,
1H), 3.03 (d, J = 5.1 Hz, 3H),
2.36 - 2.13 (m, 2H), 2.15 -
1.84 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
1.9 Hz, 1H), 8.56 (d, J :19
Hz, 1H), 8.33 (d, J :19 Hz,
1H), 6.85 (s, 2H), 5.07 (d, J =
8.1 Hz, 1H), 4.86 (d, J = 6.4
Hz, 4H), 4.23 (s, 2H), 3.90 -
3.62 (m, 4H), 3.35 (q, J = 7.1
Hz, 1H), 2.73 (qd, J = 7.6, 2.3
Hz, 2H), 2.27 (d, J = 10.1 Hz,
3H), 2.12 - 1.82 (m, 6H), 1.28
(t, J = 7.6 Hz, 3H).
1H NMR (300 MHz,
Chloroform-d) 6 8.83 (dt, J =
6.4, 1.4 Hz, 2H), 8.51 (d, J =
4.7 Hz, 1H), 7.78 (s, 1H), 7.68
(d, J = 1.7 Hz, 1H), 7.34 (dd, J
= 4.9, 0.9 Hz, 1H), 6.38 (s,
319 1H), 5.32 (d, J = 0.9 Hz, 1H),
4.87 (s, 1H), 4.43 (q, J = 2.8
Hz, 2H), 4.17 - 3.94 (m, 3H),
3.03 (dd, J = 51,10 Hz, 3H),
2.76 - 2.59 (m, 2H), 2.23 (d, J
= 12.7 Hz, 2H), 1.98 (d, J =
7.7 Hz, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.10 (d, J = 6.0 Hz,
1H), 6.97 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.6 Hz, 1H), 6.15
(d, J = 6.0 Hz, 1H), 4.99 (s,
1H), 4.81 (s, 1H), 4.19 - 4.08
(m, 1H), 3.94 - 3.69 (m, 5H),
3.63 (t, J = 11.3 Hz, 2H), 3.04
(td, J = 11.9, 3.5 Hz, 1H), 2.92
- 2.80 (m, 1H), 2.50 (s, 3H),
2.20 (d, J = 8.9 Hz, 2H), 1.90
d, J = 5.6 Hz, 7H.
1H NMR (300 MHz,
form-d) 6 8.81 - 8.67
(m, 2H), 8.42 (s, 1H), 7.89 (s,
1H), 7.58 (d, J = 1.8 Hz, 1H),
7.09 (s, 1H), 6.28 (dq, J = 3.0,
321 1.6 Hz, 1H), 4.81 (s, 1H), 4.33
(q, J = 2.8 Hz, 2H), 3.92 (t, J =
.4 Hz, 2H), 2.93 (d, J = 5.1
Hz, 3H), 2.67 - 2.48 (m, 2H),
2.18 (d, J =11.3 Hz, 2H), 1.98
- 1.73 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.52 (d, J :19
Hz, 1H), 6.85 (dd, J = 18.8,
2.5 Hz, 2H), 5.59 (d, J = 8.3
322 Hz, 1H), 5.24 (s, 1H), 4.72 (s,
1H), 3.84 (t, J = 4.9 Hz, 5H),
3.66 - 3.39 (m, 3H), 3.30 -
3.19 (m, 5H), 2.78 (t, J = 7.0
Hz, 2H), 2.11 (s, 1H), 2.00 -
1.66 (m, 6H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3) 5
8.71 (d, J = 1.9 Hz, 1H), 8.63
(d, J = 1.9 Hz, 1H), 7.79 (d, J
= 5.9 Hz, 1H), 6.97 (d, J = 2.4
Hz, 1H), 6.91 (d, J = 2.4 Hz,
1H), 6.13 (dd, J = 5.9, 2.1 Hz,
1H), 5.87 (d, J = 2.0 Hz, 1H),
4.87 — 4.70 (m, 1H), 4.32 (q, J
= 7.1 Hz, 2H), 4.21 (d, J = 7.8
Hz, 1H), 4.05 — 3.81 (m, 4H),
3.60 — 3.45 (m, 1H), 3.45 —
3.24 (m, 4H), 2.33 — 2.10 (m,
2H), 2.02 — 1.77 (m, 6H), 1.39
t,J=7.1Hz,3H. 2
1H NMR (300 MHz, CDCI3) 5
11.03 (s, 1H), 8.71 (d, J = 1.9
Hz, 1H), 8.62 (d, J = 1.9 Hz,
1H), 7.09 (d, J = 7.1 Hz, 1H),
6.97 (d, J = 2.4 Hz, 1H), 6.90
(d, J = 2.4 Hz, 1H), 5.67 (dd, J
325 = 7.2, 2.1 Hz, 1H), 5.58 (d, J =
2.1 Hz, 1H), 4.84 — 4.75 (m,
1H), 4.41 (d, J = 7.6 Hz, 1H),
4.02 — 3.87 (m, 4H), 3.54 —
3.43 (m, 1H), 3.42 — 3.27 (m,
4H), 2.28 — 2.15 (m, 2H), 2.05
— 1.78 (m, 6H).
nd ESMS
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 7.01 - 6.83 (m, 2H),
.34 (s, 1H), 4.73 (d, J = 6.1
423.4
Hz, 1H), 3.91 (dd, J = 6.1, 3.7
Hz, 4H), 3.59 (s, 4H), 3.44 (s,
1H), 3.33 (t, J = 4.9 Hz, 4H),
2.17 (s, 5H), 1.86 (q, J = 9.1,
6.3 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
2.0 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 8.00 (d, J = 1.3 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.5 Hz, 1H), 4.88
(d, J = 8.2 Hz, 1H), 4.77 (s,
523.35 1H), 4.63 (d, J = 9.0 Hz, 2H),
4.15 (s, 1H), 3.92 (t, J = 4.9
Hz, 4H), 3.39 - 3.26 (m, 4H),
2.91 (td, J = 8.6, 3.9 Hz, 1H),
2.72 - 2.55 (m, 2H), 2.50 -
2.10 (m, 7H), 1.91 (d, J = 5.5
Hz, 6H), 1.72 (d, J = 4.7 Hz,
1H NMR (300 MHz,
Chloroform-d) 6 8.81 - 8.59
(m, 3H), 8.54 (d, J :19 Hz,
1H), 6.92 - 6.73 (m, 2H), 5.50
(d, J = 8.2 Hz, 1H), 4.72 (s,
521 .69 1H), 4.01 (s, 2H), 3.84 (t, J =
4.9 Hz, 5H), 3.50 (q, J = 5.3
Hz, 3H), 3.37 - 3.17 (m, 5H),
2.62 (t, J = 5.6 Hz, 2H), 2.34
(s, 7H), 2.13 (d, J = 10.7 Hz,
2H), 1.87 (d, J = 22.1 Hz, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (t, J =
1.7 Hz, 1H), 8.55 (t, J = 1.7
Hz, 1H), 8.37 (dt, J = 4.6, 1.5
Hz, 1H), 7.78 (dt, J = 7.9, 1.5
329 46044
Hz, 1H), 6.93 - 6.77 (m, 3H),
4.71 (d, J = 6.1 Hz, 1H), 3.96 -
3.77 (m, 6H), 3.33 - 3.18 (m,
4H), 2.23 - 2.07 (m, 2H), 2.01
- 1.77 (m, 6H).
1H NMR (300 MHz,
form-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.53 (d, J :19
Hz, 1H), 8.10 (dd, J = 4815
Hz, 1H), 7.61 (dd, J = 8.0, 1.5
Hz, 1H), 7.12 (dd, J = 8.1, 4.8
330 4636
Hz, 1H), 6.95 - 6.76 (m, 2H),
.39 (s, 1H), 4.74 (s, 1H),
3.96 - 3.75 (m, 5H), 3.26 (t, J
= 4.9 Hz, 4H), 2.16 (d, J =
12.8 Hz, 2H), 2.05 - 1.71 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.53 (d, J :19
Hz, 1H), 7.28 (d, J = 0.7 Hz,
1H), 6.94 - 6.77 (m, 2H), 5.39
331 4554
(s, 1H), 5.09 (d, J = 7.8 Hz,
1H), 4.71 (s, 1H), 3.93 - 3.77
(m, 4H), 3.58 (s, 1H), 3.26
(dd, J = 6.0, 3.7 Hz, 4H), 2.11
(s, 2H), 1.97 - 1.66 (m, 6H).
Compound ESMS H NMR
nd Structure
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
335 421 .37
336 446.35
1H NMR (300 MHz,
Chloroform-d) 6 8.67 - 8.58
(m, 1H), 8.58 - 8.49 (m, 1H),
8.33 (s, 2H), 6.92 - 6.78 (m,
2H), 5.41 (d, J = 8.1 Hz, 1H),
337 533.2 4.72 (s, 1H), 3.98 (d, J = 8.6
Hz, 1H), 3.84 (t, J = 4.8 Hz,
4H), 3.58 (s, 4H), 3.26 (t, J =
4.9 Hz, 4H), 2.36 (t, J = 4.9
Hz, 4H), 2.25 (s, 3H), 2.13 (d,
J = 10.8 Hz, 2H), 1.84 (s,6H).
nd ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.59 (d, J = 1.9 Hz, 1H), 7.17
(d, J = 2.5 Hz, 1H), 6.84 (d, J
= 2.4 Hz, 1H), 6.69 — 6.61 (m,
1H), 6.50 (m, 2H), 4.94 (m,
1H), 4.50 (t, J = 8.7 Hz, 2H),
4.27 (d, J = 8.2 Hz, 1H), 3.79
(m, 4H), 3.45 (m, 1H), 3.32
(m, 4H), 3.13 (t, J = 8.7 Hz,
2H), 1.98 (m, 2H), 1.74 (m,
6H).
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.58 (d, J = 1.9 Hz, 1H), 7.14
(d, J = 2.5 Hz, 1H), 6.84 (d, J
= 2.3 Hz, 1H), 6.64 (t, J = 8.0
339 Hz, 1H), 6.36 (d, J = 8.2 Hz,
1H), 6.22 (dd, J = 7.7, 1.0 Hz,
1H), 5.89 (s, 2H), 4.96 (m,
2H), 3.79 (m, 4H), 3.51 (m,
1H), 3.32 (m, 4H), 2.03 (m,
2H), 1.75 (m, 6H).
1H NMR (300 MHz, DMSO-
d6) 5 8.73 (d, J = 1.9 Hz, 1H),
8.59 (d, J = 1.9 Hz, 1H), 7.25
(m, 1H), 7.14 (d, J = 2.4 Hz,
1H), 6.89 — 6.78 (m, 3H), 5.47
(d, J = 7.7 Hz, 1H), 4.94 (m,
1H), 4.29 (s, 2H), 3.79 (m,
4H), 3.51 (m, 1H), 3.06 (s,
3H), 2.09 (m, 2H), 1.81 (m,
6H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, DMSO-
d6) 6 8.72 (d, J = 1.9 Hz, 1H),
8.58 (d, J = 1.9 Hz, 1H), 8.17
(s, 2H), 7.15 (d, J = 2.4 Hz,
1H), 6.83 (d, J = 2.3 Hz, 1H),
6.06 (d, J = 7.8 Hz, 1H), 4.92
(m, 1H), 4.77 (s, 1H), 3.79 (m,
4H), 3.50 (m, 1H), 3.30 (m,
4H), 2.02 (m, 2H), 1.80 (m,
6H), 1.42 (s, 6H).
1H NMR (400 MHz, CDCI3) 6
8.86 (d, J = 0.9 Hz, 1H), 8.84
(s, 1H), 8.16 (s, 1H), 7.73 —
7.63 (m, 2H), 7.17 (d, J = 7.0
342 Hz, 1H), 5.24 (d, J = 7.8 Hz,
1H), 5.03 (s, 2H), 4.83 (s, 2H),
4.79 (s, 1H), 4.12 — 3.99 (m,
1H), 2.26 — 2.14 (m, 2H), 2.01
— 1.84 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
2.0 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 8.00 (d, J = 1.3 Hz,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.5 Hz, 1H), 4.88
(d, J = 8.2 Hz, 1H), 4.77 (s,
343 1H), 4.63 (d, J = 9.0 Hz, 2H),
4.15 (s, 1H), 3.92 (t, J = 4.9
Hz, 4H), 3.39 - 3.26 (m, 4H),
2.91 (td, J = 8.6, 3.9 Hz, 1H),
2.72 - 2.55 (m, 2H), 2.50 -
2.10 (m, 7H), 1.91 (d, J = 5.5
Hz, 6H), 1.72 (d, J = 4.7 Hz,
1H .
WO 59690
1H NMR (300 MHz, DMSO-
d6) 69.18 (d, J = 1.5 Hz, 1H),
8.98 (t, 1H), 8.87 (d, J = 2.5
Hz, 1H), 8.76 — 8.69 (m, 2H),
8.57 (d, J = 1.9 Hz, 1H), 7.12
345 44959
(d, J = 2.6 Hz, 1H), 6.82 (d, J
= 2.3 Hz, 1H), 4.94 (m, 1H),
3.78 (m, 4H), 3.27 (m, 6H),
1.99 (m, 2H), 1.83 — 1.48 (m,
7H).
1H NMR (300 MHz, DMSO-
d6) 6 8.71 (d, J = 1.9 Hz, 1H),
8.59 (d, J = 1.9 Hz, 1H), 7.85
(t, 1H), 7.12 (d, J = 2.5 Hz,
346 385.56 1H), 6.83 (d, J = 2.4 Hz, 1H),
4.93 (m, 1H), 3.78 (m, 4H),
3.31 (m, 3H), 2.95 (t, J = 6.0
Hz, 2H), 2.03 — 1.90 (m, 2H),
1.80 (s, 3H), 1.52 (m, 7H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.59 (s, 1H), 7.60 (d, J = 2.3
Hz, 1H), 7.46 (s, 1H), 7.13 (s,
1H), 6.83 (s, 1H), 6.46 (s, 1H),
.97 (m, 1H), 4.96 (m 1H),
3.87 — 3.70 (m, 7H), 3.30 (s,
4H), 2.95 (t, J = 5.7 Hz, 2H),
1.99 (m, 2H), 1.62 (t, J = 18.1
Hz, 7H).
1H NMR (300 MHz, DMSO-
d6) 6 8.72 (d, J = 1.9 Hz, 1H),
8.60 (d, J = 1.9 Hz, 1H), 8.24
(d, J = 4.7 Hz, 1H), 7.22 (t, J =
6.0 Hz, 1H), 7.11 (d, J = 2.6
348 Hz, 1H), 6.82 (d, J = 2.3 Hz,
1H), 6.51 (t, J = 4.7 Hz, 1H),
4.93 (m, 1H), 3.78 (m, 4H),
3.31 m, 4H), 3.19 (t, J = 6.5
Hz, 2H), 1.97 (m, 2H), 1.55
(m, 7H).
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.57 (d, J = 1.9 Hz, 1H), 7.59
(d, J = 5.9 Hz, 1H), 7.14 (d, J
= 2.5 Hz, 1H), 6.82 (d, J = 2.3
Hz, 1H), 6.44 (d, J = 7.7 Hz,
1H), 6.22 (dd, J = 5.8, 2.1 Hz,
1H), 5.80 — 5.74 (m, 1H), 5.19
— 5.11 (m, 1H), 4.92 (m, 1H),
3.79 (m, 4H), 3.32 (m, 4H),
2.01 (m, 2H), 1.75 (m, 6H),
1.21 (d, J = 6.1 Hz, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 4.79 (s, 1H),
4.24 - 3.76 (m, 5H), 3.50 -
3.20 (m, 4H), 3.02 (d, J = 5.1
Hz, 3H), 2.20 (d, J = 12.8 Hz,
350 464.42 2H), 2.09 - 1.75 (m, 6H), 5.29
- 5.19 (m, 1H), 8.70 (d, J = 1.9
Hz, 1H), 8.62 (d, J :19 Hz,
1H), 8.49 (d, J = 4.8 Hz, 1H),
7.77 (s, 1H), 7.32 (d, J = 4.9
Hz, 1H), 7.02 - 6.86 (m, 2H).
1H NMR (300 MHz,
form-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J = 2.0
Hz, 1H), 8.38 (d, J = 4.9 Hz,
1H), 6.93 (dd, J = 14.5, 2.4
351 478.38 Hz, 2H), 6.68 (d, J = 4.9 Hz,
1H), 5.28 (s, 1H),4.79(s,1H),
4.22 - 3.86 (m, 5H), 3.34 (t, J
= 4.8 Hz, 4H), 3.17 - 2.97 (m,
6H), 2.20 (s, 2H), 1.91 (d, J =
.1 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.91 - 8.75
(m, 2H), 8.11 (d, J = 5.9 Hz,
1H), 7.68 (d, J = 1.8 Hz, 1H),
6.37 (tt, J = 3.0, 1.5 Hz, 1H),
6.16 (d, J = 6.0 Hz, 1H), 4.99
(s, 1H), 4.88 (d, J = 6.0 Hz,
1H), 4.43 (q, J = 2.8 Hz, 2H),
4.02 (t, J = 5.4 Hz, 2H), 3.85
(s, 1H), 2.77 - 2.64 (m, 2H),
2.51 (s, 3H), 2.23 (d, J = 13.2
Hz, 2H), 2.03 - 1.82 (m, 6H).
WO 59690
Compound ESMS H NMR
Compound Structure
No. M+H
1H NMR (300 MHz,
Chloroform-d) 6 8.67 (d, J =
1.9 Hz, 1H), 8.54 (d, J = 1.9
Hz, 1H), 8.11 (d, J = 6.0 Hz,
1H), 6.85 (s, 2H), 6.16 (d, J =
353 6.0 Hz, 1H), 5.00 (s, 1H), 4.85
(d, J = 6.5 Hz, 3H), 3.93 - 3.57
(m, 5H), 3.35 (q, J = 7.1 Hz,
1H), 2.62 (d, J = 8.0 Hz, 1H),
2.50 (s, 3H), 2.24 (d, J = 8.9
Hz, 2H), 2.01 - 1.81 (m, 6H).
1H NMR (300 MHz, DMSO-
d6) 5 8.73 (d, J = 1.9 Hz, 1H),
8.61 (d, J = 3.1 Hz, 1H), 8.58
(d, J = 2.0 Hz, 1H), 8.47 (d, J
= 6.2 Hz, 1H), 7.15 (d, J = 2.4
354 Hz, 1H), 6.99 (d, J = 7.8 Hz,
1H), 6.83 (d, J = 2.3 Hz, 1H),
6.65 (m, 1H), 4.94 (m, 1H),
3.79 (m, 4H), 3.55 (m, 1H),
3.35 (m, 4H), 2.03 (m, 2H),
1.78 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.8 Hz, 1H), 8.61
o :1 (d, J = 1.8 Hz, 1H), 8.17 (s,
M. 1H), 6.93 (d, J = 2.2 Hz, 1H),
6.71 (d, J = 2.2 Hz, 1H), 5.36
(d, J = 7.8 Hz, 1H), 5.04 (s,
355 421 .23
2H), 4.85 (s, 2H), 4.74 — 4.61
(m, 1H), 4.40 — 4.28 (m, 1H),
4.02 — 3.82 (m, 4H), 3.43 —
3.27 (m, 4H), 3.26 — 3.13 (m,
2H), 2.35 (dd, J = 19.4, 9.4
Hz, 2H).
2014/024767
Compound ESMS
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 5
8.72 (s, 1H), 8.62 (d, J = 1.5
Hz, 1H), 8.50 (s, 1H), 7.74 (d,
J = 1.9 Hz, 1H), 6.95 (d, J =
2.0 Hz, 1H), 6.86 (d, J = 1.9
Hz, 1H), 6.73 (d, J = 2.1 Hz,
1H), 5.44 (d, J = 7.5 Hz, 1H),
4.82 — 4.72 (m, 1H), 4.72 —
4.61 (m, 1H), 4.00 — 3.86 (m,
4H), 3.40 — 3.32 (m, 4H), 3.32
— 3.22 (m, 2H), 2.53 — 2.40 (m,
2H).
1H NMR (400 MHz, CDCI3) 5
8.71 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.12 (d, J
= 5.9 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.70 (d, J = 2.4 Hz,
1H), 6.13 (d, J = 5.9 Hz, 1H),
.06 (s, 1H), 4.72 (p, J = 6.9
Hz, 1H), 4.18 (s, 1H), 3.98 —
3.85 (m, 4H), 3.40 — 3.27 (m,
4H), 3.27 — 3.13 (m, 2H), 2.50
(s, 3H), 2.36 (ddd, J = 12.7,
.0, 2.9 Hz, 2H).
1H NMR (300 MHz, DMSO-
d6) 6 8.72 (d, J = 1.9 Hz, 1H),
8.57 (d, J = 1.9 Hz, 1H), 8.22
(m, 1H), 8.00 (d, J = 2.7 Hz,
1H), 7.73 (d, J = 8.6 Hz, 1H),
7.15 (d, J = 2.3 Hz, 1H), 7.02
358 (dd, J = 8.7, 2.8 Hz, 1H), 6.83
(d, J = 2.4 Hz, 1H), 6.50 (d, J
= 7.6 Hz, 1H), 4.93 (m, 1H),
3.79 (m, 4H), 3.52 (m, 1H),
3.34 (m, 4H), 2.76 (d, J = 4.9
Hz, 3H), 2.04 (m, 2H), 1.79
(m, 6H).
Compound ESMS
C d St t
1H NMR (300 MHz,
form-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.99 (d, J = 1.3 Hz,
1H), 6.92 (dd, J = 16.0, 2.5
Hz, 2H), 5.12 (d, J = 7.5 Hz,
1H), 4.76 (d, J = 5.4 Hz, 1H),
4.69 - 4.54 (m, 1H), 4.15 (s,
537.71
1H), 4.01 - 3.82 (m, 4H), 3.72
(ddd, J = 13.2, 7.6, 2.9 Hz,
1H), 3.44 - 3.21 (m, 5H), 3.21
- 2.99 (m, 1H), 2.46 (dq, J =
7.9, 3.9 Hz, 1H), 2.34 (s, 3H),
2.22 (t, J = 8.8 Hz, 3H), 1.86
(dd, J = 10.0, 4.8 Hz, 7H),
1.79- 1.51 m, 2H.
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 7.16 (d, J = 1.2 Hz,
1H), 6.93 (dd, J = 17.1, 2.5
464.58 Hz, 2H), 5.38-5.21 (m,1H),
4.90 - 4.77 (m, 1H), 3.91 (dd,
J = 6.0, 3.7 Hz, 5H), 3.44 -
3.26 (m, 4H), 3.00 (d, J = 5.1
Hz, 3H), 2.23 (d, J = 11.4 Hz,
2H), 2.04 - 1.76 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz,1H),8.61 (d, J :19
Hz, 1H), 8.38 (d, J = 4.9 Hz,
1H), 7.00 - 6.85 (m, 2H), 6.68
478.57 (d, J = 4.9 Hz, 1H), 5.29 (d, J
= 7.7 Hz, 1H), 4.79 (s, 1H),
4.04 (s, 1H), 3.92 (dd, J = 6.0,
3.8 Hz, 4H), 3.41 - 3.26 (m,
4H), 3.10 (s, 3H), 3.04 (s, 3H),
2.19 (d, J = 8.7 Hz, 2H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.63 (t, J = 1.6
Hz, 1H), 8.04 (s, 1H), 6.95 (d,
J = 2.3 Hz, 1H), 6.90 (d, J =
2.7 Hz, 1H), 4.88 (d, J = 8.3
362 512.55
Hz, 1H), 4.80 (s, 1H), 4.48 (t,
J = 5.9 Hz, 2H), 4.17 (s, 1H),
4.01 - 3.81 (m, 4H), 3.34 (t, J
= 4.7 Hz, 4H), 2.73 (t, J = 5.9
Hz, 2H), 2.33 (d, J = 1.2 Hz,
8H), 2.07 - 1.73 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 6.92 (dd, J = 21.1,
2.5 Hz, 2H), 4.74 (s, 1H), 4.35
(d, J = 7.9 Hz, 1H), 4.12 (d, J
363 469.62 = 8.0 Hz, 1H), 4.03 - 3.67 (m,
5H), 3.63 - 3.50 (m, 1H), 3.47
- 3.20 (m, 4H), 2.77 (d, J =
11.3 Hz, 2H), 2.28 (s, 3H),
2.22 - 2.04 (m, 4H), 1.90 (dd,
J = 38.6, 8.3 Hz, 8H), 1.45
(qd, J = 11.1, 3.8 Hz, 2H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.59 (d, J = 2.0
Hz, 1H), 6.92 (dd, J = 21.8,
2.5 Hz, 2H), 4.75 (s, 1H), 4.47
(dd, J = 28.7, 10.8 Hz, 2H),
364 497.61
4.19 (d, J = 7.7 Hz, 1H), 3.99 -
3.68 (m, 6H), 3.46 - 3.27 (m,
4H), 3.18 (t, J = 11.7 Hz,1H),
2.85 - 2.64 (m, 1H), 2.11 (s,
5H), 1.83 (d, J = 4.9 Hz, 6H),
1.41 - 1.17 (m, 5H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz,
Chloroform-d) 6 8.67 (dd, J =
21.6, 1.9 Hz, 2H), 8.01 (s,
1H), 6.94 (dd, J = 16.5, 2.5
Hz, 2H), 4.79 (s, 1H), 4.67 (s,
365 2H), 4.18 (s, 2H), 3.93 (t, J =
4.8 Hz, 4H), 3.41 - 3.27 (m,
6H), 2.20 (d, J = 9.9 Hz, 2H),
1.93 (d, J = 5.5 Hz, 6H), 0.63 -
0.50 (m, 2H), 0.29 (t, J = 5.0
Hz, 2H).
1H NMR (400 MHz, CDCI3) 5
8.90 (dd, J = 7.2, 1.8 Hz, 2H),
8.75 (dd, J = 4.5, 1.6 Hz, 2H),
8.10 (d, J = 6.0 Hz, 1H), 7.97
(d, J =1.7 Hz, 1H), 7.62 (dd, J
367 = 4.5, 1.6 Hz, 2H), 7.38 (d, J =
1.7 Hz, 1H), 6.15 (d, J = 6.0
Hz, 1H), 4.98 (s, 1H), 4.93 (s,
1H), 3.86 (s, 1H), 2.49 (s, 3H),
2.34 — 2.18 (m, 2H), 1.96 (dd,
J = 20.7, 8.9 Hz, 6H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz, DMSO-
d6) 5 8.73 (d, J = 2.0 Hz, 1H),
8.60 (d, J = 2.0 Hz, 1H), 7.96
(s, 2H), 7.15 (d, J = 2.5 Hz,
1H), 6.85 (d, J = 2.4 Hz, 1H),
368 343.48
4.97 (m, 1H), 3.79 (t, J = 4.9
Hz, 4H), 3.35 (t, J = 4.9 Hz,
4H), 2.72 (t, J = 6.2 Hz, 2H),
2.65 (m, 1H), 2.01 (m, 2H),
1.77 — 1.48 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.71 (s, 1H), 6.94
(dd, J = 14.6, 2.5 Hz, 2H),
369 436.5 5.09 (d, J = 7.7 Hz, 1H), 4.80
(d, J = 5.4 Hz, 1H), 4.29 (s,
2H), 4.01 - 3.84 (m, 4H), 3.45
- 3.28 (m, 4H), 2.49 (s, 3H),
2.21 (q, J = 6.1 Hz, 2H), 1.95
(dt, J = 10.0, 4.1 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (t, J =
1.9 Hz, 1H), 8.64 (dd, J = 3.9,
2.0 Hz, 1H), 8.11 (s, 1H), 7.01
- 6.90 (m, 2H), 4.75 (d, J =
370 448.25 20.3 Hz, 2H), 4.23 (s, 2H),
3.93 (t, J = 4.8 Hz, 4H), 3.68
(t, J = 8.7 Hz, 2H), 3.42 - 3.29
(m, 4H), 2.90 (t, J = 8.7 Hz,
2H), 2.34 - 2.12 (m, 2H), 2.11
- 1.83 (m, 6H).
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz,
form-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 7.79 (d, J = 5.6 Hz,
1H), 7.03 - 6.89 (m, 2H), 6.05
(d, J = 5.6 Hz, 1H), 4.77 (d, J
371 447.5 = 5.9 Hz, 1H), 4.21 (s,1H),
3.93 (dd, J = 6.0, 3.7 Hz, 4H),
3.68 (t, J = 8.7 Hz, 2H), 3.36
(dd, J = 5.8, 4.0 Hz, 4H), 2.85
(t, J = 8.7 Hz, 2H), 2.20 (q, J =
12.1, 9.5 Hz, 2H), 1.94 (t, J =
.8 Hz, 6H).
372 446.44
1H NMR (400 MHz, CDCI3) 6
8.71 (d, J = 1.8 Hz, 1H), 8.63
(d, J = 1.8 Hz, 1H), 7.70 (d, J
= 5.0 Hz, 2H), 6.97 (d, J = 1.6
Hz, 1H), 6.92 (d, J = 2.1 Hz,
373 421.51
1H), 4.81 (s, 1H), 4.65 (s, 1H),
3.99 — 3.85 (m, 5H), 3.40 —
3.30 (m, 4H), 2.37 (s, 3H),
2.28 — 2.16 (m, 2H), 2.01 —
1.82 (m, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.81 - 8.67
(m, 2H), 8.01 (d, J = 6.0 Hz,
1H), 7.46 (dd, J = 1.7, 0.7 Hz,
1H), 6.98 (d, J = 1.7 Hz, 1H),
6.06 (d, J = 6.0 Hz, 1H), 4.80
(d, J = 38.5 Hz, 2H), 4.13 -
3.97 (m, 3H), 3.51 (td, J =
11.3, 3.5 Hz, 2H), 2.99 - 2.80
(m, 1H), 2.41 (s, 3H), 2.21 -
2.03 (m, 2H), 1.94 - 1.70 (m,
7H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.07 (s, 1H), 6.93
(dd, J = 17.0, 2.5 Hz, 2H),
376 4.98 - 4.71 (m, 2H), 4.17 (s,
1H), 4.00 (s, 3H), 3.92 (dd, J
= 5.8, 3.9 Hz, 4H), 3.42 - 3.26
(m, 4H), 2.22 (d, J = 9.5 Hz,
2H), 1.93 (dd, J = 6.1, 2.4 Hz,
6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.95 (d, J = 1.2 Hz,
1H), 6.92 (dd, J = 16.9, 2.5
Hz, 2H), 4.98 (s, 1H), 4.81 -
377 512.36
4.66 (m, 2H), 4.16 (s, 1H),
3.97 - 3.87 (m, 4H), 3.46 (d, J
= 6.1 Hz, 2H), 3.39 - 3.29 (m,
4H), 2.19 (d, J = 12.5 Hz, 2H),
1.91 (d, J = 5.4 Hz, 6H), 1.26
(s, 6H), 0.94 - 0.83 (m, 1H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.99 (d, J = 1.3 Hz,
1H), 6.92 (dd, J = 17.1, 2.5
Hz, 2H), 4.77 (s, 1H), 4.66 (d,
378 J = 8.5 Hz, 1H), 4.41 (d, J =
7.7 Hz, 1H), 4.23 - 4.10 (m,
2H), 4.05 - 3.87 (m, 6H), 3.54
(td, J = 11.7, 2.1 Hz, 2H), 3.39
- 3.29 (m, 4H), 2.19 (d, J =
11.3 Hz, 2H), 2.08 - 1.85 (m,
8H), 1.64 - 1.44 (m, 2H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.00 (d, J =1.3 Hz,
1H), 6.95 (d, J = 2.5 Hz, 1H),
379 6.89 (d, J = 2.5 Hz, 1H), 4.87 -
4.56 (m, 4H), 4.16 (s, 1H),
4.04 - 3.65 (m, 8H), 3.46 -
3.26 (m, 4H), 2.43 - 2.26 (m,
1H), 2.20 (q, J = 6.6, 5.9 Hz,
2H), 1.90 (t, J = 5.5 Hz, 6H).
nd ESMS
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
2.0 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.00 - 7.91 (m, 1H),
6.92 (dd, J = 17.2, 2.5 Hz,
2H), 4.87 - 4.64 (m, 2H), 4.59
(d, J = 5.7 Hz, 1H), 4.16 (ddt,
380 J = 9.7, 6.8, 3.7 Hz, 2H), 4.01
- 3.85 (m, 4H), 3.75 (d, J =
11.2 Hz, 1H), 3.58 (dd, J =
.9, 7.0 Hz, 1H), 3.48 - 3.23
(m, 4H), 2.36 - 2.07 (m, 2H),
1.91 (d, J = 5.5 Hz, 6H), 1.28
(d, J = 6.8 Hz, 3H), 0.97 - 0.78
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.98 (d, J = 7.3 Hz,
1H), 6.92 (dd, J = 16.7, 2.5
Hz, 2H), 4.87 (d, J = 8.6 Hz,
1H), 4.77 (s, 2H), 4.61 (s, 2H),
4.15 (s, 1H), 3.91 (dd, J = 5.9,
3.8 Hz, 4H), 3.46 - 3.29 (m,
4H), 2.99 - 2.77 (m, 2H), 2.74
- 2.54 (m, 2H), 2.46 - 2.10 (m,
6H), 1.91 (d, J = 5.5 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.00 (s, 1H), 6.92
(dd, J = 16.5, 2.5 Hz, 2H),
4.92 (s, 1H), 4.77 (s, 1H),
382 4.64 (d, J = 8.5 Hz, 1H), 4.16
(s, 1H), 4.03 - 3.82 (m, 4H),
3.65 (q, J = 5.8, 5.4 Hz, 2H),
3.56 (ddd, J = 5.6, 4.7, 1.0 Hz,
2H), 3.48 - 3.21 (m, 7H), 2.19
(d, J = 10.1 Hz,2H),1.91 (d, J
= 5.4 Hz, 6H).
nd ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (s, 1H),
8.62 (d, J = 1.9 Hz, 1H), 8.55
(d, J :19 Hz, 1H), 6.93 - 6.71
(m, 3H), 6.22 (dd, J = 3.6, 2.0
383 Hz, 1H), 5.01 (d, J = 8.1 Hz,
1H), 4.71 (s, 1H), 4.34 (s, 1H),
3.92 - 3.78 (m, 7H), 3.26 (dd,
J = 5.9, 3.9 Hz, 4H), 2.15 (d, J
= 10.8 Hz, 2H), 1.98 - 1.78
(m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.72 (d, J
2.0 Hz, 1H), 8.65 (d, J =1. Hz, 1H), 8.39 (s, 1H), 7.01 ILOII
6.90 (m, 3H), 6.35 (d, J = 3.5
Hz, 1H), 5.05 (t, J = 8.6 Hz,
1H), 4.83 (d, J = 5.6 Hz, 1H),
4.41 (s, 1H), 4.01 - 3.87 (m,
4H), 3.82 (d, J =1.1 Hz, 3H),
3.44 - 3.30 (m, 4H), 2.27 (d, J
= 8.9 Hz, 2H), 2.12 - 1.86 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.72 (d, J =
1.9 Hz, 1H), 8.65 (d, J :19
Hz, 1H), 8.03 (d, J = 5.6 Hz,
1H), 7.11 (d, J = 3.6 Hz,1H),
7.03 - 6.91 (m, 2H), 6.41 (d, J
= 3.6 Hz, 1H), 6.28 (d, J = 5.7
Hz, 1H), 4.83 (s, 1H), 4.56 (d,
J = 8.0 Hz,1H),4.01 - 3.88
(m, 4H), 3.78 (s, 1H), 3.44 -
3.30 (m, 4H), 2.28 (d, J = 10.0
Hz, 2H), 2.11 - 1.85 (m, 6H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 7.49 (s,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.25
386 480.41
(s, 1H), 4.72 (s, 1H), 4.18 (s,
1H), 3.96 — 3.87 (m, 4H), 3.77
(s, 3H), 3.39 — 3.30 (m, 4H),
3.10 (s, 6H), 2.21 — 2.12 (m,
2H), 2.02 — 1.85 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 7.49 (s,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.25
387 466.4
(s, 1H), 4.72 (s, 1H), 4.18 (s,
1H), 3.96 — 3.87 (m, 4H), 3.77
(s, 3H), 3.39 — 3.30 (m, 4H),
3.10 (s, 6H), 2.21 — 2.12 (m,
2H), 2.02 — 1.85 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.63
(d, J = 1.9 Hz, 1H), 8.04 (s,
1H), 6.94 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.15
388 480.41 (d, J = 8.4 Hz, 1H), 4.75 (s,
1H), 4.14 (s, 1H), 3.97 — 3.83
(m, 4H), 3.59 (s, 3H), 3.38 —
3.28 (m, 4H), 3.09 (s, 6H),
2.25 — 2.13 (m, 2H), 2.00 —
1.83 (m, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz,1H),8.61 (d, J :19
Hz, 1H), 8.50 (d, J =1.1 Hz,
1H), 6.93 (dd, J = 16.5, 2.5
Hz, 2H), 6.49 (s, 1H), 4.90 (s,
389 504.48
1H), 4.80 (s, 1H), 4.08 - 3.87
(m, 5H), 3.44 - 3.29 (m, 6H),
2.45 (t, J = 5.3 Hz, 4H), 2.26 -
2.14 (m, 2H), 1.90 (t, J = 6.5
Hz, 6H), 1.63 (d, J = 5.7 Hz,
4H), 1.53 - 1.43 (m, 2H).
1H NMR (300 MHz,
form-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.50 (d, J =1.1 Hz,
1H), 6.93 (dd, J = 16.5, 2.5
390 464.62 Hz, 2H), 6.44 (d, J =1.1 Hz,
1H), 4.93 (s, 1H), 4.80 (s, 1H),
3.97 - 3.87 (m, 4H), 3.47 -
3.29 (m, 6H), 2.31 (s, 6H),
2.21 (d, J = 9.1 Hz, 2H), 1.89
(t, J = 6.9 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
1.9 Hz, 1H), 8.58 (d, J :19
Hz, 1H), 6.94 (d, J = 2.5 Hz,
1H), 6.86 (d, J = 2.5 Hz, 1H),
4.81 - 4.61 (m, 3H), 4.47 (td, J
391 500.63 = 8.7, 5.2 Hz, 1H), 3.98 - 3.88
(m, 4H), 3.85 - 3.66 (m, 4H),
3.40 - 3.25 (m, 4H), 2.24 -
2.07 (m, 2H), 1.93 - 1.74 (m,
6H), 1.71-1.64 (m, 1H). 1.58 -
1.39 (m, 2H), 0.93 (t, J = 6.3
Hz, 6H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, DMSO-
d6) 6 8.71 (d, J = 1.9 Hz, 1H),
8.58 (d, J = 1.9 Hz, 1H), 7.10
(d, J = 2.5 Hz, 1H), 6.82 (d, J
392 443.61
= 2.6 Hz, 2H), 4.92 (m, 1H),
3.78 (m, 4H), 3.30 (m, 5H),
2.84 (t, J = 6.0 Hz, 2H), 1.96 —
1.33 (m, 18H).
1H NMR (300 MHz, DMSO-
d6) 6 8.73 (d, J = 1.9 Hz, 1H),
8.58 (d, J = 1.9 Hz, 1H), 8.10
(d, J = 2.7 Hz, 1H), 7.97 (d, J
= 8.9 Hz, 1H), 7.38 (dd, J =
393 450.58 9.0, 2.7 Hz, 1H), 7.16 (d, J =
2.4 Hz, 1H), 6.84 (d, J = 2.3
Hz, 1H), 4.96 (m, 1H), 3.79
(m, 4H), 3.66 (m, 1H), 3.3 (m,
4H), 2.14 - 1.95 (m, 2H), 1.81
(m, 5H).
1H NMR (300 MHz, DMSO-
d6) 6 8.72 (d, J = 1.9 Hz, 1H),
8.58 (d, J = 1.9 Hz, 1H), 7.54
(d, J = 8.6 Hz, 1H), 7.14 (d, J
= 2.4 Hz, 1H), 6.83 (d, J = 2.3
394 Hz, 1H), 6.48 (d, J = 7.7 Hz,
1H), 6.30 — 6.18 (m, 2H), 4.92
(m, 1H), 3.79 (m, 4H), 3.74 (s,
3H), 3.66 (s, 3H), 3.55 (m,
1H), 3.34 (m, 4H), 2.03 (m,
2H), 1.78 (m, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.53 (d, J = 2.0
Hz, 1H), 7.13 (d, J = 5.3 Hz,
1H), 6.84 (dd, J = 20.0, 2.4
395 441 .2 Hz, 2H), 5.40 (d, J = 8.2 Hz,
1H), 4.72 (s, 1H), 4.31 (d, J =
7.0 Hz, 1H), 3.83 (dd, J = 5.8,
3.8 Hz, 4H), 3.26 (t, J = 4.9
Hz, 4H), 2.14 (d, J = 12.3 Hz,
2H), 1.95 - 1.68 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 7.72 (d, J = 2.9 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
396 455.2 6.81 (d, J = 2.5 Hz, 1H), 5.03
(d, J = 7.8 Hz, 1H), 4.71 (s,
1H), 4.16 (s, 2H), 3.83 (q, J =
3.9, 3.1 Hz, 7H), 3.32 - 3.21
(m, 4H), 2.13 (d, J = 11.2 Hz,
2H), 1.83 (t, J = 6.5 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.89 (d, J = 5.8 Hz,
1H), 7.02 - 6.88 (m, 2H), 5.79
(d, J = 5.7 Hz, 1H), 4.80 (s,
1H), 4.61 (s, 2H), 4.08 - 3.88
(m, 5H), 3.35 (dd, J = 5.6, 4.1
Hz, 4H), 2.27 - 2.09 (m, 2H),
1.91 (d, J = 5.0 Hz, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 8.38 (s, 1H), 6.94 -
6.74 (m, 2H), 4.69 (s, 1H),
398 4.34 (s, 1H), 4.25 (s, 1H),
3.84 (dd, J = 5.9, 3.8 Hz, 4H),
3.30 - 3.14 (m, 6H), 2.79 (d, J
= 5.7 Hz, 2H), 2.71 (d, J = 5.6
Hz, 2H), 2.49 (s, 3H), 2.13 (m,
2H), 1.85 (d, J = 5.5 Hz, 6H).
1H NMR (300 MHz, CDCI3) 6
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J :19 Hz, 1H), 8.08 (d, J
= 6.3 Hz, 1H), 6.96 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.4 Hz,
399 1H), 6.23 (d, J = 6.3 Hz, 1H),
4.87 (s, 1H), 4.69 (s, 1H),
4.00 — 3.83 (m, 4H), 3.45 —
3.24 (m, 4H), 2.98 (s, 3H),
2.50 (s, 3H), 2.45 — 2.30 (m,
2H), 1.92 — 1.64 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 6.94 (dd, J = 19.8,
400 2.4 Hz, 2H), 5.09 (s, 1H), 4.81
(s, 1H), 4.01 - 3.88 (m, 4H),
3.42 - 3.29 (m, 4H), 2.91 (d, J
= 4.8 Hz, 3H), 2.18 (m, 2H),
1.90 (s, 6H).
WO 59690
Compound ESMS H NMR
Compound Structure
1H NMR (300 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 7.51 (s,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.56
401 471.32
(d, J = 8.0 Hz, 1H), 4.75 (s,
1H), 4.25 (s, 1H), 3.96 — 3.89
(m, 4H), 3.88 (s, 3H), 3.47 —
3.23 (m, 4H), 2.29 — 2.06 (m,
2H), 2.06 — 1.78 (m, 6H).
1H NMR (300 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 8.14 (s,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.5 Hz, 1H), 5.52
402 471.36
(d, J = 8.6 Hz, 1H), 4.79 (s,
1H), 4.18 (s, 1H), 3.96 — 3.89
(m, 4H), 3.89 (s, 3H), 3.41 —
3.27 (m, 4H), 2.31 — 2.14 (m,
2H), 2.03 — 1.83 (m, 6H).
1H NMR (300 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 6.95 (d, J
= 2.4 Hz, 1H), 6.89 (d, J = 2.5
Hz, 1H), 4.77 (s, 1H), 4.68 (d,
403 463.4 J = 8.4 Hz, 1H), 4.58 (t, J =
9.1 Hz, 2H), 4.25 (s, 1H), 3.98
— 3.84 (m, 4H), 3.40 — 3.27 (m,
4H), 3.19 (t, J = 9.0 Hz, 2H),
2.49 (s, 3H), 2.25 — 2.10 (m,
2H), 2.00 — 1.82 (m, 6H).
nd ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.57 (d, J = 1.9 Hz, 1H), 7.69
(s, 1H), 7.15 (d, J = 2.5 Hz,
404 480.56 1H), 7.01 (s, 1H), 6.84 (d, J =
2.3 Hz, 1H), 4.94 (m, 1H),
3.75 (m, 8H), 3.34 (m, 4H),
2.05 (m, 2H), 1.86 — 1.70 (m,
6H).
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.57 (d, J = 1.9 Hz, 1H), 8.01
(m, 1H), 7.14 (s, 1H), 7.01 —
6.90 (m, 1H), 6.82 (m, 2H),
405 480.56
6.71 (m, 1H), 5.70 (d, J = 7.9
Hz, 1H), 4.91 (m, 1H), 3.79
(m, 4H), 3.34 (m, 5H), 2.74 (d,
J = 4.6 Hz, 3H), 2.02 (m, 2H),
1.76 (m, 6H).
1H NMR (300 MHz, DMSO-
d6) 5 8.72 (d, J = 1.9 Hz, 1H),
8.58 (d, J = 1.9 Hz, 1H), 8.27
(d, J = 5.2 Hz, 1H), 7.46 (dd, J
= 8.4, 7.1 Hz, 1H), 7.15 (d, J =
2.4 Hz, 1H), 7.10 (dd, J = 7.1,
0.9 Hz, 1H), 6.83 (d, J = 2.3
406 463.68
Hz, 1H), 6.75 (d, J = 7.8 Hz,
1H), 6.68 (dd, J = 8.4, 0.9 Hz,
1H), 4.91 (m, 1H), 4.14 (m,
1H), 3.80 (m, 4H), 3.35 (m,
4H), 2.82 (d, J = 4.9 Hz, 3H),
2.03 (m, 2H), 1.93 — 1.73 (m,
6H .
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) rotomers, 6
9.07 (m, 1H), 8.89 (m, 1H),
8.75 (m, 1H), 7.47 (m, 1H),
407 536.49
6.96 (s, 1H), 4.95 (m, 1H),
3.97 (m, 4H), 3.82 (m, 4H),
3.38 (s, 3H), 2.24 (m, 8H),
1.60 (s, 9H).
1H NMR (300 MHz, DMSO-
d6) 6 8.72 (d, J :19 Hz, 1H),
8.57 (d, J :19 Hz, 1H), 7.13
(d, J = 2.4 Hz, 1H), 6.94 (t, J =
8.0 Hz, 1H), 6.83 (d, J = 2.3
408 435.6 Hz, 1H), 6.26 — 6.14 (m, 2H),
6.10 — 6.03 (m, 1H), 5.57 (d, J
= 7.8 Hz, 1H), 4.90 (m, 1H),
3.79 (m, 4H), 3.66 (s, 3H),
3.33 (m, 4H), 2.03 (m, 2H),
1.77 (m, 6H).
1H NMR (300 MHz, CDCI3) 6
8.70 (d, J = 1.9 Hz, 1H), 8.63
(d, J =1.9 Hz, 1H), 8.47 (s,
1H), 8.18 (s, 1H), 6.96 (d, J =
2.4 Hz, 1H), 6.91 (d, J = 2.4
409 Hz, 1H), 5.47 (d, J = 7.6 Hz,
1H), 4.80 (s, 1H), 4.31 — 4.19
(m, 1H), 4.02 — 3.79 (m, 4H),
3.48 — 3.24 (m, 4H), 2.32 —
2.17 (m, 2H), 2.09 — 1.79 (m,
6H).
nd ESMS
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
2.0 Hz, 1H), 8.59 (d, J :19
Hz, 1H), 6.94 (d, J = 2.5 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
4.73 (d, J = 5.5 Hz, 1H), 4.49 -
4.19 (m, 2H), 4.03 - 3.87 (m,
410 4H), 3.81 (q, J = 6.6 Hz, 1H),
3.44 - 3.25 (m, 4H), 2.99 (t, J
= 6.3 Hz, 2H), 2.13 (q, J = 7.5,
.0 Hz, 2H), 1.99 - 1.57 (m,
11H), 1.42 (dqd, J = 10.0, 7.1,
6.7, 3.4 Hz, 1H), 1.20 (tt, J =
17.8, 10.5 Hz, 3H), 0.91 (q, J
= 12.1 Hz, 2H
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 6.94 (d, J = 2.5 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
4.70 (d, J = 2.6 Hz, 1H), 4.41
(d, J = 7.7 Hz, 1H), 3.97 - 3.81
(m, 4H), 3.41 - 3.25 (m, 4H),
2.91 (s, 6H), 2.15 (d, J = 9.2
Hz, 2H), 1.98 - 1.71 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 6.90 (dd, J = 21.6,
2.5 Hz, 2H), 4.72 (s, 1H), 4.48
(d, J = 7.9 Hz, 1H), 4.04 - 3.82
(m, 4H), 3.78 - 3.62 (m, 4H),
3.34 (dt, J = 5.0, 3.2 Hz, 8H),
2.15 (s, 2H), 1.84 (d, J = 4.8
Hz, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 ,8.61 (d, J = 2.0
Hz, 1H), 6.94 (d, J = 2.5 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
413 4.71 (d, J = 5.4 Hz, 1H), 4.37
(d, J = 7.9 Hz, 1H), 3.99 - 3.81
(m, 4H), 3.44 - 3.09 (m, 8H),
2.24 - 2.06 (m, 2H), 1.94 -
1.73 (m, 6H), 1.15 (t, J = 7.1
Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 6.94 (d, J = 2.5 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
414 4.72 (d, J = 5.6 Hz, 1H), 4.50
(d, J = 7.6 Hz, 1H), 4.02 - 3.80
(m, 4H), 3.49 - 3.18 (m, 8H),
2.41 (t, J = 5.1 Hz, 4H), 2.32
(s, 3H), 2.22 - 2.05 (m, 2H),
1.95 - 1.75 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 6.94 (d, J = 2.5 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
4.70 (s, 1H), 4.24 (d, J = 7.9
Hz, 1H), 4.02 - 3.82 (m, 5H),
3.44 - 3.23 (m, 8H), 2.61 (s,
1H), 2.26 - 2.06 (m, 2H), 1.99
- 1.73 (m, 9H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 6.94 (d, J = 2.4 Hz,
1H), 6.87 (d, J = 2.5 Hz, 1H),
416 4.70 (d, J = 4.4 Hz, 1H), 4.48
(d, J = 7.6 Hz, 1H), 4.03 - 3.80
(m, 5H), 3.49 (d, J = 4.2 Hz,
2H), 3.45 - 3.17 (m, 8H), 2.23
- 2.04 (m, 2H), 2.02 - 1.73 (m,
6H), 1.56 - 1.49 (m, 4H).
1H NMR (300 MHz,
Chloroform-d) 6 8.81 - 8.55
(m, 3H), 6.94 (dd, J = 17.2,
2.5 Hz, 2H), 6.65 (d, J =1.1
417 Hz, 1H), 4.84 (td, J = 5.1, 2.4
Hz, 1H), 4.01 - 3.86 (m, 4H),
3.42 - 3.29 (m, 4H), 2.35 -
2.11 (m, 2H), 2.05 - 1.82 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.49 (d, J = 4.9 Hz,
1H), 7.04 - 6.89 (m, 2H), 6.81
418 (d, J = 4.9 Hz, 1H), 5.54 (d, J
= 7.9 Hz, 1H), 4.80 (d, J = 5.2
Hz, 1H), 4.17 - 3.98 (m, 1H),
3.98 - 3.87 (m, 4H), 3.42 -
3.31 (m, 4H), 2.33 - 2.12 (m,
2H), 2.06 - 1.72 (m, 6H).
Compound ESMS H NMR
“d St“‘6 ”ret
1H NMR (300 MHz,
Chloroform-d) rotomers 6 8.82
(d, J = 2.9 Hz, 1H), 8.74 (m,
1H), 8.00 (m, 1H), 7.55 - 7.47
(m, 1H), 7.25 (m, 1H), 7.14
(m, 1H), 7.05 (m, 1H), 3.97
(m, 5H), 3.47 (m, 5H), 2.30 (s,
2H), 2.0 (m, 6H)..
1H NMR (300 MHz, DMSO-
d6) 5 8.73 (d, J :19 Hz, 1H),
8.58 (d, J = 2.0 Hz, 1H), 7.27 —
6.96 (m, 4H), 6.83 (d, J = 2.3
Hz, 1H), 4.92 (m, 1H), 3.85 —
3.74 (m, 4H), 3.45 (m, 1H),
3.34 (m, 4H), 2.05 (m, 2H),
1.76 (m, 6H).
1H NMR (300 MHz, DMSO-
d6) 6 8.93 (d, J = 1.8 Hz, 1H),
8.80 (d, J = 1.8 Hz, 1H), 7.20
(s, 1H), 7.13 - 6.85 (m, 4H),
4.92 (m, 1H), 3.86 - 3.79 (m,
4H), 3.32 (m, 5H), 2.09 (m,
2H), 1.90 - 1.73 (m, 6H), 1.55
(s, 9H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.72 - 8.52
(m, 3H), 8.38 (s, 1H), 6.87
(dd, J = 15.7, 2.5 Hz, 2H),
.50 (d, J = 7.9 Hz, 1H), 4.79
422 432.5
(p, J = 3.5 Hz, 1H), 4.20 (dp, J
= 14.0, 5.2, 4.7 Hz, 1H), 3.90 -
3.76 (m, 4H), 3.32 - 3.22 (m,
4H), 2.29 - 2.07 (m, 2H), 1.99
- 1.71 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.74 (d, J =
1.9 Hz, 1H), 8.65 (s, 1H), 8.01
(s, 1H), 7.05 - 6.88 (m, 2H),
4.87 (s, 1H), 3.95 (d, J = 4.7
423 481 .3
Hz, 4H), 3.77 - 3.56 (m, 1H),
3.37 (dd, J = 5.8, 3.8 Hz, 4H),
3.11 (qd, J = 7.4, 4.2 Hz,1H),
2.28 (s, 2H), 1.98 (dd, J =
22.7, 9.4 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.52 (d, J :19
Hz, 1H), 8.46 - 8.35 (m, 1H),
6.84 (dd, J = 16.8, 2.5 Hz,
424 437.3 2H), 6.28 - 6.20 (m, 1H), 5.08
(s, 1H), 4.72 (d, J = 5.2 Hz,
1H), 4.58 - 4.43 (m, 2H), 3.93
- 3.77 (m, 4H), 3.34 - 3.19 (m,
4H), 2.14 (dd, J = 9.6, 5.4 Hz,
2H), 1.93 - 1.73 (m, 6H).
nd ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.68 (d, J =
2.0 Hz, 1H), 8.59 (d, J = 2.0
Hz, 1H), 6.93 (d, J = 2.5 Hz,
1H), 6.86 (d, J = 2.5 Hz, 1H),
425 4.72 (s, 1H), 4.20 (s, 1H),
4.11 (s, 1H), 3.98 - 3.85 (m,
4H), 3.78 (s, 1H), 3.40 - 3.24
(m, 4H), 2.14 (d, J = 9.2 Hz,
2H), 1.81 (t, J = 6.3 Hz, 6H),
1.33 (s, 9H).
1H NMR (300 MHz,
Chloroform-d) 6 9.26 (m, 2H),
8.90 (m, 1H), 8.79 - 8.64 (m,
426 2H), 7.22 - 7.01 (m, 3H), 4.97
(m, 1H), 4.01 - 3.87 (m, 4H),
3.38 (m, 5H), 2.77 (s, 3H),
2.19 (m, 9H).
1H NMR (300 MHz,
Chloroform-d) 6 8.94 - 8.63
(m, 2H), 8.07 (d, J = 2.8 Hz,
1H), 7.45 (d, J = 8.7 Hz, 1H),
7.14 - 6.87 (m, 3H), 4.84 (m,
1H), 3.99 - 3.87 (m, 4H), 3.62
- 3.48 (m, 1H), 3.35 (dt, J =
42.8, 4.8 Hz, 4H), 2.32 - 2.14
(m, 2H), 1.91 (d, J = 17.8 Hz,
6H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.81 - 8.64
(m, 2H), 8.20 (s, 2H), 7.08 (d,
J = 2.4 Hz, 1H), 6.94 (d, J =
428 475.41 2.4 Hz, 1H), 4.90 - 4.82 (m,
1H), 4.42 (m, 1H), 3.98 - 3.88
(m, 4H), 3.57 (m, 1H), 3.45 -
3.26 (m, 4H), 2.33 - 2.18 (m,
2H), 2.04 - 1.82 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
2.0 Hz, 1H), 8.63 (d, J = 2.0
Hz, 1H), 8.42 (m, 1H), 8.16 -
8.08 (m, 1H), 7.20 (s, 1H),
429 7.04 - 6.98 (m, 1H), 6.94 (d, J
= 2.4 Hz, 1H), 4.84 (m, 1H),
4.01 - 3.87 (m, 4H), 3.54 (m,
1H), 3.42 - 3.26 (m, 4H), 2.33
- 2.19 (m, 2H), 2.08 - 1.80 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.15 (s, 2H), 7.03 -
6.85 (m, 2H), 5.09 (d, J = 8.1
430 Hz, 1H), 4.78 (s, 1H), 3.92
(dd, J = 5.9, 3.7 Hz, 5H), 3.40
- 3.24 (m, 4H), 2.71 - 2.33 (m,
8H), 2.30 (s, 3H), 2.20 (s, 2H),
1.91 (d, J = 5.0 Hz, 6H), 1.26
(d, J = 3.1 Hz, 4H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.15 (s, 2H), 6.99 -
6.86 (m, 2H), 5.10 (d, J = 8.1
431 478.47 Hz, 1H), 4.79 (d, J = 5.9 Hz,
1H), 4.09 - 3.85 (m, 5H), 3.41
- 3.25 (m, 4H), 2.68 - 2.51 (m,
2H), 2.52 - 2.37 (m, 2H), 2.28
(s, 6H), 2.19 (q, J = 6.2, 5.8
Hz, 2H), 2.02 - 1.81 (m, 6H).
1H NMR (300 MHz,
form-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.16 (s, 2H), 6.98 -
6.86 (m, 2H), 5.10 (d, J = 8.1
432 504.44
Hz, 1H), 4.78 (s, 1H), 4.08 -
3.83 (m, 5H), 3.39 - 3.27 (m,
4H), 2.60 (d, J = 16.9 Hz, 8H),
2.19 (d, J = 7.8 Hz, 2H), 2.01 -
1.74 (m, 10H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.15 (s, 2H), 6.99 -
6.85 (m, 2H), 5.09 (d, J = 8.1
Hz, 1H), 4.78 (s, 1H), 4.06 -
433 518.72
3.85 (m, 5H), 3.40 - 3.27 (m,
4H), 2.67 - 2.55 (m, 2H), 2.47
(d, J = 9.1 Hz, 6H), 2.19 (d, J
= 9.6 Hz, 2H), 1.91 (d, J = 4.8
Hz, 6H), 1.62 (d, J = 5.5 Hz,
6H).
Compound ESMS H NMR
“d St“‘6 ”et
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 8.16 (s, 2H), 6.99 -
6.84 (m, 2H), 5.11 (d, J = 8.1
434 520.47 Hz, 1H), 4.78 (s, 1H), 4.05 -
3.87 (m, 5H), 3.78 - 3.66 (m,
4H), 3.40 - 3.27 (m, 4H), 2.69
- 2.43 (m, 8H), 2.19 (d, J = 8.2
Hz,2H), 1.91 (d, J = 4.8 Hz,
6H).
1H NMR (400 MHz, CDCI3) 6
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 7.68 (d, J
= 2.1 Hz, 1H), 6.96 (d, J = 2.4
Hz, 1H), 6.91 (d, J = 2.4 Hz,
1H), 6.76 (d, J = 2.2 Hz, 1H),
435 461.37
.21 (d, J = 8.4 Hz, 1H), 4.86 —
4.76 (m, 1H), 4.45 — 4.33 (m,
1H), 3.98 — 3.84 (m, 4H), 3.39
— 3.25 (m, 4H), 2.59 (s, 3H),
2.31 — 2.16 (m, 2H), 2.06 —
1.89 (m, 6H).
1H NMR (400 MHz, CDCI3) 6
8.70 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 6.95 (d, J
= 2.4 Hz, 1H), 6.90 (d, J = 2.4
Hz, 1H), 4.88 — 4.70 (m, 2H),
436 449.44
4.32 (s, 1H), 3.98 — 3.85 (m,
4H), 3.41 — 3.27 (m, 4H), 2.53
(s, 3H), 2.40 (s, 3H), 2.26 —
2.14 (m, 2H), 1.99 (s, 3H),
1.94 — 1.88 (m, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.72 (d, J =
2.0 Hz, 1H), 8.65 (d, J :19
Hz, 1H), 8.31 (s, 1H), 7.02 -
6.88 (m, 2H), 6.77 (d, J = 2.6
437 Hz, 1H), 5.42 (d, J = 8.1 Hz,
1H), 4.90 - 4.78 (m, 1H), 4.42
(d, J = 7.8 Hz, 1H), 3.99 - 3.85
(m, 4H), 3.43 - 3.27 (m, 4H),
2.37 - 2.13 (m, 2H), 2.10 -
1.88 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.72 (d, J =
2.0 Hz, 1H), 8.64 (d, J = 1.9
Hz, 1H), 8.28 (s, 1H), 7.72 (s,
1H), 6.94 (dd, J = 16.4, 2.5
438 Hz, 2H), 5.45 (d, J = 8.2 Hz,
1H), 4.76 (d, J = 6.6 Hz, 1H),
4.26 (s, 1H), 4.01 - 3.85 (m,
7H), 3.44 - 3.28 (m, 4H), 2.30
- 2.11 (m, 2H), 2.08 - 1.82 (m,
6H).
1H NMR (400 MHz, CDCI3) 5
8.71 (d, J = 1.8 Hz, 1H), 8.63
(d, J = 1.8 Hz, 1H), 8.14 (d, J
= 5.9 Hz, 1H), 6.98 (d, J = 2.4
Hz, 1H), 6.17 (d, J = 6.0 Hz,
1H), 5.05 (s, 1H), 4.01 — 3.70
(m, 5H), 3.42 — 3.25 (m, 4H),
2.77 (q, J = 7.6 Hz, 2H), 2.32 —
2.16 (m, 2H), 2.04 — 1.80 (m,
6H), 1.32 (t, J = 7.6 Hz, 3H).
WO 59690
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 7.81 (d, J = 6.3 Hz,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.6 Hz, 1H), 6.24
440 436.22
(d, J = 6.2 Hz, 1H), 5.92 (s,
1H), 4.80 (m, 1H), 3.98 (s,
3H), 3.95 - 3.87 (m, 4H), 3.54
(m, 1H), 3.38 - 3.28 (m, 4H),
2.23 (m, 2H), 2.00 - 1.81 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) rotomers, 6
8.80 (d, 1H), 8.73 (d, 1H),
7.73 (s, 1H), 7.16 - 6.99 (m,
441 434.35
3H), 4.91 (m, 1H), 3.95 (m,
4H), 3.55 (m, 1H), 3.37 (m,
4H), 2.73 (s, 3H), 2.41 (s, 3H),
2.29 (m, 2H), 2.13 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.89 (dd, J = 5.0, 1.4
Hz, 1H), 7.19 - 7.10 (m, 1H),
442 420.4 7.03 - 6.95 (m, 2H), 6.92 (d, J
= 2.6 Hz, 1H), 4.80 (m, 1H),
3.96 - 3.87 (m, 4H), 3.79 (m,
1H), 3.51 (m, 1H), 3.38 - 3.29
(m, 4H), 2.51 (m, 3H), 2.25
(m, 2H), 2.00 - 1.87 (m, 6H).
WO 59690
Compound ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.01 (s, 1H), 7.89 (d,
J = 4.8 Hz, 1H), 7.03 (d, J =
443 420.36 4.8 Hz, 1H), 6.96 (d, J = 2.4
Hz, 1H), 6.91 (d, J = 2.5 Hz,
1H), 4.78 (m, 1H), 3.98 - 3.86
(m, 4H), 3.61 (m, 2H), 3.39 -
3.28 (m, 4H), 2.30 - 2.15 (m,
5H), 1.93 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 8.03 (dd, J = 2.7, 0.9
Hz, 1H), 7.12 - 7.00 (m, 2H),
444 420.28 6.95 (d, J = 2.5 Hz, 1H), 6.90
(d, J = 2.5 Hz, 1H), 4.79 (m,
1H), 4.08 - 3.87 (m, 5H), 3.49
(m, 1H), 3.38 - 3.28 (m, 4H),
2.53 (s, 3H), 2.21 (m, 2H),
1.84 (d, J = 6.8 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.65 (m, 1H),
8.40 (m, 1H), 7.50 (dd, J =
4.5, 2.2 Hz, 1H), 7.03 (s, 1H),
445 6.92 (s, 1H), 6.80 (m, 2H),
4.76 (m, 1H), 4.08 (s, 3H),
3.93 (m, 5H), 3.49 (m, 1H),
3.42 - 3.30 (m, 4H), 2.20 (m,
2H), 1.92 (m, 6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.60 (d, J :19
Hz, 1H), 7.71 (d, J = 2.4 Hz,
1H), 7.65 (d, J = 2.4 Hz, 1H),
6.96 (d, J = 2.4 Hz, 1H), 6.90
(d, J = 2.4 Hz, 1H), 6.55 (t, J =
2.4 Hz, 1H), 4.79 (m, 1H),
4.13 (m, 1H), 3.92 (m, 4H),
3.85 (s, 3H), 3.48 (m, 1H),
3.38 - 3.29 (m, 4H), 2.22 (m,
2H), 1.98 - 1.88 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.60 (d, J = 2.0
Hz, 1H), 7.70 (s, 1H), 7.15 (m,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.92 (m, 1H), 6.64 (d, J = 8.8
Hz, 1H), 4.80 (m, 1H), 3.90
(m, 7H), 3.45 - 3.26 (m, 5H),
2.24 - 2.12 (m, 2H), 1.98 -
1.81 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.78 (dd, J =
4.0, 2.0 Hz, 1H), 8.66 (d, J =
2.1 Hz, 1H), 8.55 (s, 1H), 8.06
(s, 1H), 7.02 (d, J = 2.5 Hz,
1H), 6.96 (d, J = 2.5 Hz, 1H),
4.88 (m, 1H), 3.93 (m, 4H),
3.55 (m, 1H), 3.40 (m, 4H),
3.29 (m, 1H), 2.58 (s, 3H),
2.28 (m, 2H), 2.07 (m, 6H).
Compound ESMS H NMR
1H NMR (300 MHz,
form-d) rotomers, 6
8.85 (d, 1H), 8.67 d, 1H), 7.92
(d, 1H), 7.07 - 6.96 (m, 2H),
449 43535
4.91 (m, 1H), 4.01 - 3.88 (m,
4H), 3.53 - 3.24 (m, 5H), 2.87
(s, 3H), 2.64 (s, 3H), 2.04 -
1.76 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 7.21 (d, J = 9.2 Hz,
450 1H), 6.99 - 6.87 (m, 3H), 4.87
(m, 1H), 3.98 - 3.82 (m, 5H),
3.39 - 3.29 (m, 4H), 2.51 (s,
3H), 2.30 - 2.22 (m, 2H), 2.11
- 1.84 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) rotomers, 6
8.92 (d, J = 1.8 Hz, 1H), 8.77
(d, J :18 Hz, 1H), 8.30 (m,
451 2H), 7.02 - 6.90 (m, 2H), 4.86
(m, 1H), 3.94 (m, 4H), 3.52 -
3.26 (m, 5H), 2.78 (s, 3H),
2.26 (d, J = 11.8 Hz, 2H), 1.90
(m, 6H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 6.95 (d, J
= 2.4 Hz, 1H), 6.89 (d, J = 2.4
Hz, 1H), 5.01 (s, 2H), 4.91 (t,
452 463.35 J = 2.5 Hz, 2H), 4.79 (s, 1H),
4.49 (s, 1H), 4.16 (s, 1H),
3.99 — 3.82 (m, 4H), 3.40 —
3.25 (m, 4H), 2.53 (s, 3H),
2.29 — 2.15 (m, 2H), 1.96 —
1.80 (m, 6H).
1H NMR (300 MHz, CDCI3) 5
8.69 (s, 1H), 8.62 (s, 1H),
7.89 (d, J = 5.9 Hz, 1H), 6.94
(s, 1H), 6.89 (s, 1H), 5.64 (d,
453 450.43 J = 6.0 Hz, 1H), 4.87 — 4.66
(m, 2H), 3.98 — 3.83 (m, 4H),
3.44 — 3.24 (m, 4H), 3.13 (s,
6H), 2.26 — 2.10 (m, 2H), 2.04
— 1.75 (m, 6H).
1H NMR (300 MHz, CDCI3) 5
8.61 (d, J = 1.8 Hz, 1H), 8.52
(d, J = 1.9 Hz, 1H), 7.69 (s,
1H), 6.86 (d, J = 2.4 Hz, 1H),
6.80 (d, J = 2.2 Hz, 1H), 5.62
454 436.34 (d, J = 6.0 Hz, 1H), 4.83 (s,
1H), 4.69 (s, 1H), 3.91 — 3.74
(m, 4H), 3.36 — 3.10 (m, 4H),
2.86 (d, J = 5.0 Hz, 3H), 2.22 —
2.03 (m, 2H), 1.91 — 1.72 (m,
6H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.05 (d, J
= 5.2 Hz, 1H), 6.94 (d, J = 2.5
Hz, 1H), 6.89 (d, J = 2.5 Hz,
1H), 6.39 (d, J = 5.2 Hz, 1H),
455 447.41
.13 (bd, 1H), 4.76 (s, 1H),
4.10 — 3.96 (m, 1H), 3.95 —
3.83 (m, 4H), 3.40 — 3.24 (m,
4H), 2.26 — 2.09 (m, 2H), 1.97
— 1.76 (m, 7H), 1.10 — 1.00 (m,
2H), 1.00 — 0.91 (m, 2H).
1H NMR (300 MHz, CDCI3) 5
8.72 (d, J = 1.9 Hz, 1H), 8.64
(d, J = 1.9 Hz, 1H), 8.23 (d, J
= 1.8 Hz, 1H), 6.97 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.4 Hz,
1H), 5.04 (d, J = 7.6 Hz, 1H),
456 465.29
4.81 (s, 1H), 4.21 (s, 1H),
4.02 — 3.82 (m, 4H), 3.44 —
3.26 (m, 4H), 2.33 — 2.10 (m,
3H), 2.06 — 1.82 (m, 6H), 1.19
— 1.11 (m, 2H), 1.06 — 0.97 (m,
2H).
1H NMR (300 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 8.21 (d, J
= 51H NMR (300 MHz,
CDCI3) 5 8.69 (d, J = 1.9 Hz,
1H), 8.62 (d, J = 1.9 Hz, 1H),
8.21 (d, J = 5.1 Hz, 1H), 6.95
(d, J = 2.5 Hz, 1H), 6.90 (d, J
457 437.38
= 2.5 Hz, 1H), 6.45 (d, J = 5.1
Hz, 1H), 5.33 (d, J = 7.6 Hz,
1H), 4.85 — 4.74 (m, 1H), 4.56
(s, 2H), 4.12 — 4.00 (m, 1H),
3.95 — 3.86 (m, 4H), 3.66 (s,
1H), 3.39 — 3.27 (m, 4H), 2.18
(dd, J = 14.1, 8.4 Hz, 2H),
2.01 — 1.83 m, 6H.
WO 59690
1H NMR (300 MHz, CDCI3) 5
8.97 (s, 2H), 8.69 (d, J = 1.9
Hz, 1H), 8.62 (d, J = 1.9 Hz,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.91 (d, J = 2.4 Hz, 1H), 5.54
458 489.41 (d, J = 8.0 Hz, 1H), 4.81 (s,
1H), 4.38 (s, 3H), 4.16 — 4.05
(m, 1H), 4.00 — 3.81 (m, 4H),
3.42 — 3.23 (m, 4H), 2.29 —
2.15 (m, 2H), 2.05 — 1.83 (m,
6H).
1H NMR (300 MHz, CDCI3) 5
8.80 — 8.64 (m, 3H), 8.62 (d, J
= 1.9 Hz, 1H), 6.97 (d, J = 2.4
Hz, 1H), 6.91 (d, J = 2.4 Hz,
1H), 5.69 (d, J = 7.6 Hz, 1H),
459 48941
4.82 (s, 1H), 4.18 (s, 3H),
4.15-4.06 (m, 1H), 4.01 —
3.83 (m, 4H), 3.44 — 3.24 (m,
4H), 2.32 — 2.18 (m, 2H), 2.07
— 1.84 (m, 6H).
1H NMR (300 MHz, CDCI3) 5
9.02 (s, 2H), 8.84 (d, J = 2.0
Hz, 1H), 8.66 (d, J = 2.0 Hz,
1H), 7.01 (d, J = 2.3 Hz, 1H),
6.94 (d, J = 2.4 Hz, 1H), 5.90
460 47537
(d, J = 7.1 Hz, 1H), 4.74 (s,
1H), 4.13 (s, 1H), 4.04 — 3.88
(m, 4H), 3.45 — 3.32 (m, 4H),
2.06 (d, J = 7.5 Hz, 2H), 1.96 —
1.84 (m, 6H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3) 5
8.72 (d, J = 1.9 Hz, 1H), 8.64
(d, J = 1.9 Hz, 1H), 8.59 (s,
1H), 8.54 (bd, 1H), 7.37 (d, J
= 4.9 Hz, 1H), 6.97 (d, J = 2.5
461 Hz, 1H), 6.93 (d, J = 2.1 Hz,
1H), 5.55 (bd, 1H), 4.83 (s,
1H), 4.14 (s, 1H), 4.00 — 3.89
(m, 4H), 3.42 — 3.29 (m, 4H),
2.30 — 2.18 (m, 2H), 1.96 (s,
6H).
1H NMR (300 MHz, CDCI3) 5
8.69 (d, J = 2.5 Hz, 3H), 8.62
(d, J = 1.9 Hz, 1H), 7.62 (d, J
= 2.3 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.91 (d, J = 2.4 Hz,
462 1H), 6.52 (d, J = 2.1 Hz, 1H),
.37 (d, J = 7.9 Hz, 1H), 4.86 —
4.75 (m, 1H), 4.14 — 4.01 (m,
1H), 3.99 — 3.83 (m, 4H), 3.41
— 3.26 (m, 4H), 2.28 — 2.15 (m,
2H), 2.01 — 1.86 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 6.95 (d, J
= 2.4 Hz, 1H), 6.90 (d, J = 2.4
Hz, 1H), 4.95 (d, J = 7.1 Hz,
463 1H), 4.78 (s, 1H), 4.23 (d, J =
3.8 Hz, 1H), 3.99 — 3.82 (m,
4H), 3.42 — 3.25 (m, 4H), 2.45
(d, J = 0.6 Hz, 3H), 2.30 (d, J
= 2.8 Hz, 3H), 2.26 — 2.14 (m,
2H), 1.99 — 1.86 (m, 6H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz, CDCI3) 6
8.69 (d, J = 1.9 Hz, 1H), 8.62
(d, J =19 Hz, 1H), 8.22 (s,
1H), 6.94 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 4.78
464 449.35 (d, J = 7.8 Hz, 2H), 4.62 (t, J =
9.1 Hz, 2H), 4.23 (s, 1H), 3.97
— 3.85 (m, 4H), 3.40 — 3.30 (m,
4H), 3.25 (t, J = 9.1 Hz, 2H),
2.27 — 2.11 (m, 2H), 2.01 —
1.82 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 7.86 (d, J = 2.7 Hz,
1H), 7.78 (s, 1H), 6.96 (d, J =
2.4 Hz, 1H), 6.90 (d, J = 2.5
465 420.19
Hz, 1H), 6.78 (t, J = 2.1 Hz,
1H), 4.78 (m, 1H), 4.00 - 3.86
(m, 4H), 3.50 (s, 1H), 3.38 -
3.28 (m, 4H), 2.28 (s, 3H),
2.25 - 2.14 (m, 2H), 1.95 -
1.85 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (m, 1H),
8.60 (d, J = 1.9 Hz, 1H), 8.20
(m, 1h), 7.93 (s, 1H), 6.97 -
466 6.89 (m, 3H), 4.77 (m, 1H),
3.92 m, 4H), 3.49 (m, 1H),
3.34 (m, 4H), 2.20 (m, 2H),
1.88 (d, J = 4.1 Hz, 6H), 1.70
(m, 4H).
nd ESMS H NMR
1H NMR (400 MHz, CDCI3) 6
8.68 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.95 (s,
1H), 6.94 (d, J = 2.5 Hz, 1H),
6.90 (d, J = 2.5 Hz, 1H), 5.00
467 (d, J = 7.9 Hz, 1H), 4.83 — 4.74
(m, 1H), 4.07 — 3.96 (m, 1H),
3.96 — 3.87 (m, 4H), 3.38 —
3.28 (m, 4H), 2.29 (s, 3H),
2.22 — 2.12 (m, 2H), 2.07 (s,
3H), 1.93 — 1.85 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 7.91 (d, J = 2.7 Hz,
1H), 7.73 (dd, J = 8.6, 0.7 Hz,
1H), 7.11 (dd, J = 8.6, 2.8 Hz,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.91 (d, J = 2.5 Hz, 1H), 5.11 -
.02 (m, 2H), 4.85 - 4.75 (m,
1H), 4.75 - 4.67 (m, 2H), 3.98
- 3.86 (m, 4H), 3.54 (s, 1H),
3.40 - 3.27 (m, 4H), 2.31 -
2.15 (m, 2H), 2.00 - 1.83 (m,
6H .
1H NMR (400 MHz, CDCI3) 6
8.69 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 8.03 (s,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 4.77
469 (s, 1H), 4.67 (s, 1H), 4.60 (s,
1H), 4.16 (s, 1H), 4.00 — 3.82
(m, 4H), 3.41 — 3.25 (m, 4H),
3.04 (d, J = 5.0 Hz, 3H), 2.28 —
2.11 (m, 2H), 1.99 — 1.84 (m,
6H).
Compound ESMS H NMR
C d St t
1H NMR (400 MHz, CDCI3) 6
8.69 (d, J :19 Hz, 1H), 8.63
(d, J :19 Hz, 1H), 7.88 (d, J
= 5.5 Hz, 1H), 7.61 (d, J = 2.1
Hz, 1H), 6.94 (d, J = 2.4 Hz,
1H), 6.91 (d, J = 2.4 Hz, 1H),
470 6.84 (d, J = 5.5 Hz, 1H), 6.70
(d, J = 2.1 Hz, 1H), 4.92 (s,
1H), 4.82 — 4.74 (m, 1H), 4.44
— 4.28 (m, 1H), 3.95 — 3.86 (m,
4H), 3.39 — 3.26 (m, 4H), 2.28
— 2.17 (m, 2H), 2.06 — 1.92 (m,
6H).
1H NMR (300 MHz,
form-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.54 (d, J = 2.0
Hz, 1H), 8.42 (s, 1H), 7.91 (d,
J = 13.5 Hz, 1H), 6.93 - 6.78
471 (m, 2H), 4.71 (s, 1H), 4.57 (d,
J = 7.9 Hz, 1H), 4.22 (s, 1H),
3.91 - 3.78 (m, 4H), 3.33 -
3.19 (m, 4H), 2.16 (d, J = 6.6
Hz, 2H), 1.96 (s, 3H), 1.91 -
1.77 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.54 (d, J =1.9
Hz, 1H), 8.10 (d, J = 0.8 Hz,
1H), 6.92 - 6.77 (m, 2H), 5.36
(dd, J = 7.9, 0.9 Hz, 1H), 4.71
472 (q, J = 5.2, 4.2 Hz, 2H), 3.97 -
3.69 (m, 7H), 3.58 - 3.37 (m,
4H), 3.30 - 3.03 (m, 6H), 2.22
- 2.04 (m, 2H), 1.93 - 1.73 (m,
6H), 1.52 (dtd, J = 12.8, 8.9,
3.8 Hz, 2H), 1.28 - 1.16 (m,
3H).
2014/024767
Compound ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
2.0 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 8.16 (s, 1H), 6.92
(dd, J = 15.4, 2.5 Hz, 2H),
4.77 (d, J = 5.4 Hz, 1H), 4.25 -
4.07 (m, 2H), 3.98 - 3.86 (m,
5H), 3.51 (dd, J = 9.3, 8.2 Hz,
2H), 3.40 - 3.29 (m, 5H), 2.92
(s, 3H), 2.87 - 2.71 (m, 2H),
2.19 (d, J = 7.1 Hz, 2H), 1.91
(t, J = 4.0 Hz, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.99 (d, J
= 1.5 Hz, 1H), 6.94 (d, J = 2.4
Hz, 1H), 6.89 (d, J = 2.4 Hz,
1H), 4.82 (d, J = 5.5 Hz, 1H),
4.77 (s, 1H), 4.15 (s, 1H),
3.96 — 3.85 (m, 4H), 3.76 —
3.65 (m, 4H), 3.38 — 3.26 (m,
4H), 2.59 — 2.45 (m, 4H), 2.34
(s, 3H), 2.27 — 2.13 (m, 2H),
1.96 — 1.85 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.60
(d, J = 1.9 Hz, 1H), 8.52 (s,
1H), 6.95 (d, J = 2.4 Hz, 1H),
6.89 (d, J = 2.4 Hz, 1H), 5.01
475 (d, J = 2.6 Hz, 2H), 4.98 — 4.89
(m, 2H), 4.80 (s, 1H), 4.54 (s,
1H), 4.22 (s, 1H), 3.95 — 3.86
(m, 4H), 3.39 — 3.27 (m, 4H),
2.29 — 2.16 (m, 2H), 1.98 —
1.84 (m, 6H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.63
(d, J = 1.9 Hz, 1H), 8.03 (d, J
=1.7 Hz, 1H), 6.97 (d, J = 2.5
Hz, 1H), 6.92 (d, J = 2.5 Hz,
1H), 5.18 — 5.04 (m, 1H), 4.80
(s, 1H), 3.99 — 3.90 (m, 5H),
3.40 — 3.32 (m, 4H), 2.36 (d, J
= 2.4 Hz, 3H), 2.23 — 2.15 (m,
2H), 1.95 — 1.85 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 8.26 (d, J
= 1.7 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.4 Hz,
477 1H), 5.07 (d, J = 7.2 Hz, 1H),
4.80 (s, 1H), 4.30 — 4.13 (m,
1H), 3.98 — 3.83 (m, 4H), 3.38
— 3.26 (m, 4H), 2.36 (d, J = 2.8
Hz, 3H), 2.29 — 2.16 (m, 2H),
1.97 — 1.85 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.64 (t, J = 9.6 Hz, 1H), 8.53
(d, J = 1.9 Hz, 1H), 8.02 (d, J
= 5.9 Hz, 1H), 6.89 (d, J = 2.4
Hz, 1H), 6.83 (d, J = 2.4 Hz,
478 1H), 6.07 (d, J = 6.0 Hz, 1H),
4.91 (s, 1H), 4.73 (s, 1H),
3.83 (dd, J =17.8, 12.9 Hz,
5H), 3.25 (dd, J =17.8, 13.0
Hz, 4H), 2.14 (dd, J = 8.9, 5.0
Hz, 2H), 1.91 — 1.76 (m, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.53 (d, J :19
Hz, 1H), 8.15 (s, 1H), 6.84
(dd, J = 17.3, 2.5 Hz, 2H),
479 4.70 (s, 1H), 4.55 (dd, J = 9.2,
8.3 Hz, 2H), 4.36 (s, 1H), 4.16
(s, 1H), 3.92 - 3.76 (m, 4H),
3.35 - 3.15 (m, 4H), 3.03 -
2.83 (m, 2H), 2.14 (s, 2H),
1.84 (d, J = 5.4 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
2.0 Hz, 1H), 8.61 (d, J = 1.9
Hz, 1H), 8.20 (d, J = 0.9 Hz,
1H), 6.93 (dd, J = 17.6, 2.5
Hz, 2H), 5.65 (d, J = 0.9 Hz,
480 1H), 5.54 - 5.38 (m, 1H), 4.97
(d, J = 8.0 Hz, 1H), 4.80 (s,
1H), 4.04 - 3.85 (m, 5H), 3.81
- 3.62 (m, 3H), 3.41 - 3.24 (m,
4H), 2.62 (s, 1H), 2.31 - 2.11
(m, 2H), 1.90 (dd, J = 8.0, 3.5
Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.18 (s, 2H), 6.99 -
6.87 (m, 2H), 5.16 (d, J = 8.1
481 Hz, 1H), 4.78 (s, 1H), 4.03 -
3.87 (m, 5H), 3.80 (t, J = 6.5
Hz, 2H), 3.39 - 3.29 (m, 4H),
2.67 (t, J = 6.5 Hz, 2H), 2.26 -
2.14 (m, 2H), 1.90 (t, J = 6.5
Hz, 6H).
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (400 MHz, CDCI3)6
8.68 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.65 (d, J
= 3.6 Hz, 1H), 6.94 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.4 Hz,
482 454.35
1H), 5.14 (s, 1H), 4.90 (s, 1H),
4.76 (s, 1H), 4.01 — 3.87 (m,
5H), 3.39 — 3.31 (m, 4H), 3.01
(d, J = 5.0 Hz, 3H), 2.23 — 2.12
(m, 2H), 1.99 — 1.81 (m, 6H).
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 1.98 (m, 6 H), 2.11
— 2.23 (m, 2 H), 2.29 (s, 6 H),
3.29 — 3.38 (m, 6 H), 3.89 —
483 464.3 3.94 (m, 4 H), 3.98 — 4.08 (m,
1 H), .82 (m, 1 H),
.21 (d, J = 7.9 Hz, 1 H), 6.61
(d, J = 5.1 Hz, 1 H), 6.90 (d, J
= 2.3 Hz, 1 H)
1H NMR (300 MHz, CDCI3):
ppm 1.79 — 1.98 (m, 6 H), 2.13
— 2.26 (m, 2 H), 2.34 (s, 3 H),
2.46 — 2.78 (m, 8 H), 3.28 —
484 3.38 (m, 4 H), 3.60 (s, 2 H),
3.78 — 3.98 (m, 5 H), 4.76 —
4.85 (m, 1 H), 5.10 (brs,1 H),
6.18 (d, J = 6.0 Hz, 1 H), 6.90
(d, J = 2.4 H
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 5
8.68 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 8.20 (s,
2H), 6.96 (d, J = 2.3 Hz, 1H),
485 6.90 (d, J = 2.4 Hz, 1H), 5.27
(d, J = 7.4 Hz, 1H), 4.79 (s,
1H), 4.01 — 3.84 (m, 5H), 3.40
— 3.25 (m, 4H), 2.25 — 2.12 (m,
2H), 1.97 — 1.82 (m, 6H).
1H NMR (400 MHz, CDCI3) 6
8.62 (d, J = 1.9 Hz, 1H), 8.54
(d, J = 1.9 Hz, 1H), 8.49 (s,
1H), 8.08 (d, J = 6.0 Hz, 1H),
6.89 (d, J = 2.5 Hz, 1H), 6.83
(d, J = 2.5 Hz, 1H), 6.24 (dd, J
= 6.0, 1.1 Hz, 1H), 4.88 (s,
1H), 4.78 - 4.67 (m, 1H), 3.87
- 3.82 (m, 4H), 3.25 (dd, J =
13.6, 8.8 Hz, 4H), 2.15 (dd, J
= 8.8, 5.1 Hz, 2H), 1.90 - 1.78
(m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.45 (s,
1H), 6.94 (d, J = 2.4 Hz, 1H),
6.87 (t, J = 9.8 Hz, 1H), 4.77
(s, 1H), 4.49 (d, J = 8.0 Hz,
1H), 4.28 (s, 1H), 3.96 — 3.86
(m, 4H), 3.40 — 3.28 (m, 4H),
2.95 — 2.85 (m, 2H), 2.73 —
2.61 (m, 2H), 2.28 — 2.17 (m,
2H), 2.17 — 2.06 (m, 2H), 1.94
— 1.89 (m, 6H).
WO 59690
1H NMR (400 MHz, CDCI3) 6
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 8.48 (s,
1H), 7.73 (d, J = 2.1 Hz, 1H),
6.96 (d, J = 2.4 Hz, 1H), 6.91
(d, J = 2.4 Hz, 1H), 6.85 (d, J
488 44737
= 2.1 Hz, 1H), 5.29 (d, J = 8.3
Hz, 1H), 4.88 — 4.75 (m, 1H),
4.46 — 4.33 (m, 1H), 3.95 —
3.87 (m, 4H), 3.38 — 3.30 (m,
4H), 2.31 — 2.19 (m, 2H), 2.06
— 1.91 (m, 6H).
1H NMR (400 MHz, CDCI3) 6
8.68 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.85 (d, J
= 6.1 Hz, 1H), 6.94 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.4 Hz,
489 450.34 1H), 5.81 (d, J = 6.1 Hz, 1H),
4.92 (s, 1H), 4.75 (s, 1H),
4.02 (s, 1H), 3.97 — 3.86 (m,
4H), 3.32 (dd, J =17.6, 12.8
Hz, 4H), 3.04 (s, 6H), 2.18
(dd, J = 24.2, 17.3 Hz, 2H).
1H NMR (400 MHz, CDCI3) 6
8.70 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 7.87 (d, J
= 0.7 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.4 Hz,
490 435.35 1H), 4.78 (s, 1H), 4.67 (s, 1H),
4.41 — 4.28 (m, 1H), 3.96 —
3.88 (m, 4H), 3.38 — 3.30 (m,
4H), 2.52 (s, 3H), 2.28 — 2.16
(m, 2H), 2.00 (s, 3H), 1.98 —
1.90 (m, 6H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.7 Hz, 1H), 8.61
(d, J = 1.7 Hz, 1H), 8.42 (s,
1H), 6.95 (s, 1H), 6.90 (s, 1H),
491 4.79 (s, 2H), 4.28 (s, 1H),
3.98 — 3.86 (m, 4H), 3.40 —
3.28 (m, 4H), 2.42 (s, 3H),
2.30 — 2.16 (m, 2H), 2.02 (s,
3H), 1.99 — 1.89 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 8.20 (d, J = 0.8 Hz,
1H), 6.97 (d, J = 2.4 Hz, 1H),
6.92 (d, J = 2.5 Hz, 1H), 5.47
(d, J = 1.0 Hz, 1H), 4.76 (d, J
= 23.9 Hz, 2H), 4.12 - 3.75
(m, 7H), 3.41 - 3.28 (m, 4H),
3.20 (ddd, J = 13.2, 9.6, 3.2
Hz, 2H), 2.20 (d, J = 6.9 Hz,
2H), 1.91 (d, J = 5.2 Hz, 6H).
1H NMR (400 MHz, DMSO) 5
8.72 (d, J = 1.9 Hz, 1H), 8.57
(d, J = 1.9 Hz, 1H), 7.77 (s,
1H), 7.45 (s, 1H), 7.14 (d, J =
2.4 Hz, 1H), 6.83 (d, J = 2.3
Hz, 1H), 6.15 (d, J = 5.8 Hz,
1H), 4.92 (s, 1H), 4.26 (t, J =
6.1 Hz, 2H), 4.09 — 3.89 (m,
1H), 3.83 — 3.72 (m, 4H), 3.34
(d, J = 7.7 Hz, 4H), 2.57 (t, J =
6.1 Hz, 2H), 2.36 (d, J = 24.2
Hz, 4H), 2.01 (d, J = 17.5 Hz,
2H), 1.76 (d, J = 4.8 Hz, 6H),
1.52— 1.35 m, 6H.
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.54 (d, J = 1.9
Hz, 1H), 7.82 (d, J = 3.4 Hz,
1H), 6.88 (d, J = 2.5 Hz, 1H),
6.82 (d, J = 2.5 Hz, 1H), 4.96
494 439.23
(d, J = 8.0 Hz, 1H), 4.72 (d, J
= 3.1 Hz, 1H), 4.18 (s, 1H),
3.90 - 3.78 (m, 4H), 3.35 -
3.19 (m, 4H), 2.41 (d, J = 0.9
Hz, 3H), 2.13 (q, J = 6.4 Hz,
2H), 1.84 (t, J = 6.3 Hz, 6H).
1H NMR (300 MHz, CDCI3):
ppm 1.37 — 1.47 (m, 2 H), 1.51
— 1.60 (m, 4 H), 1.82- 1.99
(m, 6 H), 2.14 — 2.24 (m, 2 H),
495 504.3 2.30 — 2.41 (m, 4 H), 3.29 (s, 2
H), 3.30 — 3.35 (m, 4 H), 3.89 —
3.93 (m, 4 H), 3.96 — 4.06 (m,
1 H), .81 (m, 1 H),
.18 (d, J =
1H NMR (300 MHz, CDCI3):
ppm 1.38 — 1.49 (m, 2 H), 1.56
— 1.64 (m, 4 H), 1.79— 1.97
(m, 6 H), 2.15 — 2.26 (m, 2 H),
496 2.45 — 2.57 (m, 4 H), 3.28 —
3.38 (m, 4 H), 3.53 (s, 2 H),
3.68 — 3.99 (m, 5 H), 4.76 —
4.85 (m, 1 H), 5.11 (brs,1 H),
6.18 (d, J = 6.0
WO 59690
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.22 (s, 2H), 7.01 -
6.85 (m, 2H), 5.21 (d, J = 8.1
Hz, 1H), 4.79 (d, J = 5.3 Hz,
1H), 4.11 - 3.87 (m, 5H), 3.35
(q, J = 3.4 Hz, 6H), 2.46 (s,
6H), 2.29 (s, 3H), 2.19 (s, 3H),
2.01 - 1.83 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.72 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.23 (dd, J = 7.6, 0.8
Hz, 1H), 7.85 (d, J = 2.2 Hz,
1H), 6.97 (d, J = 2.5 Hz, 1H),
6.92 (d, J = 2.5 Hz, 1H), 6.12
(dd, J = 2.2, 0.8 Hz, 1H), 6.00
(d, J = 7.6 Hz, 1H), 4.91 (d, J
= 7.9 Hz, 1H), 4.81 (s,1H),
4.20 (s, 1H), 4.01 - 3.88 (m,
4H), 3.42 - 3.28 (m, 4H), 2.22
(s, 2H), 1.97 (dd, J = 7.8, 5.5
Hz, 6H .
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.19 (d, J = 0.8 Hz,
1H), 6.93 (dd, J = 16.4, 2.5
Hz, 2H), 5.42 (d, J = 1.0 Hz,
1H), 4.87 - 4.67 (m, 2H), 4.01
- 3.77 (m, 5H), 3.61 (dt, J =
27.3, 5.1 Hz, 6H), 3.41 - 3.26
(m, 4H), 2.73 (t, J = 5.3 Hz,
1H), 2.59 (ddd, J = 6.2, 5.0,
3.7 Hz, 6H), 2.19 (d, J = 6.6
Hz, 2H), 1.89 (t, J = 5.2 Hz,
6H .
Compound ESMS H NMR
Compound ure
1H NMR (300 MHz,
Chloroform-d) 6 8.64 (d, J =
1.9 Hz, 1H), 8.55 (d, J = 1.9
Hz, 1H), 8.21 (s, 1H), 6.88
(dd, J = 16.1, 2.5 Hz, 2H),
500 461 .24 6.16 (d, J = 8.3 Hz, 1H), 5.98
(s, 1H), 4.80 (d, J = 2.9 Hz,
1H), 3.90 - 3.77 (m, 4H), 3.72
- 3.51 (m, 1H), 3.33 - 3.20 (m,
4H), 2.51 (s, 3H), 2.34 - 1.66
(m, 8H).
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.55 (d, J :19
Hz, 1H), 6.95 (dd, J = 3.6, 2.3
Hz, 1H), 6.86 (dd, J = 13.7,
501 480.1 5 2.4 Hz, 2H), 6.30 (dd, J = 3.6,
2.0 Hz, 1H), 5.22 (m, 1H),
4.74 (s, 1H), 4.30 (s, 1H),
3.91 - 3.79 (m, 4H), 3.35 -
3.19 (m, 4H), 2.15 (m, 2H),
2.03 - 1.76 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.54 (d, J = 2.0
Hz, 1H), 8.25 (s, 1H), 6.88 (d,
J = 2.4 Hz, 1H), 6.82 (d, J =
502 462.19
2.5 Hz, 1H), 4.73 (s, 1H), 4.54
(s, 1H), 4.12 (s, 1H), 3.84 (dd,
J = 6.0, 3.7 Hz, 4H), 3.37 -
3.19 (m, 5H), 2.17 (d, J = 10.1
Hz, 2H), 1.92 - 1.71 (m, 6H).
nd ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3):
ppm 1.79 F] 1.99 (m, 6 H),
2.15 - 2.26 (m, 2 H), 2.54 -
2.65 (m, 4 H), 3.29 - 3.37 (m,
503 506.3 4 H), 3.58 (s, 2 H), 3.74 - 3.83
(m, 5 H), 3.88 - 3.95 (m, 4 H),
4.75 -4.85 (m, 1 H), 5.11 (br.
s, 1 H), 6.19 (d, J = 5.9 Hz,1
H), 6.90 (d, J
1H NMR (300 MHz, CDCI3):
ppm 1.40 — 1.49 (m, 2 H), 1.55
— 1.65 (m, 4 H), 1.84-1.96
(m, 6 H), 2.12 — 2.23 (m, 2 H),
504 504.3 2.43 (br. s, 4 H), 3.30 — 3.40
(m, 6 H), 3.88 — 3.95 (m, 4 H),
3.97-4.08 (m, 1 H), 4.75—
4.82 (m, 1 H), 5.17 (d, J = 7.9
Hz, 1 H), 6.68
1H NMR (300 MHz, CDCI3):
ppm 1.83 — 1.96 (m, 6 H), 2.13
— 2.23 (m, 2 H), 2.53 (br. s, 4
H), 3.30 — 3.36 (m, 4 H), 3.42
505 (s, 2 H), 3.72 — 3.78 (m, 4 H),
3.88 — 3.95 (m, 4 H), 4.03 (br.
s, 1 H), 4.75 -4.82 (m, 1 H),
.21 (d, J = 8.0 Hz, 1 H), 6.67
(d, J = 5)
H NMR
1H NMR (300 MHz, DMSO-
d6): ppm 1.71 - 1.85 (m, 6 H),
1.98 - 2.10 (m, 2 H), 3.33 -
3.38 (m, 4 H), 3.74 - 3.91 (m,
506 5 H), 4.87 - 4.96 (m, 1 H),
6.02 (d, J = 7.2 Hz, 1 H), 6.51
(s, 1 H), 6.83 (d, J = 1.9 Hz, 1
H), 7.14 (d, J :19 Hz, 1 H),
7.94 (s, 1 H), 8.3
1H NMR (300 MHz, :
ppm 1.39 — 1.48 (m, 2 H), 1.54
— 1.69 (m, 4 H), 1.83-1.98
(m, 8 H), 2.12 — 2.24 (m, 2 H),
507 2.33 — 2.47 (m, 6 H), 3.31 —
3.35 (m, 4 H), 3.89 — 3.99 (m,
7 H), 4.74 -4.81 (m, 1 H),
4.95 (d, J = 8.2 Hz, 1 H), 6.90
(d, J = 2.3 Hz, 1
1H NMR (300 MHz, CDCI3):
ppm 1.82 — 1.98 (m, 8 H), 2.13
— 2.23 (m, 2 H), 2.29 (s, 3 H),
2.35 — 2.62 (m, 10 H), 3.29 —
508 3.37 (m, 4 H), 3.87 — 3.94 (m,
H), 3.97 (t, J = 6.3 Hz, 2 H),
4.74 -4.81 (m, 1 H), 4.96 (d, J
= 8.1 Hz, 1 H), 6.90 (d, J = 2.3
Hz, 1 H
2014/024767
H NMR
1H NMR (300 MHz, CDCI3)
ppm 1.77 - 1.96 (m, 10 H),
2.11 - 2.25 (m, 2 H), 2.57 -
2.65 (m, 4 H), 2.86 (t, J = 5.7
509 Hz, 2 H), 3.31 - 3.35 (m, 4 H),
3.87 - 3.98 (m, 5 H), 4.05 (t, J
= 5.7 Hz, 2 H), 4.74 - 4.81 (m,
1 H), 4.98 (d, J = 8.2 Hz, 1 H),
6.90 (d, J =
1H NMR (300 MHz,
Chloroform-d) 6 8.95 (d, J =
1.3 Hz, 1H), 8.72 (d, J = 1.9
Hz, 1H), 8.64 (d, J :19 Hz,
1H), 8.14 (s, 1H), 6.95 (dd, J
= 16.0, 2.5 Hz, 2H), 6.36 (d, J
:13 Hz, 1H), 5.11 (d, J = 7.8
Hz, 1H), 4.83 (dd, J = 5.5, 2.9
Hz, 1H), 4.01 - 3.84 (m, 4H),
3.73 - 3.55 (m, 1H), 3.40 -
3.30 (m, 4H), 2.34 - 2.21 (m,
2H), 2.08 - 1.83 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.55 (d, J :19
Hz, 1H), 7.93 (d, J = 1.7 Hz,
1H), 6.85 (dd, J = 16.5, 2.5
Hz, 2H), 4.74 (ddd, J = 21.7,
511 7.5, 3.9 Hz, 2H), 4.09 (p, J =
7.7, 7.2 Hz, 1H), 3.92 - 3.79
(m, 4H), 3.71 (dd, J = 5.7, 3.7
Hz, 4H), 3.57 (dd, J = 5.7, 3.7
Hz, 4H), 3.34 - 3.20 (m, 4H),
2.15 (td, J = 11.0, 10.0, 6.2
Hz, 2H), 1.94 - 1.79 (m, 6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.64 (d, J :19
Hz, 1H), 7.99 (d, J = 1.8 Hz,
1H), 7.00 - 6.85 (m, 2H), 4.77
(d, J = 6.6 Hz, 2H), 4.14 (q, J
= 7.2 Hz, 1H), 4.03 - 3.87 (m,
4H), 3.78 - 3.64 (m, 1H), 3.43
- 3.28 (m, 4H), 3.15 (d, J = 2.5
Hz, 6H), 2.98 - 2.84 (m, 1H),
2.20 (d, J = 11.9 Hz, 2H), 1.94
(p, J = 5.8, 5.3 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 10.85 (d, J =
3.0 Hz, 1H), 8.66 (d, J = 1.9
Hz, 1H), 8.40 (d, J = 2.0 Hz,
1H), 7.22 (t, J = 2.9 Hz, 1H),
6.85 (d, J = 2.4 Hz, 1H), 6.75
513 (d, J = 2.4 Hz, 1H), 6.36 (dd, J
= 31,19 Hz, 1H), 5.86 (d, J =
7.8 Hz, 1H), 4.59 (s, 1H), 4.25
(s, 1H), 3.82 (dd, J = 6.0, 3.7
Hz, 4H), 3.24 (dd, J = 6.0, 3.8
Hz, 4H), 1.71 (s, 11H), 1.51 (t,
J = 10.1 Hz, 2H).
1H NMR (300 MHz,
Chloroform-d) 6 10.96 (s, 1H),
8.64 (d, J = 1.9 Hz, 1H), 8.40
(d, J :19 Hz, 1H), 6.84 (d, J
= 2.4 Hz, 1H), 6.75 (d, J = 2.4
Hz, 1H), 6.34 (dd, J = 31,19
Hz, 1H), 6.02 (d, J = 7.8 Hz,
1H), 4.59 (s, 1H), 4.23 (td, J =
8.8, 8.3, 4.2 Hz, 1H), 3.89 -
3.74 (m, 4H), 3.30 - 3.03 (m,
4H), 1.89 - 1.61 (m, 6H), 1.61
- 1.39 (m, 2H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 9.53 (s, 1H),
8.71 (d, J = 2.0 Hz, 1H), 8.64
(d, J :19 Hz, 1H), 8.35 (s,
1H), 7.06 (dd, J = 3.6, 2.1 Hz,
1H), 7.00 - 6.85 (m, 2H), 6.39
515 446.42
(dd, J = 3618 Hz, 1H), 5.14
(d, J = 8.3 Hz, 1H), 4.82 (s,
1H), 4.40 (d, J = 8.0 Hz, 1H),
4.01 - 3.81 (m, 4H), 3.44 -
3.25 (m, 4H), 2.26 (d, J = 9.8
Hz, 2H), 2.08 - 1.86 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 12.29 (s, 1H),
8.71 (d, J = 1.9 Hz, 1H), 8.64
(d, J :19 Hz, 1H), 8.43 (s,
1H), 7.95 (s, 1H), 7.00 - 6.89
516 447.32
(m, 2H), 6.03 (s, 1H), 4.86 (s,
1H), 4.42 (s, 1H), 3.92 (dd, J
= 6.0, 3.7 Hz, 4H), 3.40 - 3.30
(m, 4H), 2.27 (d, J = 10.1 Hz,
2H), 2.07 - 1.88 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 11.28 (s, 1H),
8.75 (d, J = 1.9 Hz, 1H), 8.53
(d, J = 2.0 Hz, 1H), 8.47 (s,
1H), 7.34 (s, 1H), 6.93 (d, J =
2.3 Hz, 1H), 6.82 (d, J = 2.5
517 446.33 Hz, 1H), 1.93 - 1.71 (m, 6H),
6.54 (d, J = 3.0 Hz, 1H), 5.57
(d, J = 7.9 Hz, 1H), 4.64 (s,
1H), 4.33 (s, 1H), 3.90 (t, J =
4.8 Hz, 4H), 3.31 (t, J = 4.9
Hz, 4H), 1.80-1.68 (m, 6H),
1.54 (d, J = 9.2 Hz, 2H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.55 (d, J :19
Hz, 1H), 8.32 (s, 1H), 7.42 (d,
J = 2.5 Hz, 1H), 6.88 (d, J =
2.5 Hz, 1H), 6.83 (d, J = 2.5
518 447.2
Hz, 1H), 6.58 (d, J = 2.5 Hz,
1H), 5.07 (s, 1H), 4.74 (s, 1H),
4.26 (s, 1H), 3.84 (dd, J = 6.0,
3.7 Hz, 4H), 3.42 - 3.10 (m,
4H), 2.18 (d, J = 10.2 Hz, 2H),
2.06 - 1.70 (m, 6H).
1H NMR (300 MHz,
form-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 8.07 (s, 2H), 6.93 -
6.79 (m, 2H), 5.04 (d, J = 8.1
Hz, 1H), 4.70 (s, 1H), 4.02 -
519 543.21
3.76 (m, 5H), 3.34 - 3.20 (m,
4H), 3.02 - 2.87 (m, 2H), 2.66
(t, J = 6.9 Hz, 2H), 2.53 - 2.42
(m, 2H), 2.35 - 2.22 (m, 1H),
2.10 (td, J = 11.6, 3.0 Hz, 3H),
1.90 - 1.46 (m, 11H).
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
2.0 Hz, 1H), 8.56 (d, J = 0.6
Hz, 2H), 8.53 (d, J :19 Hz,
1H), 6.86 (d, J = 2.5 Hz, 1H),
520 455.17
4.67 (d, J = 6.1 Hz, 1H), 3.89 -
3.81 (m, 4H), 3.79 (d, J = 0.7
Hz, 2H), 3.31 - 3.17 (m, 4H),
2.60 (s, 1H), 2.20 - 2.03 (m,
2H), 1.79 - 1.59 (m, 6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.74 (d, J =
1.9 Hz, 1H), 8.66 (d, J = 2.0
Hz, 1H), 7.93 (s, 1H), 6.99 (d,
J = 2.4 Hz, 1H), 6.93 (d, J =
521 465.16
2.5 Hz, 1H), 6.20 (d, J = 8.5
Hz, 1H), 4.87 (s, 1H), 4.36 (s,
1H), 3.94 (dd, J = 5.9, 3.8 Hz,
4H), 3.42 - 3.32 (m, 4H), 2.26
(s, 2H), 1.93 (s, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 8.17 (s, 2H), 7.01 -
6.89 (m, 2H), 5.12 (d, J = 8.1
522 552.21 Hz, 1H), 4.80 (s, 1H), 4.09 -
3.86 (m, 5H), 3.63 (t, J = 7.1
Hz, 2H), 3.40 - 3.29 (m, 4H),
3.06 (d, J = 11.3 Hz, 2H), 2.79
(t, J = 7.1 Hz, 2H), 2.39 -2.15
(m, 4H), 2.02 - 1.53 (m, 10H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.18 (s, 2H), 7.02 -
6.86 (m, 2H), 5.12 (d, J = 8.1
523 518.2
Hz, 1H), 4.80 (s, 1H), 4.09 -
3.87 (m, 5H), 3.42 - 3.29 (m,
4H), 3.12 (d, J = 11.2 Hz, 2H),
2.60 - 1.54 (m, 17H), 1.15 (t, J
= 7.2 Hz, 3H).
Compound ESMS H NMR
nd Structure
No. M+H
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 6.91 (d, J
= 2.5 Hz, 1H), 6.61 (d, J = 2.5
Hz, 1H), 5.19 — 5.05 (m, 1H),
524 301 .24
3.97 — 3.85 (m, 5H), 3.37 —
3.29 (m, 4H), 2.71 (ddd, J =
16.1, 7.8, 5.0 Hz, 2H), 2.34
(ddd, J = 13.6, 7.0, 4.1 Hz,
2H).
1H NMR (400 MHz, CDCI3) 5
8.71 (d, J = 1.9 Hz, 1H), 8.63
(d, J = 1.9 Hz, 1H), 8.31 (s,
1H), 8.30 (s, 1H), 6.93 (d, J =
2.4 Hz, 1H), 6.64 — 6.54 (m,
2H), 5.38 (d, J = 5.1 Hz, 1H),
525 379.26
.17 — 5.07 (m, 1H), 4.68 —
4.56 (m, 1H), 3.95 — 3.85 (m,
4H), 3.35 — 3.27 (m, 4H), 2.94
(ddd, J = 13.4, 8.2, 5.1 Hz,
2H), 2.59 (ddd, J = 13.9, 7.0,
4.5 Hz, 2H).
1H NMR (300 MHz, CDCI3):
ppm 1.80 — 2.07 (m, 8 H), 2.11
— 2.25 (m, 2 H), 2.39 — 2.76
(m, 6 H), 3.27 — 3.40 (m, 4 H),
526 3.70 — 3.84 (m, 4 H), 3.87 —
3.96 (m, 5 H), 3.99 (t, J = 6.2
Hz, 2 H), 4.73 — 4.82 (m, 1 H),
4.97 (d, J = 8.1 Hz, 1 H), 6.90
(d, J = 2.4 H
WO 59690
H NMR
1H NMR (300 MHz, CDCI3):
ppm 1.39 — 1.48 (m, 2 H), 1.56
— 1.67 (m, 4 H), 1.78- 1.96
(m, 6 H), 2.14 — 2.25 (m, 2 H),
527 2.44 — 2.52 (m, 4 H), 2.72 (t, J
= 6.0 Hz, 2 H), 3.31 — 3.35 (m,
4 H), 3.63 — 3.75 (m, 1 H),
3.90 — 3.93 (m, 4 H), 4.41 (t, J
= 6.0 Hz, 2
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.31 (s, 2H), 7.02 -
6.86 (m, 2H), 5.52 (d, J = 8.0
Hz, 1H), 4.81 (dt, J = 6.8, 3.4
528 Hz, 1H), 4.04 (td, J = 8.0, 4.0
Hz, 1H), 3.97 - 3.86 (m, 4H),
3.64 (s, 2H), 3.43 - 3.27 (m,
4H), 2.75 (t, J = 5.4 Hz, 4H),
2.32 - 2.15 (m, 2H), 2.07 (s,
2H), 1.92 (tt, J = 6.7, 3.6 Hz,
8H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.22 (s, 2H), 7.02 -
6.86 (m, 2H), 5.21 (d, J = 8.1
529 Hz, 1H), 4.81 (dt, J = 7.5, 3.7
Hz, 1H), 4.04 (d, J = 6.9 Hz,
1H), 3.96 - 3.82 (m, 4H), 3.41
- 3.30 (m, 4H), 3.27 (s, 2H),
2.24 (m, 8H), 2.07 - 1.77 (m,
6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.53 (d, J :19
Hz, 1H), 8.13 (s, 2H), 6.87 (d,
J = 2.5 Hz, 1H), 6.83 (d, J =
2.5 Hz, 1H), 5.10 (d, J = 8.1
Hz, 1H), 4.71 (s, 1H), 3.94 (s,
1H), 3.88 - 3.78 (m, 4H), 3.67
- 3.56 (m, 4H), 3.32 - 3.17 (m,
6H), 2.41 - 2.26 (m, 4H), 2.12
(d, J = 8.7 Hz, 2H), 1.92 - 1.76
(m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.64 (d, J :19
Hz, 1H), 8.39 (dd, J = 2.7, 0.5
Hz, 1H), 8.04 (d, J = 3.4 Hz,
1H), 6.97 (d, J = 2.5 Hz, 1H),
531 6.92 (d, J = 2.5 Hz, 1H), 5.15
(d, J = 8.1 Hz, 1H), 4.83 (dq, J
= 5.1, 2.6 Hz, 1H), 4.25 (dd, J
= 8.1, 4.6 Hz, 1H), 3.98 - 3.88
(m, 4H), 3.39 - 3.28 (m, 4H),
2.34 - 2.17 (m, 2H), 2.03 -
1.84 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J :19 Hz, 1H), 8.13 (d, J
= 4.8 Hz, 1H), 6.96 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.5 Hz,
532 1H), 6.54 (d, J = 5.2 Hz, 1H),
.36 (s, 1H), 4.79 (s, 1H),
4.03 (s, 1H), 3.97 — 3.84 (m,
4H), 3.41 — 3.23 (m, 4H), 2.26
— 2.12 (m, 2H), 1.98 — 1.81 (m,
6H).
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.60
(d, J = 1.9 Hz, 1H), 7.99 (s,
1H), 6.96 (d, J = 2.4 Hz, 1H),
6.90 (d, J = 2.4 Hz, 1H), 6.22
533 441 .25 (d, J = 5.9 Hz, 1H), 5.22 (s,
1H), 4.81 (s, 1H), 4.03 (dt, J =
12.1, 6.2 Hz, 1H), 3.94 — 3.86
(m, 4H), 3.40 — 3.26 (m, 4H),
2.27 — 2.13 (m, 2H), 1.90 (t, J
= 17.4 Hz, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (s, 1H), 8.61 (s, 1H),
7.89 (d, J = 5.5 Hz, 1H), 6.95
(s, 1H), 6.89 (s, 1H), 5.71 (d,
534 492.39 J = 5.8 Hz, 1H), 4.76 (s, 2H),
4.01 — 3.81 (m, 5H), 3.74 (s,
8H), 3.41 — 3.26 (m, 4H), 2.26
— 2.12 (m, 2H), 1.98 — 1.81 (m,
6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.88 (d, J
= 5.7 Hz, 1H), 6.95 (d, J = 2.4
Hz, 1H), 6.89 (d, J = 2.4 Hz,
1H), 5.67 (d, J = 5.8 Hz, 1H),
535 505.35
4.84 — 4.63 (m, 2H), 3.99 —
3.83 (m, 5H), 3.82 — 3.73 (m,
4H), 3.37 — 3.27 (m, 4H), 2.49
— 2.40 (m, 4H), 2.33 (s, 3H),
2.23—2.11 (m, 2H), 1.96 —
1.82 (m, 6H).
H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.73 (d, J =
1.9 Hz, 1H), 8.65 (d, J :19
Hz, 1H), 8.30 (s, 1H), 6.97
(dd, J = 15.8, 2.5 Hz, 2H),
6.23 (d, J = 8.2 Hz, 1H), 6.07
(s, 1H), 4.90 (dt, J = 5.1, 2.4
Hz, 1H), 3.99 - 3.88 (m, 4H),
3.72 (dq, J = 9.2, 4.7 Hz, 1H),
3.40 - 3.29 (m, 4H), 2.60 (s,
3H), 2.34 (dt, J = 14.1, 5.2 Hz,
2H), 2.23 - 1.79 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.7 Hz, 1H), 8.60
(d, J = 1.7 Hz, 1H), 8.18 (s,
1H), 6.95 (d, J = 2.2 Hz, 1H),
6.90 (s, 1H), 5.42 (s, 1H),
4.78 (s, 1H), 4.71 (d, J = 8.3
Hz, 1H), 3.98 — 3.87 (m, 4H),
3.83 (s, 1H), 3.65 — 3.48 (m,
4H), 3.41 — 3.24 (m, 4H), 2.54
— 2.42 (m, 4H), 2.33 (s, 3H),
.11 (m, 2H), 1.97 —
1.82 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.74 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 7.57 (d, J = 1.6 Hz,
1H), 7.38 (dd, J = 1.7, 0.8 Hz,
538 1H), 7.05 - 6.88 (m, 3H), 5.52
(d, J = 8.1 Hz, 1H), 4.87 (d, J
= 4.0 Hz, 1H), 4.47 - 4.31 (m,
1H), 3.98 - 3.88 (m, 4H), 3.42
- 3.30 (m, 4H), 2.35 - 2.21 (m,
2H), 2.16 - 1.88 (m, 6H).
Compound ESMS H NMR
“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3):
ppm 1.76 — 1.97 (m, 6 H), 2.15
— 2.26 (m, 2 H), 3.31 — 3.35
(m, 4 H), 3.43 (s, 3 H), 3.61 —
539 3.72 (m, 3 H), 3.90 — 3.93 (m,
4 H), 4.45 -4.48 (m, 2 H),
4.76 — 4.82 (m, 1 H), 4.94 (d, J
= 7.1 Hz, 1 H), 5.73 (s, 1 H),
6.89 (d, J = 2.
1H NMR (300 MHz, CDCI3):
ppm 1.82 — 1.99 (m, 6 H), 2.13
— 2.25 (m, 2 H), 3.29 — 3.38
(m, 4 H), 3.73 (br. s, 1 H),
540 3.84 — 3.98 (m, 4 H), 4.45 (br.
s, 1 H), 4.74 -4.84 (m, 1 H),
6.31 (s, 1 H), 6.43 — 6.47 (m, 1
H), 6.91 (d, J = 2.3 Hz, 1 H),
6.93 — 6.99 (m
1H NMR (300 MHz, CDCI3):
ppm 1.40 — 1.48 (m, 2 H), 1.56
— 1.67 (m, 4 H), 1.84— 1.99
(m, 6 H), 2.11 — 2.24 (m, 2 H),
541 2.45 — 2.52 (m, 4 H), 2.72 (t, J
= 6.2 Hz, 2 H), 3.32 — 3.35 (m,
4 H), 3.90 — 3.93 (m, 4 H),
3.96 — 4.08 (m, 1 H), 4.40 (t, J
= 6.2 Hz, 2
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.56 (d, J = 1.9
Hz, 1H), 8.18 (s, 1H), 7.83 (d,
J = 6.3 Hz, 1H), 6.96 - 6.80
(m, 3H), 6.23 (d, J = 8.2 Hz,
542 447.25
1H), 4.77 (dd, J = 5.8, 3.3 Hz,
1H), 4.23 (dq, J = 8.6, 4.3 Hz,
1H), 3.89 - 3.75 (m, 4H), 3.35
- 3.20 (m, 4H), 2.20 (d, J =
12.8 Hz, 2H), 2.10 - 1.79 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.53 (s, 1H),
8.18 (s, 2H), 6.96 - 6.80 (m,
2H), 5.14 (d, J = 8.1 Hz,1H),
4.78 (s, 1H), 4.08 - 3.86 (m,
543 518.2
5H), 3.33 (dd, J = 6.0, 3.8 Hz,
4H), 3.07 - 2.94 (m, 2H), 2.71
(s, 3H), 2.35 (s, 3H), 2.26 -
1.97 (m, 4H), 1.99 - 1.57 (m,
11H).
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (s, 1H),
8.18 (s, 2H), 7.02 - 6.87 (m,
2H), 5.12 (d, J = 8.2 Hz,1H),
4.80 (s, 1H), 4.05 - 3.87 (m,
544 _\ 518.2
5H), 3.38 - 3.27 (m, 4H), 3.01
(d, J = 11.4 Hz, 3H), 2.74 (s,
3H), 2.36 (s, 3H), 2.20 (m,
2H), 2.06 (m,2H), 2.00 - 1.58
(m, 11H).
nd ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.73 (d, J =
2.0 Hz, 1H), 8.64 (d, J = 2.0
Hz, 1H), 8.39 (s, 1H), 7.92 (s,
545 461.24 1H), 7.05 - 6.89 (m, 2H), 4.88
(s, 1H), 4.06 (s, 3H), 3.94 (dd,
J = 6.0, 3.8 Hz, 4H), 3.36 (t, J
= 4.9 Hz, 5H), 2.29 (s, 2H),
1.98 (d, J = 35.4 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.55 (d, J = 1.9
Hz, 1H), 8.32 (s, 1H), 7.66 (s,
546 461.24 1H), 6.92 - 6.81 (m, 2H), 4.79
(s, 1H), 3.87 - 3.80 (m, 4H),
3.75 (s, 3H), 3.31 - 3.22 (m,
4H), 2.18 (d, J = 12.7 Hz, 2H),
2.08 - 1.75 (m, 6H).
1H NMR (400 MHz, CDCI3) 6
8.70 (d, J = 1.9 Hz, 1H), 8.63
(d, J = 1.9 Hz, 1H), 7.90 (d, J
= 6.0 Hz, 1H), 6.96 (d, J = 2.4
Hz, 1H), 6.92 (d, J = 2.3 Hz,
1H), 5.89 (d, J = 6.1 Hz, 1H),
547 4.96 (s, 1H), 4.77 (s, 1H),
4.08 — 3.98 (m, 1H), 3.96 —
3.87 (m, 4H), 3.70 — 3.53 (m,
4H), 3.43 — 3.27 (m, 4H), 2.53
— 2.42 (m, 4H), 2.35 (s, 3H),
2.25 — 2.13 (m, 2H), 2.00 —
1.85 (m, 6H).
nd ESMS H NMR
C d St t
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.8 Hz, 1H), 8.63
(d, J :19 Hz, 1H), 7.93 (d, J
= 5.9 Hz, 1H), 6.96 (d, J = 2.3
Hz, 1H), 6.91 (d, J = 2.3 Hz,
1H), 5.87 (d, J = 6.1 Hz, 1H),
4.97 (s, 1H), 4.77 (s, 1H),
4.02 (s, 1H), 3.97 — 3.88 (m,
4H), 3.83 — 3.70 (m, 4H), 3.63
— 3.52 (m, 4H), 3.39 — 3.27 (m,
4H), 2.25 — 2.12 (m, 2H), 2.01
— 1.85 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.18 (d, J = 5.1 Hz,
1H), 6.98 - 6.89 (m, 2H), 6.42
(d, J = 5.1 Hz, 1H), 5.18 (d, J
549 = 8.0 Hz, 1H), 4.79 (dt, J =
7.9, 3.7 Hz, 1H), 4.11 - 3.87
(m, 5H), 3.42 - 3.25 (m, 4H),
3.00 (dq, J = 9.9, 3.3 Hz, 2H),
2.63 - 2.35 (m, 5H), 2.27 -
2.04 (m, 4H), 1.97 - 1.82 (m,
9H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.16 (s, 2H), 7.05 -
6.83 (m, 2H), 5.14 (d, J = 8.1
Hz, 1H), 4.79 (d, J = 5.3 Hz,
550 1H), 4.10 - 3.85 (m, 5H), 3.41
- 3.28 (m, 4H), 2.87 (tt, J =
12.8, 3.2 Hz, 1H), 2.20 (q, J =
6.2 Hz, 2H), 1.91 (p, J = 3.7,
2.8 Hz, 6H), 1.73 (dd, J =
13.1, 3.2 Hz, 2H), 1.29 (d, J =
24.9 Hz, 12H).
nd ESMS H NMR
H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.64 (d, J :19
Hz, 1H), 8.20 (d, J = 5.1 Hz,
1H), 7.01 - 6.89 (m, 2H), 6.42
(d, J = 5.1 Hz, 1H), 5.15 (d, J
551 = 7.9 Hz, 1H), 4.80 (s, 1H),
4.05 (s, 1H), 3.97 - 3.88 (m,
4H), 3.43 - 3.31 (m, 4H), 3.24
(d, J = 12.3 Hz, 2H), 2.84 -
2.69 (m, 2H), 2.59 (m, 1H),
2.20 (m, 2H), 1.92 (t, J = 8.2
Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
2.0 Hz, 1H), 8.53 (d, J = 1.9
Hz, 1H), 7.85 (s, 1H), 6.94 -
6.73 (m, 2H), 5.33 (d, J = 7.9
Hz, 1H), 4.69 (s, 1H), 4.00 -
3.78 (m, 5H), 3.38 (d, J = 1.0
Hz, 2H), 3.33 - 3.20 (m, 4H),
2.19 - 1.99 (m, 2H), 1.83 (h, J
= 5.6 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 6.93 (dd, J = 17.8,
2.5 Hz, 2H), 5.07 (s, 1H), 4.78
553 (d, J = 6.2 Hz, 1H), 4.68 (d, J
= 7.9 Hz, 1H), 4.03 - 3.90 (m,
4H), 3.87 (s, 3H), 3.71 (s, 1H),
3.42 - 3.28 (m, 4H), 3.13 (s,
6H), 2.27 - 2.00 (m, 2H), 2.00
- 1.79 (m, 6H).
WO 59690
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.04 (s, 1H), 5.04 (d,
J = 8.2 Hz, 1H), 4.79 (s, 1H),
554 462.2 4.09 - 3.90 (m, 5H), 3.85 (s,
2H), 3.42 - 3.31 (m, 4H), 3.11
(t, J = 5.8 Hz, 2H), 2.63 (t, J =
.8 Hz, 2H), 2.19 (d, J = 8.1
Hz, 2H), 1.91 (d, J = 5.5 Hz,
6H).
1H NMR (400 MHz, CDCI3) 5
8.68 (d, J :19 Hz, 1H), 8.61
(d, J :19 Hz, 1H), 6.94 (d, J
= 2.4 Hz, 1H), 6.87 (d, J = 2.4
Hz, 1H), 5.47 (s, 1H), 5.30 (s,
555 357.15
1H), 4.50 (s, 1H), 4.00 — 3.84
(m, 4H), 3.40 — 3.27 (m, 4H),
2.45 — 2.33 (m, 2H), 2.33 —
2.18 (m, 1H), 2.15 — 2.00 (m,
2H), 1.74 (d, J = 5.4 Hz, 4H).
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.53 (d, J :19
Hz, 1H), 7.97 (s, 1H), 6.92 -
6.77 (m, 2H), 4.95 (d, J = 8.1
Hz, 1H), 4.76 - 4.64 (m, 1H),
556 476.23
3.97 - 3.75 (m, 5H), 3.34 (s,
2H), 3.30 - 3.17 (m, 4H), 2.60
(dq, J = 9.7, 5.3, 4.8 Hz, 4H),
2.37 (s, 3H), 2.10 (td, J =
.8, 10.3, 6.1 Hz, 2H), 1.90 -
1.62 (m, 6H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
2.0 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 8.20 (d, J = 5.1 Hz,
1H), 7.01 - 6.89 (m, 2H), 6.40
(d, J = 5.1 Hz, 1H), 5.20 (s,
557 1H), 4.81 (d, J = 6.1 Hz,1H),
4.23 (s, 2H), 4.04 (s, 1H),
3.97 - 3.89 (m, 4H), 3.42 -
3.28 (m, 4H), 2.82 (t, J = 12.8
Hz, 2H), 2.67 - 2.44 (m, 1H),
2.27 - 2.11 (m, 2H), 1.98 -
1.87 (m, 8H), 1.49 (s, 9H).
1H NMR (300 MHz, CDCI3):
ppm 1.84 — 1.99 (m, 6 H), 2.11
— 2.25 (m, 2 H), 3.32 — 3.36
(m, 4 H), 3.43 (s, 3 H), 3.70 —
558 3.73 (m, 2 H), 3.90 — 3.93 (m,
4 H), 3.96 —4.07 (m, 1 H),
4.41 —4.44 (m, 2 H), 4.72 —
4.80 (m, 1 H), 5.10 (br. s,1
H), 6.06 (d, J = 5.6
1H NMR (300 MHz, CDCI3):
ppm 1.84 — 1.98 (m, 6 H), 2.13
— 2.23 (m, 2 H), 2.32 (s, 6 H),
2.68 (t, J = 5.8 Hz, 2 H), 3.30 —
559 3.37 (m, 4 H), 3.88 — 3.95 (m,
4 H), 3.98 -4.08 (m, 1 H),
4.37 (t, J = 5.8 Hz, 2 H), 4.73 —
4.80 (m, 1 H), 5.05 (d, J = 7.5
Hz, 1 H)
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3):
ppm 1.83 — 2.00 (m, 8 H), 2.10
— 2.25 (m, 2 H), 2.52 — 2.59
(m, 4 H), 2.78 (t, J = 5.8 Hz, 2
560 536.3 H), 3.31 — 3.38 (m, 4 H), 3.70 —
3.77 (m, 4 H), 3.89 — 3.95 (m,
4 H), 4.03 (br. s, 1 H), 4.41 (t,
J = 5.8 Hz, 2 H), 4.72 — 4.80
(m, 1 H),
1H NMR (300 MHz, :
ppm 1.78 — 1.94 (m, 8 H), 2.14
— 2.25 (m, 2 H), 2.32 (s, 8 H),
2.87 (t, J = 5.5 Hz, 2 H), 3.28 —
561 3.38 (m, 4 H), 3.88 (br. s, 1
H), 3.84 — 3.98 (m, 4 H), 4.39
(t, J = 5.5 Hz, 2 H), 4.79 (br. s,
1 H), 4.90 (d, J = 7.2 Hz, 1 H),
.73
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 1.94 (m, 8 H), 2.14
— 2.24 (m, 2 H), 2.28 (s, 3 H),
2.47 (br. s, 4 H), 2.59 (br. s, 4
562 H), 2.78 (t, J = 5.8 Hz, 2 H),
3.30 — 3.37 (m, 4 H), 3.89 (br.
s, 1 H), 3.88 — 3.95 (m, 4 H),
4.42 (t, J = 5.8 Hz, 2 H), 4.75 —
4.83
nd ESMS H NMR
1H NMR (400 MHz, CDCI3) 5
8.68 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 8.48 (d, J
= 0.6 Hz, 1H), 7.75 (d, J = 2.2
Hz, 1H), 6.94 (d, J = 2.4 Hz,
1H), 6.92 — 6.88 (m, 1H), 6.67
563 44737
(d, J = 1.4 Hz, 1H), 5.22 (t, J =
9.5 Hz, 1H), 4.79 (s, 1H), 4.06
(s, 1H), 4.00 — 3.84 (m, 4H),
3.40 — 3.24 (m, 4H), 2.16 (t, J
= 21.2 Hz, 2H), 1.98 — 1.85
(m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 8.07 (s, 1H), 6.99 —
6.84 (m, 2H), 5.10 (d, J = 8.1
Hz, 1H), 4.78 (d, J = 5.7 Hz,
564 56225
1H), 4.42 (s, 2H), 4.10 — 3.85
(m, 5H), 3.64 (t, J = 5.6 Hz,
2H), 3.40 — 3.29 (m, 4H), 2.65
(dt, J = 6.2, 2.8 Hz, 2H), 2.19
(q, J = 6.0 Hz, 2H), 1.98 — 1.85
(m, 6H), 1.49 (s, 9H).
1H NMR (300 MHz,
Chloroform-d) 6 8.55 (d, J =
1.9 Hz, 1H), 8.47 (d, J = 1.9
Hz, 1H), 6.93 (s, 1H), 6.86 -
6.72 (m, 2H), 5.25 (s, 1H),
4.66 (s, 1H), 4.05 - 3.90 (m,
1H), 3.86 - 3.71 (m, 7H), 3.30
- 3.09 (m, 4H), 2.27 (d, J = 2.2
Hz, 3H), 2.04 (d, J = 9.2 Hz,
2H), 1.75 (d, J = 4.8 Hz, 6H).
2014/024767
Compound ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J
2.0 Hz, 2H), 8.63 (d, J =1. Hz, 1H), 7.42 (s, 1H), 7.01 ILOII
566 475.15 6.86 (m, 2H), 5.64 (d, J = 8.2
Hz, 1H), 4.83 (s, 1H), 3.92
(dd, J = 6.0, 3.7 Hz, 4H), 3.34
(dd, J = 5.8, 3.9 Hz, 4H), 2.11
- 1.78 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.74 (s, 1H), 7.00 -
6.89 (m, 2H), 4.91 (s, 1H),
567 504.1 4.76 (d, J = 6.1 Hz, 1H), 4.04 -
3.93 (m, 5H), 3.43 - 3.28 (m,
4H), 2.26 - 2.14 (m, 2H), 2.08
(d, J = 0.8 Hz, 3H), 2.00 - 1.92
(m, 6H), 1.69 (d, J = 21.2 Hz,
10H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 2.0
Hz, 1H), 8.22 (s, 2H), 7.04 -
6.88 (m, 2H), 5.14 (d, J = 8.1
Hz, 1H), 4.80 (d, J = 5.5 Hz,
568 1H), 4.09 - 3.85 (m, 5H), 3.41
- 3.31 (m, 4H), 3.29 - 3.13 (m,
1H), 3.04 - 2.92 (m, 1H), 2.81
(q, J = 8.1 Hz, 1H), 2.68 (dt, J
= 9.2, 4.6 Hz, 1H), 2.52 - 2.26
(m, 5H), 2.24 - 2.13 (m, 2H),
2.02 - 1.78 (m, 7H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.54 (d, J = 1.9
Hz, 1H), 8.10 (s, 2H), 6.93 -
6.76 (m, 2H), 5.07 (d, J = 8.1
569 476.06 Hz, 1H), 4.68 (d, J = 15.8 Hz,
1H), 4.00 - 3.78 (m, 5H), 3.35
- 3.20 (m, 4H), 3.18 - 2.92 (m,
3H), 2.70 (dd, J = 10.7, 8.4
Hz, 1H), 2.24 - 2.02 (m, 3H),
1.94 - 1.62 (m, 7H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
2.2 Hz, 1H), 8.63 (d, J = 2.1
Hz, 1H), 8.19 (s, 2H), 7.03 -
6.86 (m, 2H), 4.10 - 3.86 (m,
570 576.2
5H), 3.46 - 3.28 (m, 4H), 3.24
- 3.13 (m, 1H), 2.35 - 2.16 (m,
1H), 2.05 - 1.84 (m, 8H), 1.81
- 1.66 (m, 1H), 1.55 - 1.41
(m,11H).
1H NMR (400 MHz, CDCI3) 6
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.88 (d, J
= 2.4 Hz, 1H), 6.96 (d, J = 2.5
Hz, 1H), 6.90 (d, J = 2.4 Hz,
571 476.31 1H), 6.76 (s, 1H), 4.98 (s, 2H),
4.78 (s, 1H), 4.00 — 3.86 (m,
4H), 3.83 (s, 1H), 3.39 — 3.27
(m, 4H), 2.21 (d, J = 9.6 Hz,
2H), 1.89 (dd, J = 13.3, 8.6
Hz, 6H), 1.50 (s, 6H).
nd ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, CDCI3):
ppm 1.82 — 1.99 (m, 6 H), 2.14
— 2.28 (m, 2 H), 3.32 — 3.35
(m, 4 H), 3.80 — 3.88 (m, 1 H),
572 472.2 3.90 — 3.93 (m, 4 H), 4.70 —
4.83 (m, 2 H), 6.37 (d, J = 8.8
Hz, 1 H), 6.38 (t, J = 73.8 Hz,
1 H), 6.90 (d, J = 2.3 Hz, 1 H),
6.95 (d, J =
1H NMR (300 MHz, CDCI3):
ppm 1.52 (s, 6 H), 1.73 (br s,
1 H), 1.85 - 1.96 (m, 6 H),
2.11 - 2.25 (m, 2 H), 3.30 -
573 464.3 3.36 (m, 4 H), 3.88 - 4.00 (m,
H), 4.55 (d, J = 8.1 Hz, 1 H),
4.74 -4.81 (m, 1 H), 6.52 (s, 1
H), 6.57 (dd, J = 5.4, 1.4 Hz, 1
H), 6.90 (d,
1H NMR (400 MHz, CDCI3) 6
8.69 (d, J = 1.9 Hz, 1H), 8.61
(d, J :19 Hz, 1H), 7.99 (s,
2H), 6.95 (d, J = 2.4 Hz, 1H),
574 6.89 (d, J = 2.4 Hz, 1H), 4.78
(s, 1H), 4.01 — 3.84 (m, 7H),
3.41 (s, 2H), 3.37 — 3.27 (m,
4H), 2.26 — 2.14 (m, 2H), 1.93
— 1.81 (m, 6H).
Compound ESMS H NMR
C d St t
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J :19 Hz, 1H), 8.62
(d, J :19 Hz, 1H), 8.57 (s,
1H), 8.13 (s, 2H), 6.98 (d, J =
2.4 Hz, 1H), 6.91 (d, J = 2.5
Hz, 1H), 4.86 — 4.73 (m, 1H),
3.95 — 3.88 (m, 4H), 3.56 —
3.49 (m, 1H), 3.39 — 3.31 (m,
4H), 2.30 — 2.18 (m, 2H), 1.97
— 1.84 (m, 6H).
1H NMR (300 MHz,
form-d) 6 8.71 (d, J =
2.0 Hz, 1H), 8.63 (d, J =1.9
Hz, 1H), 8.13 (s, 1H), 7.01 -
6.87 (m, 2H), 4.81 (s, 1H),
4.57 (s, 2H), 4.06 (s, 1H),
3.99 - 3.87 (m, 4H), 3.35 (dd,
J = 5.9, 3.8 Hz, 4H), 2.45 (s,
3H), 2.20 (d, J = 8.0 Hz, 2H),
1.93 (d, J = 5.1 Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 2.0
Hz, 1H), 8.02 (d, J = 1.4 Hz,
1H), 7.87 (d, J = 1.5 Hz, 1H),
577 6.94 (dd, J = 16.2, 2.5 Hz,
2H), 4.89 - 4.71 (m, 2H), 4.65
(s, 2H), 4.06 - 3.85 (m, 4H),
3.40 - 3.27 (m, 4H), 2.23 (dt, J
= 11.5, 5.5 Hz, 2H), 2.04 -
1.80 (m, 6H).
nd ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
2.0 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 7.01 - 6.88 (m, 2H),
6.87 - 6.66 (m, 2H), 3.94 (t, J
= 4.9 Hz, 4H), 3.65 (s, 3H),
3.42 - 3.30 (m, 4H), 2.19 (s,
2H), 1.91 (d, J = 4.9 Hz, 6H).
1H NMR (400 MHz, CDCI3) 6
8.88 (s, 1H), 8.61 (s, 1H),
8.07 (s, 2H), 8.94 (s, 1H),
6.90 (s, 1H), 4.98 (d, J = 8.1
Hz, 1H), 4.78 (s, 1H), 4.02 —
3.81 (m, 5H), 3.47 — 3.19 (m,
5H), 3.19 — 2.83 (m, 4H), 2.78
— 2.52 (m, 3H), 2.37 (s, 3H),
2.28 — 2.11 (m, 2H), 2.03 —
1.82 (m, 8H).
1H NMR (300 MHz, CDCI3):
ppm 1.84 — 2.17 (m, 8 H), 2.23
— 2.35 (m, 2 H), 3.31 — 3.38
(m, 4 H), 3.83 F) 3.75 (m, 1 H),
580 3.87 — 3.98 (m, 4 H), 4.82 —
4.89 (m, 1 H), 5.88 (d, J = 7.2
Hz, 1 H), 8.11 (d, J = 7.8 Hz,
1 H), 8.44 (d, J = 2.2 Hz, 1 H),
6.90 F) 6.95(
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, CDCI3):
ppm 1.85 — 2.18 (m, 6 H), 2.24
— 2.36 (m, 2 H), 3.31 — 3.39
(m, 4 H), 3.64 — 3.77 (m, 1 H),
581 446.3 3.88 — 3.97 (m, 4 H), 4.82 —
4.89 (m, 1 H), 5.91 (d, J = 7.9
Hz, 1 H), 6.12 (d, J = 7.9 Hz,
1 H), 6.93 (d, J = 2.4 Hz, 1 H),
6.98 (d, J =
1H NMR (300 MHz, CDCI3):
ppm 1.83 F] 1.96 (m, 6 H),
2.14 - 2.26 (m, 2 H), 3.30 -
3.36 (m, 4 H), 3.41 (s, 3 H),
582 450.3 3.87 F) 3.95 (m, 5 H), 4.36 (s,
2 H), 4.59 - 4.89 (m, 2 H),
6.38 (s, 1 H), 6.48 (d, J = 5.2
Hz, 1 H), 6.90 (d, J = 2.4 Hz,
1 H), 6.95 (d, J = 2.4
1H NMR (300 MHz, CDCI3):
ppm 1.84 — 2.00 (m, 6 H), 2.09
— 2.24 (m, 2 H), 3.30 — 3.37
(m, 4 H), 3.64 — 3.74 (m, 1 H),
583 466.3 3.78 (s, 3 H), 3.89 — 3.95 (m, 7
H), 4.71 —4.79 (m, 1 H), 5.88
(d, J = 8.3 Hz, 1 H), 6.90 (d, J
= 2.4 Hz, 1 H), 6.95 (d, J = 2.4
Hz, 1 H)
nd ESMS H NMR
Compound Structure
1H NMR (300 MHz, CDCI3):
ppm 1.86 — 2.04 (m, 6 H), 2.12
— 2.26 (m, 2 H), 3.28 — 3.39
(m, 4 H), 3.88 — 3.96 (m, 4 H),
584 436.3 4.26 (br s, 1 H), 4.62 (s, 2 H),
4.69 — 4.78 (m, 1 H), 5.56 (br
s, 1 H), 6.50 (t, J = 5.3 Hz, 1
H), 6.90 (d, J = 1.9 Hz, 1 H),
6.93 (d, J
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 1.96 (m, 6 H), 2.11
— 2.25 (m, 2 H), 2.56 (br s, 4
H), 2.76 (t, J = 5.3 Hz, 2 H),
585 536.3 3.30 — 3.36 (m, 4 H), 3.74 (t, J
= 4.4 Hz, 4 H), 3.88 — 3.96 (m,
H), 4.06 (t, J = 5.3 Hz, 2 H),
4.73 -4.81 (m, 1 H), 4.99 (d, J
= 7.8
1H NMR (300 MHz, CDCI3):
ppm 1.88 F] 2.01 (m, 6 H),
2.10 (s, 3 H), 2.15 - 2.25 (m, 2
H), 3.30 - 3.37 (m, 4 H), 3.89
586 420.3 F) 3.95 (m, 4 H), 4.25 (br s, 2
H), 4.71 -4.78 (m, 1 H), 6.51
(dd, J = 6.8, 5.4 Hz, 1 H), 6.90
(d, J = 2.3 Hz, 1 H), 6.94 (d, J
= 2.3 Hz, 1
Compound ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, CDCI3):
ppm 1.82 — 1.98 (m, 8 H), 2.12
— 2.28 (m, 2 H), 3.25 — 3.43
(m, 4 H), 3.82 — 3.98 (m, 5 H),
587 474.2 4.80 (br s, 2 H), 8.52 (d, J =
8.4 Hz, 1 H), 8.87 — 8.93 (m, 2
H), 8.95 — 7.00 (m, 1 H), 7.50
(t, J = 7.9 Hz, 1 H), 8.83 (d, J
= 1.2 Hz, 1
1H NMR (300 MHz, :
ppm 1.38 (t, J = 7.0 Hz, 3 H),
1.83 —2.00 (m, 8 H), 2.11 —
2.24 (m, 2 H), 3.30 — 3.37 (m,
588 450.3 4 H), 3.75 — 3.85 (m, 1 H),
3.89 — 3.94 (m, 4 H), 4.25 (q, J
= 7.0 Hz, 2 H), 4.42 — 4.54 (m,
1 H), 4.72—4.79 (m, 1 H),
.94 (d, J = 7.7 H
1H NMR (300 MHz, CDCI3):
ppm 1.88 — 1.99 (m, 8 H), 2.18
— 2.27 (m, 2 H), 3.31 — 3.38
(m, 4 H), 3.88 — 3.95 (m, 5 H),
589 474.2 4.77 — 4.84 (m, 1 H), 4.90 (br
s, 1 H), 8.55 (s, 1 H), 8.72 (d,
J = 5.0 Hz, 1 H), 8.91 (d, J =
2.4 Hz, 1 H), 8.95 (d, J = 2.4
Hz, 1 H), 8.
WO 59690
Compound ESMS H NMR
1H NMR (300 MHz, CDCI3):
ppm 1.82 — 1.98 (m, 6 H), 2.10
— 2.22 (m, 2 H), 3.31 — 3.35
(m, 4 H), 3.41 — 3.45 (m, 4 H),
590 491.3 3.69 — 3.82 (m, 5 H), 3.90 —
3.93 (m, 4 H), 4.43 (d, J = 7.7
Hz, 1 H), 4.70 —4.77 (m, 1 H),
.81 (d, J = 8.0 Hz, 1 H), 5.90
(d, J = 8.0 H
1H NMR (300 MHz, CDCI3):
ppm 1.88 — 2.00 (m, 6 H), 2.13
— 2.28 (m, 2 H), 3.29 — 3.38
(m, 4 H), 3.88 — 3.95 (m, 4 H),
591 4.21 (brs, 1 H), 4.62 -4.84
(m, 2 H), 6.45 — 6.54 (m, 1 H),
6.90 (d, J = 2.4 Hz, 1 H), 6.95
(d, J = 2.4 Hz, 1 H), 7.07 —
7.18(m, 1 H),
1H NMR (300 MHz, CDCI3):
ppm 1.84 — 2.03 (m, 6 H), 2.11
— 2.24 (m, 2 H), 3.30 — 3.37
(m, 4 H), 3.84 (s, 3 H), 3.89 —
592 3.95 (m, 4 H), 4.17 — 4.29 (m,
1 H), 4.67-4.76 (m, 1 H),
.08 (d, J = 7.4 Hz, 1 H), 6.50
(dd, J = 7.3, 5.2 Hz, 1 H), 6.82
(d, J = 7.4 Hz
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3):
ppm 1.88 — 2.00 (m, 8 H), 2.13
— 2.28 (m, 2 H), 3.30 — 3.38
(m, 4 H), 3.88 — 3.97 (m, 4 H),
593 474.2 .35 (m, 1 H), 4.73—
4.80 (m, 1 H), 4.89 — 4.99 (m,
1 H), 8.80 (dd, J = 7.1, 5.1 Hz,
1 H), 8.91 (d, J = 2.3 Hz, 1 H),
8.98 (d, J =
1H NMR (300 MHz, CDCI3):
ppm 1.85 — 2.00 (m, 8 H), 2.11
— 2.28 (m, 2 H), 3.29 — 3.39
(m, 4 H), 3.87 — 3.97 (m, 4 H),
594 4.08 —4.18 (m, 1 H), 4.58 (d, J
= 7.8 Hz, 1 H), 4.73 —4.81 (m,
1 H), 8.90 (d, J = 2.4 Hz, 1 H),
8.95 (d, J = 2.4 Hz, 1 H), 7.05
(ddd, J =
1H NMR (300 MHz, CDCI3):
ppm 1.88 — 2.02 (m, 8 H), 2.08
(s, 3 H), 2.15 (s, 3 H), 2.14 —
2.24 (m, 2 H), 3.31 — 3.38 (m,
595 4 H), 3.89 — 3.95 (m, 4 H),
4.03 —4.18 (m, 1 H), 4.23 (br
s, 1 H), 4.89 —4.77 (m, 1 H),
8.90 (d, J = 2.4 Hz, 1 H), 8.94
(d, J = 2.4 Hz
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
2.0 Hz, 1H), 8.63 (d, J = 2.0
Hz, 1H), 6.99 (d, J = 2.4 Hz,
1H), 6.92 (t, J = 2.8 Hz, 1H),
596 6.08 (d, J = 1.1 Hz, 1H), 5.21
(s, 1H), 4.81 (s, 2H), 3.98 -
3.87 (m, 4H), 3.43 - 3.30 (m,
4H), 2.51 (d, J = 1.0 Hz, 3H),
2.19 (s, 2H), 2.01 - 1.77 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.07 - 6.87 (m, 2H),
6.02 (s, 1H), 4.83 (d, J = 5.5
597 Hz, 1H), 4.03 - 3.81 (m, 5H),
3.44 - 3.25 (m, 4H), 2.72 -
2.57 (m, 1H), 2.51 (s, 3H),
2.29 - 2.11 (m, 2H), 2.05 -
1.72 (m, 6H), 1.27 (t, J = 7.6
Hz, 3H).
1H NMR (300 MHz,
Chloroform-d) 6 8.61 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 6.93 - 6.72 (m, 3H),
598 6.55 (s, 1H), 4.71 (s, 1H),
4.01 (s, 1H), 3.92 - 3.76 (m,
4H), 3.34 - 3.18 (m, 4H), 2.98
(s, 6H), 2.07 (d, J = 24.1 Hz,
2H), 1.87 (d, J = 9.2 Hz, 6H).
nd ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.54 (t, J = 2.4
Hz, 1H), 6.85 (dd, J = 18.9,
599 2.4 Hz, 2H), 6.63 - 6.50 (m,
1H), 4.68 (s, 1H), 3.92 - 3.76
(m, 4H), 3.66 (s, 1H), 3.32 -
3.17 (m, 4H), 2.16 - 1.99 (m,
5H), 1.92 - 1.72 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
2.0 Hz, 1H), 8.62 (d, J = 2.0
Hz, 1H), 7.00 - 6.85 (m, 2H),
.44 (d, J = 8.5 Hz, 1H), 4.78
(s, 1H), 3.93 (t, J = 4.8 Hz,
4H), 3.35 (t, J = 4.9 Hz, 4H),
3.06 - 2.91 (m, 1H), 2.15 (d, J
= 26.6 Hz, 2H), 1.89 (s, 6H),
1.30 - 0.94 (m, 4H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.06 (d, J = 9.1 Hz,
1H), 6.98 - 6.86 (m, 2H), 6.58
(d, J = 9.1 Hz, 1H), 4.81 (dq, J
601 = 5.5, 2.7 Hz, 1H), 4.52 (s,
1H), 4.17 (d, J = 5.0 Hz,1H),
4.01 - 3.87 (m, 4H), 3.67 (dq,
J = 8.9, 8.1 Hz, 1H), 3.43 -
3.30 (m, 4H), 2.47 - 2.29 (m,
4H), 2.22 (dt, J = 11.9, 5.5 Hz,
2H), 2.05 - 1.82 (m, 6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.04 - 6.92 (m, 2H),
4.82 (d, J = 3.0 Hz, 1H), 3.93
602 464.1 (dd, J = 5.9, 3.8 Hz, 4H), 3.65
(d, J = 8.7 Hz, 1H), 3.44 - 3.29
(m, 4H), 3.08 (s, 6H), 2.39 (s,
3H), 2.21 (d, J = 14.4 Hz, 2H),
1.92 (dt, J = 17.0, 10.7 Hz,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.18 (s, 1H), 7.02 -
603 450.1 6.86 (m, 2H), 4.81 (s, 2H),
4.00 - 3.76 (m, 5H), 3.42 -
3.26 (m, 4H), 3.07 (s, 6H),
2.20 (q, J = 6.3, 5.8 Hz, 2H),
2.01 - 1.79 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.62 (d, J =
1.9 Hz, 1H), 8.53 (d, J :19
Hz, 1H), 6.87 (d, J = 2.5 Hz,
1H), 6.81 (d, J = 2.6 Hz, 1H),
4.71 (s, 1H), 3.94 - 3.72 (m,
7H), 3.25 (dd, J = 5.8, 3.8 Hz,
4H), 2.29 (d, J = 10.4 Hz, 3H),
2.21 - 2.02 (m, 2H), 1.93 -
1.71 (m, 6H).
WO 59690
Compound ESMS H NMR
Compound Structure
No. M+H
1H NMR (300 MHz,
Chloroform-d) 6 9.41 (s, 1H),
8.20 (dd, J = 4.8, 2.4 Hz, 2H),
6.98 - 6.77 (m, 3H), 6.44 (dt, J
606 = 7.5, 4.8 Hz, 2H), 4.71 (s,
2H), 3.83 (dd, J = 5.7, 4.0 Hz,
6H), 3.27 (dt, J = 30.0, 4.9 Hz,
5H), 2.13 (s, 2H), 2.00 - 1.68
(m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.79 (d, J = 2.9 Hz,
1H), 6.93 (dd, J = 17.8, 2.5
Hz, 2H), 5.19 - 5.07 (m, 1H),
4.80 (dt, J = 6.7, 3.4 Hz, 1H),
4.32 (q, J = 7.1 Hz, 3H), 3.98 -
3.87 (m, 4H), 3.41 - 3.29 (m,
4H), 2.30 - 2.13 (m, 2H), 2.03
- 1.84 (m, 6H), 1.41 (t, J = 7.1
Hz, 3H).
Compound ESMS H NMR
1H NMR (300 MHz,
form-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 2.0
Hz, 1H), 6.94 (dd, J = 18.9,
2.5 Hz, 2H), 5.42 (d, J = 8.4
Hz, 1H), 4.79 (s, 1H), 4.22 -
4.06 (m, 1H), 4.03 - 3.89 (m,
10H), 3.42 - 3.22 (m, 4H),
2.19 (m, 2H), 2.01 - 1.79 (m,
6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.72 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.03 - 6.84 (m, 2H),
609 5.66 (d, J = 9.1 Hz, 1H), 4.82
(s, 1H), 4.09 - 3.84 (m, 7H),
3.35 (dd, J = 5.5, 3.6 Hz, 4H),
2.20 (s, 2H), 1.91 (d, J = 6.4
Hz, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.51 (s, 2H), 6.95 (d,
J = 2.5 Hz, 1H), 6.91 (d, J =
2.6 Hz, 1H), 5.39 (d, J = 8.1
Hz, 1H), 4.88 (d, J = 1.8 Hz,
4H), 4.80 (d, J = 6.2 Hz, 1H),
4.13 - 3.98 (m, 1H), 3.96 -
3.89 (m, 4H), 3.38 - 3.30 (m,
4H), 3.06 (s, 1H), 2.28 - 2.11
(m, 2H), 1.98 - 1.84 (m, 6H).
nd ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz,
Chloroform-d) 6 8.67 (d, J =
1.9 Hz, 1H), 8.60 (d, J = 1.9
Hz, 1H), 6.91 (dd, J = 16.1,
2.5 Hz, 2H), 4.81 (q, J = 3.6,
2.4 Hz, 1H), 4.03 - 3.75 (m,
4H), 3.59 (d, J = 2.9 Hz, 2H),
3.45 - 3.28 (m, 4H), 2.20 (dt, J
= 9.5, 4.6 Hz, 2H), 1.74 - 1.23
(m, 7H) 1.41 (s,1H).
1H NMR (300 MHz, CDCI3):
ppm 1.83 — 1.96 (m, 6 H), 2.14
— 2.24 (m, 2 H), 3.31 — 3.35
(m, 4 H), 3.44 (s, 3 H), 3.69 —
612 3.72 (m, 2 H), 3.89 — 3.95 (m,
H), 4.06 —4.09 (m, 2 H),
4.74-4.83 (m, 1 H), 5.04—
.15 (m, 1 H), 6.90 (d, J = 2.4
Hz, 1 H), 6.94 (d,
1H NMR (300 MHz, CDCI3):
ppm 1.39 - 1.75 (m, 6 H),
1.82 - 1.95 (m, 6 H), 2.11 -
2.24 (m, 2 H), 2.37 - 2.63 (m,
613 4 H), 2.67 - 2.90 (m, 2 H),
3.33 (t, J = 4.7 Hz, 4 H), 3.87 -
3.97 (m, 5 H), 4.01 - 4.20 (m,
2 H), 4.74 - 4.82 (m, 1 H),
4.98 (d, J = 7.9 Hz, 1
Compound ESMS H NMR
1H NMR (300 MHz, CDCI3):
ppm 1.83 — 1.95 (m, 6 H), 2.12
— 2.26 (m, 2 H), 3.30 — 3.40
(m, 4 H), 3.85 — 3.96 (m, 5 H),
614 4.55-4.68 (m, 1 H), 4.74—
4.82 (m, 1 H), 6.10 (dd, J =
7718 Hz, 1 H), 6.18 (dd, J =
8018 Hz, 1 H), 6.90 (d, J =
1.8 Hz, 1 H), 6
1H NMR (300 MHz, :
ppm 1.82 — 2.10 (m, 7 H), 2.14
— 2.29 (m, 2 H), 3.26 — 3.40
(m, 4 H), 3.82 — 4.05 (m, 5 H),
615 4.64 (s, 2 H), 4.75 — 4.84 (m, 1
H), 4.85 — 5.13 (m, 1 H), 6.46
(s, 1 H), 6.51 (d, J = 5.3 Hz, 1
H), 6.90 (d, J = 1.7 Hz, 1 H),
6.94 (d,
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 6.95 (dd, J = 16.6,
2.5 Hz, 2H), 6.30 (s, 1H), 5.02
616 (s, 1H), 4.82 (s, 1H), 4.38 (d,
J = 0.9 Hz, 2H), 3.99 - 3.83
(m, 5H), 3.39 - 3.24 (m, 4H),
2.49 (s, 3H), 2.33 - 2.11 (m,
2H), 1.91 (q, J = 9.0, 6.9 Hz,
6H).
Compound ESMS H NMR
nd Structure
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (s, 1H),
8.20 (d, J = 4.8 Hz, 2H), 6.90
(dd, J = 16.2, 2.5 Hz, 2H),
6.44 (t, J = 4.8 Hz, 1H), 5.15
617 437.1
(d, J = 8.1 Hz, 1H), 4.90 (d, J
= 3.9 Hz, 2H), 4.79 - 4.64 (m,
1H), 3.99 - 3.71 (m, 6H), 3.32
- 3.19 (m, 4H), 2.21 - 2.04 (m,
2H), 1.95 - 1.70 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.55 (d, J :19
Hz, 1H), 6.86 (dd, J = 16.5,
2.5 Hz, 2H), 5.94 (s, 1H), 4.73
618 463.13 (s, 1H), 3.85 (dd, J = 5.9, 3.7
Hz, 4H), 3.35 - 3.20 (m, 4H),
2.67 - 2.51 (m, 2H), 2.26 (s,
3H), 2.09 (d, J = 36.8 Hz, 3H),
1.94 - 1.59 (m, 6H), 0.91 (t, J
= 7.4 Hz, 3H).
Chloroform-d) 6 8.77 (s, 1H),
8.29 (d, J = 4.7 Hz, 2H), 7.02
(d, J = 2.5 Hz, 1H), 6.97 (d, J
= 2.5 Hz, 1H), 6.53 (t, J = 4.8
619 I1H NMR (300 MHz, Hz, 1H), 5.16 (dd, J = 16.9,
7.5 Hz, 2H), 4.81 (s, 1H), 3.93
(t, J = 4.8 Hz, 5H), 3.34 (t, J =
4.9 Hz, 4H), 2.27 (d, J = 21.1
Hz, 2H), 2.06 - 1.76 (m, 6H),
1.66 (d, J = 6.6 Hz, 3H).
Compound ESMS H NMR
Compound Structure
1H NMR (300 MHz,
form-d) 6 10.21 (s, 1H),
9.26 (s, 1H), 8.30 (d, J = 4.8
Hz, 2H), 7.09 - 6.88 (m, 2H),
6.54 (t, J = 4.8 Hz, 1H), 4.89
620 435.1
(dq, J = 4.9, 2.5 Hz, 1H), 4.04
(q, J = 6.5 Hz, 1H), 3.99 - 3.87
(m, 5H), 3.55 - 3.39 (m, 5H),
2.35 - 2.17 (m, 3H), 2.09 -
1.82 (m, 6H).
1H NMR (400 MHz, CDCI3) 5
8.68 (d, J = 1.7 Hz, 1H), 8.61
(d, J = 1.7 Hz, 1H), 7.95 (s,
1H), 6.94 (d, J = 2.1 Hz, 1H),
6.90 (s, 1H), 5.12 (d, J = 7.5
621 449.55 Hz, 1H), 4.77 (s, 1H), 4.60 (t,
J = 8.5 Hz, 2H), 4.00 (s, 1H),
3.94 — 3.84 (m, 4H), 3.38 —
3.27 (m, 4H), 3.11 (t, J = 8.3
Hz, 2H), 2.25 — 2.10 (m, 2H),
1.97 — 1.82 (m, 6H).
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 1.98 (m, 6 H), 2.13
— 2.25 (m, 2 H), 3.29 — 3.38
(m, 4 H), 3.75 — 3.85 (m, 1 H),
622 424.2 3.88 — 3.96 (m, 4 H), 4.56 —
4.71 (m, 1 H), 4.75 — 4.83 (m,
1 H), 6.36 (dd, J = 9.1, 3.3 Hz,
1 H), 6.90 (d, J = 1.9 Hz, 1 H),
6.95 (d, J =
2014/024767
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (300 MHz, CDCI3):
ppm 1.80 — 1.98 (m, 6 H), 2.13
— 2.23 (m, 2 H), 2.38 (s, 3 H),
3.25 — 3.37 (m, 4 H), 3.62 —
623 420.3 3.77 (m, 1 H), 3.88 — 3.97 (m,
4 H), 4.76 -4.83 (m, 1 H),
6.23 (d, J = 7.9 Hz, 1 H), 6.43
(d, J = 7.3 Hz, 1 H), 6.91 (d, J
= 2.5 Hz, 1 H)
1H NMR (300 MHz, CDCI3):
ppm 1.78 — 2.01 (m, 6 H), 2.11
— 2.24 (m, 2 H), 2.33 (s, 6 H),
2.38 — 2.45 (m, 1 H), 2.69 (t, J
624 ‘ 494.3 = 5.2 Hz, 2 H), 3.26 — 3.42 (m,
4 H), 3.84 — 3.98 (m, 4 H),
4.01 (t, J = 5.2 Hz, 2 H), 4.72 —
4.83 (m, 1 H), 4.97 (d, J = 7.5
Hz, 1 H)
1H NMR (300 MHz, CDCI3):
ppm 1.81 - 1.95 (m, 6 H),
2.11 - 2.26 (m, 2 H), 3.31 -
3.35 (m, 4 H), 3.44 (s, 3 H),
625 480.3 3.69 - 3.73 (m, 2 H), 3.76 -
3.84 (m, 1 H), 3.89 - 3.93 (m,
4 H), 4.04 - 4.08 (m, 2 H),
4.44 (br s, 1 H), 4.74 - 4.81
(m, 1 H), 6.37 (d, J = 8.9
nd ESMS H NMR
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 1.98 (m, 6 H), 2.12
— 2.25 (m, 2 H), 2.37 — 2.48
(m, 3 H), 2.58 — 2.77 (m, 4 H),
626 3.04 — 3.16 (m, 4 H), 3.28 —
3.37 (m, 4 H), 3.77 — 3.85 (m,
1 H), 3.87 — 3.97 (m, 4 H),
4.32—4.51 (m, 1 H), 4.73—
4.83 (m, 1 H), 6.38(
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 2.03 (m, 7 H), 2.12
— 2.28 (m, 2 H), 3.28 — 3.39
(m, 4 H), 3.81 (s, 3 H), 3.87 —
627 3.98 (m, 5 H), 4.76 — 4.84 (m,
1 H), 5.87 (d, J = 1.5 Hz, 1 H),
6.21 (dd, J = 5915 Hz, 1 H),
6.91 (d, J = 1.7 Hz, 1 H), 6.95
(d, J =1
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J = 1.9
Hz, 1H), 6.94 (dd, J = 14.6,
628 2.5 Hz, 2H), 5.57 (s, 1H), 4.86
- 4.72 (m, 1H), 4.02 - 3.86 (m,
4H), 3.50 - 3.26 (m, 5H), 2.65
(s, 3H), 2.32 - 2.06 (m, 2H),
2.06 - 1.73 (m, 6H).
nd ESMS H NMR
C°mp°”“d St“‘6 ”et
1H NMR (300 MHz, CDCI3) 6
8.62 (s, 1H), 8.54 (s, 1H),
8.15 — 7.93 (m, 1H), 7.40 (d, J
= 8.0 Hz, 1H), 6.88 (s, 1H),
6.84 (s, 1H), 6.34 (d, J = 8.6
629 518.4
Hz, 1H), 4.83 — 4.56 (m, 2H),
4.40 — 4.22 (m, 1H), 4.00 —
3.62 (m, 5H), 3.47 — 3.04 (m,
7H), 2.24 — 2.02 (m, 2H), 1.96
— 1.70 (m, 6H).
1H NMR (400 MHz, CDCI3) 6
8.68 (d, J = 1.8 Hz, 1H), 8.59
(d, J = 1.8 Hz, 1H), 8.06 (s,
1H), 7.55 (d, J = 8.3 Hz, 1H),
6.94 (d, J = 2.3 Hz, 1H), 6.89
(d, J = 2.2 Hz, 1H), 6.41 (d, J
630 504.22
= 8.7 Hz, 1H), 4.88 (dd, J =
13.4, 6.7 Hz, 1H), 4.85 — 4.71
(m, 2H), 3.98 — 3.85 (m, 5H),
3.39 — 3.28 (m, 4H), 2.25 —
2.12 (m, 2H), 1.94 — 1.82 (m,
6H).
1H NMR (400 MHz, CDCI3) 6
8.68 (d, J = 1.7 Hz, 1H), 8.61
(d, J :18 Hz, 1H), 7.01 (d, J
= 8.4 Hz, 1H), 6.94 (d, J = 2.3
Hz, 1H), 6.89 (s, 1H), 5.96 (d,
J = 8.4 Hz, 1H), 4.75 (s, 1H),
631 464.53
4.43 — 4.35 (m, 2H), 4.22 (s,
1H), 4.19 — 4.10 (m, 2H), 3.98
— 3.86 (m, 4H), 3.82 (s, 1H),
3.36 — 3.28 (m, 4H), 2.23 —
2.08 (m, 2H), 1.94 — 1.79 (m,
6H).
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 7.98 (s, 1H), 7.02 -
6.85 (m, 2H), 5.04 (d, J = 8.2
Hz, 1H), 4.79 (s, 1H), 4.02 (s,
632 476.44
1H), 3.96 - 3.87 (m, 4H), 3.40
- 3.25 (m, 4H), 2.82 (t, J = 5.9
Hz, 2H), 2.73 (t, J = 5.8 Hz,
2H), 2.48 (s, 3H), 2.19 (d, J =
8.5 Hz, 2H), 1.91 (d, J = 5.3
Hz, 5H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.18 (d, J = 5.1 Hz,
1H), 7.01 - 6.88 (m, 2H), 6.42
(d, J = 5.1 Hz, 1H), 5.15 (d, J
= 8.0 Hz, 1H), 4.79 (d, J = 5.7
633 435.2
Hz, 1H), 4.17 - 4.00 (m, 1H),
3.98 - 3.83 (m, 4H), 3.67 (td, J
= 6.7, 4.0 Hz, 1H), 3.42 - 3.31
(m, 4H), 2.59 (q, J = 7.6 Hz,
2H), 2.20 (q, J = 6.1 Hz, 2H),
2.03 - 1.86 (m, 6H), 1.26 (t, J
= 7.6 Hz, 3H
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.63 (d, J :19
Hz, 1H), 8.19 (d, J = 5.1 Hz,
1H), 7.01 - 6.88 (m, 2H), 6.42
(d, J = 5.2 Hz, 1H), 5.14 (d, J
634 449.2 = 7.9 Hz, 1H), 4.80 (dt, J =
7.8, 3.8 Hz, 1H), 4.06 (d, J =
4.1 Hz, 0H), 3.99 - 3.85 (m,
4H), 3.46 - 3.24 (m, 4H), 2.78
(hept, J = 7.0 Hz, 1H), 2.34 -
2.11 (m, 2H), 2.04 - 1.81 (m,
7H), 1.25 (d, J = 7.0 Hz, 6H).
Compound ESMS H NMR
C d St t
1H NMR (300 MHz,
form-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 6.85 (dd, J = 17.6,
2.5 Hz, 2H), 5.86 - 5.70 (m,
635 481 .05 1H), 4.89 - 4.67 (m, 2H), 3.94
- 3.77 (m, 5H), 3.34 - 3.20 (m,
4H), 3.02 (q, J = 7.3 Hz, 2H),
2.27 - 2.04 (m, 5H), 1.93 -
1.63 (m, 6H), 1.30 (t, J = 7.3
Hz, 3H).
1H NMR (300 MHz,
Chloroform-d) 6 8.63 (d, J =
1.9 Hz, 1H), 8.54 (d, J :19
Hz, 1H), 6.86 (dd, J = 16.2,
2.5 Hz, 2H), 5.85 (s, 1H), 4.75
636 461.1 (d, J = 5.5 Hz, 1H), 3.96 - 3.76
(m, 4H), 3.34 - 3.19 (m, 4H),
2.41 (s, 3H), 2.13 (d, J = 8.5
Hz, 2H), 1.82 (q, J = 10.2, 8.8
Hz, 6H), 1.58 - 1.33 (m, 3H),
1.03 - 0.86 (m, 3H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 7.02 - 6.82 (m, 2H),
.41 (d, J = 0.8 Hz, 1H), 4.76
(td, J = 5.9, 3.0 Hz, 1H), 4.03 -
3.84 (m, 4H), 3.49 (q, J = 5.8
Hz, 1H), 3.40 - 3.25 (m, 5H),
2.33 - 2.10 (m, 4H), 2.00 -
1.77 (m, 7H).
Compound ESMS H NMR
Compound Structure
1H NMR (300 MHz, :
ppm 1.82 — 1.95 (m, 6 H), 2.14
— 2.26 (m, 2 H), 3.31 — 3.35
(m, 4 H), 3.77 — 3.85 (m, 1 H),
638 478.3 3.90 — 3.93 (m, 4 H), 4.71 —
4.80 (m, 3 H), 4.92 (t, J = 6.6
Hz, 2 H), 5.10 (quint., J = 5.6
Hz, 1 H), 6.39 (d, J = 8.9 Hz,
1 H), 6.90 (d,
1H NMR (300 MHz, CDCI3):
1.80 — 1.95 (m, 6 H), 2.10—
2.25 (m, 2 H), 2.52 — 2.64 (m,
4 H), 2.77 (t, J = 5.6 Hz, 2 H),
639 535.3 3.33 (t, J = 4.7 Hz, 4 H), 3.74
(t, J = 4.7 Hz, 4 H), 3.70 — 3.85
(m, 1 H), 3.91 (t, J = 4.7 Hz, 4
H), 4.06 (t, J = 5.6 Hz, 2 H),
4.30 —
1H NMR (300 MHz, CDCI3):
ppm 1.40 — 1.50 (m, 2 H), 1.56
— 1.70 (m, 4 H), 1.84— 1.94
(m, 6 H), 2.11 — 2.23 (m, 2 H),
640 533.4 2.46 — 2.58 (m, 4 H), 2.71 —
2.80 (m, 2 H), 3.33 (t, J = 4.7
Hz, 4 H), 3.76 — 3.84 (m, 1 H),
3.91 (t, J = 4.7 Hz, 4 H), 4.07
(t, J = 5.7 H
2014/024767
Compound ESMS H NMR
C d St t
1H NMR (400 MHz, CDC|3)6
8.73 — 8.65 (m, 1H), 8.60 (d, J
= 1.8 Hz, 1H), 6.93 (d, J = 2.4
Hz, 1H), 6.89 (d, J = 2.3 Hz,
1H), 4.75 (s, 1H), 3.95 — 3.87
(m, 4H), 3.39 — 3.28 (m, 4H),
3.05 — 2.93 (m, 1H), 2.82 —
2.69 (m, 1H), 2.24 — 2.08 (m,
2H), 1.80 — 1.71 (m, 6H), 1.07
(d, J = 6.2 Hz, 6H).
1H NMR (400 MHz, CDCI3) 5
8.70 (d, J = 1.9 Hz, 1H), 8.61
(d, J = 1.9 Hz, 1H), 7.78 (d, J
= 5.8 Hz, 1H), 6.96 (d, J = 2.4
Hz, 1H), 6.90 (d, J = 2.4 Hz,
1H), 6.36 — 6.26 (m, 1H), 5.99
(d, J = 1.9 Hz, 1H), 4.79 (d, J
= 2.4 Hz, 1H), 4.47 (d, J = 7.1
Hz, 1H), 3.99 — 3.85 (m, 4H),
3.56 — 3.49 (m, 1H), 3.39 —
3.26 (m, 4H), 2.28 — 2.16 (m,
2H), 1.98 — 1.80 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.61 (d, J = 1.9
Hz, 1H), 8.57 - 8.45 (m, 1H),
7.81 (d, J = 8.4 Hz, 1H), 7.18
(d, J = 1.2 Hz, 1H), 6.93 (dd, J
643 = 16.8, 2.5 Hz, 2H), 5.48 (s,
1H), 4.83 (dp, J = 4.5, 2.4 Hz,
1H), 4.23 (dp, J = 8.3, 6.6 Hz,
1H), 4.00 - 3.85 (m, 4H), 3.42
- 3.23 (m, 4H), 2.35 - 2.15 (m,
2H), 1.97 - 1.76 (m, 6H), 1.26
(d, J = 6.6 Hz, 6H).
2014/024767
Compound ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 6.93 (dd, J = 17.5,
2.5 Hz, 2H), 5.47 (s, 1H), 4.90
(s, 1H), 4.31 (q, J = 7.1 Hz,
2H), 3.92 (dd, J = 5.9, 3.7 Hz,
4H), 3.60 (s, 1H), 3.38 - 3.28
(m, 4H), 2.40 (s, 3H), 2.19 (d,
J = 9.4 Hz, 2H), 1.97 - 1.80
(m, 6H), 1.36 (t, J = 7.1 Hz,
3H), 4.83 - 4.76 (m, 1H).
1H NMR (400 MHz, CDCI3) 5
8.68 (d, J = 1.8 Hz, 1H), 8.60
(d, J :19 Hz, 1H), 6.94 (d, J
= 2.4 Hz, 1H), 6.87 (d, J = 2.4
Hz, 1H), 4.83 (t, J = 6.9 Hz,
645 2H), 4.76 (s, 1H), 4.45 (t, J =
6.6 Hz, 2H), 4.14 — 4.05 (m,
1H), 3.94 — 3.88 (m, 4H), 3.35
— 3.30 (m, 4H), 2.65 (s, 1H),
2.24 — 2.15 (m, 2H), 1.75 —
1.64 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.71 (d, J =
1.9 Hz, 1H), 8.57 (d, J :19
Hz, 1H), 7.01 - 6.84 (m, 2H),
646 6.18 (d, J = 1.4 Hz, 1H), 4.80
(s, 1H), 4.43 (s, 1H), 3.93 (t, J
= 4.9 Hz, 5H), 3.48 (s, 3H),
3.43 - 3.25 (m, 5H), 2.38 -
1.86 (m, 9H).
WO 59690
Compound ESMS H NMR
C°mp°”“d St“‘6 ”ret
1H NMR (400 MHz, CDCI3) 5
8.67 (d, J = 1.9 Hz, 1H), 8.59
(d, J = 1.9 Hz, 1H), 6.94 (d, J
= 2.5 Hz, 1H), 6.88 (d, J = 2.5
Hz, 1H), 4.75 (s, 1H), 4.03 —
3.94 (m, 2H), 3.94 — 3.83 (m,
4H), 3.41 (td, J = 11.7, 2.1 Hz,
2H), 3.36 — 3.25 (m, 4H), 2.89
— 2.77 (m, 2H), 2.24 — 2.13 (m,
2H), 1.85 — 1.68 (m, 8H), 1.40
(ddd, J = 16.2, 12.3, 4.4 Hz,
3H).
1H NMR (400 MHz, CDCI3) 5
8.69 (d, J = 1.9 Hz, 1H), 8.62
(d, J = 1.9 Hz, 1H), 7.17 (dd, J
= 8.5, 7.4 Hz, 2H), 6.95 (d, J =
2.5 Hz, 1H), 6.90 (d, J = 2.4
648 Hz, 1H), 6.69 (t, J = 7.3 Hz,
1H), 6.63 (d, J = 7.9 Hz, 2H),
4.75 (s, 1H), 3.98 — 3.71 (m,
5H), 3.52 (s, 1H), 3.40 — 3.30
(m, 4H), 2.24 — 2.11 (m, 2H),
1.94 — 1.84 (m, 6H).
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.62 (d, J = 1.9
Hz, 1H), 7.10 (d, J = 2.3 Hz,
1H), 6.99 - 6.81 (m, 2H), 5.52
(d, J = 2.3 Hz, 1H), 4.76 (t, J =
.9 Hz, 1H), 4.06 - 3.86 (m,
5H), 3.72 (s, 3H), 3.49 (t, J =
.3 Hz, 1H), 3.40 - 3.18 (m,
4H), 2.19 (dq, J = 12.9, 7.1,
6.7 Hz, 2H), 1.90 (dd, J = 9.4,
.2 Hz, 7H).
WO 59690
Compound ESMS H NMR
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.62 (d, J :19
Hz, 1H), 8.47 - 8.36 (m, 1H),
6.96 (d, J = 2.5 Hz, 1H), 6.90
650 (d, J = 2.5 Hz, 1H), 6.18 (d, J
= 1.2 Hz, 1H), 4.95 - 4.73 (m,
2H), 4.04 - 3.78 (m, 5H), 3.44
- 3.24 (m, 4H), 2.30 - 2.12 (m,
2H), 2.03 - 1.70 (m, 7H), 1.17
- 0.80 (m, 4H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz, 1H), 8.61 (d, J :19
Hz, 1H), 8.50 (d, J =1.1 Hz,
1H), 6.93 (dd, J = 15.9, 2.5
Hz, 2H), 6.17 (d, J =1.1 Hz,
651 1H), 4.98 (d, J = 8.1 Hz, 1H),
4.86 - 4.75 (m, 1H), 3.97 -
3.87 (m, 4H), 3.39 - 3.29 (m,
4H), 2.61 (q, J = 7.6 Hz, 2H),
2.21 (dt, J = 11.2, 5.0 Hz, 2H),
2.04 - 1.82 (m, 6H), 1.25 (t, J
= 7.6 Hz, 3H).
1H NMR (300 MHz,
Chloroform-d) 6 8.70 (d, J =
1.9 Hz,1H),8.61 (d, J :19
Hz, 1H), 8.52 (d, J =1.1 Hz,
1H), 6.93 (dd, J = 16.0, 2.5
Hz, 2H), 6.19 - 6.12 (m, 1H),
652 4.91 (d, J = 8.0 Hz, 1H), 4.81
(d, J = 5.4 Hz, 1H), 4.13 - 3.77
(m, 5H), 3.40 - 3.29 (m, 4H),
2.80 (hept, J = 6.8 Hz, 1H),
2.27 - 2.00 (m, 2H), 1.99 -
1.83 (m, 6H), 1.40 - 1.12 (m,
6H).
Compound ESMS H NMR
“d St“‘6 ”et
1H NMR (300 MHz, Methanol-
d4/ CDCI3) 5 8.82 — 8.68 (m,
2H), 8.61 (d, J = 0.8 Hz, 1H),
7.38 (t, J = 0.8 Hz, 1H), 7.18
653 451 .07 (s, 1H), 5.11 —4.99 (m, 1H),
4.47 —4.31 (m, 1H), 3.99 —
3.88 (m, 4H), 3.74 — 3.58 (m,
4H), 2.37 — 2.23 (m, 2H), 2.13
— 1.80 (m, 6H).
1H NMR (300 MHz, CDCI3):
ppm 1.82 — 1.95 (m, 6 H), 2.11
— 2.24 (m, 2 H), 2.32 (s, 6 H),
2.68 (t, J = 5.7 Hz, 2 H), 3.29 —
654 493.3 3.37 (m, 4 H), 3.76 — 3.86 (m,
1 H), 3.88 — 3.95 (m, 4 H),
4.00 (t, J = 5.7 Hz, 2 H), 4.29
(d, J = 8.2 Hz, 1 H), 4.70 —
4.83 (m, 1 H)
1H NMR (300 MHz, CDCI3):
ppm 1.81 — 1.97 (m, 6 H), 2.10
— 2.25 (m, 2 H), 2.33 (s, 3 H),
2.42 — 2.83 (m, 8 H), 2.78 (t, J
655 548.3 = 5.6 Hz, 2 H), 3.28 — 3.39 (m,
4 H), 3.75 — 3.85 (m, 1 H),
3.86 — 3.97 (m, 4 H), 4.05 (t, J
= 5.6 Hz, 2 H), 4.29 (t, J = 8.4
Hz, 1 H)
Compound ESMS H NMR
“d St“‘6 ”ret
1H NMR (300 MHz, DMSO-
d6) 5 8.64 (d, J = 1.9 Hz, 1H),
8.47 (d, J = 1.9 Hz, 1H), 8.25
(d, J = 4.8 Hz, 2H), 7.15 (d, J
= 7.3 Hz, 1H), 6.59 — 6.47 (m,
2H), 6.31 (d, J = 2.2 Hz, 1H),
.80 — 5.68 (m, 1H), 4.85 (s,
2H), 4.62 (d, J = 5.3 Hz, 0H),
4.24 (t, J = 7.4 Hz, 2H), 3.83
(s, 1H), 3.71 (dd, J = 8.4, 4.7
Hz, 2H), 2.14 — 1.97 (m, 2H),
1.79 (d, J = 19.4 Hz, 5H).
1H NMR (300 MHz,
Chloroform-d) 6 8.59 (d, J =
1.9 Hz, 1H), 8.50 (d, J = 1.9
Hz, 1H), 8.11 (s, 2H), 6.91 -
657 6.70 (m, 2H), 4.66 (s, 1H),
3.92 - 3.56 (m, 7H), 3.45 (d, J
= 4.3 Hz, 3H), 3.31 - 3.18 (m,
6H), 2.08 (s, 2H), 1.84 (d, J =
38.5 Hz, 8H).
1H NMR (300 MHz, CDCI3):
ppm 1.37 (t, J = 7.0 HZ, 3 H),
1.84 — 1.94 (m, 6 H), 2.10—
2.25 (m, 2 H), 3.29 — 3.38 (m,
658 4 H), 3.75 — 3.85 (m, 1 H),
3.88 — 3.95 (m, 4 H), 3.97 (q, J
= 7.0 Hz, 2 H), 4.22 — 4.34 (m,
1 H), 4.73-4.80 (m, 1 H),
6.36 (d, J = 9.0 H
Compound ESMS
C d St t
1H NMR (300 MHz,
Chloroform-d) 6 8.69 (d, J =
1.9 Hz, 1H), 8.60 (d, J = 1.9
Hz, 1H), 6.92 (dd, J = 19.6,
659 2.5 Hz, 2H), 5.25 (s, 1H), 4.76
(q, J = 8.3, 7.2 Hz, 2H), 3.97 -
3.87 (m, 4H), 3.58 - 3.28 (m,
8H), 2.40 (s, 3H), 2.24 - 2.13
(m, 2H), 2.07 - 1.78 (m, 6H).
Biological assay ofcompounds ofthe invention
DNA-PK tion Assay
Compounds were screened for their ability to inhibit DNA—PK kinase using a
standard radiometric assay. Briefly, in this kinase assay the transfer of the terminal
33P—phosphate in 33P—ATP to a e substrate is interrogated. The assay was carried out
in 384-well plates to a final volume of 50 uL per well containing approximately 6 nM
DNA—PK, 50 mM HEPES (pH 7.5), 10 mM MgC12, 25 mM NaCl, 0.01% BSA, 1 mM
DTT, 10 ug/mL sheared double-stranded DNA (obtained from Sigma), 0.8 mg/mL DNA-
PK peptide ro-Pro-Leu-Ser-Gln-Glu-Ala-Phe-Ala-Asp-Leu-Trp-Lys-Lys- Lys,
obtained from an Peptide), and 100 uM ATP. Accordingly, compounds of the
invention were dissolved in DMSO to make 10 mM initial stock solutions. Serial
dilutions in DMSO were then made to obtain the final ons for the assay. A 0.75 uL
aliquot of DMSO or inhibitor in DMSO was added to each well, followed by the addition
ofATP substrate solution containing 33P-ATP (obtained from Perkin Elmer). The
on was started by the addition of DNA-PK, peptide and ds-DNA. After 45 min, the
on was ed with 25 uL of 5% phosphoric acid. The reaction mixture was
transferred to MultiScreen HTS 384-well PH plates (obtained from Millipore), allowed to
bind for one hour, and washed three times with 1% phosphoric acid. Following the
addition of 50 uL of Ultima GoldTM high efficiency scintillant (obtained from Perkin
Elmer), the samples were counted in a Packard TopCount NXT Microplate Scintillation
and Luminescence Counter (Packard BioScience). The K, values were calculated using
Microsoft Excel Solver macros to fit the data to the kinetic model for competitive tight-
binding inhibition.
] Each of compounds 1-291, 295—331, 333—367, 369—523, 525-640, 642-644,
646, and 648—659 has a K of less than 1.0 micromolar for the inhibition of DNA-PK.
Each of compounds 3, 6—14, 16—18, 23—34, 36—37, 39—41, 43—46, 49—72, 74—76, 78, 84—101,
103—123, 127—200, 202-291, 295-299, 305, 307-331, 1, 343, 347-366, 4,
376-391, 393-519, 521-523, 526-554, 556-610, 612-640, 642-644, 646, 648-655 and 657-
659 has a K of less than 0.10 micromolar for the inhibition of DNA-PK.
gh the foregoing invention has been described in some detail by way of
illustration and example for purposes of clarity of understanding, it will be y
apparent to those of ry skill in the art in light of the teachings of this invention that
certain changes and modifications may be made thereto without departing from the spirit
or scope of the appended claims.
Claims (68)
1. A compound having the formula: (I), or a pharmaceutically acceptable salt thereof, wherein: Ring A is , , , , or ; Ring B is , , , , , , , , , , or , wherein Ring B is optionally tuted with up to 4 fluorine atoms, up to two OH, or up to two C1-4alkyl which is optionally substituted with up to 3 fluorine atoms, up to two OH, or up to two OC1-2alkyl groups; Ring C is a cyclohexane or a cyclobutane ring; X is –NH-, -O-, or -OC1-4 alkyl-; each of R1 and R2 is, independently, hydrogen, -C(O)NHR4, -C(O)OR4, -NHC(O)R4, -NHC(O)OR4, )NHR4, -NHS(O)2R4, -C0-4 alkyl-NHR4, or -OR4, wherein R1 and R2 cannot simultaneously be hydrogen, and wherein R1 and R2 and the ening carbon atom can form a dioxane or dioxolane ring; R3 is hydrogen, -C1-4alkyl, fluoro, chloro, -OC1-2alkyl, -C(O)H, -C(O)OH, -C(O)OC1-2alkyl, - CN, -C(O)NHC1-2alkyl, or H2, wherein each of said R3 alkyl is ally substituted with up to 3 fluorine atoms, up to two OH, or up to two -OC1-2alkyl groups; R4 is hydrogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-5cycloalkyl, , a 5membered monocyclic or bicyclic heteroaryl ring selected from pyrrole, imidazole, pyrazole, triazole, thiazole, isothiazole, oxazole, pyridine, pyrimidine, pyrimidinone, pyrazine, pyridazine, and quinoline, or a 4membered monocyclic or bicyclic heterocyclyl ring selected from e, tetrahydrofuran, tetrahydropyran, dihydroisoxazole, pyrimidine- 2,4(1H,3H)-dione, dihydrofuropyrimidine, opyranopyrimidine, dihydropyrrolopyrimidine, tetrahydropteridine, and tetrahydropyridopyrimidine, wherein each of said R4 groups is optionally tuted with up to four Br, Cl, F, or kyl, up to three CN, NO2, kenyl, C2-4alkynyl, C3-6cycloalkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C(O)OC1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl)2, C(O)NH(C0-4 alkyl-C3-5 cycloalkyl), CH2OR5, C0-4 alkyl-C(O)R5, C0-4 alkyl-C(O)N(R5)2, C0-4 alkyl-C(O)OR5, C0-4 alkyl-NHC(O)R5, C0-4 alkyl-N(R5)2, a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine, and piperazine, a heteroaryl ring system selected from furan, oxazole, zole, pyrrole, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is ally substituted with up to four fluorine atoms, up to two C1-4alkyl groups, up to two OH groups, up to two OC1-4alkyl groups, up to two SC1-4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and each R5 is, independently, hydrogen, C1-4alkyl, a 5membered aryl selected from imidazole, triazole, thiazole, pyridine, and pyrimidine, or a 4membered heterocyclyl selected from e, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the intervening nitrogen atom form a line ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
2. The nd of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring C is cyclobutane.
3. The compound of claim 2, having the following formula: (II), or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3, having the ing formula: (II-A), or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4, having the following formula: (II-A-1), or a pharmaceutically acceptable salt thereof.
6. The nd of claim 4 or 5, or a pharmaceutically acceptable salt thereof, wherein R2 is -C0-4 alkyl-NHR4.
7. The compound of claim 3, having the ing formula: (II-B), or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7, having the following formula: (II-B-1), or a pharmaceutically acceptable salt thereof.
9. The compound of claim 7 or 8, or a pharmaceutically acceptable salt thereof, wherein R1 is -C0-4 alkyl-NHR4.
10. The compound of any one of claims 2-9, or a pharmaceutically able salt thereof, wherein X is –O- or -OC1-4 alkyl-.
11. The compound of any one of claims 2-10, or a pharmaceutically acceptable salt thereof, wherein is , , , , or .
12. The compound of claim 11, or a pharmaceutically acceptable salt f, wherein is .
13. The compound of any one of claims 2-12, or a ceutically acceptable salt thereof, wherein R3 is hydrogen.
14. The compound of any one of claims 2-13, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-5cycloalkyl, or phenyl, wherein each of said R4 groups is optionally substituted with up to four Br, Cl, F, or C1-4alkyl, up to three CN, NO2, C2-4alkenyl, C2-4alkynyl, cloalkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl- O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 lkyl, 1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, C(O)NH(C0-4 alkyl- C3-5 cycloalkyl), CH2OR 5, C 5, C 5) 5, C 0-4 alkyl-C(O)R 0-4 alkyl-C(O)N(R 2, C0-4 alkyl-C(O)OR 0-4 alkyl-NHC(O)R 5, C 5) 0-4 alkyl-N(R 2, a heterocyclic ring system ed from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, dine, pyrrolidine, and piperazine, a heteroaryl ring system ed from furan, oxazole, oxadiazole, e, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is optionally substituted with up to four fluorine atoms, up to two kyl groups, up to two OH groups, up to two OC1-4alkyl groups, up to two SC1- 4alkyl groups, a C(O)C1-4 alkyl, a 1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and each R5 is, independently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from imidazole, triazole, thiazole, pyridine, and pyrimidine, or a 4membered heterocyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the ening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
15. The nd of any one of claims 2-13, or a pharmaceutically acceptable salt thereof, wherein R4 is a 5membered monocyclic or bicyclic heteroaryl ring selected from pyrrole, imidazole, pyrazole, triazole, thiazole, isothiazole, oxazole, pyridine, pyrimidine, pyrimidinone, pyrazine, pyridazine, and quinoline, wherein each of said R4 groups is ally substituted with up to four Br, Cl, F, or kyl, up to three CN, NO2, C2- 4alkenyl, C2-4alkynyl, cloalkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C(O)OC1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, C(O)NH(C0-4 C3-5 cycloalkyl), CH2OR 5, C 5, C 5) 5, 0-4 alkyl-C(O)R 0-4 alkyl-C(O)N(R 2, C0-4 alkyl-C(O)OR C0-4 alkyl-NHC(O)R 5, C 5) 0-4 alkyl-N(R 2, a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine, and piperazine, a aryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is optionally substituted with up to four fluorine atoms, up to two C1-4alkyl groups, up to two OH groups, up to two lkyl groups, up to two SC1- 4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 C3-5 cycloalkyl; and each R5 is, independently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from imidazole, triazole, thiazole, ne, and pyrimidine, or a 4membered heterocyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three ne atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the ening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
16. The compound of any one of claims 2-13, or a pharmaceutically acceptable salt thereof, wherein R4 is a 4membered monocyclic or bicyclic heterocyclyl ring ed from oxetane, tetrahydrofuran, tetrahydropyran, dihydroisoxazole, pyrimidine-2,4(1H,3H)-dione, dihydrofuropyrimidine, dihydropyranopyrimidine, opyrrolopyrimidine, tetrahydropteridine, and tetrahydropyridopyrimidine, wherein each of said R4 groups is optionally substituted with up to four Br, Cl, F, or C1-4alkyl, up to three CN, NO2, C2- 4alkenyl, C2-4alkynyl, C3-6cycloalkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, 1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, C(O)NH(C0-4 C3-5 cycloalkyl), CH2OR 5, C 5, C 5) 5, 0-4 alkyl-C(O)R 0-4 alkyl-C(O)N(R 2, C0-4 alkyl-C(O)OR C0-4 alkyl-NHC(O)R 5, C 5) 0-4 alkyl-N(R 2, a heterocyclic ring system selected from oxetane, ine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, dine, pyrrolidine, and zine, a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is optionally substituted with up to four fluorine atoms, up to two C1-4alkyl groups, up to two OH , up to two OC1-4alkyl groups, up to two SC1- 4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and each R5 is, independently, hydrogen, kyl, a 5membered heteroaryl selected from imidazole, triazole, thiazole, pyridine, and pyrimidine, or a 4membered heterocyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally tuted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, n Ring C is cyclohexane.
18. The compound of claim 17, having the following formula: (III), or a pharmaceutically acceptable salt thereof.
19. The compound of claim 17 or 18, or a pharmaceutically acceptable salt thereof, wherein X is –NH-.
20. The compound of any one of claims 17-19, having the following formula: or a ceutically acceptable salt thereof.
21. The compound of claim 20, having the following formula: -1) or (III-A-2), or a ceutically acceptable salt thereof.
22. The nd of claim 20 or 21, or a pharmaceutically acceptable salt thereof, wherein R2 is -C0-4 alkyl-NHR4 or -OR4.
23. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein R2 is -NHR4.
24. The compound of claim 22, or a pharmaceutically acceptable salt thereof, wherein R2 is -OR4.
25. The compound of any one of claims 17-19, having the ing formula: (III-B), or a pharmaceutically acceptable salt thereof.
26. The compound of claim 25, having the following formula: (III-B-1) or (III-B-2), or a pharmaceutically acceptable salt thereof.
27. The compound of claim 25 or 26, or a pharmaceutically acceptable salt thereof, wherein R1 is -C0-4 alkyl-NHR4 or -OR4.
28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R1 is -NHR4.
29. The compound of claim 27, or a pharmaceutically acceptable salt f, wherein R1 is -OR4.
30. The compound of any one of claims 17-29, or a pharmaceutically acceptable salt thereof, wherein is , , , , or .
31. The compound of claim 30, or a pharmaceutically acceptable salt thereof, wherein is .
32. The compound of claim 17 or 18, or a pharmaceutically acceptable salt thereof, n X is –O-.
33. The compound of claim 17, 18 or 32, having the following formula: (III-C), or a pharmaceutically acceptable salt thereof.
34. The compound of claim 33, having the following formula: (III-C-1) or -2), or a pharmaceutically acceptable salt thereof.
35. The compound of claim 33 or 34, or a pharmaceutically acceptable salt thereof, wherein R2 is -C0-4 alkyl-NHR4 or -OR4.
36. The compound of claim 35, or a pharmaceutically acceptable salt thereof, wherein R2 is -NHR4.
37. The compound of claim 35, or a pharmaceutically acceptable salt f, wherein R2 is -OR4.
38. The compound of claim 17, 18 or 32, having the following formula: or a pharmaceutically acceptable salt thereof.
39. The compound of claim 38 having the following formula: (III-D-1) or (III-D-2), or a pharmaceutically acceptable salt thereof.
40. The compound of claim 38 or 39, or a pharmaceutically acceptable salt thereof, wherein R1 is -C0-4 alkyl-NHR4 or -OR4.
41. The compound of claim 40, or a ceutically able salt thereof, wherein R1 is -NHR4.
42. The compound of claim 40, or a ceutically acceptable salt thereof, wherein R1 is -OR4.
43. The compound of claim 38 or 39 having the ing formula: (III-D-3), or a pharmaceutically acceptable salt thereof, wherein Y is –O- or –NH-.
44. The compound of any one of claims 32-43, or a pharmaceutically acceptable salt thereof, wherein is , , , , or .
45. The compound of claim 44, or a pharmaceutically acceptable salt thereof, wherein is .
46. The compound of any one of claims 17-45, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, C1-4alkyl, OC1-2alkyl, C(O)NH2, or C(O)H, wherein each of said R3 alkyl is optionally substituted with OH.
47. The compound of claim 46, or a ceutically acceptable salt thereof, wherein R3 is hydrogen.
48. The compound of any one of claims 17-47, or a pharmaceutically able salt thereof, wherein R4 is hydrogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C3-5cycloalkyl, or phenyl, wherein each of said R4 groups is optionally substituted with up to four Br, Cl, F, or C1-4alkyl, up to three CN, NO2, C2-4alkenyl, C2-4alkynyl, C3-6cycloalkyl, C0-4 alkyl-C3-5 lkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C(O)OC1-4 alkyl, C(O)OC 0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, C(O)NH(C 5, C 5, C 5) 0-4 alkyl-C3-5 cycloalkyl), CH2OR 0-4 alkyl-C(O)R 0-4 C(O)N(R 2, C0-4 alkyl-C(O)OR 5, C 5, C 5) 0-4 alkyl-NHC(O)R 0-4 alkyl-N(R 2, a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine, and piperazine, a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, le, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is optionally substituted with up to four fluorine atoms, up to two C1-4alkyl , up to two OH groups, up to two OC1-4alkyl groups, up to two SC1- 4alkyl , a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and each R5 is, ndently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from imidazole, triazole, thiazole, ne, and pyrimidine, or a 4membered cyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two lkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
49. The compound of any one of claims 17-47, or a pharmaceutically acceptable salt thereof, wherein R4 is a 5membered monocyclic or bicyclic heteroaryl ring selected from e, imidazole, pyrazole, triazole, thiazole, isothiazole, oxazole, pyridine, pyrimidine, pyrimidinone, pyrazine, pyridazine, and quinoline, wherein each of said R4 groups is optionally substituted with up to four Br, Cl, F, or C1-4alkyl, up to three CN, NO2, C2-4alkenyl, kynyl, C3-6cycloalkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C(O)OC1-4 alkyl, 0-4 alkyl-C3-5 cycloalkyl, C0-4 C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, (C0-4 C3-5 cycloalkyl), CH2OR 5, C 5, C 5) 5, C 0-4 alkyl-C(O)R 0-4 alkyl-C(O)N(R 2, C0-4 alkyl-C(O)OR 0-4 alkyl-NHC(O)R 5, C 5) 0-4 alkyl-N(R 2, a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine, and piperazine, a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is optionally substituted with up to four ne atoms, up to two C1-4alkyl groups, up to two OH groups, up to two OC1-4alkyl , up to two SC1- 4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and each R5 is, independently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from imidazole, triazole, thiazole, ne, and pyrimidine, or a 4membered cyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the ening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
50. The compound of claim 49, or a pharmaceutically acceptable salt thereof, wherein R4 is pyridine or pyrimidine, which is optionally substituted with up to four Br, Cl, F, or C1-4alkyl, up to three CN, NO2, C2-4alkenyl, C2-4alkynyl, C3-6cycloalkyl, C0-4 alkyl-C3-5 lkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C(O)OC1-4 alkyl, C(O)OC 0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH 2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl) 2, C(O)NH(C 5, C 5, C 5) 0-4 alkyl-C3-5 cycloalkyl), CH2OR 0-4 alkyl-C(O)R 0-4 alkyl-C(O)N(R 2, C0-4 alkyl-C(O)OR 5, C 5, C 5) 0-4 alkyl-NHC(O)R 0-4 alkyl-N(R 2, a heterocyclic ring system ed from oxetane, azetidine, tetrahydrofuran, dihydropyran, ydropyran, morpholine, piperidine, pyrrolidine, and zine, a heteroaryl ring system selected from furan, e, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, n each of said optional R4 substituents is optionally substituted with up to four fluorine atoms, up to two kyl groups, up to two OH groups, up to two OC1-4alkyl groups, up to two SC1- 4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 C3-5 cycloalkyl; and each R5 is, ndently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from imidazole, triazole, thiazole, ne, and pyrimidine, or a 4membered heterocyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the intervening en atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
51. The compound of any one of claims 17-47, or a pharmaceutically acceptable salt thereof, wherein R4 is a 4membered monocyclic or bicyclic heterocyclyl ring ed from oxetane, tetrahydrofuran, tetrahydropyran, dihydroisoxazole, pyrimidine-2,4(1H,3H)-dione, dihydrofuropyrimidine, opyranopyrimidine, dihydropyrrolopyrimidine, tetrahydropteridine, and ydropyridopyrimidine, wherein each of said R4 groups is optionally substituted with up to four Br, Cl, F, or kyl, up to three CN, NO2, C2- 4alkenyl, kynyl, cloalkyl, C0-4 C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C(O)OC1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-C(O)NH2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl)2, C(O)NH(C0-4 alkyl-C3-5 lkyl), CH2OR5, C0-4 alkyl-C(O)R5, C0-4 alkyl-C(O)N(R5)2, C0-4 alkyl-C(O)OR5, C0-4 alkyl-NHC(O)R5, C0-4 alkyl-N(R5)2, a heterocyclic ring system selected from e, azetidine, ydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, pyrrolidine, and piperazine, a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, oxadiazole, and tetrazole, or up to two OR5, wherein each of said optional R4 substituents is optionally substituted with up to four fluorine atoms, up to two C1-4alkyl groups, up to two OH groups, up to two OC1-4alkyl groups, up to two SC1- 4alkyl groups, a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and each R5 is, independently, hydrogen, C1-4alkyl, a 5membered heteroaryl selected from ole, triazole, thiazole, pyridine, and pyrimidine, a 4membered heterocyclyl selected from oxetane, tetrahydrofuran, and tetrahydropyran, and each R5 group is optionally substituted with chloro, up to three fluorine atoms, up to two C1-2alkyl, CH2OH, CN, up to two OH, up to two OC1-2alkyl, a spirooxetane, pyrrolidine, or triazole, or two R5 groups together with the intervening nitrogen atom form a morpholine ring, azetidine ring, pyrrolidine ring, piperidine ring, or piperazine ring.
52. The compound of claim 32 having the formula: (IV), or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, -C1-4alkyl, fluoro, , -OC1-2alkyl, -C(O)NH2, -C(O)H, or -CN, n each of said R3 alkyl is optionally substituted with OH or up to 3 fluorine atoms; R4 is X1 is N, CH, CF, CCl, or CC1-2 alkyl optionally substituted with up to 3 fluorine atoms; X2 is N or CR4c, wherein X1 and X2 cannot simultaneously be N; each of R4a , R4b, and R4c is, independently, hydrogen, F, Cl, Br, CN, NO2, C1-4 alkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, C(O)OC1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C(O)NH2, C(O)NHC1-4 alkyl, C(O)N(C1-4 alkyl)2, C(O)NH(C0-4 alkyl-C3-5 cycloalkyl), a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, morpholine, piperidine, and zine, or a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, and tetrazole, or R4c, R4a, and the ening atoms form a dihydrofuran, a dihydropyran, or a tetrahydropyridine heterocyclic ring system; wherein each of said R4a, R4b, or R4c heterocyclic or heteroaryl ring systems is optionally tuted with up to four fluorine atoms, up to two C1-4 alkyl, up to two OH , a C(O)C1-4 alkyl, a C(O)OC1-4 alkyl, or a C(O)OC0-4 C3-5 cycloalkyl; and wherein each of said R4a, R4b, or R4c alkyl or cycloalkyl is optionally substituted with up to 2 non-geminal OH groups or up to 3 fluorine atoms.
53. The compound of claim 52, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, -C1-4alkyl, alkyl, -C(O)NH2, or -C(O)H, wherein each of said R3 alkyl is optionally substituted with OH.
54. The compound of claim 52 or 53, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen.
55. The compound of any one of claims 52-54, or a pharmaceutically acceptable salt thereof, wherein each of X1 and X2 is, independently, CH or N, wherein X1 and X2 cannot simultaneously be N.
56. The nd of any one of claims 52-55, or a ceutically acceptable salt thereof, wherein each of R4a and R4b is, independently, a heterocyclic ring system selected from oxetane, azetidine, tetrahydrofuran, dihydropyran, tetrahydropyran, line, piperidine, and piperazine, wherein each of said R4a or R4b heterocyclic ring systems is optionally substituted with up to four fluorine atoms, up to two C1-4 alkyl, up to two OH groups, a -4 alkyl, a C(O)OC 1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and wherein each of said R4a or R4b alkyl or cycloalkyl is ally substituted with up to 2 nongeminal OH groups or up to 3 fluorine atoms.
57. The compound of any one of claims 52-55, or a pharmaceutically acceptable salt thereof, wherein each of R4a and R4b is, independently, a heteroaryl ring system selected from furan, oxazole, oxadiazole, pyrrole, pyrazole, triazole, and tetrazole, wherein each of said R4a or R4b heteroaryl ring systems is ally substituted with up to four fluorine atoms, up to two C1-4 alkyl, up to two OH groups, a -4 alkyl, a C(O)OC 1-4 alkyl, or a C(O)OC0-4 alkyl-C3-5 cycloalkyl; and wherein each of said R4a or R4b alkyl or cycloalkyl is optionally substituted with up to 2 nongeminal OH groups or up to 3 fluorine atoms.
58. The compound of any one of claims 52-55, or a pharmaceutically acceptable salt thereof, wherein each of R4a and R4b is, independently, en, F, Cl, Br, CN, NO2, C1-4 alkyl, C0-4 alkyl-C3-5 cycloalkyl, C0-4 alkyl-O-C1-4 alkyl, C0-4 alkyl-O-C0-4 alkyl-C3-5 cycloalkyl, C2-4 alkenyl, C2-4 alkynyl, 1-4 alkyl, C(O)OC0-4 alkyl-C3-5 cycloalkyl, C(O)NH2, C(O)NHC 1-4 alkyl, C(O)N(C1-4 alkyl) 2, or C(O)NH(C0-4 alkyl-C3-5 cycloalkyl), wherein each of said R4a or R4b alkyl or cycloalkyl is optionally substituted with up to 2 nongeminal OH groups or up to 3 fluorine atoms.
59. A compound, or a pharmaceutically able salt thereof, selected from HN N N i U O H 0* w a \NH O ONH /|\ N\|/ NE\I/ c/H3 o W HN IN N H HN 01 OUA O 0NH /|\N] NE\|/ IN mHL s HN W H3 O IN coGig o 0 H3 N OHAO n0 /|\N] /|\ N\|/ HN N W HN IN H 0w OUA NH 0 0NH /|\ N\|/ HN N N o 0 HN 03/ H3leC Hw OX NH H 0 ea NH /|\ N\|/ NE \I/ HN IN N O HN H 0 my A0 NH H3c O /|\N10 HANH c N/|\ 279 279 N N H3C N N N N N O O O N O N N N N N N N O OH N O N N N N N N N O N HN N N O N N N O HN 284 284 O N N N HN O O N CN N O N N N 288 288 289 289 290 290 O N O N O N N N O O O N 293 293 O N O N N N N OHO 296 296 297 297 298 298 O N N O O N F N N O 300 300 O N N N O N O N CH3 O O N O N F N S N O O N N S O O N H3C O N O O N N N O N N F N O N N Cl O
60. A compound, or a pharmaceutically acceptable salt f, selected from N N \ u. K / fl C\I, ‘o NH /1,:vI /r 3 308 308 309 309 N\(“O O NH 310 310 318 318 320 320 338 338 C] i] «an: «Q 340 340 HHHHH 343 343 346 346 347 347 348 348 349 349 350 350 351 351 m v o Ann "j" HN aN kIN W /|\ N\|/o «M! rw o In U NU H NH \ ENjo EN\|/o H. e rN v IN \I¢ xa mU "(Mo \INa /|\ N\I/o CoJ/qul/N- o k CTu UO N NAIVN| /|\ \I/ o m 352 352 and .
61. A compound of the formula: O N O N N N O N O N H CH3 , N CH3 O , , , , , , or , or a ceutically acceptable salt thereof.
62. A compound of the formula: , or a pharmaceutically acceptable salt thereof.
63. A pharmaceutical composition comprising a compound of any one of claims 1-62, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
64. Use of a compound of any one of claims 1-62, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 63, in the cture of a medicament for sensitizing a breast , colorectal cancer, gastroesophageal cancer, head and neck cancer, melanoma, lung cancer, pancreatic cancer or te cancer cell to a chemotherapeutic agent.
65. Use of a compound of any one of claims 1-62, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 63, in the manufacture of a medicament for iating radiotherapy or a chemotherapeutic agent for the treatment of breast cancer, colorectal cancer, gastroesophageal cancer, head and neck cancer, ma, lung cancer, pancreatic cancer or te cancer in a patient.
66. Use of a compound of any one of claims 1-62, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 63, in the manufacture of a medicament for treating breast cancer, colorectal , gastroesophageal cancer, head and neck cancer, melanoma, lung cancer, pancreatic cancer, or prostate cancer in a patient.
67. Use of a compound of any one of claims 1-62, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 63, in the manufacture of a ment for inhibiting breast cancer, colorectal cancer, gastroesophageal cancer, head and neck cancer, melanoma, lung cancer, pancreatic cancer, or prostate cancer cell growth in a patient.
68. A compound as claimed in any one of claims 1, 61 or 62, substantially as herein bed with reference to any one of the Examples thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361777816P | 2013-03-12 | 2013-03-12 | |
US61/777,816 | 2013-03-12 | ||
PCT/US2014/024767 WO2014159690A1 (en) | 2013-03-12 | 2014-03-12 | Dna-pk inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ712576A NZ712576A (en) | 2020-11-27 |
NZ712576B2 true NZ712576B2 (en) | 2021-03-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10973830B2 (en) | Substituted quinoxaline DNA-PK inhibitors | |
US11021465B2 (en) | DNA-PK inhibitors | |
CA2927392C (en) | Dna-pk inhibitors | |
CA3222626A1 (en) | Compound having anti-tumor activity and use thereof | |
NZ712576B2 (en) | Dna-pk inhibitors |